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Preface 
 
 
 This manual provides the scientific and technical foundations for bioassay program design and 
interpretation, and for the assessment of occupational intakes and internal doses.  The Hanford Internal 
Dosimetry Project Manual (PNNL-MA-552)(a) applies these foundations to define the recommended 
worker bioassay monitoring programs and internal dose assessment efforts at the Hanford Site. 
 
 According to the DOE Internal Dosimetry Program Guide (DOE G 441.1-3, 03-17-99), a technical 
basis document should record the approach to evaluating internal doses from bioassay data, and where 
appropriate, from workplace monitoring data.  It should also describe the physical and chemical 
characteristics of radioactive materials encountered in the workplace; methods for calculating internal 
doses and dose equivalents and the methods for documenting those calculations; dose evaluation quality 
assurance; recording and reporting practices for internal dosimetry; selection of workers for monitoring; 
and establishment of the type and frequency of measurements to be used.  Furthermore, statistical 
methods for evaluating bioassay data, identifying bioassay results above environmental background 
values, using appropriate blanks, and analyzing trends should be described. 
 
 This manual describes the basic methods and biokinetic models used for bioassay program design, 
interpretation, and internal dose assessment.  These methods and models are combined with good 
practices and professional judgment to give the operational recommendations for routine and special 
bioassay monitoring contained in the Hanford Internal Dosimetry Project Manual (PNNL-MA-552).  The 
actual selection of workers for monitoring and the characterization of the physical, chemical, and 
radiological properties of contaminants in the many Hanford facilities are the domain of the individual 
Hanford contractors. 
 
 The recommendations in this manual are provided as guidance, not requirements, to personnel 
responsible for designing and operating bioassay monitoring programs and evaluating bioassay results.  
Commitments by contractors to use these recommendations may be found in the contractor radiation 
protection plans.  This manual is on a 3-year revision schedule, however individual sections are revised as 
necessary, and upon revision, commence their own 3-year revision cycle. 
 
 This manual is maintained by the Hanford Internal Dosimetry Program, operated by the Pacific 
Northwest National Laboratory’s (PNNL’s) Radiation and Health Technology group.  The contact person 
for questions or comments regarding the content of this manual is Eugene H. Carbaugh at 376-6632.  
Available email address:  gene.carbaugh@pnl.gov 
 
                                                     
 
(a) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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CINDY code for internal dosimetry 
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CFR Code of Federal Regulations 
CL contract limit 
 
DAC derived air concentration 
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GI gastrointestinal 
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ICRP International Commission on Radiological Protection 
IL investigation level 
IRF intake retention function 
IVRRF In Vivo Radioassay and Research Facility 
 
Lc critical level of detection 
Ld detection level 
LLD lower limit of detection 
 
MDA minimum detectable activity or amount 
MDD minimum detectable dose 
MDI minimum detectable intake 
MKIV Mark IV 
MPBB maximum permissible body burden 
 
NBS National Bureau of Standards 
NCRP National Council on Radiation Protection and Measurements 
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NU natural uranium 
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OBT organically bound tritium 
ORNL Oak Ridge National Laboratory 
OSHA Occupational Safety and Health Administration 
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PEL permissible exposure limit 
PFP Plutonium Finishing Plant 
PHS Public Health Services 
PNL Pacific Northwest Laboratory 
PNNL Pacific Northwest National Laboratory 
PUREX Plutonium-Uranium Extraction Plant (or process) 
 
RU recycled uranium 
 
SEE specific effective energy 
SI small intestine 
SL screening level 
STC special tritium compound 
STEL short-term exposure limit 
 
TLV threshold limit valve 
TPU total propagated uncertainty 
UNSCEAR United Nations Scientific Committee on the Effects of Atomic Radiation 
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UO3 Uranium Oxide (Plant) 
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WHO World Health Organization 
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1.0 Introduction 
 
 
The Hanford Internal Dosimetry Program (HIDP) provides internal 
dosimetry support services for operations at the Hanford Site.  The 
HIDP is staffed and managed by the Radiation and Health 
Technology group, within the Pacific Northwest National Laboratory 
(PNNL).  Operations supported by the HIDP include research and 
development, the decontamination and decommissioning of facilities 
formerly used to produce and purify plutonium, and waste 
management activities.  Radioelements of particular interest are 
plutonium, uranium, americium, and tritium and the fission and 
activation product radionuclides 137Cs, 90Sr, and 60Co. 
 
This manual describes the technical basis for the design of the 
routine bioassay monitoring program and for assessment of internal 
dose.  The purposes of the manual are to 
 
• provide assurance that the HIDP derives from a sound 
technical base 
 
• promote the consistency and continuity of routine program 
activities 
 
• provide a historical record 
 
• serve as a technical reference for radiation protection personnel 
 
• aid in identifying and planning for future needs. 
 
The internal dosimetry philosophy documented in this manual is 
based on the concepts of dose equivalent and effective dose 
equivalent described in publications 26 and 30 of the International 
Commission on Radiological Protection (ICRP 1977; 1979).  The 
committed dose equivalents (doses integrated over a period of 
50 years following intake) are the basis for evaluating compliance 
with regard to the 10 CFR 835.202 dose limits of 5 rem/y for 
effective dose equivalent and 50 rem/y for single organs and tissues. 
 
1.1 Document Description 
 
This manual establishes the science underlying internal dosimetry as 
practiced by the HIDP.  The general methods chapter describes the 
fundamental principles used for internal dose calculations, and 
subsequent chapters deal with specific radioelements or a related 
group of radionuclides.  The appendixes (beginning with a glossary 
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in Appendix A) provide information that is general to all of the 
chapters.  Radionuclides not specifically mentioned are rarely 
encountered at levels of dosimetric concern at Hanford.  The basis 
for dosimetry for additional radionuclides will be added to this 
manual as the need arises.  A “special topics” chapter provides for a 
documented record of technical issues that do not fit under other 
specific chapters, or that will subsequently be incorporated into other 
chapters upon major revisions of chapters.  The recommendations for 
specific bioassay programs and capabilities of such programs for 
demonstrating compliance with regulations are presented in the 
companion Hanford Internal Dosimetry Project Manual 
(PNL-MA-552).(a)
 
The tables, figures, and appendixes included in this manual (PNNL-
MA-860) reflect the most current information at the time of the 
revision of this manual; information may be changed without the 
change being reflected in this manual prior to the next scheduled 
revision. 
 
1.2 Document History 
 
The first version of this manual was the Technical Basis for Internal 
Dosimetry at Hanford, issued in April 1989 as a technical document 
(PNL-6866; Sula et al. 1989).  During its first 2 years of publication, 
the document found a wide audience throughout the U.S. Department 
of Energy (DOE), its contractors, and other organizations involved in 
internal dosimetry.  It not only served well as the intended reference 
for data, but also became a template for other sites in developing 
their own technical basis documents. 
 
The “Technical Basis” was always intended to be a “living” 
document, responsive to the needs of the HIDP.  The first revision of 
the document (Sula et al. 1991) was prompted by the desire to have 
additional information readily available for routine use in dose 
assessment and bioassay program design.  Also, changes were made 
in the presentation of information to make the document easier to 
use.  Throughout the next 8 years, no revisions were made to the 
document proper, although some updates and additions were made 
by supplemental letter reports addressing specific issues.  The 
document itself remained unchanged due to program priorities and 
the fact that the essence of the material in the document was still 
current. 
 
                                                     
(a) Pacific Northwest National Laboratory.  1997.  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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In January 2000, the Hanford technical basis changed its format from 
a document to a manual.  Although the content and layout remained 
similar to previous versions, the manual format was adopted to allow 
future changes to be accomplished without republishing the entire 
document.  The name change to Methods and Models of the Hanford 
Internal Dosimetry Program was made to more accurately reflect the 
manual’s purpose and content, and avoid confusion that one 
document constitutes the entire “technical basis.” 
 
Shut down and cleanup of Hanford facilities have continued since 
the last revision.  Plutonium production and fuel reprocessing have 
ceased, and facilities are in the midst of decontamination and 
decommissioning.  Relatively short-lived fission and activation 
products have decayed to the point where the need for their 
dosimetry is substantially reduced, and the additional time since the 
end of reprocessing has changed the expected isotopic ratios in 
reference plutonium mixtures.  As new missions are added or 
existing site programs modified, further modification of this manual 
may be required. 
 
The HIDP seeks to implement technically appropriate and cost-
effective methods and tools to carry out its functions.  Recent 
recommendations from the ICRP include a new lung model, 
improved biokinetic models for radionuclides in the body, new 
recommendations for organs of concern and revised organ dose 
weighting factors.  Many of those recommendations are gaining 
acceptance, however the tools to implement them are limited.  The 
HIDP will continue to evaluate new models and tools for internal 
dosimetry, as they become available and incorporate cost-effective 
improvements that are consistent with regulatory and contractual 
requirements.  This manual incorporates some of the newer 
biokinetic models.  Regulatory requirements of 10 CFR 835 and 
contractual requirements for the Hanford Radiological Health and 
Safety Document (DOE 2001) preclude the adoption of recent ICRP 
recommendations for organ dose weighting factors (ICRP 1990) and 
effective dose coefficients based on those factors. 
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2.0 General Methods for Internal Dosimetry 
 
 
The HIDP uses the fundamental concepts described by the ICRP for 
calculations of intake, deposition, and dose.  The basic concepts and 
techniques are those described in ICRP 30, Part 1 and its supplement 
(1979a and b), including specific effective energy (SEE) factors, 
Reference Man parameters, annual limit on intake (ALI), and derived 
air concentration (DAC), with radiation quality factors and 
organ/tissue weighting factors as mandated by 10 CFR 835.  The 
biokinetic models used to describe distribution, retention, and 
excretion for various radionuclides are described in the pertinent 
chapters of this manual.  Generally, preference is given to well-
documented and peer-reviewed models; particularly those published 
by the ICRP.  This chapter summarizes the calculational methods 
and factors most commonly used for intake assessment and internal 
dosimetry.  In some cases, discussion is included concerning 
scientific recommendations that are currently incompatible with 
regulatory requirements.  Such discussion is intended to provide 
guidance for alternate assessments appropriate for purposes other 
than regulatory compliance.  This chapter also describes the various 
reference levels and derived reference levels used by the HIDP. 
 
2.1 Radiation Quality and Tissue Weighting Factors 
 
The quality factors and tissue weighting factors of 10 CFR 835 are 
used for routine calculations.  Generally, these factors have been 
incorporated into the computer codes and dose coefficients used in 
the calculations.  These factors are consistent with those also found 
in 10 CFR 20 and ICRP 30 (1979a).  Some significant differences in 
tissue weighting factors are found in the recommendations of 
ICRP 60 (1990), however these newer values are not consistent with 
10 CFR 835, and thus are not used for compliance dose calculations.  
Table 2.1 provides a comparison of the radiation quality factors 
pertinent to the HIDP, and Table 2.2 compares the tissue weighting 
factors. 
 
Table 2.1.  Comparison of Radiation Quality Factors 
 
Radiation 10 CFR 835 10 CFR 20 ICRP 30 ICRP 60 
Alpha 20 20 20 20 
Proton 10 10 10 5 
Beta 1 1 1 1 
Gamma, X 1 1 1 1 
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Table 2.2.  Comparison of Organ/Tissue Weighting Factors 
 
Tissue or 
Organ 10 CFR 835 10 CFR 20 ICRP 30 ICRP 60 
Gonads 0.25 0.25 0.25 0.20 
Breasts 0.15 0.15 0.15 0.05 
Red Bone 
Marrow 0.12 0.12 0.12 0.12 
Lungs 0.12 0.12 0.12 0.12 
Thyroid 0.03 0.03 0.03 0.05 
Bone Surfaces 0.03 0.03 0.03 0.01 
Colon - - - 0.12 
Stomach - - - 0.12 
Bladder - - - 0.05 
Liver - - - 0.05 
Esophagus - - - 0.05 
Skin - - - 0.01 
Remainder 0.06 for 
each of 5 
other organs 
with highest 
dose 
0.06 for 
each of 5 
other organs 
with highest 
dose 
0.06 for 
each of 5 
other organs 
with highest 
dose 
0.05 total, 
with 
maximum 
of 0.025 to 
any single 
tissue 
 
2.2 Biokinetic Models 
 
Biokinetic models are used to describe the deposition and movement 
of material throughout the body.  The ICRP 30 models for the 
respiratory tract, gastrointestinal (GI) tract, and metabolic 
distribution are used for most assessments (ICRP 1979a, b; 1980; 
1981a, b; 1982a, b; 1988b).  Specific metabolic retention and 
excretion models for various elements are described in the 
corresponding chapters of this manual.  If adjustments are made to 
the parameter values of these models, those adjustments are 
explained in the documentation associated with the assessment. 
 
Intake retention functions (IRFs) combine various biokinetic models 
to provide an expression of the amount of a radionuclide retained in 
a compartment of the body (or excreted by a particular pathway) as a 
fractional value of the amount of the intake.  Values of the functions 
at various times post intake are tabulated in this manual for intake 
circumstances of greatest interest to the HIDP.  Other common 
sources of IRF values that may be used include the computer code 
CINDY (code for internal dosimetry; Strenge et al. 1992), ICRP 54 
(1988a), NUREG 4884 (Lessard et al. 1987), and peer-reviewed 
literature or hand calculations. 
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The CINDY computer code is the preferred code used for internal 
dosimetry by the HIDP.  This code incorporates the ICRP 30 lung 
and GI tract models, along with the metabolic distribution models to 
give bioassay projections, intake assessments based on bioassay data, 
and estimates of dose equivalent. 
 
Committed dose coefficients, hT,50 and hE,50, sometimes referred to as 
dose conversion factors, are the factors that express the committed 
tissue or effective dose equivalent, respectively, for a unit intake.  
They are derived based on a specified set of conditions.  The dose 
coefficients tabulated in this manual are for circumstances most 
commonly encountered at Hanford.  Typically, these are transport-
able injection (instant uptake) and inhalation of class D, W, or Y 
materials, assuming a 1-:m or 5-µm activity median aerodynamic 
diameter (AMAD) particle size.  Other tabulations of dose 
coefficients that might be useful include Federal Guidance Report 
No. 11 (EPA 1988), ICRP 30 supplements, and the newer ICRP 
publications, as summarized in publications 68, 72, and 78 
(ICRP 1994b; 1996; 1997).  In addition, coefficients for differing 
conditions can be calculated using the CINDY computer code. 
 
2.3 Bioassay Measurements 
 
Bioassay is defined as the direct measurement of radioactivity in the 
body or the indirect measurement of radioactivity in the body by 
analyzing material excreted or otherwise removed from the body.  
Direct measurements are commonly called in vivo measurements, 
and use detector systems such as whole body counters, lung 
counters, and wound counters.  Indirect measurements are called in 
vitro measurements, and involve the laboratory analysis of material 
excreted or removed from the body.  In vitro measurements may 
include urine, feces, tissue samples, blood, or sputum.  As a practical 
matter, most in vitro bioassays are made using urine or feces, and 
these measurements are generically referred to at Hanford as excreta 
bioassay. 
 
2.4 Internal Dosimetry Assessments 
 
The HIDP uses intake assessment as the principal means for most 
dose evaluation, with internal doses calculated based on estimated 
intake.  The intake is estimated using available data, preferably 
bioassay measurements, but exposure time to air concentrations may 
also be used.  The 50-year committed effective dose equivalent 
(CEDE) and any appropriate 50-year committed organ or tissue dose 
equivalents are calculated based on the intake.  In some cases 
(notably, tritium), dose may be directly calculated from bioassay  
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measurements, with intake subsequently estimated based on the 
assessed dose.  The 50-year committed dose equivalents, assigned to 
the year of intake, are used as the basis for compliance monitoring. 
 
The concept of deposition assessment was often used by the HIDP 
through 1993, particularly for the assessment of plutonium, and is 
described here primarily for historical reference to archived 
evaluations.  Rather than calculating an intake, this method used 
bioassay data to estimate the amount of material initially deposited in 
the intake compartments of interest.  For example, instead of 
calculating a total inhalation intake, the bioassay data would be used 
to estimate the quantity initially retained in long-term compartments 
of the lung.  In addition, a “presystemic deposition” was estimated to 
be the amount initially deposited in a compartment that would 
eventually translocate to the systemic circulation.  (The term 
“presystemic deposition” was coined for use in the Technical Basis 
for Internal Dosimetry at Hanford [Sula et al. 1989].  Prior to that 
document the term “deposition” had been used, often very 
imprecisely.)  Clearance rates were estimated for both non-systemic 
and presystemic depositions.  Compliance with regulatory 
requirements was demonstrated either by calculating annual (not 
committed) dose equivalents to critical organs for comparison with 
the radiation protection standards in effect at the time, or, prior to 
1989, by comparing the presystemic deposition with the maximum 
permissible body burden (MPBB).  Tabulations of MPBBs in ICRP 2 
(1959) or earlier National Bureau of Standards (NBS) handbooks 
(NBS 1953; 1959) were used as the radiation protection standards.  
In 1989, the ICRP 26 (1977) system was implemented for calculating 
effective dose equivalent using tissue weighting factors applied to 
organ and tissue dose equivalents, and calculated annual doses (not 
committed doses) were used as the basis for compliance.  With the 
1994 implementation of the DOE Radiological Control Manual 
(DOE 1994), compliance monitoring became based on assigning the 
committed dose equivalent to the year of intake. 
 
2.5 Organs or Tissues of Concern 
 
The DOE has established limiting values for occupational exposure 
to radiation in 10 CFR 835.202.  These values include a limit on dose 
to individual organs or tissues to prevent deleterious nonstochastic 
effects, and a limit on the effective dose equivalent based on the risk 
of stochastic effects.  Requirements for recording committed dose 
equivalents to organs and tissues of concern as well as the committed 
effective dose equivalent are given in 10 CFR 835.702(c)(4).  
However, neither the rule nor its implementation guide (DOE 1999) 
specifically defines “organs and tissues of concern.”  Practices for 
recording doses to “organs and tissues of concern” are defined in the 
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Hanford Internal Dosimetry Program Manual (PNNL-MA-552).(a)  
In cases involving relatively small effective dose equivalents, there 
may be no single organ that meets the recording criteria, whereas for 
a very significant exposure, several organs may qualify.  Candidate 
organs and tissues used by the HIDP are those identified by ICRP 30 
(1979a) and the tissue weighting factors of 10 CFR 835, however the 
element-specific chapters of this manual (PNNL-MA-860) narrow 
those candidates to the appropriate organs and tissues.  As noted 
below, doses received by localized tissues are not included in either 
the assessment of effective dose equivalent or in the assessment of 
dose equivalent to organs and tissues of concern. 
 
Intakes of radionuclides via wounds may result in the irradiation of 
local tissues at the wound site, as well as regional lymph nodes that 
drain the wound region.  Because of their small mass, the absorbed 
dose to the regional lymph nodes may greatly exceed that to other 
tissues.  Evidence from studies of experimental animals suggests that 
the lymph nodes are not primary sites for development of radiation-
induced malignant disease (Nenot and Stather 1979).  For this 
reason, there has been no attempt by either the ICRP (1979a) or the 
Biological Effects of Ionizing Radiation (BEIR) Committee 
(National Research Council 1988) to derive stochastic risk estimates 
for lymphatic tissue.  Similarly, the irradiation of local tissues at the 
wound site is not considered to carry significant risk of 
carcinogenesis. 
 
Concentrated activity in such localized sources can be expected to 
result in relatively high doses and cell death or tissue fibrosis (e.g., 
scar tissue) within a limited area, but unless this area comprises more 
than a minor fraction of the organ/tissue, there will likely be no 
observable nonstochastic effect at any dose.  Assessment of organ or 
tissue dose equivalent from highly localized sources, made by 
averaging the energy deposited in the organ over the organ mass, is 
not a relevant measure for comparison with the limiting values for 
assessed dose based on nonstochastic effects.  Furthermore, in most 
situations, it is not possible to determine the actual mass of affected 
tissue for computing the absorbed dose.  Because the absorbed dose 
is highly nonuniform over the tissue and only a limited number of 
cells within the organ/tissue are affected, the use of dose equivalent 
for assessing this localized exposure is not valid. 
 
                                                     
(a) Pacific Northwest National Laboratory.  1997.  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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For these situations, the HIDP will estimate the quantity of 
radionuclide(s) locally deposited and the projected retention 
half-time.  These estimates become part of the individual’s radiation 
protection record, but are not used for determining compliance with 
either the stochastic or nonstochastic limits.  This approach is 
analogous to the approach described in 10 CFR 835.205(b)(3) for 
irradiation of limited areas of the skin. 
 
2.6 Particle Size 
 
The ICRP 30 (1979a) lung model recommended a default particle 
size of 1-µm AMAD, and that recommendation was used by the 
HIDP for most applications through the 1980s and 1990s.  The 
ICRP 66 lung model (ICRP 1994a) provided two particle size 
recommendations for radiological protection purposes, in the 
absence of more specific information.  For occupational exposure 
circumstances, a reference AMAD of 5 µm was recommended, and a 
1-µm AMAD was recommended for exposures in the general 
environment. 
 
Dorrian and Bailey (1995) reported on a survey of 52 publications 
addressing radioactive aerosol particle size distributions in the 
workplace.  Reported values ranged from 0.12 µm to 25 µm, and 
were well fitted by a lognormal distribution with a median value of 
4.4 µm.  They noted that nuclear power and nuclear fuel handling 
facilities gave median values of about 4 µm.  Uranium mills gave a 
median value of 6.8 µm, with AMADs frequently above 10 µm.  
High temperature and arc saw cutting operations generated 
submicron particles.  They concluded that a 5-µm AMAD was a 
realistic default value for occupational exposure to unknown 
aerosols, and considered that value a better choice than the 1-µm 
value of ICRP 30.  They also cautioned that, where possible, particle 
sizes should be measured for individual work practices to provide 
realistic parameters for dose assessment, because the 5-µm value of 
the ICRP 66 lung model was chosen to be deliberately realistic rather 
than conservative. 
 
Kelso and Wraight (1996) reported on 50 AMAD measurements 
associated with reactor fuel reprocessing in several buildings at 
Sellafield.  They found a mean value of 3.7-µm AMAD over the six 
buildings examined, with results consistently larger than the 1-µm 
value.  They also concluded that the use of 5 µm as a default particle 
size was reasonable as a realistic rather than conservative assumption 
for occupational aerosols. 
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Heid and Jech (1972) reported that measurements in the majority of 
Hanford incidents indicated a mean particle size of 4-µm for 
plutonium oxide particles.  Palmer, Perkins, and Stuart (1964) 
reported submicron particle sizes for radon in mines.  These two 
reports provide some older historical data in support of the ICRP 66 
lung model recommendations. 
 
This technical basis work for the HIDP addresses both 1-µm and 5-
µm AMAD particle sizes.  This is done as a point of reference for the 
environmental and occupational radiation protection 
recommendations of ICRP 66, and as a cross-over to mark the 
change from the 1-µm default of ICRP 30 to the 5-µm default of 
ICRP 66 for occupational radiation protection.  It is the intent of the 
HIDP to follow the particle size recommendations of ICRP 66 and 
assume occupational exposure to radioactive aerosols of a 5-µm 
particle size, unless exposure information suggests otherwise. 
 
2.7 Assumed Date of Intake 
 
The actual intake time or period, when that time is known, is used for 
assessment of intake and dose. 
 
When the actual intake time or period is not known, it is necessary to 
identify the probable intake date(s).  This may be done by 
considering available evidence, such as air monitoring results, 
contamination surveys, operating periods, and previous bioassay 
measurement results.  After the intake time is narrowed to a probable 
time period, it is assumed that an acute intake occurred at the 
midpoint of that period.  This approach is consistent with 
recommendations of the ICRP (1988a; 1997) and the National 
Council on Radiation Protection and Measurements (NCRP 1987). 
 
If the evidence suggests that a chronic intake is more reasonable, it is 
assumed that the chronic intake occurred uniformly throughout the 
probable exposure period. 
 
For describing the capability of a bioassay program (i.e., the 
minimum detectable intake or dose associated with a bioassay 
measurement protocol), the intake is assumed to be at a worst-case 
date (i.e., the minimum IRF value for the interval is used).  
Typically, that date is the longest elapsed time between  
measurements. 
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2.8 Intake Pattern 
 
Occupational intakes in a well-engineered and -operated facility 
usually occur as acute inhalations due to unplanned or unanticipated 
events.  Thus, acute inhalations are used for most bioassay program 
designs and as default intake patterns for assessment of high routine 
bioassay samples.  Exceptions to this may include tritium exposures, 
which can be expected to occur as acute or chronic uptake events 
combining both inhalation and absorption.  Historically at Hanford, 
there has also been planned chronic exposure to uncontained 
uranium in several facilities, however the work associated with such 
patterns is now quite rare.  Very low-level chronic exposure, below 
the sensitivity of normal air sampling and bioassay monitoring may 
be present for areas of uncontained radioactivity. 
 
2.9 Interpretation of Bioassay Program Capability 
 
Bioassay program capability (i.e., sensitivity) is described by the 
minimum detectable intake (MDI) and its associated minimum 
detectable dose (MDD), based on an assumed bioassay measurement 
equal to the minimum detectable activity or amount (MDA) and an 
assumed time between measurements. 
 
Occasionally it is desirable to make a statement based on an actual 
bioassay measurement, showing no detectable result, as to what 
might be the potentially undetected dose associated with the 
measurement.  When a bioassay measurement has been made with a 
result showing no detection, the MDA value, rather than the critical 
level for detection (Lc) should be used as a basis for determining a 
potentially undetected dose.  The MDA and critical level for 
detection concepts are discussed in Appendix B of this manual. 
 
2.10 Normalizing Bioassay Data 
 
Indirect bioassay data may be normalized differently based on the 
sampling protocol.  Generally, Hanford urine data are automatically 
normalized to a total 24-hour excretion by use of the standard 
“simulated 24-hour” sampling protocol of collecting all urine voided 
between 30 minutes before retiring at night and 30 minutes after 
rising in the morning for two consecutive nights (NCRP 1987).  This 
protocol was originated at Hanford in the mid-1940s, based on 
unpublished work by J. W. Healy.(a)  Medley, Kathren, and Miller 
(1994) identified a potential bias of up to a factor of 2 for this 
protocol. 
                                                     
(a) Personal correspondence, J. W. Healy to E. H. Carbaugh. 
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If the sample is collected properly, a total or simulated 24-hour urine 
sample result is used as is; no further normalization is done.  A 
proper 12-hour sample result is normalized by doubling the result.  If 
it is suspected that a sample has not been provided according to 
instructions, several approaches are considered for normalization.  A 
sample that is supposed to contain 24-hour excretion may not be 
analyzed if the volume is less than 500 ml because the volume is too 
small to represent a true 24-hour collection, and the worker may be 
asked to provide another sample.  Alternatively, the result may be 
1) normalized to 24-hour excretion based on information from the 
provider, 2) ignored, or 3) normalized by volume to 24-hour 
excretion.  To normalize by volume, 1400 ml for males and 1000 ml 
for females (from Reference Man [ICRP 1974]) should be used for 
24-hour excretion unless the person-specific daily excretion rate is 
known. 
 
Normalization by creatinine or specific gravity has been suggested 
(NCRP 1987; NIOSH 1974; Anderson et al. 1995; Karpas et al. 
1998; Duke 1998).  However, various studies suggest that 
normalization by these methods does not provide any improved 
confidence in the result over normalization by time or volume 
(Jackson 1966; Kim 1995; Boeniger, Lowry, and Rosenberg 1993; 
and Graul and Stanley 1982).  The best way to ascertain if the sample 
represents 24-hour excretion may be to simply ask the worker 
providing the sample. (Harris 2000) 
 
The one exception to the above discussion concerns the analysis for 
tritium in urine.  Because tritium is usually considered to be in 
equilibrium with body water, dosimetry can be accomplished using 
urine concentration rather than a daily excretion rate. 
 
The fecal excretion for Reference Man (ICRP 1974) for adults ranges 
from 60 to 500 g/day, with a recommended average of 135 g/day for 
an adult male and 110 g/day for an adult female.  Note that these 
values represent excretion “per day,” not excretion “per bowel 
movement.”  When a single bowel movement is collected, it is 
generally interpreted as representing excretion for one day.  If the 
sample is greater than 60 g, no normalization is used.  If the sample 
is less than 60 g, normalizing to 135 g for males and 110 g for 
females may be appropriate. 
 
If total accumulated fecal excretion over a time period was requested 
and there is no apparent reason to suspect that total excretion was not 
provided, then all sample results should be used as they are, without 
regard for the mass of individual samples.  If excretions were missed 
during the time period, then normalization of the total mass to the 
 
Issued:  January 31, 2003  PNNL-MA-860 Chapter 2.0 
  Page 2.9 
total mass expected based on the reference values given above 
should be used. 
 
2.11 Fitting Bioassay Data to Biokinetic Models 
 
The assessment of intakes or internal dose requires fitting bioassay 
data to an appropriate biokinetic model to assess the integrated 
retention function (i.e., the cumulative activity or the number of 
radionuclide transformations over the time period of interest).  
Normally the HIDP uses the CINDY computer code (Strenge et al. 
1992) to make these assessments.  Curve-fitting routines within the 
code are addressed in Appendix D.  Although curve fitting for a 
given type of bioassay (e.g., a set of urine samples from one person) 
can be refined by rigorous mathematics, often excretion and 
retention curves for a single intake of an individual do not lead to 
compatible intake estimates.  In such cases, the dosimetrist must 
exercise considerable judgment in estimating the true intake. 
 
2.12 Reference Levels and Derived Reference Levels 
 
A reference level is a predetermined value of a quantity that triggers 
a specified course of action when exceeded or expected to be 
exceeded.  Reference levels at Hanford are expressed as dose-based 
or intake-based.  Derived reference levels are the measurement 
values for particular bioassay or air sampling results that correspond 
to a more general reference level under specifically defined circum-
stances.  The reference and derived reference levels used in this 
document are the following: 
 
• screening level (SL)—The level below which a bioassay 
measurement need not be considered for investigation of intake 
and assignment of dose.  The Hanford SL is based on a 
committed effective dose equivalent of 10 mrem. 
 
• derived screening level (DSL)—The value of a bioassay 
measurement or airborne exposure estimate corresponding to a 
committed effective dose equivalent of 10 mrem for the 
referenced conditions or an estimated normal environmental 
levels. 
 
• verification level (VL)—The level above which an attempt 
should be made to confirm the intake as real (i.e., special 
follow-up measurements should be made to a high routine 
measurement).  The Hanford VL is 100-mrem committed 
effective dose equivalent. 
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• investigation level (IL)—The level above which a bioassay or air 
monitoring result shall be investigated, to the extent reasonable, 
to determine actual conditions and parameters for dose evalua-
tion.  An investigation may involve special measurements, work 
history review, determination of material form, and modification 
of biokinetic parameters.  The Hanford IL is 100-mrem 
committed effective dose equivalent.  In practice, Hanford does 
not discriminate between the VL and the IL. 
 
• derived investigation level (DIL)—The bioassay measurement or 
airborne exposure measurement corresponding to a committed 
effective dose equivalent of 100 mrem for the referenced 
conditions. 
 
• derived compliance level (DCL)—The bioassay measurement 
level corresponding to the 10 CFR 835 dose limit, i.e., 5-rem 
committed effective dose equivalent or 50-rem committed 
organ/tissue dose equivalent. 
 
Values of DCLs, DILs, and DSLs are tabulated in the various 
chapters of this document. 
 
2.13 Fundamental Relationships 
 
The first principles equation for dose equivalent rate to an organ or 
tissue is described as 
 
  (2.1) ( ) s10T ASTSEE10x6.1H ×←×= −•
 
where  = dose equivalent rate in the target organ or tissue (T) 
from radioactive transformations in a source organ 
or tissue, in units of sieverts per second (Sv/s), 
TH
•
)ST(SEE ←  = specific effective energy deposited in the target 
organ or tissue from a radionuclide transformation 
in a source organ or tissue in units of MeV per 
gram – transformation (MeV/g-trans), and 
 As = radioactivity present in the source organ or tissue in 
becquerels (Bq). 
 
Integrating Equation (2.1) with respect to retention time gives the 
following dose equivalent: 
 
  (2.2) dt)t(RA)ST(SEE106.1H 0s
10
T ∫×←××= −
 
where  = dose equivalent in sieverts (Sv), TH
 R(t) = retention function in the source organ or tissue, and 
 
Issued:  January 31, 2003  PNNL-MA-860 Chapter 2.0 
  Page 2.11 
dt)t(RAs ∫  = total number of transformations in the source organ 
over the time interval of interest.  This latter term is 
also known as cumulative activity.  For most 
internal dosimetry calculations, the integral is 
solved for t = 50 years (or 1.58 x 109 seconds).  
ICRP 30 nomenclature identifies this term as . sU
 
In conventional health physics units, Equation (2.2) is expressed as 
 
  (2.3) dt)t(RA)ST(SEE2.51H 0sT ∫×←×=
 
where  = rems, TH
  = microcuries (µCi), and sA
 t = the time interval in days. 
 
A few fundamental relationships are repetitively used for most 
internal dosimetry calculations.  Some of these relationships are 
described conceptually in the following equations.  Because these are 
intended to be conceptual relationships, no units or unit conversion 
factors are shown.  It is understood that consistency in units will be 
addressed by the specific application of the relationship. 
 
Bioassay Result = Intake × Intake Retention (or Excretion) Fraction 
 
 )t(IRFI)t(M ×=  (2.4) 
 
Intake Estimate from a Single Bioassay Measurement 
 
 
)t(IRF
)t(MI =  (2.5) 
 
Intake Estimate from Air Concentration Data 
 
 
actorFrotectionPespiratoryR
DurationExposureRateBreathingC
I air
××=  (2.6) 
 
Calculation of Airborne Exposure (DAC-hours) 
 
 )hours(ExposureofDuration
DAC
C
hoursDAC
n
1i i
i,air ×=− ∑
=
 (2.7) 
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Annual Limit on Intake, the most limiting from Dose Limit and Dose 
Coefficient 
 
 
50,T50,E h
rem50or,
h
rem5
tCoefficienDose
LimitDoseALI ==  (2.8) 
 
Intake Estimate from Airborne Exposure (DAC-hours) and Annual 
Limit on Intake 
 
 hoursDAC
hoursDAC2000
ALII −×−=  (2.9) 
 
Committed Effective Dose Equivalent based on Intake and Dose 
Coefficient 
 
 50,E50,E hIH ×=  (2.10) 
 
Committed Organ/Tissue Dose Equivalent based on Intake and Dose 
Coefficient 
 
 50,T50,T hIH ×=  (2.11) 
 
Committed Dose from DAC-hours 
 
 
hoursDAC2000
rem5hoursDACH 50,E −×−=  (2.12) 
 
(for stochastically based DACs) 
 
 
hoursDAC2000
rem50hoursDACH 50,T −×−=  (2.13) 
 
(for deterministically based DACs) 
 
Minimum Detectable Intake (MDI) 
 
 
)t(IRF
MDAMDI =  (2.14) 
 
Minimum Detectable Dose (MDD) 
 
 50,TorEhMDIMDD ×=  (2.15) 
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 3.0 Special Topics
This chapter provides a subject area for technical basis discussions of
special issues that arise and do not fit neatly in other chapters or
appendices of this manual.  These topics may be of short-term
application, limited scope, or simultaneously deal with multiple
chapters of this manual.  This chapter will include sequentially
numbered sections as topics are issued.
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 4.0 Tritium
This chapter provides information on the sources and biokinetics of
tritium and summarizes the technical basis used for the internal
dosimetry of tritium (3H) at Hanford.  This chapter is not intended to
be an all-encompassing technical basis for any type of tritium
exposure, but rather to provide the approach to be used for routinely
encountered exposures at Hanford.  A detailed review of tritium
metabolism and dosimetry was published by Hill and Johnson
(1993).  There is broad consensus on the internal dosimetry for
tritiated water vapor.  However, organic forms and stable tritium
particulates (notably metal tritides) are currently undergoing
substantial technical evaluation within the DOE complex and the
dosimetry for such materials is subject to change with emerging
knowledge.  Therefore, this chapter addresses such special forms of
tritium in only a cursory manner at this time.  Internal dosimetry staff
should be contacted for concerns about these materials.
4.1 Sources and Environmental Levels of Tritium
Tritium exists as part of the natural background of environmental
radiation (NCRP 1979a) originating from cosmic ray interactions.
It is also a man-made nuclide that has been widely dispersed in the
environment from nuclear weapons tests, nuclear power programs,
and radioisotope applications.
Tritium work at Hanford has included tritium production, research
associated with tritium production, the decontamination and
decommissioning (D&D) of former tritium production facilities and
laboratories associated with such facilities, radioluminescent lights
developed by PNNL, and as a tracer or labeling compound for
biological research projects.  Tritium waste is also received at
Hanford from other sites.  Predominant forms of tritium have been
tritium oxide (tritiated water), tritium gas, and at least one project
involving stable metal tritides (notably, zirconium tritide).
Tritium in the human body can be routinely detected at levels well
below those of any dosimetric concern.  Therefore, in addition to its
use for dosimetry, tritium bioassay can be readily used as a work-
place monitoring technique supplemental to air sampling or
contamination surveys.
It can be assumed that the tritium concentration of the body water of
nonoccupationally exposed persons should be reasonably close to
that of their drinking water.  The EPA has reported that background
tritium concentrations in U.S. drinking water range from 100 to
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400 pCi/l (EPA 1985), which corresponds to about 0.2 to 1 dpm/ml.
In addition, the EPA has promulgated a limit for tritium in drinking
water of 20 nCi/l, based on 4 mrem/yr (EPA 1976), although an
upward revision of this limit seems technically justifiable (Moghissi
and Cothern 1986).
Tritium has been widely distributed in the public domain as a source
of luminosity for various “glow-in-the-dark” applications, such as
the faces of watches, clocks, instruments, and exit signs.  Breakage
or other loss of containment in such devices could result in tritium
levels in urine being substantially above background without
occupational exposure.  Normal diffusion of tritium through watch
cases can account for detectable urinary excretion of tritium.
Brunner et al. (1996) reported urine concentrations of 197 to
1133 Bq/l (12 to 68 dpm/ml) in 108 persons wearing plastic case
watches containing tritium.
4.2 Chemical Forms of Tritium
Tritium occurs in several chemical forms that significantly affect the
internal dosimetry associated with it.  These forms include tritium
gas (which is an external dose hazard posing little internal dosimetry
impact, and thus is not addressed here), tritiated water vapor or liquid
(HTO), and special tritium compounds including organically bound
tritium and stable metal particulates.  Tritiated water is the typical
form encountered at Hanford, and routine Hanford dosimetry is
based on this form.  Organically bound tritium may be associated
with things such as contaminated oils or experiments using tritium as
a tracer.  Stable metal particulates are often linked to metal tritides
associated with tritium storage devices or tritium rust (tritiated iron
oxide).  Limited activities involving stable metal tritides have been
identified by PNNL.  The internal dosimetry for organically bound
tritium and stable metal particulates is undergoing substantial review
within the DOE complex, and this technical basis document will be
augmented as needed to address new guidance.  Organically bound
tritium and stable metal particulates of tritium can deliver
substantially more dose per unit intake than tritiated water.
Internal dosimetry for each of the three tritium forms of greatest
concern is discussed in the following sections.
4.3 Internal Dosimetry for Tritiated Water
Determining the dose from tritium exposures involves calculating the
dose to soft tissue from tritium that is assumed to be uniformly
distributed throughout the body water.  The body water
concentration can be determined by first sampling the body fluids
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(typically urine), then by directly measuring tritium using liquid
scintillation techniques.  For acute exposure situations, the initial
body water concentration can be estimated from the retention
function, and a total tritium uptake can be calculated using the
Reference Man body water mass from ICRP 23 (1974).  From this
uptake, the soft tissue dose equivalent can be calculated for any
pertinent time period.  For chronic exposure situations, an
equilibrium body burden of tritium can be estimated from the body
water concentration, and a dose equivalent can be calculated for any
pertinent time period using a dose rate factor.  A summary of
selected Hanford internal dosimetry factors for HTO is shown in
Table 4.1.  Their derivation is described in the following paragraphs.
Table 4.1.  Hanford Tritiated Water (HTO) Dosimetry Factors
Radiological Half-Life 12.35 yr
Specific Effective Energy (SEE) Factor 9.0E-08 MeV/g-transformation
Effective Energy per Transformation 5.7 keV (0.0057 MeV)
Quality Factor 1.0
Biological Half-Life 10 days
Effective Half-Life 10 days
Tissue Weighting Factor 1.0
Source Organ Body water
Source Organ Mass 42,000 g
Target Organ Soft tissue
Target Organ Mass 63,000 g
Hanford HTO Dose Coefficient 1.8E-11 Sv/Bq, or 0.066 mrem/mCi
Dose Equivalent per Unit
Concentration Factor
1.3E-04 mrem per dpm/ml
2.8 mrem per mCi/l
Dose Rate per Unit Body Water
Concentration Factor
0.19 mrem/day per mCi/l
8.7E-5 mrem/day per dpm/ml
Derived Air Concentration
(10 CFR 835 Appendix A)
2E-05 mCi/m. or
8E+05 Bq/m3
Historically, the approach to tritium dosimetry used in ICRP 2,
ICRP 10, and American National Standards Institute (ANSI)
N13.14-1983 was to calculate the dose to body water as the critical
organ (ICRP 1959, 1969; ANSI 1983).  A body water mass of
42,000 g was assumed for ICRP 23 Reference Man (1974).  It was
assumed that the dose to body water was essentially the same as the
dose to soft tissue.  In ICRP 30 (1979), a more realistic approach to
tritium dosimetry was defined.  The body water mass of ICRP 23
Reference Man (42,000 g) was recognized to be essentially
uniformly distributed throughout the body mass of soft tissue
(63,000 g).  Consequently, tritium is now considered to be uniformly
distributed throughout soft tissue, and it is the soft tissue mass that is
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irradiated rather than merely the body water.  The net effect is to
distribute the decay energy over a larger mass of tissue, resulting in a
lowered total dose.  Although less conservative, this approach is
more accurate from a biological and technical point of view.
Reported tritium doses for exposures to tritium at Hanford prior to
the 1989 implementation of this approach were approximately 33%
higher than if they had been calculated using the newer approach.
Tritium as HTO is assumed to be instantaneously and uniformly
mixed with body water immediately following intake.  The f1 factor
is assumed to be 1 for all ages.  This makes HTO a special case
where total intake and systemic uptake are identical.  Although the
NCRP (1976) suggests that 2 or more hours may be required for this
distribution and mixing to occur, from a practical standpoint the
process is quite rapid and an approximate equilibrium condition will
probably be reached by the time a sample can be collected.  The
collection of overnight urine samples provides good assurance that
an equilibrium condition in the body has been achieved, however
adequate dosimetry can be done using single void samples.
The metabolic model used for tritium is described in ICRP 30
(1979).  Tritiated water is assumed to be uniformly distributed
among all soft tissues at any time following intake.  Its retention,
R(t), is described as a single exponential with an effective clearance
half-time of 10 days.  Thus, the fraction of tritium taken into the
body as tritiated water, which is retained in the body at time t days
later, is given by:
t0693.0t10
693.0
ee)t(R -
´-
== (4.1)
Radioactive decay is insignificant in this determination because the
biological clearance half-time of 10 days far surpasses the physical
decay half-time of 12 years as a mode of clearance from the body.
This retention function has been well established and is considered
appropriate for exposures to tritiated water (HPS 1994).  It can be
expected that the retention of tritiated water in individuals will vary
from this, and if sufficient data are available to establish an alternate
model for an individual worker’s exposure, they should be used.   In
addition to body water, ICRP 30 acknowledged the existence of two
organically bound tritium components.  However, the ICRP
concluded that these could be ignored for radiation protection
purposes, and Johnson (1982) estimated that these components
would add approximately 10% to the committed dose equivalent.
Unless worker data specifically indicate the existence of significantly
longer-term components, the HIDP will follow the ICRP
recommendation of single compartment retention.  The number of
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transformations )U( s  resulting from an intake of 1 Bq can be
calculated by integrating the retention function over the appropriate
time interval.  This calculation is shown below for the 50-year
committed dose period:
tionstransforma1025.1
sh600,3hd24Bqd43.14
dteU
6
11
250,18
0
t0693.0
s
´=
´´=
=
--
ò
(4.2)
4.3.1 Dose Calculation for an Acute Exposure to HTO
The uniform concentration of tritium in body water and its single
component clearance rate allow for the estimation of uptake based on
concentration rather than total daily excretion.  The retention
function (Equation [4.1]) can be used to directly estimate the body
water concentration as follows:
t0693.0
0t eCC
-´= (4.3)
where C t is body water concentration on day t, C0 is initial body
water concentration, and t is elapsed time (days) post intake.  C0 can
be determined from Ct and t by simple algebraic manipulation of this
equation.
t0693.0
t
0
e
C
C
-
= (4.4)
Once C0 has been determined, the intake I0 (same as uptake for
tritiated water) for an acute exposure can be estimated by
multiplying C0 by the source organ (body water) mass as shown in
Equation (4.5):
VolumeorMassWaterBodyCI 00 ´= (4.5)
where concentration and body water mass or volume units are
consistent.  The ICRP Reference Man body water mass of 42 kg or
volume of 42,000 ml is used for normal internal dose calculations.
Using the ICRP 30 fundamental dose calculation described in
Chapter 2.0 (Equation [2.2]), the transformations per unit intake
factor derived above, and the tritium SEE factor, the committed
effective dose equivalent for an intake of 1 Bq of tritiated water is
calculated to be
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Sv1080.1
)100.9()1025.1()106.1()Sv(H
11
8610
50,E
-
--
´=
´´´´´=
(4.6)
giving a dose coefficient (hE,50) of 1.80E-11 Sv Bq-1.  This dose
coefficient and its conventional unit’s conversion (0.0666 mrem/mCi)
are the factors used for tritiated water for Hanford internal dosimetry.
Using conventional units of mrem for HE,50 and mCi for I0, as is
customary for the HIDP, the committed effective dose equivalent
from an intake of tritium is calculated as
)Ci(I0666.0)mrem(H 050,E m´= (4.7)
Substituting concentration C0 (in mCi/l) times the Reference Man
body water volume of 42 l for I0, gives the following relationship, as
described in American National Standard HPS N13.14 (1983):
)l/Ci(C79.2)mrem(H 050,E m´= (4.8)
which, when converted to the Hanford reporting units for
concentration of dpm/ml, becomes
)ml/dpm(C00126.0)mrem(H 050,E ´= (4.9)
A comparison of HTO dose coefficients from several published
sources is shown in Table 4.2.  The reason for the discrepancy
between the Hanford dose coefficient derived by Equation (4.6), the
ICRP 30 value, and the EPA value is differences in rounding
conventions between the calculations.  The reason for discrepancies
between the Hanford value and the ICRP 56 and ICRP 78 (1989;
1997) values is more complex.  According to discussions between
Hanford internal dosimetry staff and the internal dosimetry modeling
group at Oak Ridge National Laboratory (ORNL) that originated the
values, the ICRP 56 ingestion value was in error and was updated in
ICRP 67 (1993) without notice of an erratum.  As opposed to the
ICRP 30 soft tissue mass of 63 kg, the ICRP 67 model used a body
mass of 68.831 kg representing the total body mass minus the
contents of the GI tract and urinary and gall bladders.  Thus the
resulting ICRP 67 SEE factor was 8.25E-08 Mev/g-trans (compared
with the ICRP 30 value of 9E-08 Mev/g-trans).  This adjustment
offset the 10% increase in the number of transformations resulting
from using the ICRP 56 two-component biokinetic model (97% of
the tritium clearing with a 10-d half-time and 3% clearing with a
40-d half-time, representing a small organically bound component).
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Table 4.2.  Comparison of Tritium Dose Factors
Tritiated Water (HTO) Reference
Dose Coefficients
1.8E-11 Sv/Bq
(0.0666 mrem/ mCi) Hanford (this manual)
1.7E-11 Sv/Bq ICRP 30 (1979)
1.73E-11 Sv/Bq EPA (1988)
1.6E-11 Sv/Bq ICRP 56 (1989)
1.8E-11 Sv/Bq ICRP 67 (1993), 68 (1994), 71 (1995) and 78 (1997)
Derived Air Concentration (DAC)
2E-05 mCi/ml (8E+05 Bq/m3) 10 CFR 835 Appendix A
2E-05 mCi/ml (8E+05 Bq/m3) EPA (1988)
8E+05 Bq/m3 ICRP 30 (1979)
Organically Bound Tritium (OBT)
Dose Coefficients
4.0E-11 Sv/Bq Ingestion ICRP 56 (1989)
4.2E-11 Sv/Bq Ingestion ICRP 67 (1993), 68 [1994]), 78 (1997)
4.1E-11 Sv/Bq Inhalation ICRP 71 (1995), 78 (1997)
Derived Air Concentration (DAC)
1E-05 mCi/ml. (4E+05 Bq/m3) DOE (1999)
Stable Tritiated Particulates (STP)
Dose Coefficients – all from ICRP 71 (1995)
6.2E-12 Sv/Bq Inhalation of 1-mm AMAD particles, type F, f1=1
4.5E-11 Sv/Bq Inhalation of 1-mm AMAD particles, type M, f1=0.2
2.6E-10 Sv/Bq Inhalation of 1-mm AMAD particles, type S, f1=0.02
Derived Air Concentration (DAC)—all from
DOE (1999)
Type F 9E-05 mCi/ml (3E+06 Bq/m3)
Type M 1E-05 mCi/ml (4E+05 Bq/m3)
Type S 2E-06 mCi/ml (8E+04 Bq/m3)
Thus, there is not a significant difference in the ICRP 30 dose
coefficient calculated by the HIDP using first principles and the
ICRP 67, 68, and 78 dose coefficients calculated by ICRP using a
reduced SEE factor (ICRP 1979; 1993; 1994; 1997).  As of this
writing, it has not been resolved to the satisfaction of the HIDP staff
that the later ICRP method is a significantly improved approach.
Consequently, the Hanford dose coefficient as derived from basic
principles using ICRP 30 methods in this chapter is used for
dosimetry.
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4.3.2 Dose Calculation for a Chronic Exposure to HTO
For chronic exposure, or a series of continuing acute exposures, an
equilibrium concentration in body water is assumed.  The dose
equivalent rate during the period when the concentration is
maintained can be calculated by substituting the equilibrium body
water concentration (Ceq (µCi/l) ´  42) for sA  in Equation (2.1) and
addressing units conversion, which gives
)l/Ci(C19.0)d/mrem(H eqeq,E m´=
·
(4.10)
and in units typically reported by the Hanford radiochemistry
bioassay laboratory:
)ml/dpm(C107.8)d/mrem(H eq
5
eq,E ´´=
-
·
(4.11)
The dose equivalent for the time period during which the equilibrium
body water concentration is maintained can then be calculated by
tH)mrem(H eq,EE ´=
·
(4.12)
where t = duration of exposure in days.
The total committed dose resulting from a chronic exposure interval
consists of the dose incurred during the interval (as calculated by
Equation (4.12) and the dose incurred following the termination of
intake.  This latter component can be calculated using the equation
for an acute exposure (e.g., Equation [4.8]) where C0 is equal to Ceq)
in mCi/l as follows:
)C8.2()tH()mrem(H 0eq,Etotal,E ´+´=
·
(4.13)
4.3.3 HTO Dosimetry Based on Multiple Sample Results
When data from routine monitoring indicate that multiple acute
intakes or combinations of acute and chronic exposure conditions
may exist, dosimetry may be performed by integrating the body
water concentration over time and multiplying by the dose rate per
unit concentration factor listed in Table 4.2 (as shown in Equation
[4.14]).  This method is particularly useful if samples are obtained
frequently enough to provide an accurate estimate of the integral
value.
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dtC19.0H tE ò= (4.14)
where HE = mrem and Ct is in mCi/l.
4.3.4 Bioassay for Intakes of Tritiated Water
Bioassay monitoring for intakes of tritiated water is relatively simple
and involves sampling a representative body fluid.  Any body fluid
can be used, but from a practical standpoint urine is the medium of
choice.  Because dosimetry can be readily performed using
concentration data and because the models are quite simple, a single
voiding (spot) urine sample is sufficient to obtain an adequate
volume for analysis.  Only a few milliliters are actually used in the
liquid scintillation analysis procedure.  Sufficient time should pass
following exposure to allow for uniform distribution throughout
body fluids.  The NCRP suggests that 2 or more hours may be
required for this (NCRP 1976).  For this reason, it is usually
recommended that tritium samples be collected at home using a
multiple voiding sampling protocol to obtain an average
concentration.
The Hanford bioassay laboratory’s liquid scintillation procedure
involves direct mixing of a small quantity (1ml) of the urine sample
with the scintillation cocktail solution.  The sample is then counted
in a liquid scintillation analyzer.
4.3.5 Derived Reference Levels for HTO Bioassay
Derived screening levels, investigation levels, and compliance levels,
based on committed effective dose equivalents of 10-mrem,
100-mrem, and 5,000 mrem, respectively, are shown in Table 4.3 for
a single acute intake, and Table 4.4 for multiple intakes.
4.3.6 Bioassay Measurements Capability for Acute HTO Exposures
The detection capability of a routine tritium bioassay monitoring
program for acute exposures has been considered in terms of
minimum detectable dose (committed effective dose equivalent) per
intake and year, using an analytical procedure sensitivity of
20 dpm/ml.  In making these calculations, it was assumed that an
acute intake occurred on the day immediately following a sample;
thus, the time post intake was considered equal to the length of the
sample interval.  It was also assumed that the pattern of one intake at
the start of each interval might be maintained for a year.  The results
of these calculations are listed in Table 4.5 and plotted as the acute
intake curve in Figure 4.1.
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Table 4.3.  Single Acute Intake Derived Reference Levels for Tritium Urine Excretion
Days Post
Intake
Body Water IRF
100% - 10 day
ICRP 30 HTO
10-mrem HE,50
Derived
Screening
Level(a)
(dpm/ml)
100-mrem HE,50
Derived
Investigation
Level(b) (dpm/ml)
5-rem HE,50
Derived
Compliance
Level(c)
(dpm/ml)
0 1.0E+00 7.9E+03 7.9E+04 4.0E+06
1 9.3E-01 7.4E+03 7.4E+04 3.7E+06
2 8.7E-01 6.9E+03 6.9E+04 3.5E+06
3 8.1E-01 6.4E+03 6.4E+04 3.2E+06
7 6.2E-01 4.9E+03 4.9E+04 2.4E+06
14 3.8E-01 3.0E+03 3.0E+04 1.5E+06
30 1.3E-01 9.9E+02 9.9E+03 5.0E+05
60 1.6E-02 1.2E+02 1.2E+03 6.2E+04
90 2.0E-03 1.6E+01 1.6E+02 7.8E+03
180 3.8E-06 3.0E-02 3.0E-01 1.5E+01
365 1.0E-11 8.2E-08 8.2E-07 4.1E-05
(a) Based on 150 mCi intake.
(b) Based on 1,500 mCi intake.
(c) Based on 75,000 mCi intake.
Table 4.4.  Multiple Acute Intake Derived Reference Levels for Tritium Urine Excretion
Days Post
Intake
Body Water IRF
100% - 10 day
ICRP 30 HTO
Monitoring
Intervals
per Year
10-mrem HE,50
Derived
Screening
Level(a)
(dpm/ml)
100-mrem HE,50
Derived Investigation
Level(b) (dpm/ml)
1 9.3E-01 3.7E+02 2.0E+01 2.0E+02
2 8.7E-01 1.8E+02 3.8E+01 3.8E+02
3 8.1E-01 1.2E+02 5.3E+01 5.3E+02
7 6.2E-01 5.2E+01 9.4E+01 9.4E+02
14 3.8E-01 2.6E+01 1.2E+02 1.2E+03
30 1.3E-01 1.2E+01 8.3E+01 8.3E+02
60 1.6E-02 6.0E+00 2.1E+01 2.1E+02
90 2.0E-03 4.0E+00 3.9E+00 3.9E+01
180 3.8E-06 2.0E+00 1.5E-02 1.5E-01
365 1.0E-11 1.0E+00 8.2E-08 8.2E-07
(a) Assumes one intake per monitoring interval and ignores residual from previous intakes.
(b) Based on 10-mrem screening level intake of 150 mCi cumulative for 1 year.
(c) Based on 100-mrem investigation level intake of 1500 mCi cumulative for 1 year.
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Table 4.5. Minimum Detectable Intakes (MDIs) and Doses (MDDs)(a) for Acute Tritium Intake Based
on the ICRP 30 Retention Model and Analytical Sensitivity of 20 dpm/ml in Body Water
Days Post
Intake
ICRP 30(b)
Retention
Fraction
MDI for
Interval
(mCi)
Interval
MDD
(mrem)
Monitoring
Intervals per
Year
Maximum
Annual
MDD(c)
(mrem)
Chronic
Exposure
(mrem)
1 9.3E-01 4.1E-01 2.7E-02 NA NA 0.64
2 8.7E-01 4.3E-01 2.9E-02 NA NA 0.64
3 8.1E-01 4.7E-01 3.1E-02 NA NA 0.64
7 6.2E-01 6.1E-01 4.1E-02 52 2.1E+00 0.64
14 3.8E-01 1.0E+00 6.6E-02 26 1.7E+00 0.64
30 1.3E-01 3.0E+00 2.0E-01 12 2.4E+00 0.64
60 1.6E-02 2.4E+01 1.6E+00 6 9.7E+00 0.64
90 2.0E-03 1.0E+02 1.3E+01 4 5.2E+01 0.64
120 2.4E-04 1.5E+03 1.0E+02 4 4.1E+04 0.64
180 3.8E-06 9.9E+04 6.6E+03 2 1.3E+04 0.64
365 1.0E-11 3.7E+10 2.4E+09 1 2.4E+09 0.64
(a) Committed effective dose equivalent.
(b) ICRP 30 model is 100% retained with a 10-day biological half-time.
(c) Assumes one intake per interval and no buildup from intakes.
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Figure 4.1. Tritium Bioassay Monitoring Program Detection Capability for Analytical Sensitivity of
20 dpm/ml using the ICRP 30 Retention Model
PNNL-MA-860 Chapter 4.0 Issued:  January 31, 2000
Page 4.12
As previously noted, there is evidence for an organically bound
component of a tritium oxide intake that can affect bioassay data
interpretation at long times (e.g., >90 days) post intake.  Table 4.6
shows the bioassay program capability for a program factoring in the
3% organically bound component.  Because of the uncertainties
associated with this component and the significant impact on
minimum detectable dose of extending bioassay intervals to periods
in excess of 90 days (compare with Table 4.5), this component is not
being incorporated into routine program design and interpretation.  If
post-intake monitoring of an individual worker shows evidence of
this organically bound component, it will be factored into the
calculations.
Table 4.6. Minimum Detectable Intakes (MDIs) and Doses (MDDs)(a) for Acute Tritium Intakes,
Assuming the ICRP 56 Two-Component Body Water Retention Model and an Analytical
Sensitivity of 20 dpm/ml in Body Water
Days Post
Intake
ICRP 56(b)
Retention
Fraction
MDI for
Interval (mCi)
Interval
MDD (mrem)
Monitoring
Intervals per
Year
Maximum
Annual
MDD(c)
(mrem)
1 9.3E-01 4.0E-01 2.9E-02 NA NA
2 8.7E-01 4.3E-01 3.1E-02 NA NA
3 8.2E-01 4.6E-01 3.4E-02 NA NA
7 6.2E-01 6.1E-01 4.4E-02 52 2.3E+00
14 3.9E-01 9.7E-01 7.0E-02 26 1.8E+00
30 1.4E-01 2.7E+00 2.0E-01 12 2.4E+00
60 2.6E-02 1.5E+01 1.1E+00 6 6.4E+00
90 8.2E-03 4.6E+01 3.3E+00 4 1.3E+01
120 4.0E-03 9.5E+01 6.9E+00 4 2.8E+01
180 1.3E-03 2.8E+02 2.1E+01 2 4.1E+01
365 5.4E-05 7.03E+03 5.1E+02 1 5.1E+02
(a) Committed effective dose equivalent.
(b) ICRP 56 retention model is 97% retained with a 10-day half-life and 3% retained with a
40-day half-life.
(c) Assumes 1 intake per interval and no buildup from multiple intakes.
4.3.7 Bioassay Measurement Capability for Chronic HTO Exposures
If the exposure condition is chronic and an equilibrium body water
concentration of 20 dpm/ml is assumed (equal to the sensitivity of
the analytical procedure and implying a daily intake rate of 26 nCi),
then the resulting committed effective dose equivalent from 365 days
of intake would be 0.64 mrem.  Because of the assumption of
chronic equilibrium conditions, this estimate is independent of
sample frequency, and is thus shown as a flat line in Figure 4.1.
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4.3.8 Optimum Bioassay Sampling Intervals for HTO Exposures
From Figure 4.1, it is apparent that the optimum routine bioassay
sampling frequency for tritium is once every 2 weeks (biweekly) for
periodic acute intakes of tritium.  Where exposure conditions are
well established and anticipated tritium doses are low (e.g.,
<100 mrem for the year), less frequent intervals (e.g., monthly to
quarterly) are adequate.  However, the uncertainties with dose
estimates associated with longer sampling intervals become much
higher.  Because of the 10-day effective half-life and the
uncertainties associated with a possible organically bound tritium
component, sampling intervals for HTO greater than 90 days are
specifically not recommended.  If the potential exposure to tritium is
anticipated only for a very limited interval, starting and ending
bioassay samples might be more suitable than participation in a
continuing monitoring program.
Based on Table 4.5, a worker monitoring program using screening
levels of 110 dpm/ml for biweekly samples or 80 dpm/ml for
monthly samples is capable of detecting a 10-mrem dose equivalent
in a year based on a series of acute or chronic HTO intakes.  These
screening levels are conservative because they ignore the buildup of
excretion of tritium in urine as the number of periodic intakes
increases during the year, as shown in Figure 4.2.  At these screening
levels, sampling schedules should be reviewed to ensure that workers
are on an adequate routine monitoring program consistent with their
work.  If indications are that annual doses may exceed 100 mrem
from ongoing work, then a biweekly sampling program is
recommended.
4.3.9 Special Monitoring for HTO
Special monitoring may be required after unplanned or unusual
exposures.  When an unusual exposure has been suspected or
reported, arrangements should be made to collect a urine specimen
within a reasonably short period of time following the exposure,
allowing for the achievement of body water equilibrium.  For
potentially high exposures, this sample might be a single voiding
sample collected at the workplace.  For less serious exposures, an
overnight (simulated 12-hour) or simulated 24-hour sample provides
confidence that body equilibrium has been achieved and may be
more convenient.
Follow-up sampling should be performed to confirm the initial
sample results if implied doses might exceed 100 mrem.  Additional
follow-up samples may be warranted to verify the applicability of the
10-day retention half-time in the individual, or to assess a more
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Figure 4.2. Excretion of Tritium Following Multiple Intakes Based on the ICRP 30 Model and
Assuming 1-µCi Intake per Interval
suitable half-time.  To adequately determine the degree of agreement
between observed and anticipated retention may require only two or
three samples over a period of about 3 weeks, or it may involve a
more extended sampling program.  The evaluator must exercise
judgment in determining the number of samples warranted.  If the
exposed worker is already on a routine (e.g., bi-weekly) monitoring
frequency, additional special sampling for follow-up may not be
required.
Once an exposure has been evaluated, elevated urine samples might
be expected for some time (several months).  If the worker returns to
work that involves potential tritium exposure, a more frequent
sampling program may be required until normal baselines are re-
established.  During this time period, consideration may need to be
given to the possibility that additional low-level uptakes of tritium
might occur, which could be undetectable due to variability in the
excretion pattern of tritium retained from the earlier intake.
4.4 Internal Dose Assessment Protocols for HTO
This section provides summary protocols for the assessment of
occupational internal dose for HTO.  As such, it applies the concepts
described in Section 4.3 of the HIDP.
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4.4.1 Dose Assessment for a Single Acute Exposure
To calculate the committed effective dose equivalent from an acute
intake of tritium based on a single urine sample result, proceed as
follows:
1. Calculate the sample concentration, Ct, in dpm/ml.
ml,volumesample
dpm,resultreportedCt = (4.15)
2. Calculate the initial body water concentration, C0, in dpm/ml.
t0693.0
t
0
e
C
C ´-= (4.16)
where t is the time in days between the intake and the collection of
the urine sample.
3. Calculate the committed effective dose equivalent, HE, in mrem.
0E C0013.0H ´= (4.17)
4.4.2 Dose Assessment for Chronic Exposure
To calculate the committed effective dose equivalent from a chronic
exposure to tritium (assuming the equilibrium condition), proceed as
follows:
1. Calculate the body water equilibrium concentration, Ceq, in
dpm/ml.
)ml(volumesample
)dpm(resultreportedCeq = (4.18)
2. Calculate the committed effective dose equivalent, HE, in mrem,
for the interval of the exposure (t, in days).
( )[ ] eq5E C0013.0t107.8H ´+´´= - (4.19)
4.4.3 Dose Assessment for Periodic Samples
In situations where periodic samples are obtained, not associated
with specifically identified intakes but rather with ongoing work
practices, an average concentration and dose associated with a
sampling interval can be calculated.  The choice of an arithmetic
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mean versus a logarithmic mean has little impact on the dose
estimates for intervals of 1 month or less (La Bone 1992).  The dose
for each sampling interval can be calculated using Equations (4.11)
and (4.12), and the total dose for multiple intervals (e.g., for a year)
can be calculated by summing the interval doses for the total period.
This approach lends itself well to a simple computer spreadsheet
application software, which the HIDP typically uses for these cases.
4.5 Management of Internal Contamination Cases
The primary treatment for reducing internal dose from a tritium
uptake is to accelerate the turnover of body water.  This can be done
by substantially increasing the fluid intake rate of an individual
through oral or intravenous means, and/or using diuretics
(Bhattacharyya et al. 1992; NCRP 1980; IAEA 1978).  A case study
by Lloyd et al. (1986) of therapy for two HTO intakes indicated that
diuresis therapy while hospitalized resulted in a 2.7-day clearance
half-time, compared with a 10-day normal clearance half-time, and a
sustained drinking regime gave a clearance half-time of about 6 days.
Dose-mitigating actions should be recommended by the
Occupational Medicine Department of the Hanford Environmental
Health Foundation (HEHF) in consultation with Internal Dosimetry.
4.6 Tritium Monitoring Program for the 400 Area
The 400 Area of Hanford Site, which includes the Fast Flux Test
Facility (FFTF), obtains its drinking water from groundwater wells.
Some of these wells contain low levels of tritium (below the EPA
drinking water standards) originating from aquifer contamination by
the past operation of 200 Area fuel processing and waste manage-
ment facilities (Jaquish and Bryce 1989).  Planned operations
supporting fusion materials research were expected to produce large
quantities of tritium, resulting in the need for a routine tritium
bioassay program.  In FFTF workers, the existence of potentially
detectable tritium, which could be attributable to environmental
sources rather than occupational exposure, warranted establishing a
screening level to use as a basis for initiating investigations and dose
assessments of potential occupational exposure.
A baseline bioassay monitoring program was undertaken for FFTF
workers prior to the commencement of the tritium operations
(Carbaugh, Sula, and McFadden 1990).  Forty-seven urine samples
were collected from FFTF operations personnel over a 5-month
period in early 1989.  The sample data are plotted in Figure 4.3.
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Figure 4.3.  Tritium Urine Concentration in Occupationally Unexposed FFTF Workers
Based on the curve fit, it was estimated that the geometric mean was
3 dpm/ml and the tritium concentration corresponding to the
99.9 percentile for environmental exposure at FFTF was 40 dpm/ml.
This concentration is similar to the present 20,000 pCi/l (44 dpm/ml)
EPA Drinking Water Standard for tritium (EPA 1976).
The minimum detectable committed effective dose equivalent
associated with a 40-dpm/ml tritium screening level was estimated to
be 1.2 mrem for chronic equilibrium exposure conditions, 5 mrem
for acute intakes with weekly to monthly sample intervals (the
anticipated range of sampling intervals), and 100 mrem for quarterly
intervals.
Because of the low dose potentially associated with chronic exposure
or anticipated sampling intervals, use of the 99.9 percentile is
justifiable on a cost-benefit basis.  Thus, 40 dpm/ml was selected as
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a baseline level for tritium in 400 Area workers.  Results below
40 dpm/ml are considered normal for persons working in the
400 Area.  Results in excess of 40 dpm/ml indicate potential
occupational exposure.
4.7 Organically Bound Tritium
While this chapter was being written a DOE work group was
studying the issue of special tritium compounds (STCs), including
organically bound tritium (OBT).  The HIDP should be contacted for
the status of this work and any recommendations associated with
monitoring or dosimetry for OBT.  Hanford facilities have not
specifically identified sources of OBT.  It is anticipated that OBT
can be found in ingested foods, machinery oil used in tritium
facilities, in laboratory compounds labeled for research purposes, or
in wastes received from other DOE facilities.  The NCRP has also
addressed the issue of dosimetry for tritium-labeled organic
compounds incorporated into genetic material in NCRP 63 (NCRP
1979b).  The following paragraphs provide a current summary of
work in progress.
In its publication 56 (1989), the ICRP recommended a f1 factor of 1.0
for GI tract absorption to blood for OBT, and proposed a
two-component retention model for OBT.  The OBT model
suggested that 50% of the OBT would be associated with body water
and demonstrate the tritiated water half-time of 10 days.  The
remaining 50% would be associated with carbon-hydrogen bonding
in tissues and would demonstrate a metabolic turnover rate similar to
carbon (biological half-time of 40 days).  The formulation of the
retention function is as follows:
40
t693.0
10
t693.0
e5.0e5.0)t(R
--
+= (4.20)
with t in days.
Equilibrium between body water (e.g., urine) and OBT is not an
appropriate assumption because of the substantial fraction bound to
organic molecules.  Thus, daily urinary excretion of OBT must be
considered for bioassay interpretation.
The effective dose coefficients, e(50), for OBT, as tabulated by ICRP
in publications 67 (1993), 68 (1994), 71 (1995), and 78 (1997) are as
follows:
Inhalation e(50) 4.1E-11 Sv/Bq
Ingestion e(50) 4.2E-11 Sv/Bq
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The DOE (1999) has established a radiological control technical
position for OBT.  In that position it was stated that the dose
conversion factors of ICRP 71 for OBT provide an acceptable basis
for determining air concentration values for meeting workplace
controls and demonstrating compliance with dose limits.  The
inhalation air concentration value of 1E-5 mCi/ml or 4E+5 Bq/m3
may be used in a manner similar to a DAC.
4.8 Tritiated Particulate Aerosols
While this chapter was being written, a DOE working group was
studying the issue of STCs, including tritiated particulate aerosols.
The HIDP should be contacted for the status of this work and any
recommendations associated with monitoring or dosimetry for
tritiated particulates.  The following paragraphs provide a current
summary of work in progress.
Tritiated particulate aerosols result from tritium being absorbed and
retained on metal surfaces such as getters for tritium collection and
storage devices (typically these are in the form of metal tritides) and
as a residual contaminant in tritium production facilities.  An
additional possibility for tritiated particulates is tritiated metal oxides
(e.g., rust and dust).  At Hanford, a limited source of zirconium
tritide metal filings has been identified in the 325 Building.
Data available to the DOE STC Working Group suggest that
solubility in lung fluid could vary over 5 orders of magnitude,
making urine bioassay for the more insoluble forms highly
ineffective.  The ICRP has noted in publication 71 that titanium
tritide powder demonstrated absorption type M characteristics and
provided f1 values and effective dose coefficients for absorption
types F, M, and S.  The desirability of a fecal analysis procedure for
tritiated particulates has been identified but such a procedure does
not presently exist.  The DOE Mound Laboratory is using air
sampling (including lapel samplers) to measure worker exposure to
air concentrations and calculating internal dose from air
concentration and exposure time data.
As interim guidance, the DOE has established a technical position
(1999) that the adult effective dose coefficients provided by ICRP
publication 71 for tritium particulate aerosols provide an acceptable
basis for determining air concentration values (corresponding to
DACs), which may be used for meeting the workplace controls.
That position included the statement that the most restrictive forms
of tritiated particulate aerosols (type S) should be used unless
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material-specific parameters are developed and appropriately
reviewed.  Table 4.2 lists the effective dose coefficients and the air
concentration values.
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5.0 Cesium 
 
 
This chapter provides technical information on the sources, 
characteristics, and biokinetics of radiocesium and summarizes the 
technical basis used for its internal dosimetry at Hanford.  Dosimetry 
methods used for radiocesium are based on the concepts of ICRP 30 
(ICRP 1979a), as implemented using the CINDY computer code 
(Strenge et al. 1992).  A summary of 137Cs dosimetric data is 
tabulated in Table 5.1.  Details are provided in the following 
sections. 
 
 Table 5.1.  Summary of 137Cs Hanford Dosimetric Data 
 
Radiological Half-Life 30.0 years  
Inhalation Model Class D—all compounds (ICRP 30, ICRP 54) 
GI Absorption (f1) 1 for all compounds  
Systemic Biokinetic Model Uniform distribution in all body organs and tissues.  
Two component exponential compartment retention. 
 Component Fraction Half-Time
 A 0.1 2 d 
 B 0.9 110 d 
Excretion Fractions Urine 0.80 
Feces 0.20 
Dose (HE,50) Coefficients(a)
1-µm AMAD Inhalation 
5-µm AMAD Inhalation 
Soluble Ingestion 
 
0.032 mrem/nCi and 8.6E-09 Sv/Bq 
0.046 mrem/nCi and 1.2E-08 Sv/Bq 
0.050 mrem/nCi and 1.4E-08 Sv/Bq 
Derived Air Concentration(b) (DAC) 7E-08 µCi/ml and 2E+03 Bq/m3
Annual Limit on Intake 
Inhalation(c) 
Soluble Ingestion(d)
 
168 µCi and 4.8 MBq 
100 µCi and 4 MBq 
(a) Calculated using CINDY and ICRP 30 methods for Reference Man. 
(b) From 10 CFR 835 Appendix B, stochastic limit-based, class D, 1-µm AMAD. 
(c) Calculated as 10 CFR 835 DAC x 2400 m3. 
(d) From EPA Federal Guidance Report No. 11 (EPA 1988). 
 
5.1 Sources and Characteristics of Radiocesium 
 
The most important radionuclide of cesium at Hanford from an 
internal exposure standpoint is 137Cs (T1/2 = 30.0 y), a fission 
product.  Historically, 134Cs (T1/2 = 2.1 y, produced by neutron 
activation of stable 133Cs) was observed at activities on the order of 
less than 5% of the 137Cs activity during Hanford production 
operations.  However, with the lack of production by new sources at  
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Hanford and the normal radiological decay process, 134Cs is no 
longer a significant nuclide in Hanford fission product or waste 
mixtures.  Further discussion for this technical basis is limited to 
137Cs. 
 
Because of its relatively high fission yield and its long half-life, 
137Cs, along with 90Sr, is one of the most abundant radionuclides in 
aged fission product mixtures.  More volatile than most of the 
longer-lived fission product radionuclides, cesium is more apt to 
escape containment or confinement and is commonly the most 
abundant radionuclide found in fission product releases within a 
facility.  As discussed later, 137Cs is easily detected using in vivo 
bioassay techniques and can serve as a good indicator radionuclide 
for intakes of fission products, waste mixtures, and spent fuel. 
 
In addition to its presence in mixtures, 137Cs has existed in relatively 
pure form at the Waste Fractionation Facility (B-Plant, 221-B) and 
the Waste Encapsulation and Storage Facility (WESF, 225-B).  
Encapsulation programs at WESF have been terminated; however, 
cesium-bearing capsules and cesium-contaminated equipment are 
stored in the facility. 
 
Cesium has been found to be more dispersible than strontium, and 
therefore in most intake situations involving 137Cs and 90Sr, 137Cs will 
likely constitute the major component of intake.  In cases where it is 
suspected that 90Sr or other radionuclides may be present along with 
137Cs but no radionuclide ratio information exists, it is prudent to 
consider additional bioassay appropriate for the other radionuclides 
of concern. 
 
5.2 Environmental Levels of 137Cs 
 
Cesium-137 is present throughout the world environment as a result 
of atmospheric testing of nuclear weapons and releases from the 
1986 Chornobyl nuclear accident in Ukraine.  Elevated levels of 
137Cs in caribou and reindeer have long been recognized as 
contributing to detectable levels in people who consume such meats, 
and fish have also been identified as concentrators of environmental 
cesium (NCRP 1977).  Following the Chornobyl accident, whole 
body activity levels of 137Cs in humans were widely reported in the 
literature (e.g., Tarroni et al. 1990; Strand et al. 1989; Lloyd 1990; 
and Kang 1989).  Generally these levels were in the range of a few 
nanocuries, although Strand et al. indicated microcurie quantities in 
Lapps who breed reindeer. 
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Potential transfer of radioactivity through the food chain received 
world-wide attention following the Chornobyl accident.  In 1989 the 
joint World Health Organization (WHO)/Food and Agriculture 
Organization (FAO) established a guideline level of 1000 Bq/kg 
(27 nCi/kg) for cesium contamination in foods moving in 
international trade (WHO 1989).  As summarized by Woodman and 
Nisbet (1999), the European Union has established additional 
intervention levels for cesium marketed in human foodstuffs and 
animal feeds. 
 
Mushrooms can also be a potentially significant source of 
radiocesium intake.  The radiocesium content of mushrooms depends 
on the species, locality of growth, and radiocesium in the local soil.  
Nakajima et al. (1998) reported levels of 3 to 18 nCi/g in mushrooms 
grown in the contaminated areas near Chornobyl.  Mushrooms 
imported to France from Austria were removed from the retail 
market in 1998 after levels as high as 135 nCi/kg were discovered. 
 
The possible existence of 137Cs at the foregoing levels complicates 
interpretation of the source of low-level cesium that might be 
detected in routine whole body examinations.  An attempt should be 
made to ascertain whether the detected levels are most likely of 
occupational or environmental origin:  if occupational, then dose 
assessment may be warranted; if environmental, then occupational 
dose assessment is not warranted. 
 
For workers who regularly consume large wild game, it might be 
reasonable to conclude that a few nanocuries of 137Cs may represent 
nonoccupational intake.  This can be further investigated if samples 
of meat can be obtained for direct assessment.  However, even then 
conclusions may be tenuous because only limited data are available 
regarding expected variation throughout the Pacific Northwest.  
These data, obtained by counting meat samples provided by Hanford 
workers showing detectable levels of 137Cs in their periodic whole 
body exams, indicate over 3 orders of magnitude of variability 
(MacLellan et al. 1993). 
 
Likewise, for a worker who has spent time in a location known to be 
potentially affected by elevated cesium levels (e.g., Ukraine, Europe, 
Scandinavian countries, or Russia), it may also be reasonable to 
assume environmental exposure.  Such exposure would probably 
result from consumption of locally obtained meat, dairy products, or 
produce.  Consideration should be given to the location where one 
was exposed, length of time there, food consumption, and elapsed 
time since exposure in determining the likelihood that environmental 
sources were responsible for cesium intake. 
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5.3 Biokinetic Behavior of Radiocesium 
 
ICRP 30 (1979a) classifies all isotopes of cesium as inhalation 
class D, indicating that inhaled material will be absorbed rapidly 
from the respiratory tract into the circulatory system.  This is 
consistent with observations at Hanford.  From the blood, cesium is 
distributed uniformly in the body with no organ or tissues showing a 
higher concentration than muscle.  For dose assessment purposes, 
cesium is assumed to be completely and rapidly absorbed into 
systemic circulation from both the respiratory tract and the GI tract 
(f1 factor = 1).  The retention of stable cesium is described as two 
compartments, with 10% exhibiting a clearance half-time of 2 days 
and 90% exhibiting a clearance half-time of 110 days.  
Mathematically, the systemic compartment biokinetic model for 
stable cesium is depicted as follows: 
 
 ⎥⎦
⎤⎢⎣
⎡ ×−+⎥⎦
⎤⎢⎣
⎡ ×−=
110
t693.0exp9.0
2
t693.0exp1.0)t(R  (5.1) 
 
where R(t) is the fraction of the initial uptake that is present in the 
body at t days post uptake.  This systemic retention function is used 
for Hanford dosimetry unless there are sufficient data on an 
individual to identify an alternate function.  For systemic excretion, 
the ICRP 54 (1988) split of 80% to urine and 20% to feces is used as 
the normal assumption. 
 
The ICRP 30 systemic model is also used in the more recent ICRP 
publications 68 (ICRP 1994a) and 78 (ICRP 1997).  Publication 78 
notes that the biological clearance half-time from the transfer 
compartment to the systemic compartment (i.e., the translocation to 
body tissues) is 0.25 days.  That publication also notes that females 
may exhibit significantly shorter retention half-times in the long-
term compartment than males. 
 
The whole body retention fractions, urine excretion fractions, and 
feces excretion fractions for inhalation of class D particles of 1-µm, 
5-µm AMAD, and for a soluble ingestion intake are shown in 
Tables 5.2, 5.3, and 5.4, respectively. 
 
5.4 Internal Dosimetry for Radiocesium 
 
Internal dosimetry for 137Cs can be performed using hand 
calculations based on the fundamental principles of time-integrated 
concentration of radioactivity in the body or by using the CINDY 
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Table 5.2.  137Cs Whole Body Retention Fractions 
 
Days Post 
Intake 
1-µm-AMAD 
Class D Inhalation 
5-µm-AMAD 
Class D Inhalation 
Soluble 
Ingestion 
1 0.62 0.89 0.98 
2 0.60 0.86 0.95 
7 0.55 0.79 0.87 
14 0.52 0.75 0.83 
30 0.47 0.68 0.75 
60 0.39 0.56 0.62 
90 0.32 0.46 0.51 
180 0.18 0.26 0.29 
365 0.056 0.080 0.088 
730 0.0055 0.0079 0.0087 
1825 5.1E-06 7.4E-06 8.1E-06 
 
Table 5.3.  137Cs Urine Excretion Fractions 
 
Days Post 
Intake 
1-µm-AMAD 
Class D Inhalation 
5-µm-AMAD 
Class D Inhalation 
Soluble 
Ingestion 
1 1.3E-02 2.1E-02 2.5E-02 
2 1.3E-02 1.8E-02 2.0E-02 
7 4.8E-03 6.6E-03 7.2E-03 
14 2.8E-03 4.0E-03 4.4E-03 
30 2.4E-03 3.4E-03 3.8E-03 
60 2.0E-03 2.8E-03 3.1E-03 
90 1.6E-03 2.3E-03 2.6E-03 
180 9.1E-04 1.3E-03 1.4E-03 
365 2.8E-04 4.0E-04 4.5E-04 
730 2.8E-05 4.0E-05 4.4E-05 
1825 2.6E-08 3.7E-08 4.1E-08 
 
Table 5.4.  137Cs Feces Excretion Fractions 
 
Days Post 
Intake 
1-µm-AMAD 
Class D Inhalation 
5-µm-AMAD 
Class D Inhalation 
Soluble 
Ingestion 
1 3.2E-03 5.4E-03 6.2E-03 
2 3.2E-03 4.6E-03 5.1E-03 
7 1.2E-03 1.7E-03 1.8E-03 
14 7.0E-04 1.0E-03 1.1E-03 
30 5.9E-04 8.5E-04 9.4E-04 
60 4.9E-04 7.1E-04 7.8E-04 
90 4.0E-04 5.8E-04 6.4E-04 
180 2.3E-04 3.3E-04 3.6E-04 
365 7.0E-05 1.0E-04 1.1E-04 
730 6.9E-06 9.9E-06 1.1E-05 
1825 6.5E-09 9.3E-09 1.0E-08 
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computer code as an implementation of the ICRP 30 methodology.  
Similar approaches can be used for 134Cs, if dosimetry for that 
radionuclide is required. 
 
5.4.1 Fundamental Principles Method 
 
Because cesium is assumed to be distributed evenly throughout all 
tissues in the body, the stochastic dose equivalent (effective dose 
equivalent) is limiting for compliance purposes.  Dose conversion 
factors for the radiocesiums were developed by Snyder et al., and 
published in ORNL-5000 (1974).  These factors include the “total 
body dose” from activity deposited in the total body.  Dosimetrically, 
this represents the most straightforward and technically appropriate 
way to express the total dose equivalent to the body when a 
radionuclide is uniformly distributed.  The effective dose equivalent 
is derived from the “total body dose” by using a weighting factor of 
1.0 for the total body as an organ.  That is, the effective dose 
equivalent is equal to the “total body dose.”  The total body dose 
conversion factors (DCFs) from ORNL-5000, are as follows: 
 
DCF(134Cs) = 5.1 E-7 rem/nCi-day 
 
DCF(137Cs) = 3.2 E-7 rem/nCi-day. 
 
Because cesium distributes relatively uniformly in the body, the dose 
received by individual organs and tissues is about the same as the 
total body dose.  Thus, the dose received by specific organs and 
tissues can be assumed to be equivalent to the total body dose 
equivalent. 
 
Integrating the retention function (Equation 5.1) with respect to time 
and multiplying by the initial systemic uptake (Uo) yields the 
cumulated internal activity in activity-days (e.g., nCi-days).  
Multiplying this product by the DCF gives the effective dose 
equivalent over the time period of interest as follows: 
 
⎥⎥⎦
⎤
⎢⎢⎣
⎡
λ×+λ××=
×λ−−×λ−−
2eff
texp1
1eff
texp1
0t,E
2eff1eff
9.01.0UxDCFH (5.2) 
 
where t = days post uptake 
 λeff1 for both 134Cs and 137Cs = 0.35/day 
 λeff2 (134) = 0.0072/day 
 λeff2 (137) = 0.0064/day 
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The λeff values provided above are based on ICRP recommendations.  
However, for retrospective dose assessments, λeff values may be 
empirically determined from whole body counts. 
 
Equations 5.1 and 5.2 are specifically for the calculation of an 
internal dose equivalent following an acute uptake.  In actuality, most 
uptakes occur following inhalation of airborne contamination and 
deposition in the lung precedes systemic uptake.  Nevertheless, for 
exposures to readily transportable forms of cesium (class D), the 
dose received by the lung is negligible in comparison with the total 
body dose and can generally be ignored for dose assessment 
purposes.  The exception to this is cases where actual retention in the 
respiratory tract exceeds a few days.  In these situations, and as a 
general application, the CINDY computer code includes the lung in 
the effective dose equivalent. 
 
5.4.2 Intake-Based Dosimetry Using the ICRP System and the CINDY Computer Code 
 
In contrast to the “total body dose” approach described in the 
preceding section, the effective dose equivalents for radiocesiums 
published in the supplement to ICRP 30 (1979b) are based on the 
summing of weighted doses to specific organs meeting the ICRP 
criteria for inclusion in the effective dose equivalent (Watson and 
Ford 1980).  Dose factors calculated in this way are slightly higher 
(about 10%) than those obtained using the total body dose approach, 
and this difference is attributed to conventions used by the ICRP 
rather than to technical merit. 
 
The computer code CINDY (Strenge et al. 1992) is used for most 
internal dose calculations at Hanford.  The code employs ICRP 30 
methods, biokinetic models, and specific effective energies for 
radiocesiums.  When bioassay data are available, CINDY calculates 
intake based on the bioassay data and the biokinetic models 
specified.  To obtain internal doses, CINDY calculates the integrated 
retention for the interval of interest (e.g., 50 years), and then applies 
the SEE factors to give committed organ and tissue dose equivalents.  
The weighted organ and tissue doses are summed to give effective 
dose.  Thus, as noted in the previous paragraph, the doses calculated 
by CINDY for radiocesium intakes are slightly higher than those that 
might be calculated using the “total body” approach.  For a 1-nCi 
intake of 137Cs, CINDY calculates the following dose coefficients: 
 
 Class D inhalation 5-µm-AMAD particles: 0.046 mrem/nCi 
 Class D inhalation 1-µm-AMAD particles: 0.032 mrem/nCi 
 Soluble ingestion: 0.050 mrem/nCi 
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Derived reporting, investigation, and compliance levels (based on HE, 
50 of 10 mrem, 100 mrem, and 5,000 mrem, respectively) have been 
calculated for 1-µm and 5-µm particle sizes.  The derived levels for 
whole body retention (as might be measured by whole body 
counting) are shown in Tables 5.5 and 5.6, and the derived levels for 
daily urine excretion are shown in Tables 5.7 and 5.8. 
 
Table 5.5.  137Cs Whole Body Reference Levels for 1-µm-AMAD Class D Inhalation 
 
  10-mrem HE,50 
Reporting Level 
100-mrem HE,50 
Investigation Level
5-rem HE,50 
Compliance Level 
Inhalation Intake (nCi)  313 3,130 156,000 
Days Post Intake 
Whole 
Body 
IRF(t) 
Derived Reporting 
Level (nCi) 
Derived 
Investigation Level 
(nCi) 
Derived 
Compliance Level 
(nCi) 
1 0.62 194 1,940 96,900 
2 0.60 188 1,980 93,700 
7 0.55 172 1,720 85,900 
14 0.52 163 1,630 81,200 
30 0.47 147 1,470 73,400 
60 0.39 122 1,220 60,900 
90 0.32 100 1,000 50,000 
180 0.18 56.3 563 28,100 
365 0.056 17.5 175 8,750 
730 0.0055 1.72 17.2 859 
1825 5.1E-06 0.00160 0.0160 0.797 
 
Table 5.6.  137Cs Whole Body Reference Levels for 5-µm-AMAD Class D Inhalation 
 
  10-mrem HE,50 
Reporting Level 
100-mrem HE,50 
Investigation Level
5-rem HE,50  
Compliance Level 
Inhalation Intake (nCi)  217 2,170 109,000 
Days Post Intake 
Whole 
Body 
IRF(t) 
Derived Reporting 
Level (nCi) 
Derived 
Investigation Level 
(nCi) 
Derived 
Compliance Level 
(nCi) 
1 0.89 193 1,930 96,700 
2 0.86 187 1,870 93,500 
7 0.79 172 1,720 85,900 
14 0.75 163 1,630 81,500 
30 0.68 148 1,480 73,900 
60 0.56 122 1,220 60,900 
90 0.46 100 1,000 50,000 
180 0.26 56.5 565 28,300 
365 0.080 17.4 174 8,700 
730 0.0079 1.72 17.2 859 
1825 7.4E-06 0.00160 0.0160 0.804 
 
 
PNNL-MA-860 Chapter 5.0  Issued:  January 31, 2003 
Page 5.8 
Table 5.7.  137Cs Urine Excretion Reference Levels for 1-µm-AMAD Particles 
 
  10-mrem HE,50 
Reporting Level 
100-mrem HE,50 
Investigation Level
5-rem HE,50 
Compliance Level 
Inhalation Intake (nCi)  313 3,130 156,000 
Days Post Intake 
Urine 
IRF(t) 
Derived Reporting 
Level (dpm) 
Derived 
Investigation Level 
(dpm) 
Derived 
Compliance Level 
(dpm) 
1 1.3E-02 9,020 90,200 4,510,000 
2 1.3E-02 9,020 90,200 4,510,000 
7 4.8E-03 3,330 33,300 1,670,000 
14 2.8E-03 1,940 19,400 971,000 
30 2.4E-03 1,670 16,700 832,000 
60 2.0E-03 1,390 13,900 694,000 
90 1.6E-03 1,110 11,100 555,000 
180 9.1E-04 631 6,310 316,000 
365 2.8E-04 194 1,940 97,100 
730 2.8E-05 19 194 9,710 
1825 2.6E-08 0.02 0.18 9.02 
 
Table 5.8.  137Cs Urine Excretion Reference Levels for 5-µm-AMAD Particles 
 
  10-mrem HE,50 
Reporting Level 
100-mrem HE,50 
Investigation Level
5-rem HE,50  
Compliance Level 
Inhalation Intake (nCi)  217 2,170 109,000 
Days Post Intake 
Urine 
IRF(t) 
Derived Reporting 
Level (dpm) 
Derived 
Investigation 
Level (dpm) 
Derived 
Compliance Level 
(dpm) 
1 2.1E-02 10,100 101,000 5,070,000 
2 1.8E-02 8,690 86,900 4,340,000 
7 6.6E-03 3,190 31,900 1,590,000 
14 4.0E-03 1,930 19,300 965,000 
30 3.4E-03 1,640 16,400 820,000 
60 2.8E-03 1,350 13,500 676,000 
90 2.3E-03 1,110 11,100 555,000 
180 1.3E-03 627 6,270 314,000 
365 4.0E-04 193 1,930 96,500 
730 4.0E-05 19.3 193 9,650 
1825 3.7E-08 0.02 0.18 8.9 
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5.4.3 Comparison of Dosimetric Factors 
 
The HIDP uses the dose factors of CINDY as the basis for most 
internal dosimetry applications.  However, it is recognized that 
compilations of dosimetric factors have been made by various 
scientific and governmental bodies, based on different calculational 
methods or models.  The dose coefficient for unit intake, DAC, and 
ALI calculated using CINDY, and as tabulated by DOE in 10 CFR 
835, Appendix A (DOE 1998), the ICRP in publication 54 (ICRP 
1988), the EPA in Federal Guidance Report No. 11 (EPA 1988), and 
the ICRP in publication 68 (ICRP 1994a) are shown in Table 5.9.  
Generally speaking, the differences in these tabulated values (with 
the exception of ICRP 68 inhalation values) are not significant and 
can be attributed to slightly different computer code algorithms and 
rounding practices.  The ICRP 68 inhalation values, based on the 
ICRP 66 lung model (ICRP 1994b) and different organ/tissue 
weighting factors, are approximately a factor of 2 lower than those 
calculated using the ICRP 30 model.  These values are tabulated for 
information and as a simple reference for the potential impact of 
dosimetry under different systems. 
 
5.5 Bioassay for Radiocesium 
 
The bioassay techniques, the recommended routine program, and the 
measurements required for monitoring radiocesium after an acute 
intake are discussed in the following sections. 
 
5.5.1 Bioassay Method 
 
The presence of 137Cs is detected by gamma spectroscopy using the 
0.661-MeV photon of 137mBa, which is the short half-life (T1/2  = 
2.5 min) progeny that exists in secular equilibrium with 137Cs.  
Gamma spectroscopy can be either for in vivo measurements or for 
excreta analysis.  In vivo whole body counting is the preferred 
method for 137Cs bioassay, due to its simplicity.  Urine sample 
gamma spectroscopy can also be highly effective if in vivo 
measurements cannot be readily obtained.  Fecal sampling is not 
normally recommended due to the high absorption (theoretically, 
100%) in the GI tract.  (An exception might occur if a person was 
being treated with Prussian blue, whereby fecal results would aid in 
determining efficacy of the treatment.) 
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Table 5.9.  Comparison of 137Cs Dosimetric Factors 
 
Reference Source 
Class D Inhalation 
1-µm AMAD 
Class D Inhalation 
5-µm AMAD Soluble Ingestion 
Dose Coefficients    
CINDY (HE,50) 0.032 mrem/nCi 
8.6E-09 Sv/Bq 
0.046 mrem/nCi 
1.2E-08 Sv/Bq 
0.050 mrem/nCi 
1.4E-08Sv/Bq 
    
ICRP 54 (HE,50) 8.7E-09 Sv/Bq 
(0.0322 mrem/nCi) 
NA NA 
    
EPA Federal 
Guidance Report 
No.11 (HE,50) 
8.63E-09 Sv/Bq and 
0.0319 mrem/nCi 
NA 1.35E-08 Sv/Bq and 
0.050 mrem/nCi 
    
ICRP 68 [e(50)] 4.8E-09 Sv/Bq 
(0.0178 mrem/nCi) 
6.7E-09 Sv/Bq 
(0.0248 mrem/nCi) 
1.3E-08 Sv/Bq 
(0.0481 mrem/nCi) 
    
Stochastic DAC    
    
10 CFR 835, App. A 7E-08 µCi/ml and 
2E+03 Bq/m3
NA NA 
    
EPA Federal 
Guidance Report 
No. 11 
6E-08 µCi/ml and 
2E-03 MBq/m3
NA NA 
    
ICRP 30, ICRP 54 2E+03 Bq/m3 NA NA 
    
Annual Limit on 
Intake, ALI 
   
    
Calculated from 
10 CFR 835 DAC  
168 µCi and  
4.8 MBq 
NA NA 
    
ICRP 30 6 MBq NA 4 MBq 
    
EPA Federal 
Guidance Report 
No. 11 
6 MBq and 200 µCi NA 4 MBq and 100 µCi 
NA = not applicable. 
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5.5.2 In Vivo Measurements 
 
Hanford whole body counting using a 3-minute count on the 5-NaI 
detector preview counter currently provides an MDA of 1.3 nCi 137Cs 
in the body of a male subject of average size.  A 10-minute count 
using the coaxial germanium scanning detector system gives an 
MDA of about 1.0 nCi.  The associated minimum detectable doses 
for class D inhalation of 1-µm and 5-µm particles are shown in 
Tables 5.10 and 5.11.  Comparing these tables with the derived 
reference levels of Tables 5.12 and 5.13 shows that whole body 
counting provides excellent sensitivity for pure 137Cs.  For the pure 
nuclide, an annual whole body count is appropriate bioassay 
monitoring. 
 
Cesium-137 is also often used as an indicator for other nuclides 
because of its isotopic abundance in Hanford waste mixtures.  For 
such circumstances, 137Cs whole body counting can be used as an 
effective monitor for other nuclides (notably 90Sr and plutonium).  
The dosimetric significance of 137Cs compared with the other 
nuclides is highly variable, depending on the mixture ratios.  
Statements of minimum detectable dose for mixtures are beyond the 
scope of this chapter, and are treated elsewhere in the technical basis 
documentation (see Appendix E of this manual and the exhibits in 
Chapter 5.0 of PNL-MA-552).(a)
 
5.5.3 Excreta Analysis 
 
Urine sample gamma spectroscopy can also be used to detect internal 
radiocesium; however, because of the ease and sensitivity of in vivo 
detection methods, it is not commonly used for Hanford monitoring.  
As shown in the minimum detectable dose compilations of 
Tables 5.14 and 5.15, urinalysis gamma spectrometry can provide 
excellent bioassay monitoring sensitivity.  This sensitivity makes 
offsite urine sample collection a viable alternative for follow-up 
measurement of former workers who left the area without obtaining 
a termination whole body count. 
 
5.5.4 Routine Bioassay Monitoring Protocol 
 
Annual in vivo measurements are recommended for periodic 
retrospective bioassay monitoring of workers potentially exposed to 
mixtures of radionuclides containing radiocesium.  Even though in 
vivo measurement capabilities are sufficiently sensitive for a biennial 
                                                     
(a) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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Table 5.10. Minimum Detectable Intakes and Doses (HE,50) for 
1-µm-AMAD Inhalation Using the NaI Detector System (MDA = 1.3 
nCi) 
 
Days Post Intake 
Whole 
Body 
IRF(t) 
Minimum 
Detectable 
Intake (nCi) 
Minimum 
Detectable 
Dose (mrem) 
1 0.62 2.1 0.07 
2 0.60 2.2 0.07 
7 0.55 2.4 0.08 
14 0.52 2.5 0.08 
30 0.47 2.8 0.09 
60 0.39 3.3 0.11 
90 0.32 4.1 0.13 
180 0.18 7.21 0.23 
365 0.056 23 0.74 
730 0.0055 240 7.6 
1825 5.1E-06 250,000 8,2000 
 
Table 5.11. Minimum Detectable Intakes and Doses (HE,50) for 
5-µm-AMAD Inhalation Using the NaI Detector 
System (MDA = 1.3 nCi) 
 
Days Post Intake 
Whole 
Body 
IRF(t) 
Minimum 
Detectable 
Intake (nCi) 
Minimum 
Detectable 
Dose (mrem) 
1 0.89 1.5 0.07 
2 0.86 1.5 0.07 
7 0.79 1.6 0.08 
14 0.75 1.7 0.08 
30 0.68 1.9 0.09 
60 0.56 2.3 0.11 
90 0.46 2.8 0.13 
180 0.26 5.0 0.23 
365 0.08 16 0.75 
730 0.0079 170 7.6 
1825 7.4E-06 180,000 8,100 
 
 
Issued:  January 31, 2003  PNNL-MA-860 Chapter 5.0 
  Page 5.13 
Table 5.12. Minimum Detectable Intakes and Doses (HE,50) for 
1-µm-AMAD Inhalation Using the Coaxial 
Germanium Detector System (MDA = 1.0 nCi) 
 
Days Post Intake 
Whole 
Body 
IRF(t) 
Minimum 
Detectable 
Intake (nCi) 
Minimum 
Detectable 
Dose (mrem) 
1 0.62 1.6 0.05 
2 0.60 1.7 0.05 
7 0.55 1.8 0.06 
14 0.52 1.9 0.06 
30 0.47 2.1 0.07 
60 0.39 2.6 0.08 
90 0.32 3.1 0.10 
180 0.18 5.6 0.18 
365 0.056 18 0.57 
730 0.0055 180 5.8 
1825 5.1E-06 200,000 6,300 
 
Table 5.13. Minimum Detectable Intakes and Doses (HE,50) for 
5-µm-AMAD Inhalation Using the Coaxial 
Germanium Detector System (MDA = 1.0 nCi) 
 
Days Post Intake 
Whole 
Body 
IRF(t) 
Minimum 
Detectable 
Intake (nCi) 
Minimum 
Detectable 
Dose (mrem) 
1 0.89 1.1 0.05 
2 0.86 1.2 0.05 
7 0.79 1.3 0.06 
14 0.75 1.3 0.06 
30 0.68 1.5 0.07 
60 0.56 1.8 0.08 
90 0.46 2.2 0.10 
180 0.26 3.8 0.18 
365 0.08 13 0.58 
730 0.0079 130 5.8 
1825 7.4E-06 140,000 6,200 
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Table 5.14. Minimum Detectable Intakes and Doses (HE,50) for 
1-µm-AMAD Inhalation Using Urinalysis Gamma 
Spectrometry (MDA = 15 dpm/1) 
 
Days Post Intake 
Urine 
IRF(t) 
Minimum 
Detectable 
Intake (nCi) 
Minimum 
Detectable 
Dose (mrem) 
1 1.3E-02 0.7 0.02 
2 1.3E-02 0.7 0.02 
7 4.8E-03 2.0 0.06 
14 2.8E-03 3.4 0.11 
30 2.4E-03 3.9 0.13 
60 2.0E-03 4.7 0.15 
90 1.6E-03 5.9 0.19 
180 9.1E-04 10.4 0.33 
365 2.8E-04 34 1.08 
730 2.8E-05 338 10.8 
1825 2.6E-08 364,000 11,600 
 
Table 5.15. Minimum Detectable Intakes and Doses (HE,50) for 
5-µm-AMAD Inhalation Using Urinalysis Gamma 
Spectrometry (MDA = 15 dpm/1) 
 
Days Post Intake 
Urine 
IRF(t) 
Minimum 
Detectable 
Intake (nCi) 
Minimum 
Detectable 
Dose (mrem) 
1 2.1E-02 0.5 0.02 
2 1.8E-02 0.5 0.02 
7 6.6E-03 1.4 0.07 
14 4.0E-03 2.4 0.11 
30 3.4E-03 2.8 0.13 
60 2.8E-03 3.4 0.16 
90 2.3E-03 4.1 0.19 
180 1.3E-03 7 0.33 
365 4.0E-04 24 1.1 
730 4.0E-05 236 11 
1825 3.7E-08 256,000 11,800 
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frequency, the longer time between measurements makes 
investigation of potential exposures more difficult, and thus a 
minimum annual frequency is recommended. 
 
If radiocesium is detected through a routine measurement, then 
follow-up measurements to confirm the initial indication should 
generally be performed.  Follow-up measurements can usually be 
most conveniently performed immediately following the initial 
measurement, while the subject is at the In Vivo Radioassay and 
Research Facility (IVRRF).  Follow-up measurements should be 
performed as promptly as practical following an indication of an 
intake in order to facilitate any health physics investigation 
associated with the potential exposures.  However, because of the 
high sensitivity of the in vivo measurement, verification measure-
ments for cesium are not appreciably affected by delays of a few 
days to a month in obtaining them. 
 
Follow-up in vivo measurements using high-resolution germanium 
detectors are preferred for identifying other radionuclides possibly 
associated with the exposure, to discriminate against interference 
from radon progeny, and because the germanium detectors provide a 
more precise and accurate measurement.  In addition to follow-up in 
vivo measurements, special bioassay should be considered for other 
significant nuclides (e.g., 90Sr or plutonium urinalysis, plutonium 
fecal analysis), if 137Cs is a mixture indicator nuclide. 
 
5.5.5 Bioassay Measurements Following an Acute Intake 
 
An in vivo examination should be performed after any indication of 
an intake of radiocesium.  Unless the exposure appears to be of such 
magnitude that medical treatment to aid its removal is considered, 
the exam may be scheduled as convenient within several days of the 
intake, without significantly compromising the dosimetric sensitivity 
of the measurement.  Appropriate bioassay for all significant 
radionuclides potentially involved in the exposure should be 
considered in the follow-up investigation.  Because of the wide range 
of waste mixtures in Hanford facilities, a standard default mixture is 
no longer used for general internal dosimetry.  In the event of an 
exposure, the composition of the source mixture should be 
determined by appropriate analysis of a representative sample of the 
material, or alternatively, special bioassay for the appropriate specific 
nuclides should be performed. 
 
The interpretation of in vivo measurements performed shortly after 
intake may be complicated by early transport of material through the 
lung and GI tract.  Measurements performed after about 5 days post 
intake are more appropriate for dose evaluation.  For intakes 
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potentially above a 100-mrem committed effective dose equivalent 
(considering all radionuclides contributing), long-term follow-up 
bioassay measurements should be considered to monitor internal 
radioactivity levels and establish individual retention characteristics. 
 
5.6 Assessment of Internal Dose Equivalent 
 
The assessment of the internal dose equivalent from 137Cs is 
normally accomplished by evaluation of in vivo measurement 
results.  Committed dose equivalents are assessed for any confirmed 
internal exposure not attributed to environmental or other 
nonoccupational sources. 
 
Assessed committed effective dose equivalents below 100 mrem may 
be based on a single bioassay measurement and the standard 
biokinetic models described in this chapter.  Assessments of internal 
dose equivalent that potentially exceed a committed effective dose 
equivalent of 100 mrem should be based on observed retention to the 
extent practicable.  The ICRP 30 model for uptake and retention of 
cesium was described previously.  The rapidly clearing compartment 
has little effect on the total dose equivalent received from an intake 
and can be ignored in retrospective dose assessments based on 
observed in vivo retention.  As an alternative approach, default 
biokinetic assumptions about internal deposition and retention of 
cesium can be modified to obtain a better fit between the observed 
retention data and the model.  The modified model can then be used 
to calculate dose equivalents.  CINDY can be used for this intake and 
dose assessment, or if based on limited bioassay data, the tabulated 
values of this chapter can be used in conjunction with the basic 
formulas of Chapter 2.0. 
 
Because cesium distributes relatively uniformly in the body, the dose 
received by individual organs and tissues is about the same as the 
effective dose equivalent.  To simplify the recording of doses to 
specific organs and tissues, the dose to uniformly distributed 
radionuclides is ascribed to a single organ category called “total 
body.”  That is, assessments of exposure to radiocesium will include 
the committed effective dose equivalent, which is equivalent to the 
total body dose equivalent, which, in turn, is equivalent to the dose 
received by any organ.  The “total body” designation thus serves as a 
surrogate for any specific organ or tissue in the body. 
 
5.7 Management of Internal Contamination Cases 
 
Although one of the most abundant radionuclides at Hanford, 
historically 137Cs has not contributed significantly to internal doses.  
Cesium-137 is easily detected by whole body counting and therefore 
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early measurements can result in fairly rapid intake and dose 
assessments.  Primary considerations that might cause some 
difficulty for interpretation of initial in vivo measurements are 
possible external contamination on the subject, the rapid 
translocation and elimination that occurs shortly after intake, and the 
possibility of a nonoccupational source. 
 
Being a major fission product radionuclide, 137Cs is often 
accompanied by other fission product radionuclides.  Thus, 
investigation of internal exposures involving 137Cs should also 
consider that other radionuclides may be involved. 
 
The most effective measure for removal of cesium from the body is 
by oral administration of Prussian blue.  Prussian blue is a drug that 
must be administered by competent medical authorities.  Prussian 
blue is not absorbed from the intestine and it binds the cesium ions 
that are enterically cycled into the GI tract, so that the cesium is not 
reabsorbed.  The treatment can reduce the biological half-life to 
about one-third of its usual value.  The effectiveness of the treatment 
depends on how soon after exposure it is started (NCRP 1980).  
Bhattacharyya et al. (1992) recommended administrations of 3 to 4 g 
of Prussian blue in water orally divided over three doses per day, 
continued for as long as effective.  Significant human experience 
with Prussian blue therapy resulted from the Goiania, Brazil accident 
in which several members of the public incurred very high 137Cs 
intakes when a medical therapy machine was stolen for salvage and 
the source was unknowingly opened (IAEA 1988).  Dunstana et al. 
(1994) reported dose reductions of 51 to 84% based on orally 
administered dosages of Prussian blue from 3 to 10 g/d.  An 
excellent case study of this accident, the associated dosimetry, and 
the medical case management is described by the International 
Atomic Energy Agency (IAEA 1998).  The IAEA report includes a 
large citation of references appropriate for case management. 
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6.0 Strontium 
 
 
This chapter provides technical information on the sources of 
radiostrontium and its characteristics, and summarizes the technical 
basis used for its internal dosimetry at Hanford.  Dosimetry methods 
used are based on the concepts of ICRP 30 (1979), as implemented 
using the CINDY computer code (Strenge et al. 1992).  Because of 
its long radiological half-life, 90Sr (with its secular equilibrium 
progeny 90Y) is now the strontium isotope of significance at Hanford.  
Some information for the short-lived 89Sr is also included here for 
historical purposes.  A summary of the 90Sr dosimetric data is 
tabulated in Table 6.1.  A brief history of the strontium evaluation 
methods used at Hanford is also provided.  Details are provided in 
the following sections. 
 
Table 6.1.  Summary of 90Sr Hanford Dosimetric Data 
 
Systemic Excretion Fractions 
 Urine:      0.8 
 Feces:      0.2 
Chemical Form: All Forms except Sr-Titanate Titanate 
Inhalation Model Class D (default) Class Y 
GI Absorption (f1) 0.3 0.01 
Committed Effective Dose Coefficients
 1-µm AMAD Inhalation 
 5-µm AMAD Inhalation 
 Ingestion 
 Transportable Injection 
 
0.22 mrem/nCi 
0.27 mrem/nCi 
0.13 mrem/nCi (soluble) 
0.41 mrem/nCi 
 
1.3 mrem/nCi 
0.48 mrem/nCi 
0.011 mrem/nCi (insoluble) 
Not applicable 
 
6.1 Sources and Characteristics of Strontium at Hanford 
 
The isotopes of dominant concern for strontium internal dosimetry 
are 90Sr and its decay product 90Y.  These nuclides may be found in 
almost any Hanford facility that deals with fission products or fission 
product waste mixtures.  Most facilities that have strontium may also 
be expected to have other fission products present, notably 137Cs, and 
it is a common practice to use 137Cs as an indicator of potential 90Sr.  
This can be a valid assumption, because both nuclides have 
comparable yields from the fissioning of 235U (see Table 6.2).  
However, it must be noted that some Hanford chemical processes 
have separated cesium from strontium, and relatively pure 90Sr may 
be associated with laboratories, waste separation facilities (notably 
B-Plant, [221-B]) and the Waste Encapsulation and Storage Facility 
(WESF, [225-B Building]), and waste storage tank sludge. 
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Table 6.2.  90Sr Fission Product Yields(a)
 
Fissionable Nuclide FP Mass 90,% FP Mass 137,% 
233U 6.9 6.81 
235U 5.91 6.22 
239Pu 2.11 6.7 
(a) From General Electric Co. (1983) 
 
Thus, caution must be exercised because the 90Sr/137Cs ratio is highly 
variable between and within facilities.  This use of a ratio can be 
valid if the nature of facility contamination is known. 
 
When Hanford reactors were operating, the potential existed for 89Sr 
to also be a concern, most likely at N-Reactor, the fuel storage 
basins, FFTF, or the Plutonium-Uranium Extraction (PUREX) Plant.  
However, the short radiological half-life of 89Sr (50 days) and the 
long time that has elapsed since reactors operated indicates that 89Sr 
is no longer a concern at Hanford, unless a new source (e.g., material 
received from offsite) is established.  The ORIGEN computer code 
(Hedengren 1985) indicated that, for N-Reactor, 6%, Mark IV 
(MKIV) fuel at discharge, there might have been about 90 times as 
much 89Sr as 90Sr.  Exposure to such material would have been more 
limiting in terms of internal dose than exposure to just 90Sr.  But 
because of the rapid decay of 89Sr, within about 6 months 90Sr 
became the dominant isotope of concern.  Less than 1% of the 89Sr 
produced in fuel remained at 1 year after exposure, and, for practical 
purposes, that nuclide ceased to be a dosimetric concern by that time. 
 
Selected decay data for 90Sr, 90Y, and 89Sr are shown in Table 6.3. 
 
Table 6.3.  Decay Data for Strontium Isotopes 
 
Parameter 90Sr 90Y 89Sr 
Half-Life 29.12 y 64.0 h 50.5 d 
Decay Constant 6.5E-05 d-1 0.26 d-1 0.014 d-1
Decay Mode 
Beta 
(no gamma) 
Beta 
(no gamma) 
Beta 
(no gamma) 
 
For most internal dosimetry purposes, 90Sr and 90Y are the nuclides 
of concern.  These nuclides are found in equilibrium in virtually all 
circumstances under which exposure is likely.  Although strontium 
separation operations have been performed in which pure 90Sr might 
be obtained, the rapid ingrowth of the 90Y decay product results in 
the secular equilibrium condition being achieved within about 
2 weeks after separation.  Thus, even if an exposure to pure 90Sr 
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occurred involving significant metabolic uptake and internal 
deposition, within about 2 weeks of exposure equal quantities of both 
nuclides would be present in the body.  Pure 90Y was produced and 
packaged in the 325 Building during the 1990s (through 1999). 
 
6.2 Environmental Levels of 90Sr 
 
Daily dietary intake of 90Sr is estimated to range from 0.1 to 0.4 Bq/d 
(San Francisco to New York) according to the United Nations 
Scientific Committee on the Effects of Atomic Radiation 
(UNSCEAR 1982, p. 231).  Higher intakes of about 8 to 11 pCi/d 
were reported by Stroube, Jeline, and Baratta (1985).  The 
concentration in milk may run from 0.04 to 0.2 Bq/l.  A brief note by 
Irlweck and Streit (1979) indicated that normal background 90Sr in 
urine levels for Austria ranged from 0.2 to 2 pCi/l, which would 
correspond to 0.6 to 6 dpm/day for an ICRP Reference Man 
excretion rate of 1.4 l/d.  These levels were attributed to worldwide 
fallout and natural variability.  They suggested a screening level of 
5 pCi/l (15 dpm/d) as a basis for assuming intake from sources other 
than worldwide fallout.  Correcting these levels for an additional 
20 years of physical radiological decay suggests a current daily 
excretion range of 0.4 to 4 dpm/d with their proposed screening level 
for identifying an unusual intake of 10 dpm/d.  A detailed study of 
background 90Sr in the urine of unexposed Hanford workers is in 
progress. 
 
6.3 Biokinetic Behavior of Radiostrontium 
 
The biokinetic behavior of strontium is a composite of the intake 
mode, the chemical form, the inhalation class, the internal 
distribution and retention, the excretion, and the radiological half-life 
of the strontium isotope.  The basic models used for Hanford internal 
dosimetry are those of ICRP 30, as implemented using CINDY. 
 
6.3.1 Inhalation Class 
All intakes of strontium at Hanford are considered to be inhalation 
class D, in accordance with the recommendations of ICRP 30.  It is 
noted that strontium titanate is the only compound identified by the 
ICRP as belonging to inhalation class Y (Anderson et al. 1999).  
However, that compound of strontium has not been used at Hanford. 
 
Waste management practices involving strontium fluoride (SrF2) are 
of particular interest from an internal dosimetry perspective, because 
SrF2 was not specifically included in the ICRP lung model 
descriptions of strontium compounds.  The waste fractionation 
process separated and purified 90Sr at B-Plant, and then converted it 
into SrF2 powder, which was encapsulated into welded cylinders at 
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WESF.  The cylinders remain stored in a water pool at WESF.  The 
SrF2 powder was selected as the chemical form because of its 
chemical stability and only moderate solubility (i.e., its relative 
insolubility).  This relative insolubility and lack of specific 
discussion in the ICRP lung model might be cause for considering 
SrF2 to be a class W or Y material.  However, this is not thought to 
be the case.  While solubility studies for SrF2 in simulated lung fluid 
have not been identified, SrF2 is only moderately soluble on a large 
scale, having a solubility product of 3.5 × 10-4 mg/l.  A different 
picture emerges upon consideration of the microscopic scale, as 
might be encountered in human intakes.  Because of the very high 
specific activity of 90Sr, dosimetrically significant quantities of SrF2 
powder have extremely small masses that come no where near the 
solubility product and thus are very quickly dissolved in a small 
volume of fluid as might be found in the lung or GI tract.  Hence, 
90SrF2 would be expected to exhibit class D behavior upon intake. 
 
6.3.2 
6.3.3 
Uptake to Blood 
 
The absorption coefficient (f1) used for the GI tract absorption of 
readily transportable (inhalation class D) forms of strontium is 0.3, 
which is consistent with the recommendations of ICRP publications 
30 (1979), 56 (1989), 67 (1993), and 78 (1997).  Those publications 
note that the normal range of the absorption coefficient is 0.15 to 
0.45, and fasting for 24 hours can elevate it to 0.25 to 0.55.  
Suggested values for infants and children (age 1 to 15) are 0.6 and 
0.4, respectively. 
 
Where evaluation of poorly transportable (class Y) forms may be 
required, the ICRP 30 value of 0.01 will be used. 
 
Internal Distribution and Retention 
 
The biokinetic model used for the distribution, retention, and 
excretion of stable strontium is the ICRP alkaline earth model (1973; 
1979) as implemented by the CINDY computer code.  It is assumed 
that stable strontium is uniformly distributed throughout the bone 
volume, where it is retained and internally recycled according to a 
series of exponential terms modeled by Johnson and Myers (1981), 
which show good agreement with the ICRP alkaline earth model. 
 
More recent models for strontium distribution have been developed 
by Leggett, Eckerman, and Williams (1982), Leggett et al. (1984), 
and Leggett (1992) and are featured in ICRP 56, 67, and 78.  These 
models have different formulations that cannot be readily adapted to 
CINDY, and were developed to allow for age-dependent parameters  
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for assessment of doses for age groups ranging from infant to adult.  
The ICRP 30 approach used by CINDY is adequate at this time for 
assessment of occupational exposure to adult workers. 
 
For dosimetry purposes, it is assumed that the intake is the pure 
isotope of 90Sr.  The dose contribution from any 90Y present at the 
time of intake due to equilibrium with the 90Sr parent makes no 
significant difference in the total dose. 
 
6.3.4 Excretion of Strontium 
 
The alkaline earth excretion model assumes that the fraction of 
excreted uptake occurring by the urinary pathway and by the fecal 
pathway is 0.8 and 0.2, respectively.  This is consistent with past 
Hanford practices and the recommendations of ICRP 30, 56, 67, and 
78.  CINDY incorporates this pathway fractionation into its 
algorithms. 
 
Urine sample analysis is the easiest and most common bioassay 
method for both 89Sr and 90Sr, and therefore the urinary excretion 
function becomes the key for internal dosimetry evaluations of 
strontium.  The CINDY 90Sr urinary excretion function is used in this 
technical basis for strontium evaluations.  The CINDY urinary 
excretion function is identical to that of the GENMOD code formerly 
used by the Hanford Internal Dosimetry Program and similar to 
excretion derived from the Dolphin model, which was used prior to 
1989 (Sula, Carbaugh, and Bihl 1989). 
 
Urine and feces excretion fractions, respectively, are shown in 
Tables 6.4 and 6.5 for class D and Y inhalations of 1-µm- and 5-µm-
AMAD particles, soluble ingestion, and transportable injection 
(wound) intakes.  For readily transportable injection intakes (i.e., 
wounds), the total uptake to blood occurs very quickly.  In these 
cases, the calculated intake and uptake are essentially synonymous.  
For a class D inhalation, the only significant difference from a 
transportable injection excretion function is the ratio of total uptake 
to total intake (0.52 for 1-µm, class D particles), where total uptake 
includes the contributions from both the respiratory and GI tracts.  
For class Y material, the uptake to blood occurs over a long period, 
nominally characterized by the clearance rate from the lung.  
Figure 6.1 illustrates the urine excretion fractions for inhalation of 
5-µm class D and class Y particles.  As is apparent in Figure 6.1, 
urinary excretion following an acute class Y intake can be expected 
to be relatively constant from about 50 to 1000 days post intake. 
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Table 6.4.  90Sr Urine Excretion Fractions 
 
Days Post 
Intake 
1-µm-AMAD 
Class D 
Inhalation 
(f1 = 0.3) 
5-µm-AMAD 
Class D 
Inhalation 
(f1 = 0.3) 
Soluble 
Ingestion 
(f1 = 0.3) 
Transportable 
Injection 
(f1 = 0.3) 
1-µm-AMAD 
Class Y 
Inhalation 
(f1 = 0.01) 
5-µm-AMAD 
Class Y 
Inhalation 
(f1 = 0.01) 
1 4.8E-02 5.5E-02 2.6E-02 8.3E-02 8.4E-04 1.7E-03 
2 3.8E-02 4.4E-02 2.0E-02 6.6E-02 6.4E-04 1.2E-03 
7 1.5E-02 1.7E-02 7.9E-03 2.6E-02 2.5E-04 4.7E-04 
14 4.8E-03 5.7E-03 2.6E-03 8.6E-03 9.1E-05 1.6E-04 
30 5.5E-04 6.6E-04 3.0E-04 1.0E-03 2.1E-05 2.2E-05 
60 1.6E-04 1.9E-04 8.9E-05 3.0E-04 1.5E-05 9.3E-06 
90 1.2E-04 1.5E-04 7.1E-05 2.4E-04 1.5E-05 8.4E-06 
180 7.6E-05 9.3E-05 4.3E-05 1.4E-04 1.4E-05 7.0E-06 
365 3.8E-05 4.7E-05 2.2E-05 7.3E-05 1.4E-05 5.9E-06 
730 1.6E-05 2.0E-05 9.4E-06 3.1E-05 1.3E-05 4.9E-06 
1825 5.9E-06 7.3E-06 3.4E-06 1.1E-05 7.5E-06 2.8E-06 
3650 3.1E-06 3.8E-06 1.8E-06 5.8E-06 2.4E-06 9.4E-07 
7300 1.1E-06 1.3E-06 6.2E-07 2.1E-06 3.0E-07 1.3E-07 
18250 1.4E-07 1.7E-07 8.1E-08 2.7E-07 1.8E-08 9.9E-09 
 
Table 6.5.  90Sr Fecal Excretion Fractions 
 
Days Post 
Intake 
1-µm-AMAD 
Class D 
Inhalation 
(f1 = 0.3) 
5-µm-AMAD 
Class D 
Inhalation 
(f1 = 0.3) 
Soluble 
Ingestion 
(f1 = 0.3) 
Transportable 
Injection 
(f1 = 0.3) 
1-µm-AMAD 
Class Y 
Inhalation 
(f1 = 0.01) 
5-µm-AMAD 
Class Y 
Inhalation 
(f1 = 0.01) 
1 6.3E-02 1.4E-01 3.4E-01 2.1E-02 1.3E-01 2.5E-01 
2 4.0E-02 8.4E-02 2.0E-01 1.7E-02 1.5E-01 2.9E-01 
7 3.9E-03 4.9E-03 3.6E-03 6.5E-03 5.4E-03 5.7E-03 
14 1.2E-03 1.4E-03 6.6E-04 2.1E-03 1.9E-04 1.0E-04 
30 1.4E-04 1.6E-04 7.6E-05 2.5E-04 1.4E-04 5.2E-05 
60 3.9E-05 4.8E-05 2.2E-05 7.4E-05 1.4E-04 4.7E-05 
90 3.1E-05 3.8E-05 1.8E-05 5.9E-05 1.2E-04 4.5E-05 
180 1.9E-05 2.3E-05 1.1E-05 3.6E-05 1.1E-04 3.9E-05 
365 9.5E-06 1.2E-05 5.5E-06 1.8E-05 8.4E-05 3.0E-05 
730 4.1E-06 5.1E-06 2.3E-06 7.8E-06 5.1E-05 1.8E-05 
1825 1.5E-06 1.8E-06 8.4E-07 2.8E-06 1.2E-05 4.1E-06 
3650 7.6E-07 9.5E-07 4.4E-07 1.5E-06 1.3E-06 4.8E-07 
7300 2.7E-07 3.3E-07 1.6E-07 5.2E-07 7.8E-08 3.5E-08 
18250 3.5E-08 4.4E-08 2.0E-08 6.7E-08 4.4E-09 2.5E-09 
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Figure 6.1.  90Sr Urine Excretion Following an Acute Inhalation Intake 
 
6.4 Internal Dosimetry Factors for Radiostrontium 
 
The 90Sr committed effective dose equivalent coefficients of greatest 
interest to Hanford internal dosimetry are for intakes of 1-µm- and 
5-µm-AMAD particles.  Values for these coefficients, as calculated 
by CINDY, are as follows: 
 
• Class D inhalation 5-µm-AMAD particles:  0.27 mrem/nCi intake 
• Class D inhalation 1-µm-AMAD particles:  0.22 mrem/nCi intake. 
 
Committed dose coefficients for organs and tissues of significance to 
several different intake conditions are tabulated in Table 6.6.  
Committed dose coefficients for 90Y are approximately 2 to 3 orders 
of magnitude lower than those for 90Sr, hence the existence of 90Y in 
secular equilibrium to 90Sr at the time of intake does not add any 
significant dose to the intake beyond that resulting from the 90Sr. 
 
Selected internal dosimetry factors for 90Sr cited by various scientific 
and regulatory bodies are shown in Table 6.7.  The 1-µm values 
calculated by CINDY using the Hanford parameters are not 
significantly different from those tabulated by ICRP 54 (1988) and 
Federal Guidance Report No. 11 (EPA 1988).  The difference  
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Table 6.6.  Hanford 90Sr Dose Coefficients for Significant Organs (mrem/nCi Intakea, b) 
 
Class D Inhalation Class Y Inhalation 
Organ 1-µm 5-µm 1-µm 5-µm 
Soluble 
Ingestion 
Transportable
Injection 
Effective  0.22 0.27 1.3 0.48 0.13 0.41 
Bone Surfaces 2.4 3.0 [0.23] [0.15] 1.4 4.6 
Red Bone Marrow 1.1 1.3 [0.10] [0.064] 0.61 2.0 
Lung [<0.01] [<0.01] 11 3.8 [<0.01] [<0.01] 
(a) Bracketed values are considered insignificant contributors to effective dose equivalent 
and are shown for information only. 
(b) The values for 90Sr and 90Sr+90Y are not significantly different at the precision shown. 
 
between these values and those of ICRP 68 (1994) is related to 
changes in the ICRP lung model, the new metabolic model, and the 
new organ and tissue weighting factors. 
 
Derived reporting, investigation, and dose limit compliance levels 
(based on committed effective dose equivalents of 10-mrem, 
100-mrem, and 5,000 mrem, respectively) have been calculated for 
1-µm and 5-µm particle sizes.  The derived levels for daily urine 
excretion are shown in Tables 6.8 and 6.9 for inhalation class D, and 
Tables 6.10 and 6.11 for inhalation class Y.  Although there is no 
reason to suspect class Y 90Sr at Hanford, the dose coefficients and 
derived levels are provided for information purposes. 
 
6.5 Bioassay for Radiostrontium 
 
The general techniques and applicability of bioassay for strontium, 
urine and fecal sample bioassay, in vivo measurement of 90Sr, 
bioassay monitoring program capability, a recommended program, 
and special monitoring needs are discussed in the following sections. 
 
Excreta Bioassay Techniques for 90Sr 
 
The standard method of bioassay for strontium is by analysis of urine 
excreta samples.  Because strontium at Hanford is a class D material, 
its rapid transport to the systemic compartment makes urine 
sampling an accurate, reliable, and convenient means for bioassay 
monitoring.  In addition, the lack of any readily detectable gamma 
emissions makes in vivo detection somewhat ineffective, although if 
sufficient strontium is present, the bremsstrahlung can be detected by 
in vivo counting.  Fecal samples can also be analyzed; however, their 
collection is more difficult, and analysis of fecal samples is more 
costly than analysis of urine samples.  Hanford 90Sr urinalysis 
analytical sensitivities prior to 1991 were summarized by Sula,  
6.5.1 
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Carbaugh, and Bihl (1991).  Since 1988, analytical sensitivities have 
been included in the various annual reports on Hanford radiological 
protection site support services (e.g., MacLellan et al. 1999). 
 
 
Table 6.7.  Comparison of Dosimetric Factors for Soluble 90Sr (f1 = 0.3) 
 
Reference Source 
Class D Inhalation 
1-µm AMAD 
Class D Inhalation 
5-µm AMAD Soluble Ingestion 
Dose Coefficients 
CINDY [hE,50] 
0.22 mrem/nCi 
5.8E-08 Sv/Bq 
0.27 mrem/nCi 
7.3E-08 Sv/Bq 
0.13 mrem/nCi 
3.5E-08Sv/Bq 
    
ICRP-54 [hE,50] 
6.2E-08 Sv/Bq 
(0.23 mrem/nCi) NA NA 
    
EPA Federal 
Guidance Report 
No.11 [hE,50] 
6.47E-08 Sv/Bq and 
0.0239 mrem/nCi NA 
3.85E-08 Sv/Bq 
and 0.143 
mrem/nCi 
    
ICRP-68 [e(50)] 
2.4E-08 Sv/Bq 
(0.089 mrem/nCi) 
3.0E-08 Sv/Bq 
(0.11 mrem/nCi) 
2.8E-08 Sv/Bq 
(0.10 mrem/nCi) 
    
Bone Surface DAC 
10 CFR 835, App. A 
8E-09 µCi/ml and 
3E+02 Bq/m3 NA NA 
    
EPA Federal 
Guidance Report 
No. 11 
8E-09 µCi/ml and 
3E-04 MBq/m3 NA NA 
    
ICRP-30, ICRP-54 3E+02 Bq/ m3 NA NA 
    
Annual Limit on Intake, ALI (Bone Surface) 
Calculated from 
10 CFR 835 DAC  
19 µCi and 
7.2E+05 Bq NA NA 
    
ICRP-30 7E+05 Bq NA 1E+06 Bq 
    
EPA Federal 
Guidance Report 
No. 11 0.7 MBq and 20 µCi NA 1 MBq and 30 µCi 
NA = not applicable 
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Table 6.8.  90Sr Urine Excretion Reference Levels for Class D Inhalation of 1-µm-AMAD Particles 
 
10-mrem HE,50 
Reporting Level 
100-mrem HE,50 
Investigation 
Level 
5-rem HE,50 
Compliance Level
Inhalation Intake (nCi) 45.5 455 22,700 
 
Days Post Intake 
Urine Excretion 
Fraction 
(f1 = 0.3) 
Derived 
Reporting Level 
(dpm) 
Derived 
Investigation 
Level (dpm) 
Derived 
Compliance Level 
(dpm) 
1 4.8E-02 4.8E+03 4.8E+04 2.4E+06 
2 3.8E-02 3.8E+03 3.8E+04 1.9E+06 
7 1.5E-02 1.5E+03 1.5E+04 7.6E+05 
14 4.8E-03 4.8E+02 4.8E+03 2.4E+05 
30 5.5E-04 5.6E+01 5.6E+02 2.8E+04 
60 1.6E-04 1.6E+01 1.6E+02 8.1E+03 
90 1.2E-04 1.2E+01 1.2E+02 6.0E+03 
180 7.6E-05 7.7E+00 7.7E+01 3.8E+03 
365 3.8E-05 3.8E+00 3.8E+01 1.9E+03 
730 1.6E-05 1.6E+00 1.6E+01 8.1E+02 
1825 5.9E-06 6.0E-01 6.0E+00 3.0E+02 
3650 3.1E-06 3.1E-01 3.1E+00 1.6E+02 
7300 1.1E-06 1.1E-01 1.1E+00 5.5E+01 
18250 1.4E-07 1.4E-02 1.4E-01 7.1E+00 
 
Table 6.9.  90Sr Urine Excretion Reference Levels for Class D Inhalation of 5-µm-AMAD Particles 
 
10-mrem HE,50 
Reporting Level 
100-mrem HE,50 
Investigation 
Level 
5-rem HE,50 
Compliance Level
Inhalation Intake (nCi) 37 370 18,500 
 
Days Post Intake 
Urine Excretion 
Fraction 
(f1 = 0.3) 
Derived 
Reporting Level 
(dpm) 
Derived 
Investigation 
Level (dpm) 
Derived 
Compliance Level 
(dpm) 
1 5.5E-02 4.5E+03 4.5E+04 2.3E+06 
2 4.4E-02 3.6E+03 3.6E+04 1.8E+06 
7 1.7E-02 1.4E+03 1.4E+04 7.0E+05 
14 5.7E-03 4.7E+02 4.7E+03 2.3E+05 
30 6.6E-04 5.4E+01 5.4E+02 2.7E+04 
60 1.9E-04 1.6E+01 1.6E+02 7.8E+03 
90 1.5E-04 1.2E+01 1.2E+02 6.2E+03 
180 9.3E-05 7.6E+00 7.6E+01 3.8E+03 
365 4.7E-05 3.9E+00 3.9E+01 1.9E+03 
730 2.0E-05 1.6E+00 1.6E+01 8.2E+02 
1825 7.3E-06 6.0E-01 6.0E+00 3.0E+02 
3650 3.8E-06 3.1E-01 3.1E+00 1.6E+02 
7300 1.3E-06 1.1E-01 1.1E+00 5.3E+01 
18250 1.7E-07 1.4E-02 1.4E-01 7.0E+00 
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Table 6.10.  90Sr Urine Excretion Reference Levels for Class Y Inhalation of 1-µm-AMAD Particles 
 
10-mrem 
Reporting Level 
100-mrem 
Investigation 
Level 
5-rem 
Compliance Level
Inhalation Intake (nCi) 7.69 76.9 3,850 
 
Days Post Intake 
Urine Excretion 
Fraction 
(f1 = 0.01) 
Derived 
Reporting Level 
(dpm) 
Derived 
Investigation 
Level (dpm) 
Derived 
Compliance Level 
(dpm) 
1 8.4E-04 1.4E+01 1.4E+02 7.2E+03 
2 6.4E-04 1.1E+01 1.1E+02 5.5E+03 
7 2.5E-04 4.3E+00 4.3E+01 2.1E+03 
14 9.1E-05 1.6E+00 1.6E+01 7.8E+02 
30 2.1E-05 3.6E-01 3.6E+00 1.8E+02 
60 1.5E-05 2.6E-01 2.6E+00 1.3E+02 
90 1.5E-05 2.6E-01 2.6E+00 1.3E+02 
180 1.4E-05 2.4E-01 2.4E+00 1.2E+02 
365 1.4E-05 2.4E-01 2.4E+00 1.2E+02 
730 1.3E-05 2.2E-01 2.2E+00 1.1E+02 
1825 7.5E-06 1.3E-01 1.3E+00 6.4E+01 
3650 2.4E-06 4.1E-02 4.1E-01 2.1E+01 
7300 3.0E-07 5.1E-03 5.1E-02 2.6E+00 
18250 1.8E-08 3.1E-04 3.1E-03 1.5E-01 
 
Table 6.11.  90Sr Urine Excretion Reference Levels for Class Y Inhalation of 5-µm-AMAD Particles 
 
10-mrem 
Reporting Level 
100-mrem 
Investigation 
Level 
5-rem 
Compliance Level
Inhalation Intake (nCi) 20.8 208 10,400 
 
Days Post Intake 
Urine Excretion 
Fraction 
(f1 = 0.01) 
Derived 
Reporting Level 
(dpm) 
Derived 
Investigation 
Level (dpm) 
Derived 
Compliance Level 
(dpm) 
1 1.7E-03 7.8E+01 7.8E+02 3.9E+04 
2 1.2E-03 5.5E+01 5.5E+02 2.8E+04 
7 4.7E-04 2.2E+01 2.2E+02 1.1E+04 
14 1.6E-04 7.4E+00 7.4E+01 3.7E+03 
30 2.2E-05 1.0E+00 1.0E+01 5.1E+02 
60 9.3E-06 4.3E-01 4.3E+00 2.1E+02 
90 8.4E-06 3.9E-01 3.9E+00 1.9E+02 
180 7.0E-06 3.2E-01 3.2E+00 1.6E+02 
365 5.9E-06 2.7E-01 2.7E+00 1.4E+02 
730 4.9E-06 2.3E-01 2.3E+00 1.1E+02 
1825 2.8E-06 1.3E-01 1.3E+00 6.5E+01 
3650 9.4E-07 4.3E-02 4.3E-01 2.2E+01 
7300 1.3E-07 6.0E-03 6.0E-02 3.0E+00 
18250 9.9E-09 4.6E-04 4.6E-03 2.3E-01 
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The minimum detectable intakes and committed effective dose 
equivalents associated with various urinalysis sampling times post 
intake, based on a 10-dpm/d minimum detectable activity for 90Sr in 
urine for 1-µm- and 5-µm AMAD particle sizes are shown for 
inhalation intakes of class D and class Y material in Tables 6.12 and 
6.13, respectively.  Corresponding values for transportable injection 
intakes of soluble material are shown in Table 6.14. 
 
In Vivo Measurement of 90Sr 
 
Direct in vivo measurement of 90Sr in the skeleton is possible by 
counting the bremsstrahlung from its decay.  This procedure is 
subject to substantial interference by any other gamma- and beta-
emitting nuclides that might be present.  Indications are that a 
retained quantity in the skeleton of about 100 nCi might be 
detectable by head counting, however, there is no calibration for this 
measurement. 
 
If isotope activity relationships are known, in vivo whole body 
counting can be an effective indicator for the potential presence of 
strontium.  Cesium-137 is frequently used as the indicator, because 
its fission product yield is comparable to that of 90Sr.  However, this 
method is not conclusive and caution must be exercised because 
there are processes at Hanford where strontium and cesium have 
undergone chemical separation from each other.  Use of 137Cs as an 
indicator of 90Sr is more fully described in Chapter 5.0.  
Radiochemistry analyses for 137Cs and 90Sr in media representative of 
an intake may be used in lieu of supplemental bioassay 
measurements.  This method is most appropriate when dealing with 
intakes of small dosimetric consequence. 
 
It is generally recommended that in vivo measurements be used only 
as indicators of the potential for strontium being present, and that 
evaluations of any strontium intake be based on urine samples. 
 
6.5.2 
6.5.3 Recommended Periodic Bioassay Monitoring Protocol 
 
Workers potentially exposed to 90Sr should be on an annual or 
biennial urinalysis bioassay program.  Such programs should be 
easily capable of detecting class D intakes resulting in committed 
effective dose equivalents less than 100 mrem.  Similar monitoring 
programs applied to inhalation class Y are capable of detecting 
committed effective dose equivalents below 200 mrem.  For most 
Hanford applications, a whole body exam for high-energy gamma-
emitting nuclides can also be used as a screening measurement for  
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 Table 6.12. Hanford Bioassay Program Capability for 90Sr in Urine for Class D Inhalation 
(MDA = 10 dpm/d) 
 
Days Post 
Intake 
1-µm-AMAD 
Urine 
Excretion 
Fraction 
(f1 = 0.3) 
1-µm-AMAD 
Minimum 
Detectable 
Intake (nCi) 
1-µm-AMAD 
Minimum 
Detectable 
Dose 
(HE,50, mrem) 
5-µm-AMAD 
Urine 
Excretion 
Fraction 
(f1 = 0.3) 
5-µm-AMAD 
Minimum 
Detectable 
Intake (nCi) 
5-µm-AMAD 
Minimum 
Detectable 
Dose  
(HE,50, mrem)
1 4.8E-02 9.4E-02 2.1E-02 5.5E-02 8.2E-02 2.1E-02 
2 3.8E-02 1.2E-01 2.6E-02 4.4E-02 1.0E-01 2.8E-02 
7 1.5E-02 3.0E-01 6.6E-02 1.7E-02 2.6E-01 7.2E-02 
14 4.8E-03 9.4E-01 2.1E-01 5.7E-03 7.9E-01 2.1E-01 
30 5.5E-04 8.2E+00 1.8E+00 6.6E-04 6.8E+00 1.8E+00 
60 1.6E-04 2.8E+01 6.2E+00 1.9E-04 2.4E+01 6.4E+00 
90 1.2E-04 3.8E+01 8.3E+00 1.5E-04 3.0E+01 8.1E+00 
180 7.6E-05 5.9E+01 1.3E+01 9.3E-05 4.8E+01 1.3E+01 
365 3.8E-05 1.2E+02 2.6E+01 4.7E-05 9.6E+01 2.6E+01 
730 1.6E-05 2.8E+02 6.2E+01 2.0E-05 2.3E+02 6.1E+01 
1825 5.9E-06 7.6E+02 1.7E+02 7.3E-06 6.2E+02 1.7E+02 
3650 3.1E-06 1.5E+03 3.2E+02 3.8E-06 1.2E+03 3.2E+02 
7300 1.1E-06 4.1E+03 9.0E+02 1.3E-06 3.5E+03 9.4E+02 
18250 1.4E-07 3.2E+04 7.1E+03 1.7E-07 2.6E+04 7.2E+03 
 
 Table 6.13. Hanford Bioassay Program Capability for 90Sr in Urine for Class Y Inhalation 
(MDA = 10 dpm/d) 
 
Days Post 
Intake 
1-µm-AMAD 
Urine 
Excretion 
Fraction 
(f1 = 0.01) 
1-µm-AMAD 
Minimum 
Detectable 
Intake (nCi) 
1-µm-AMAD 
Minimum 
Detectable 
Dose 
(HE,50, mrem) 
5-µm-AMAD 
Urine 
Excretion 
Fraction 
(f1 = 0.01) 
5-µm-AMAD 
Minimum 
Detectable 
Intake (nCi) 
5-µm-AMAD 
Minimum 
Detectable 
Dose 
(HE,50, mrem)
1 8.4E-04 5.4E+00 7.0E+00 1.7E-03 2.6E+00 1.3E+00 
2 6.4E-04 7.0E+00 9.1E+00 1.2E-03 3.8E+00 1.8E+00 
7 2.5E-04 1.8E+01 2.3E+01 4.7E-04 9.6E+00 4.6E+00 
14 9.1E-05 5.0E+01 6.4E+01 1.6E-04 2.8E+01 1.4E+01 
30 2.1E-05 2.1E+02 2.8E+02 2.2E-05 2.0E+02 9.8E+01 
60 1.5E-05 3.0E+02 3.9E+02 9.3E-06 4.8E+02 2.3E+02 
90 1.5E-05 3.0E+02 3.9E+02 8.4E-06 5.4E+02 2.6E+02 
180 1.4E-05 3.2E+02 4.2E+02 7.0E-06 6.4E+02 3.1E+02 
365 1.4E-05 3.2E+02 4.2E+02 5.9E-06 7.6E+02 3.7E+02 
730 1.3E-05 3.5E+02 4.5E+02 4.9E-06 9.2E+02 4.4E+02 
1825 7.5E-06 6.0E+02 7.8E+02 2.8E-06 1.6E+03 7.7E+02 
3650 2.4E-06 1.9E+03 2.4E+03 9.4E-07 4.8E+03 2.3E+03 
7300 3.0E-07 1.5E+04 2.0E+04 1.3E-07 3.5E+04 1.7E+04 
18250 1.8E-08 2.5E+05 3.3E+05 9.9E-09 4.6E+05 2.2E+05 
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 Table 6.14. Hanford Bioassay Program Capability for 90Sr in Urine for Transportable Injection 
and Soluble Ingestion Intakes (MDA = 10 dpm/d; f1 = 0.3) 
 
Transportable Injection Intake Soluble Ingestion Intake 
Days Post 
Intake 
Urine 
Excretion 
Fraction 
(f1 = 0.3) 
Minimum 
Detectable 
Intake (nCi) 
Minimum 
Detectable 
Dose  
(HE,50, mrem) 
Urine 
Excretion 
Fraction 
(f1 = 0.3) 
Minimum 
Detectable 
Intake (nCi) 
Minimum 
Detectable 
Dose  
(HE,50, mrem)
1 8.3E-02 5.4E-02 2.2E-02 2.6E-02 1.7E-01 2.3E-02 
2 6.6E-02 6.8E-02 2.8E-02 2.0E-02 2.3E-01 2.9E-02 
7 2.6E-02 1.7E-01 7.1E-02 7.9E-03 5.7E-01 7.4E-02 
14 8.6E-03 5.2E-01 2.1E-01 2.6E-03 1.7E+00 2.3E-01 
30 1.0E-03 4.5E+00 1.8E+00 3.0E-04 1.5E+01 2.0E+00 
60 3.0E-04 1.5E+01 6.2E+00 8.9E-05 5.1E+01 6.6E+00 
90 2.4E-04 1.9E+01 7.7E+00 7.1E-05 6.3E+01 8.2E+00 
180 1.4E-04 3.2E+01 1.3E+01 4.3E-05 1.0E+02 1.4E+01 
365 7.3E-05 6.2E+01 2.5E+01 2.2E-05 2.0E+02 2.7E+01 
730 3.1E-05 1.5E+02 6.0E+01 9.4E-06 4.8E+02 6.2E+01 
1825 1.1E-05 4.1E+02 1.7E+01 3.4E-06 1.3E+03 1.7E+02 
3650 5.8E-06 7.8E+02 3.2E+02 1.8E-06 2.5E+03 3.3E+02 
7300 2.1E-06 2.1E+03 8.8E+02 6.2E-07 7.3E+03 9.4E+02 
18250 2.7E-07 1.7E+04 6.8E+03 8.1E-08 5.6E+04 7.2E+03 
 
potential intake of mixed fission products.  A worker scheduled only 
for a whole body exam may not be recognized as having potential 
exposure to radiostrontium. 
 
If gamma-emitting nuclides such as 137Cs are also of potential 
concern, the impact of mixtures on potentially undetected effective 
dose equivalent must also be addressed.  If other means (e.g., in vivo 
measurements) are used to monitor for other nuclides, then annual or 
biennial urine samples should be sufficient to monitor the 90Sr 
contribution to dose. 
 
6.5.4 Special Monitoring for Suspected Exposures 
 
If exposure to 90Sr has occurred or is suspected to have occurred, one 
or more urine samples should be scheduled for investigation 
purposes.  Because of the high sensitivity of the urine sample 
analysis, even slight intakes of 90Sr resulting in small fractions of a 
millirem committed effective dose equivalent can be detected if 
prompt sampling is performed.  This also permits the use of less 
sensitive analytical procedures (i.e., expedite or emergency 
processing analyses) for reasonably accurate dose estimates. 
 
As is apparent from Table 6.8 and 6.9, for class D inhalation of either 
1-µm or 5-µm particles, a urine sample result of 5 dpm/d obtained 
within 30 days following the intake would imply a committed 
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effective dose equivalent of less than 1 mrem, which could be 
rounded to zero.  Thus, although some indications exist to suggest 
that 5 dpm/d may be above the normal background levels for urinary 
excretion, the dosimetric consequence for incident evaluation is 
insignificant and no confirmation of intake is made based on results 
of 5 dpm/d or less. 
 
Isotopic strontium analyses should be considered for any potential 
exposures to 89Sr.  However, if more than 1 year has elapsed since 
the production of 89Sr, that isotope is unlikely to be a dosimetric 
concern due to its short radiological half-life. 
 
In vivo measurements should also be considered following potential 
90Sr exposures, because generally 90Sr is likely to be mixed with 
other nuclides. 
 
For relatively small intakes, fecal samples for strontium are not 
likely to be warranted because of the high degree of systemic uptake 
and the ease of detection by urine sampling.  If major intakes are 
suspected, fecal samples combined with urine samples may provide 
more accurate estimates of intake, particularly if the intake is thought 
to contain some nontransportable strontium. 
 
6.6 Assessment of Internal Dose Equivalent 
 
Internal dosimetry for radiostrontium is usually performed at 
Hanford using an intake assessment methodology and urine bioassay 
data.  The method may use either tabulated values for the excretion 
fractions or the CINDY computer code for curve fitting or 
determining excretion fractions at specific times post intake.  Doses 
may be calculated using either an intake value and tabulated dose 
coefficients or by using CINDY.  For Hanford sources, 90Sr and its 
90Y decay product have generally been the isotopes of greatest 
concern for strontium dosimetry.  As noted in the previous sections, 
89Sr may also be a concern under some conditions. 
 
The general protocol for strontium dosimetry is as follows: 
 
• Estimate the intake based on urine excreta analyses and the 
appropriate intake excretion function using CINDY or the 
appropriate equation and technique described in Chapter 2.0. 
 
 
Issued:  January 31, 2003  PNNL-MA-860 Chapter 6.0 
  Page 6.15 
• Estimate doses using CINDY or tabulated dose coefficients.  
This includes committed effective dose equivalents, as well as 
dose equivalents to specific organs of concern based on criteria 
presented in the Hanford Internal Dosimetry Program Manual.(a) 
 
When estimated intakes and associated doses are a relatively small 
fraction of the applicable radiation protection limit, direct application 
of the biokinetic models and dosimetry factors without modification 
for individual-specific considerations is appropriate.  As intakes and 
doses become more significant, it is appropriate to give 
correspondingly greater attention to those individual-specific details.  
Urine data normalization is the factor most likely to be adjusted for 
an individual-specific modification. 
 
Dose assessments use the techniques and biokinetic models 
described previously and assume ICRP 23 (1974) Reference Man 
parameters, usually without correction for individual-specific 
characteristics.  These assessments provide a basis for prospective 
bioassay program design and retrospective evaluation of doses that 
are small relative to the occupational exposure limits. 
 
6.7 Management of Internal Contamination Cases 
 
The diagnostic procedures, therapeutic actions, and long-term 
monitoring following an intake of 90Sr are discussed in the following 
sections on the management of potential internal contamination 
cases. 
 
6.7.1 
                                                     
Diagnostic Procedures 
 
A worker who may have received an intake of strontium should be 
scheduled for a whole body count and a urine sample.  These initial 
measurements can be used to confirm an intake and provide 
preliminary estimates of the magnitude of potential doses.  Suitable 
urine samples can include a single voiding, overnight, or simulated 
24-hour sample, depending on the potential severity of intake (the 
higher the severity, the more important prompt information 
becomes).  However, as noted in previous sections, the in vivo 
measurements are for the detection of gamma-emitting nuclides, 
which may or may not be indicative of 90Sr. 
 
(a) Pacific Northwest Laboratory.  1997.  Hanford Internal Dosimetry Program Manual.  PNL-MA-552, 
Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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A potential intake of 90Sr is best indicated by the results of the urine 
sample.  Where the indicated dose is small (e.g., less than tens of 
millirem), a single urine sample is adequate for dosimetry.  For more 
significant intakes, getting two or more urine samples (representing 
actual or simulated 24-hour periods) collected over several days or 
weeks following the intake is preferred.  In general, less credence for 
dosimetry is placed on a sample taken within the first couple of days 
after an intake compared with one taken several days or more after 
the intake. 
 
6.7.2 
6.7.3 
Therapeutic Actions 
 
Therapeutic actions to prevent the uptake of strontium are based 
primarily on reducing GI tract absorption and accelerating the 
passage of material through the GI tract.  These measures require 
administration under medical supervision and are addressed in NCRP 
65 (1980) and the “Guidebook for Treatment of Accidental Internal 
Radionuclide Contamination of Workers” (Bhattacharyya et al. 
1992).  Aluminum phosphate gel and sodium alginate are the drugs 
identified as being potentially effective in reducing the GI tract 
uptake of strontium.  Accelerating the passage of material through 
the GI tract can be accomplished by use of laxatives and enemas.  
These measures can only be taken under the supervision of Hanford 
Environmental Health Foundation (HEHF) Occupational Medicine.  
Frequent sampling should be used during treatment to provide 
information on treatment efficiencies.  However, standard models 
should not be used on these samples for dosimetry. 
 
Long-Term Bioassay Follow-Up Monitoring After an Intake 
 
Long-term monitoring of urinary excretion following a 90Sr intake 
may be required to validate the excretion model or to ensure that 
potential additional intakes do not go undetected.  The establishment 
of a sampling frequency for such monitoring is dependent upon the 
nature of the exposure, magnitude of deposition, and likelihood for 
additional exposure.  Appropriate long-term follow-up monitoring 
should be determined as part of the exposure evaluation. 
 
6.8 Historical 90Sr Internal Dosimetry Practices at Hanford 
 
Historically, Hanford internal dosimetry for strontium was based on 
estimating the long-term systemic deposition, using urine data and 
Dolphin’s excretion model (Dolphin and Eve 1963a; 1963b), and 
comparing it with the 2-µCi ICRP 2 MPBB (ICRP 1959).  The long-
term (formerly referred to as “permanent”) deposition was defined as 
the amount remaining in the body at 1 year post intake, which was 
calculated to be 15% of the initial systemic uptake.  This evaluation  
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technique was described in several short explanations, the most 
recent being Appendix G of the Hanford Dosimetry Evaluation 
Manual (PNL-MA-575).(a)  Earlier versions are listed by Sula et al. 
(1991). 
 
In April 1985, the practice of investigating all positive 90Sr results 
regardless of their dose implication was discontinued, and only 
results potentially indicating long-term systemic depositions in 
excess of 1% of the above-described level were investigated.  This 
change in practice was made due to increased sensitivity of the 
analytical procedure and the indication of potential background 
levels in the range of the minimum detection level for the analytical 
procedure.  Using the above method, derived investigation levels 
were calculated for various times post intake, and these were 
documented by letter to the Hanford Radiation Protection Historical 
Files as cited by Sula et al. (1991). 
 
With the issuance of Technical Basis for Internal Dosimetry at 
Hanford (Sula et al. 1989), the ICRP 30 (1979) dosimetry concepts 
of committed organ and tissue dose equivalents, and committed 
effective dose equivalent were adopted, along with the ICRP alkaline 
earth model (1973) as implemented using the GENMOD computer 
code (Johnson and Carver 1981).  The CINDY computer code 
effectively replaced GENMOD at Hanford in 1992. 
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7.0 Uranium 
 
 
This chapter provides technical information on uranium sources, 
characteristics, biokinetics, and internal dosimetry for general 
application at Hanford.  Also included are some discussions of 
historical assessment practices for exposures in specific facilities 
where uncontained uranium was routinely handled. 
 
Bioassay monitoring and internal dosimetry for uranium at Hanford 
posed relatively unique problems, primarily because, except for 
highly enriched uranium, total containment was not provided.  Thus, 
low-level chronic airborne contamination levels were assumed to 
exist in facilities in which uncontained uranium was routinely 
handled.  Such facilities associated with Hanford’s former plutonium 
production mission are no longer in operation, and have either been 
stabilized or undergone decontamination/decommissioning.  Poten-
tial exposures in these facilities are now very rare, due to infrequent 
entry.  Thus, the chronic exposure scenario is no longer considered 
routine and single acute exposures are considered the most likely.  
 
Additional difficulties with uranium dosimetry are caused by the 
relatively low sensitivity of direct (in vivo) measurement capabilities 
for depleted and low-enrichment uranium, and the presence of 
environmental uranium in urine as background interference. 
 
7.1 Sources and Characteristics 
 
The sources, isotopic composition, transportability, particle size, 
environmental background, chemical toxicity, and biokinetic 
characteristics of uranium at Hanford are discussed in the following 
sections. 
 
7.1.1 Sources 
 
Uranium at Hanford may be present from a number of possible 
sources, including residual recycled uranium (RU) from the fuel 
cycle of the production reactors, depleted uranium (DU) from an 
ongoing research and development project, and various individual 
isotopes or mixtures associated with laboratory standards.  In addi-
tion, natural uranium (NU) is ubiquitous in the environment and can 
interfere with bioassay measurements. 
 
Uranium compounds encountered during historical production 
operations at Hanford ranged from the highly soluble uranyl nitrate, 
UO2(NO3)2, to somewhat less soluble uranium trioxide, UO3, to  
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relatively insoluble uranium oxides, UO2 and U3O8.  The highly 
reactive uranium hexafluoride, UF6, and uranyl fluoride, UO2F2, 
were not handled at Hanford. 
 
Historically at Hanford, uranium was used primarily as feed material 
in the plutonium production process.  The uranium was received as 
slightly enriched metallic uranium in the form of large billets and 
extruded into fuel elements at the 300 Area Fuel Production 
Facilities, primarily Building 333 but also 303-M and some ancillary 
buildings).  After irradiation in production reactors, the elements 
were shipped to the PUREX facility for processing.  The recovered 
uranium, as uranyl nitrate-hexahydrate, was shipped to the Uranium 
Oxide (UO3) Plant in 200 West Area for conversion to uranium 
trioxide.  The final operating plutonium production reactor 
(N Reactor) and its associated fuels production facility were shut 
down in 1987, and the extraction of plutonium and uranium from the 
irradiated fuels ended at PUREX in 1990.  The UO3 Plant operated 
intermittently from 1952 to 1994.  In the early years of Hanford 
operations, when the chemical separations processes of the produc-
tion cycle were performed in the first-generation facilities (T-Plant 
[221-T] and B-Plant [221-B]) and the second-generation process 
(REDOX Plant [202-S]), the uranium was not separated from the 
waste stream but sent to the underground high-level waste storage 
tanks.  In 1952, the U-Plant (221-U) began operations that recovered 
uranium from the high-level waste tanks.  These operations continu-
ed through 1957.  A more detailed explanation and history of 
uranium processing at Hanford is contained in Volume II Part 1 of 
Recycled Uranium (DOE-RL 2000). 
 
Uranium is also used in fuel elements for the FFTF reactor.  The 
FFTF fuel consists of a mixture of plutonium and uranium oxide, 
with plutonium being the primary concern.  The fuel elements were 
not fabricated at Hanford, but received as sealed units. 
 
Depleted uranium metal is machined in shops in the 306-W Building 
in support of a long-term research and development program. 
 
Uranium isotopes (both as separated isotopes and mixtures of 
isotopes) are stored and handled in several laboratories in the 200 
and 300 Areas. 
 
7.1.2 Isotopic Composition 
 
Uranium handled at Hanford generally ranges from depleted to 
slightly enriched, based on the weight percent of 235U.  Table 7.1 
summarizes 235U enrichment levels anticipated in several Hanford 
source terms and facilities.  Table 7.2 gives radiological data for  
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uranium isotopes.  Table 7.3 gives the principal isotopic composition 
of the various types of uranium at Hanford.  Recycled uranium is 
present in the Fuel Production Facilities and in the UO3 Plant.  Table 
7.3 shows that the specific alpha activity of the recycled uranium 
exceeds that of virgin uranium for corresponding 235U weight 
percentages.  This increase is due primarily to higher levels of 234U 
and 236U in the recycled uranium.  The atom ratios used to calculate 
specific activity in Table  7.3 are based on operational data obtained 
from facility operating records and represent a reference recycled 
uranium mixture rather than any specific batch.  Knowledge of the 
isotopic composition of natural uranium is important to help 
discriminate potential occupational exposure from normal 
environmental exposure. 
 
Uranium used in the plutonium production process was recycled 
uranium and incurred ingrowth of impurities during the irradiation 
phase of the fuel cycle (Rich et al. 1988 and DOE 2000).  These 
impurities were not completely removed during the reprocessing and 
plutonium extraction phases of the production cycle and thus their 
presence in residual uranium contributes to internal dose along with 
uranium.  The impurities include 236U, 239Pu, 99Tc, 237Np, and other,  
 
Table 7.1.  Types and Enrichment of Uranium Expected in Hanford Facilities 
 
Area Facility Material Form Type 235U Enrichment 
100 Reactors Fuel elements Recycled U 0.8 to 1.25% 
200 Chemical Processing 
(PUREX, UO3) 
Exposed fuel elements, 
UNH, UO3 
Recycled U 0.8 to 1.25% 
300 Fuel Production 
Facilities 
U metal ingots 
New fuel elements 
Recycled U 0.8 to 1.25% 
 306-W U metal Depleted U 0.25% 
200 or 300 Analytical Labs U standards solutions Any Not Applicable  
 
Table 7.2.  Uranium Decay Data 
 
Half-Life  
Isotope  (Years)(a) (Days) 
Specific 
Activity (CI/G) 
232U 72 2.63E+04 2.14E+01 
233U 1.585 E+05 5.79E+07 9.68E-03 
234U 2.445 E+05 8.92E+07 6.25E-03 
235U 7.038 E+08 2.57E+11 2.16E-06 
236U 2.3415 E+07 8.55E+09 6.47E-05 
238U 4.468 E+09 1.63E+12 3.36E-07 
(a) From ICRP 38 (1983). 
 
 
PNNL-MA-860 Chapter 7.0  Issued:  September 30, 2000 
Page 7.4 
Table  7.3.  Radiological Characteristics of Uranium Mixtures 
 
Uranium Mixture  
Weight  
Percentage (a, b) 
Natural  
(NU) 
Depleted  
(DU) 
Recycled  
(RU) 
Commercial  
Fuel (CF) 
234U 0.0057 0.0005 0.0082 0.0300 
235U 0.7204 0.2500 0.9700 2.9600 
236U negligible negligible 0.0680 negligible 
238U 99.2739 99.7500 98.9500 97.0100 
Total  100.0000 100.0005 99.9962 100.0000 
Specific Constituent Activity in Mixture (uCi/g, nCi/mg, or pCi/ug (c) 
234U 0.3563 0.0313 0.5125 1.8750 
235U 0.0156 0.0054 0.0210 0.0639 
236U negligible negligible 0.0440 negligible 
238U 0.3336 0.3352 0.3325 0.3260 
Total  0.7054 0.3718 0.9099 2.2649 
Specific Constituent Activity in Mixture (dpm/ug)(c) 
234U 0.7909 0.0694 1.1378 4.1625 
235U 0.0345 0.0120 0.0465 0.1419 
236U negligible negligible 0.0977 negligible 
238U 0.7405 0.7441 0.7381 0.7236 
Total  1.5659 0.8254 2.0200 5.0281 
Constituent Fraction of Total Uranium Activity in Mixture  
234U 0.5051 0.0840 0.5632 0.8279 
235U 0.0221 0.0145 0.0230 0.0282 
236U negligible negligible 0.0484 negligible 
238U 0.4729 0.9014 0.3654 0.1439 
Total  1.0000 1.0000 1.0000 1.0000 
(a) NU, DU, and CF data from Rich et al. 1988. 
(b) RU data based on average of data presented by Sula, Carbaugh, and Bihl 1991. 
(c) Can be used to represent specific alpha activity in the mixture as well. 
 
shorter-lived, fission products.  Table 7.4 gives maximum allowed 
levels of these impurities in uranium that was handled at the UO3 
Plant (Thompson 1986).  These levels can be considered to represent 
the maximum impurity levels for recycled uranium at Hanford.  
Actual operational experience (also indicated in Table 7.4) showed 
that levels of impurities in recycled uranium at Hanford were 
substantially below the maximum allowed levels.  Default reference 
levels for these impurities are also established in the table.  These 
reference levels are used for bioassay program design and internal 
dosimetry.  While the levels of 103, 106Ru and 95Zr-Nb might have been 
pertinent to historical Hanford operations and dosimetry, the  
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Table 7.4.  Impurities in Recycled Uranium at Hanford 
 
Constituent 
Maximum 
Allowed(a) 
Observed  
Range (b) 
Reference  
Level(c) 
Plutonium 10 ppbp U <1 - 2 ppbp U 0.4 nCi Pu-alpha/g-U(d) 
Neptunium Not established 
0.04 - 0.16 ppmp 
U 0.4 nCi 237Np/g-U(e) 
Thorium 750 ppmp U 8 - 10 ppmp U 5 pCi 232Th/g-U(f) 
99Tc Not established 3 - 4 ppmp U 0.2 uCi 99Tc/g-U(g) 
103,106Ru <20 uCi/lb-U <6 uCi/lb-U 40 nCi 106Ru/g-U(h) 
95ZrNb <10 uCi/lb-U <4 uCi/lb-U 20 nCi 95ZrNb/g-U(i) 
Other Gamma Emitters 
excluding 99Tc <2 uCi/lb-U 
0.09 - 0.75 uCi/lb-
U none(j) 
(a) From UO3 Plant operating specifications, OSD-U-185-0001 (Thompson 1986). 
(b) From analysis of uranium lots 88-1, 88-2, 88-3 that were processed in 1988, and lots 93-
01, 93-02, 93-03, 93-04, and 93.05, processed in 1993. 
(c) A reference level is chosen for determining bioassay monitoring needs and for use as an 
initial assumption in evaluating intakes.  The use of the reference levels is expected to 
result in a slight overestimate of dose compared to levels actually observed in 1988. 
(d) Based on 5 ppbp U and assuming plutonium is represented by aged 6% 240Pu (weapons 
grade) material. 
(e) Based on 0.5 ppmp U of 237Np. 
(f) Based on 50 ppmp U of 232Th. 
(g) Based on 10 ppmp U of 99Tc. 
(h) Based on 20 uCi/lb-U of 106Ru. 
(i) Based on 10 uCi/lb-U of 95ZrNb. 
(j) Negligible contribution compared to other impurities. 
 
short physical half-lives of these radionuclides render them moot to 
current sources at Hanford.  236U is produced by the 235U (n,() 
reaction, and does not occur naturally.  Its presence is an indicator of 
recycled uranium as opposed to natural uranium.  Data compiled by 
Wittekind and Morey (1985) suggest that 236U concentration in cast 
uranium ingots could range from 0.03 to 0.08 weight percent for 
Hanford uranium fuel. 
 
The 234U:238U activity ratio can help in differentiating types of 
uranium.  Goldstein, Rodriguez, and Lujan (1997) reported that 
depleted uranium (234U:238U =0.15) and highly enriched uranium 
(234U:238U >100) are compositions only rarely found in natural 
samples, that typical water samples show 234U:238U activity ratios of 
0.8 to 10, and that soil sample activity ratios ranged from 0.5 to 1.2.  
They suggested that activity ratios outside of these natural limits 
could be indicative of exposure to anthropogenic sources of uranium. 
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7.1.3 Environmental Background 
 
Uranium is ubiquitous to the natural environmental background.  It is 
found in trace quantities in rocks, soil, surface water, groundwater, 
air, plants, and animals.  Some of the routine concentrations that 
might be naturally encountered are shown in Table 7.5. 
 
The presence of uranium as part of the natural environment results in 
its presence in urine.  The sensitivity of urine sampling as a uranium 
bioassay tool is limited by the presence of environmental levels of 
uranium.  The sensitivity is subject to some uncertainty in interpreta-
tion.  In ICRP 30 (1979) the average daily ingestion intake of natural 
 
Table 7.5.  Environmental Levels of Uranium 
 
Media Level Reference (a) 
3 ppm PHS (1997)  
1 pCi/g  PHS (1997) 
0.5-4.7 ppm  
(7-60 Bq 238U/kg) 
NCRP 94 (1988) 
25 Bq 238U/kg 
Soil (typical) 
(10-50 Bq 238U/kg ) 
UNSCEAR (1988) 
Soil (phosphate rich) 4.5 – 83.4 pCi/g PHS (1997) 
0.011 – 3 fCi/m3 PHS (1997) 
0.3 mBq/m3 Golchert et al. (1985) Air 
0.7 mBq/m3 Fisenne et al. (1987) 
Water <1 pCi/l PHS (1997)  
37 mBq/l Surface water 
(0.37 – 25,000 mBq/l) 
Drury et al. 1983 
111 mBq/l Ground water 
(0.037 to 24,000) 
Drury et al. 1983 
20 mg/l EPA (1991) Proposed drinking water  
standard (maybe 80 mg/l)  PHS (1997) 
Human Consumption 
0.6 – 1.0 pCi/d PHS (1997) Food 
1.3 – 1.4 mg/d Welford and Baird (1967) 
0.8 pCi/l PHS (1997) Water 
(1.13 mg/l)  
Human Excretion 
0.05 – 0.5 mg/d ICRP publication 23 (1974) 
Urine 0.2 mg/d Hanford Environmental  
Screening Level (this document) 
Feces 1.4 – 1.8 mg/d ICRP publication 23 (1974) 
(a) PHS = Public Health Services. 
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uranium in food and water is estimated to be 1.9 mg.  Assuming that 
the GI tract absorption of uranium at environmental levels is about 
1% (Wrenn 1985) at equilibrium, about 0.02 mg/d could be expected 
in the urine of occupationally unexposed workers.  The ICRP 
Reference Man Report (1974) lists urinary excretion from 0.05 to 
0.5 mg/d and fecal excretion from 1.4 to 1.8 mg/d, although the range 
reported in its cited literature is much greater.  Studies at Hanford, 
performed in 1985, 1990, and 1995, indicated that the concentrations 
of uranium in urine in the Hanford area are similar or slightly higher 
than the foregoing estimates (Carbaugh, Sula, and McFadden 1990; 
Long, Carbaugh, and Fairrow 1994; and Long and Carbaugh 1995). 
 
Urine samples were collected in mid-1985 from 21 occupationally 
unexposed Hanford workers who resided in various locations around 
Hanford, including Yakima, Benton City, Kennewick, and Richland.  
Both municipal drinking water and individual well-water systems 
were represented by the sampling.  The results ranged from below 
detectable levels (0.03 mg/d) to 0.12 mg/d.  For seven of the 
individuals, three samples were collected over a 2-week period, and 
the daily excretion remained fairly constant for each individual over 
the period.  Data for this group are shown as the 1985 curve in 
Figure 7.1.  The median daily uranium output for the 1985 study 
group was 0.06 mg and 0.2 mg/d was estimated to be the 99.9 
percentile (one in a thousand samples collected from unexposed 
workers would be expected to exceed that value).  Based on this 
study, samples containing less than 0.2 mg/d of uranium were 
considered to be within the expected environmental range, and 
results above 0.2 mg/d were considered to contain occupationally 
derived uranium.  The net amount attributed to occupational sources 
was calculated as the total observed amount minus the average 
expected environmental level of 0.06 mg/d. 
 
A second study of background uranium levels in urine commenced in 
1990.  Urine samples were collected from 20 nonoccupationally 
exposed workers in early 1990 with the intent of collecting quarterly 
samples from each worker throughout the year, as well as samples of 
their drinking water.  The workers were selected to provide an 
indication of the possible correlation between drinking water sources 
and urinary excretion.  Due to the cancellation of the analytical 
support services laboratory contract this study was terminated after 
collection of the first samples.  However, the data are useful as a 
comparison with the 1985 data and, as can be seen in Figure 7.1, 
show some very interesting variations.  The geometric mean of this  
 
PNNL-MA-860 Chapter 7.0  Issued:  September 30, 2000 
Page 7.8 
 
 
Figure 7.1.  Urinary Extraction of Uranium in Unexposed Hanford Workers 
 
sample group was 0.024 mg/d with a 99.9 percentile of 0.28 mg/d.  
The 0.2-mg/d value used as the 99.9 percentile for the 1985 data 
corresponds more closely to a 99 percentile for the 1990 data, 
implying that one in a hundred (rather than one in a thousand) 
samples from occupationally unexposed workers might exceed it.  At 
least two factors contribute to these apparent differences.  First, the 
workers sampled were a substantially different subset than the first 
group; whereas the 1985 subjects were primarily from two large 
municipal water systems, the 1990 subjects were carefully selected 
to provide an indication of possible impact from water consumption 
in numerous outlying communities around Hanford.  Second, a 
significant change in the analytical process occurred during the time 
that elapsed between the two sets of samples—namely, the practice 
of subtracting reagent blanks from sample results was initiated.  
Interpretation of the 1990 data was considered preliminary, and led 
to the 1995 study.  
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The 1995 study involved sampling 20 nonoccupationally exposed 
male Hanford workers, 8 of whom were resampled at 3-month 
intervals for a year.  Concurrent drinking water samples were 
obtained from each worker and also analyzed for uranium.  The 
workers included residents of Richland, Pasco, and Kennewick, as 
well as outlying areas, and included drinking water sources from 
surface water and groundwater wells.  The study made the following 
conclusions important to the interpretation of worker uranium 
urinalyses: 
 
· The urinary screening level of 0.2 mg U/d established by the 
1985 study was appropriate for most individuals, however 2 to 
5% of the workers could be expected to be above that value due 
to unknown nonoccupational sources.  The study indicated the 
possibility that home drinking water might be the primary source 
of the unusually high excretion of uranium, however the study 
was not extensive enough to make that a definitive conclusion.  
Complicating factors include how much home water is 
consumed, the source of the water (wells or surface, i.e., 
Columbia River water), and water treatment (e.g., water softener 
systems). 
 
· The geometric mean urinary excretion for the group was 
0.021-mg/d. 
 
· The use of the 238U to 234U ratio as a co-indicator for Hanford 
occupational exposure to recycled uranium is not feasible 
because the isotopic ratio in the slightly enriched Hanford 
recycled uranium may not be significantly different from that of 
natural environmental sources.  The ratio can be of value if 
highly enriched or depleted uranium is the potential occupational 
concern. 
 
· Correlation analyses between the amount of uranium in the urine 
sample and the amount of uranium in the drinking water samples 
showed no significant correlation.  There was a weak correlation 
when the concentration of uranium in water was high. 
 
· A water source effect was observed for uranium in water.  
Private well water typically exhibited higher uranium 
concentrations than large municipal drinking water sources. 
 
· There did not appear to be a correlation between geographic 
location of residence within the Yakima River Valley and daily 
excretion of uranium. 
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· There did not appear to be a seasonal effect on the concentration 
of uranium in urine or water when the overall data were tested, 
nor when specific mid-Columbia regions were examined. 
 
Fecal excretion of uranium from ingestion of nonoccupational 
sources of uranium in the Hanford environs has not been studied in a 
manner similar to that of urine excretion.  Lacking Hanford-specific 
information, it is assumed that the ICRP Reference Man values of 1.4 
to 1.8 mg/d are reasonable. 
 
7.2 Biokinetic Behavior 
 
This section discusses the inhalation transportability class, internal 
distribution and retention, the urinary and fecal excretion of uranium, 
and its chemical toxicity.  
 
7.2.1 Transportability Class  
 
The transportability classes for uranium are those used in the ICRP 
publication 30 (1979) respiratory tract model and are sometimes 
referred to as solubility or inhalation classes.  The class designation 
represents the relative speed at which material is solubilized and 
translocated into the transfer compartment from the deep pulmonary 
(or alveolar) region of the lung.  Classes D, W and Y, as used in this 
technical basis, are identical to the ICRP 30 classes of the same 
name.  The term “instantaneous uptake” is used in this technical 
basis to refer to the material that is essentially immediately taken up 
by the transfer compartment upon intake, and is typically applied to 
wound scenarios. 
 
The new respiratory tract model presented in ICRP publication 66 
(ICRP 1994a), replaced the ICRP 30 concepts of inhalation class D, 
W, and Y, with absorption Types F, M, and S.  Whereas the ICRP 30 
inhalation classes described overall clearance (i.e., absorption and 
mechanical clearance), the ICRP 66 type refers only to the absorption 
characteristics (i.e., dissolution and absorption into blood).  With 
regard to the dissolution and absorption rates, the ICRP 30 classes D, 
W, and Y correspond to the characteristics of ICRP 66 Types F, M, 
and S, respectively.  Although Hanford has not adopted the ICRP 66 
respiratory tract model, the use of the absorption types as a supple -
mental concept to the ICRP 30 inhalation classes may be useful, 
particularly with the application of newly published solubility studies 
or animal study data.  Unless specifically indicated, the chemical 
forms assigned to the ICRP 30 classes can be assumed to be assigned 
to the corresponding ICRP 66 absorption types (and vise versa). 
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Table 7.6 provides transportability classifications for uranium 
compounds as recommended in ICRP publication 30 and also shows 
the absorption type (F, M, or S) of ICRP publication 68 (1994b).  
Unless special dissolution analysis is performed, these assigned 
classifications are used for Hanford internal dosimetry.  Special 
dissolution studies were performed in the mid-1980s for uranium 
handled in the UO3 Plant, the Fuel Production Facilities, and the 
306-W Building, and are also summarized in Table 7.6.  It is also 
worth noting that Dang et al. (1994) identified uranium oxide as 
having an order of magnitude slower transportability than ICRP 30 
class Y.  
 
7.2.2 Gastrointestinal Uptake to Blood (f1 Factor) 
 
Table 7.6 includes the recommendations of the ICRP in publication 
30 (1979) and publication 69 (1995) for the fractional absorption of 
uranium to blood from the GI tract.  The ICRP 30 value of 0.05 for 
inorganic forms of uranium was established based mainly on human 
data for uranyl nitrate ingestion reported by Hursh et al. (1969).  
More recent data reviewed by Wrenn et al. (1985), Harrison (1991), 
and Leggett and Harrison (1995) resulted in ICRP adopting 0.02 for 
adults as a more realistic for dietary forms of uranium.  It was noted  
 
 Table 7.6. Inhalation Class, Lung Absorption Type, and f1 Factors for Occupational Exposure to 
Uranium Compounds 
 
ICRP 30 Inhalation 
Class f1 Factor Compound 
ICRP 68 Lung 
Absorption Type 
f1 Factor 
D 
0.05 
Highly soluble forms UF6, UO2F2, UO2(NO3)2,  
most hexavalent compounds 
F 
0.020 
W 
0.05 
Less soluble forms UO3, UF4, UCl4, and most other 
hexavalent compounds 
M 
0.020 
Y 
0.002 
Highly insoluble forms UO2, U3O8 S 
0.002 
80% D 
20% W 
Hanford UO3 Plant smear sample dissolution study in 
1984(a), (UO3 powder) 
 
10% D 
90% Y 
Hanford 303-M Building air sample dissolution study(b) 
(300 Area Uranium Fuel Production Facilities) 
 
29% D 
71% Y 
Hanford 333 Building air sample dissolution study(b) (300 
Area Uranium Fuel Production Facilities) 
 
20% D 
80% Y 
Hanford 306-W Building Machine Shop air sample 
dissolution study(b) 
 
(a) Sula, Bihl, and Carbaugh (1989). 
(b) Letter Report to Monte J. Sula from Darrell R. Fisher, January 20, 1986, “Particle Size Distribution and 
Solubility of Uranium Aerosols in 333 and 303M Buildings at UNC, and PNL’s 306W Building.  
(Copy available in Hanford Radiological Records Historical File). 
 
PNNL-MA-860 Chapter 7.0  Issued:  September 30, 2000 
Page 7.12 
that this value actually summarizes a range of 1 to 2 orders of 
magnitude, with the more soluble compounds being more readily 
absorbed.  Legget and Harrison noted that the range was from <0.001 
to 0.06, with a central range of 0.003 to 0.032, and their choice of a 
value was 0.01 to 0.015.  They also noted uranium may be more 
readily absorbed from water than food such as fresh vegetables and 
shellfish, because the latter may have more insoluble forms of 
uranium.  Fasting may result in enhanced absorption.  For highly 
insoluble forms of uranium, the ICRP retained its earlier value of 
0.002. 
 
The HIDP adopts the more recent ICRP recommendations of 0.02 
and 0.002 as the f1 values for, respectively, soluble and insoluble 
forms of uranium. 
 
7.2.3 Distribution, Retention, and Excretion 
 
For the design of monitoring programs and for the assessment of 
dose equivalents when there is insufficient bioassay measurement 
data to develop individual-specific characteristics, the distribution, 
retention, and excretion of uranium are assumed to follow the 
biokinetic model described in ICRP 30.  This model assigns the 
inhalation classes shown in Table 7.6.  For material entering the 
systemic circulation, fractions 0.2 and 0.023 are assumed to go to 
mineral bone and be retained there with half-lives of 20 and 
5000 days, respectively; fractions 0.12 and 0.00052 are assumed to 
go to the kidneys and to be retained with half-lives of 6 and 
1500 days, respectively; and fractions 0.12 and 0.00052 are assumed 
to go to all other tissues of the body and be retained with half-lives 
of 6 and 1500 days, respectively.  Uranium is assumed to be 
uniformly distributed among these other tissues.  The remaining 
fraction of the uranium entering the systemic circulation, 0.54, is 
assumed to go directly to excretion.  Long-lived uranium isotopes 
entering the bone are assumed to be distributed uniformly throughout 
the bone volume. 
 
The recent ICRP publication 69 (ICRP 1995) recycling model for 
uranium indicates an assumption of a small fraction (0.005) to feces.  
This is insignificant with regard to operational health physics and is 
not adopted for Hanford use at this time. 
 
Selected lung retention, urinary excretion, fecal excretion, and 
kidney retention fractions for instantaneous uptake, acute inhalations, 
and ingestion are tabulated in Tables 7.7 through 7.10 and plotted in 
Figures 7.2 through 7.5.  These factors were calculated using the 
CINDY computer code. 
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Table 7.7.  Lung Retention Fractions Following Uranium Inhalation(a) 
 
Class D Inhalation Class W Inhalation Class Y InhalationDays Post 
Intake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
0 0.33 0.17 0.33 0.17 0.33 0.17 
1 0.080 0.028 0.21 0.075 0.21 0.077 
2 0.024 0.0086 0.18 0.063 0.18 0.064 
5 5.8E-04 2.1E-04 0.15 0.051 0.15 0.054 
7 4.5E-05 1.6E-05 0.14 0.049 0.15 0.053 
14 insig. insig. 0.13 0.044 0.15 0.052 
30 insig. insig. 0.10 0.036 0.15 0.051 
60 insig. insig. 0.070 0.025 0.14 0.050 
90 insig. insig. 0.048 0.017 0.14 0.048 
180 insig. insig. 0.015 0.0053 0.12 0.044 
365 insig. insig. 0.0014 4.8E-04 0.10 0.036 
730 insig. insig. 1.1E-05 3.9E-06 0.073 0.026 
1,825 insig. insig. insig. insig. 0.029 0.010 
3,600 insig. insig. insig. insig. 0.0099 0.0035 
7,300 insig. insig. insig. insig. 0.0042 0.0015 
18,250 insig. insig. insig. insig. 0.0038 0.0013 
(a) Factors are applicable to 234U, 235U, 236U, 238U, natural uranium, depleted 
uranium, recycled uranium, or any combination thereof. 
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Figure 7.2.  Uranium Lung Retention 
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Table 7.8.  Urine Excretion Fractions Following Uranium Intake(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion Days Post  
Intake 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=0.02 f1=0.0020 
1 1.2E-02 1.0E-01 8.4E-02 1.2E-02 2.0E-02 8.0E-04 1.6E-03 4.3E-03 4.3E-04 
2 3.5E-02 4.1E-02 2.8E-02 3.9E-03 6.0E-03 2.7E-04 5.0E-04 8.4E-04 8.4E-05 
5 2.2E-02 1.2E-02 1.2E-02 2.1E-03 3.0E-03 1.2E-04 2.3E-04 4.5E-04 4.5E-05 
7 1.8E-02 9.3E-03 1.0E-02 1.8E-03 2.5E-03 1.0E-04 1.9E-04 3.7E-04 3.8E-05 
14 1.0E-02 5.0E-03 5.5E-03 1.2E-03 1.4E-03 6.3E-05 1.1E-04 2.0E-04 2.0E-05 
30 3.4E-03 1.7E-03 1.9E-03 6.5E-04 5.7E-04 3.2E-05 3.9E-05 6.9E-05 6.9E-06 
60 9.1E-04 4.4E-04 5.0E-04 3.8E-04 2.3E-04 2.1E-05 1.5E-05 1.8E-05 1.8E-06 
90 3.1E-04 1.5E-04 1.7E-04 2.6E-04 1.2E-04 1.9E-05 9.3E-06 6.3E-06 6.3E-07 
180 1.7E-05 8.4E-06 9.4E-06 9.0E-05 3.4E-05 1.8E-05 6.5E-06 3.5E-07 3.5E-08 
365 3.5E-06 1.7E-06 1.9E-06 1.1E-05 4.1E-06 1.8E-05 6.5E-06 6.9E-08 6.9E-09 
730 3.2E-06 1.5E-06 1.7E-06 5.3E-07 5.1E-07 1.7E-05 6.1E-06 6.4E-08 6.4E-09 
1,825 2.7E-06 1.3E-06 1.5E-06 3.5E-07 4.0E-07 1.1E-05 3.8E-06 5.4E-08 5.4E-09 
3,600 2.0E-06 9.7E-07 1.1E-06 2.7E-07 3.0E-07 3.7E-06 1.3E-06 4.0E-08 4.0E-09 
7,300 1.2E-06 5.6E-07 6.4E-07 1.5E-07 1.7E-07 3.7E-07 1.4E-07 2.4E-08 2.4E-09 
18,250 2.5E-07 1.2E-07 1.4E-07 3.3E-08 3.7E-08 1.7E-08 8.0E-09 5.1E-09 5.1E-10 
(a) Factors are applicable to 234U, 235U, 236U, 238U, natural uranium, depleted uranium, recycled uranium, or any combination thereof. 
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Figure 7.3.  Uranium Urinary Excretion 
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Table 7.9.  Fecal Excretion Fractions Following Intake of Uranium(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion Days Post  
Intake 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm Soluble  Insoluble  
1 0.0E+00 7.0E-02 1.7E-01 1.0E-01 2.1E-01 1.3E-01 2.5E-01 4.6E-01 4.7E-01 
2 0.0E+00 4.4E-02 1.1E-01 1.3E-01 2.5E-01 1.6E-01 2.9E-01 2.8E-01 2.8E-01 
5 0.0E+00 2.8E-03 6.7E-03 2.3E-02 3.0E-02 2.4E-02 3.4E-02 1.8E-02 1.8E-02 
7 0.0E+00 3.8E-04 9.2E-04 6.1E-03 5.4E-03 5.4E-03 5.6E-03 2.4E-03 2.5E-03 
14 0.0E+00 3.5E-07 8.4E-07 1.2E-03 4.2E-04 1.7E-04 6.3E-05 2.2E-06 2.3E-06 
30 0.0E+00 4.3E-13 1.8E-12 9.2E-04 3.2E-04 1.3E-04 4.7E-05 5.3E-12 7.7E-13 
60 0.0E+00 insig. insig. 6.1E-04 2.1E-04 1.3E-04 4.5E-05 insig. insig. 
90 0.0E+00 insig. insig. 4.0E-04 1.4E-04 1.2E-04 4.3E-05 insig. insig. 
180 0.0E+00 insig. insig. 1.2E-04 4.1E-05 1.1E-04 3.8E-05 insig. insig. 
365 0.0E+00 insig. insig. 8.9E-06 3.1E-06 8.4E-05 2.9E-05 insig. insig. 
730 0.0E+00 insig. insig. 5.6E-08 2.0E-08 5.0E-05 1.8E-05 insig. insig. 
1,825 0.0E+00 insig. insig. 1.7E-13 8.3E-15 1.1E-05 3.9E-06 insig. insig. 
3,600 0.0E+00 insig. insig. insig. insig. 9.4E-07 3.3E-07 insig. insig. 
7,300 0.0E+00 insig. insig. insig. insig. 5.6E-09 2.0E-09 insig. insig. 
18,250 0.0E+00 insig. insig. insig. insig. 1.5E-15 6.2E-16 insig. insig. 
(a) Factors are applicable to 234U, 235U, 236U, 238U, natural uranium, depleted uranium, recycled uranium, or any combination thereof. 
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Figure 7.4.  Uranium Fecal Excretion 
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Table 7.10.  Kidney Retention Fractions Following Uranium Intake(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion Days Post 
Intake 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=0.02 f1=0.0020 
1 1.0E-01 3.8E-02 5.2E-02 7.8E-03 1.3E-02 4.5E-04 9.6E-04 2.0E-03 2.0E-04 
2 9.9E-02 4.5E-02 5.3E-02 7.8E-03 1.3E-02 4.7E-04 9.8E-04 2.0E-03 2.0E-04 
3 8.9E-02 4.3E-02 4.9E-02 7.1E-03 1.2E-02 4.3E-04 8.9E-04 1.8E-03 1.8E-04 
4 7.9E-02 4.0E-02 4.4E-02 6.5E-03 1.0E-02 3.9E-04 8.0E-04 1.6E-03 1.6E-04 
5 7.1E-02 3.6E-02 3.9E-02 5.8E-03 9.3E-03 3.5E-04 7.2E-04 1.4E-03 1.5E-04 
7 5.6E-02 2.9E-02 3.1E-02 4.8E-03 7.5E-03 2.8E-04 5.7E-04 1.2E-03 1.2E-04 
14 2.5E-02 1.3E-02 1.4E-02 2.4E-03 3.5E-03 1.4E-04 2.6E-04 5.2E-04 5.2E-05 
30 4.4E-03 2.2E-03 2.4E-03 8.0E-04 7.4E-04 4.0E-05 5.1E-05 9.0E-05 9.0E-06 
60 6.3E-04 3.0E-04 3.4E-04 4.1E-04 2.1E-04 2.2E-05 1.3E-05 1.3E-05 1.3E-06 
90 5.0E-04 2.4E-04 2.7E-04 3.1E-04 1.6E-04 2.2E-05 1.2E-05 1.0E-05 1.0E-06 
180 4.8E-04 2.3E-04 2.6E-04 1.5E-04 1.0E-04 2.3E-05 1.2E-05 9.6E-06 9.6E-07 
365 4.4E-04 2.1E-04 2.4E-04 6.8E-05 6.9E-05 2.5E-05 1.2E-05 8.8E-06 8.8E-07 
730 3.7E-04 1.8E-04 2.0E-04 4.9E-05 5.5E-05 2.6E-05 1.2E-05 7.4E-06 7.4E-07 
1,825 2.2E-04 1.1E-04 1.2E-04 3.0E-05 3.3E-05 2.2E-05 9.7E-06 4.5E-06 4.5E-07 
3,650 9.6E-05 4.6E-05 5.2E-05 1.3E-05 1.4E-05 1.2E-05 5.1E-06 1.9E-06 1.9E-07 
(a)  Factors are applicable to 234U, 235U, 236U, 238U, natural uranium, depleted uranium, recycled uranium, or any combination thereof. 
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Figure 7.5.  Kidney Retention of Uranium 
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7.2.4 Chemical Toxicity 
 
Chemical toxicity is a potential concern for intakes of low-
enrichment uranium (<10% 235U, by weight) in a readily 
transportable form (class D or W).  Such concerns can make 
chemical toxicity a more limiting intake condition than dose 
equivalent.  Chemical toxicity is not a major issue for slowly 
transportable forms (class Y). 
 
The Hanford basis for chemical toxicity is now a peak kidney 
concentration of 1.1 mg-U/g-kidney resulting from either acute or 
chronic exposure.  This approach is conservative, in that a larger 
acute kidney concentration can be tolerated without significant effect 
than might result from a long-term chronic concentration.  The 
1.1-mg/g value was chosen based on acute or chronic intake 
scenarios, even though indications are that a 3-mg/g chronic value 
can be tolerated without significant effect.  (See the following 
paragraphs for more detailed discussion.)  Multiplying the 1.1-mg/g 
value by the kidney mass of 310 g gives a total kidney burden of 
341 g as a Reference Man value for a “no effect” threshold.  Acute 
intakes can be calculated which would result in such a kidney burden 
by dividing the kidney burden by the kidney retention fraction.  This 
analysis is included for several intake scenarios in Section 7.3.  
Chronic intake rates can be similarly calculated, however such levels 
have not been included in this manual because chronic intake is not 
currently a routine Hanford condition. 
 
A chronic kidney burden of 3 mg-U/g-kidney has historically been 
the basis for development of action levels for bioassay monitoring of 
workers who are chronically exposed to uranium (Hursh and Spoor 
1973).  Studies by Morrow et al. (1982) with the highly transportable 
and toxic form of uranium, UO2F2, indicated that steady-state kidney 
concentrations of 3 mg/g in dogs were sufficient to produce indica-
tions of uranium poisoning.  Although UO2F2 is not handled at 
Hanford, it is prudent for bioassay monitoring purposes to assume a 
renal toxicity threshold of less than 3 mg/g of kidney.  Based on 
recent studies by a number of investigators, Rich et al. (1988) 
suggested that the “no effect” threshold for uranium in kidney is 
1.1 mg/g.  Hanford adopted a “no effect” threshold of 0.4 mg/g as a 
sustained kidney burden value, based on one-third of the Rich value, 
rounded to one significant figure (Sula, Carbaugh, and Bihl 1989).  
This sustained kidney burden approach is now replaced for Hanford 
applications by a peak kidney concentration approach, using the 
1.1 mg/g value for both chronic and acute exposure scenarios. 
 
Additional publications have raised some question as to the 
appropriate magnitude for an assumed “no effects threshold level” of 
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uranium intake, uptake, or kidney burden.  In an extensive review 
article, Leggett (1989) noted that results and conclusions of studies 
have varied widely and that “apparent discrepancies may be due 
largely to differences in 1) perceptions and/or definitions of toxicity, 
2) sensitivity of the measurements of kidney damage or dysfunction, 
3) patterns of exposure (for example, acute versus chronic), and 
4) sensitivity to renal U in different species.”  Leggett concluded “it 
may be prudent to lower this long-standing guidance level [of 
3 mgU/g] by roughly an order of magnitude until more is known 
about subtle physiological effects of small quantities of U in the 
kidneys.”  Similar sentiment was expressed by SuLu and Zhao 
(1990) in recommending a maximum safe uranium burden in the 
kidney of 0.26 mg/g, based on a 10-fold safety factor below mild 
kidney impairment observed in one human case at 2.6 mgU/g.  
Considering Leggett noted that the early researchers cited ranges of 
“much less than 5 mg/g, probably 2 to 3 mg/g” rather than absolute 
values, the question of a 1.1 mg/g versus a 0.3 mg/g “no effects” 
threshold relates more to a matter of an assumed factor for conser-
vativeness rather than actual linkage to significant identifiable 
effects. 
 
The ICRP provided a brie f overview of chemical toxicity in 
publication 78 (ICRP 1997).  Guidance for a maximum single acute 
intake of 2.5-mg uranium in any one day was provided in ICRP 6 
(1964), based on work by Eve (1964).  However, Eve’s analysis was 
derived from the assumption that a daily intake of 2.5 mg of uranium 
could be tolerated without harm (i.e., chronic exposure of 2.5 mg/d).  
Of more relevance for acute intakes are the results of human injec-
tion studies that have shown an uptake of 0.07 mg of hexavalent 
uranium per kilogram of body weight produced transient injury and 
0.1 mgU/kg of body weight produced catalasuria and proteinuria 
(Hursh and Spoor 1973).  A renal toxicity threshold of 0.1 mg of 
acute uptake to blood per kilogram of body weight or a 7-mg of 
acute uptake for Reference Man was used at Hanford during the 
1980s and 1990s as a basis for action levels for highly soluble 
uranium bioassay monitoring.  This corresponded to an acute 
inhalation of 15 mg of class D uranium as a threshold for renal 
toxicity. 
 
The Occupational Safety and Health Administration regulations 
(29 CFR 1910.1000 Table Z-1) set airborne permissible exposure 
limits (PELs) for natural uranium of 0.05 mg/m3 for soluble 
compounds and 0.25 mg/m3 for insoluble compounds, implying daily 
intake limits of 0.48 mg (0.5 mg) and 2.4 mg, respectively.  The 
American Conference on Governmental Industrial Hygienists 
(ACGIH 1968; 1983) recommended a threshold limit value (TLV) 
for air concentration of uranium as 0.2 mg/m3.  In addition, ACGIH 
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set a short-term exposure limit (STEL) of 0.6 mg/m3 as an average 
concentration over a 15-minute period.  The OSHA PELs and 
ACGIH TLVs are time-weighted-average values that apply over an 
8-hour workday for a 40-hour workweek and a working lifetime; i.e., 
they represent a chronic occupational exposure condition. 
 
Studies of the highly soluble uranyl fluoride (UO2F2) showed that 
intravenous doses of 0.01 mgU/kg of body weight for dogs and 0.1 
mgU/kg of body weight for rats were nephrotoxic, and that the 
threshold for injury in man was thought to be about 0.07 mgU/kg of 
body weight (Morrow et al. 1982).  The renal toxicity of uranium 
varies with the compound form, with toxicity increasing with 
chemical solubility (Morrow et al. 1982).  Based on work by Just 
(1984), Just and Emler (1984), and Fisher, Swint, and Kathren 
(1990), McGuire (1991) concluded that an acute intake of soluble 
uranium of 10 mg or less is unlikely to have any detectable (even 
transient) effects, and that a 40-mg intake (possibly as high as 100 
mg) is likely to be below the level of any permanent effects.  
McGuire cited as levels corresponding to a threshold for transient 
renal injury or effect, values of 0.058 mg-U/kg of body weight, 4 mg 
in total body of 70-kg person (Reference Man), and an acute intake 
of 8.3 mg.  The ANSI standard HPS N13.22-1995, Bioassay 
Programs for Uranium (HPS 1995) repeated McGuire’s tabulations 
in its appendix. 
 
7.3 Internal Dosimetry Factors 
 
This section contains factors that are useful in making internal 
dosimetry calculations.  The factors included in this section are 
derived from the CINDY computer code and incorporate the models 
and assumptions described in the preceding section.  Their 
application is intended for those circumstances where such 
assumptions are appropriate or more specific information is lacking.  
Variation from these factors is appropriate if sufficient data are 
available. 
 
7.3.1 Intake Retention and Excretion Fractions  
 
Selected lung retention, urinary excretion, fecal excretion, and 
kidney retention fractions for instantaneous uptake, acute inhalation, 
and acute ingestion are tabulated in Tables 7.7 through 7.10 and 
plotted in Figures 7.2 through 7.5.  These factors were calculated 
using the CINDY computer code.  Chronic occupational exposure to 
uranium, though routine in the past at the UO3 Plant and the Fuel 
Production Facilities, is not a likely scenario at Hanford due to 
current work scope and workplace control practices.  If needed, 
chronic exposure factors can be calculated using the CINDY code. 
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7.3.2 Dose Coefficients 
 
Dose coefficients, expressed as committed dose equivalent per unit 
activity of intake (or mass of intake, if converted using the pure 
isotopic specific activity of Table 7.2 or the isotopic mixture specific 
activities of Table 7.3), are a convenient shortcut to estimating doses 
based on standard assumptions when the magnitude of an intake is 
known or assumed.  Acute intake dose coefficients are tabulated in 
Tables 7.11 through 7.14 for the uranium isotopes 238U, 236U, 235U, 
and 234U for instantaneous uptake, class D, W, and Y inhalations (for 
both 1-mm- and 5-mm-AMAD particle sizes) and for ingestion.  
These dose coefficients were derived using the CINDY computer 
code.  Table 7.15 gives committed effective dose equivalent 
coefficients for the constituents of recycled uranium.  Table 7.16 
summarizes dose coefficients for natural uranium, depleted uranium, 
and recycled uranium mixtures. 
 
Impurity radionuclides present in recycled uranium must be 
considered in dose assessments.  Table 7.15 includes a summary of 
the contributions to the 50-year committed effective dose equivalent 
from the presence of reference levels of impurities in recycled 
uranium.  From the table, it is seen that impurities do not signifi-
cantly affect effective dose equivalents from class Y recycled 
uranium intakes, but they do contribute sufficiently to doses of class 
D and class W intakes to warrant their consideration.  While the bone 
surface dose contributions seem significantly higher for class Y 
intakes, the effective dose poses the most limiting exposure condi-
tion, and the impurities have negligible impact on that dose.  
Contributions to total dose from non-uranium impurity radionuclides 
may be estimated by multiplying the committed dose from uranium 
isotopes by the ratio of the total committed effective dose equivalent 
to the committed dose from uranium activity alone, as given in 
Table 7.15.  This represents a reasonable assessment of the total dose 
when impurities are within the historical specifications.  If intakes 
are sufficiently large that depositions of impurity radionuclides may 
be observable via bioassay measurements, then such measurements 
should be performed and resulting measurements factored into dose 
estimates. 
 
Table 7.16 provides a tabulation of dose coefficients for acute intakes 
of uranium mixtures in term of committed dose equivalent per unit 
mass of uranium intake.  These units were selected because the mon-
itoring for such mixtures has historically been performed using 
elemental uranium mass bioassay measurements. 
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Table 7.11.  Committed Dose Coefficients for Acute Intakes of 238U (rem/nCi)(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion 
Organ or Tissue  
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=0.02 f1=0.002 
Effective 5.5E-03 2.7E-03 3.0E-03 7.0E-03 3.0E-03 1.2E-01 4.2E-02 1.2E-04 2.5E-05 
Bone Surface 7.6E-02 3.6E-02 4.1E-02 9.9E-03 1.1E-02 3.8E-03 2.0E-03 1.5E-03 1.5E-04 
Kidneys 3.1E-02 1.5E-02 1.7E-02 4.1E-03 4.6E-03 1.6E-03 8.2E-04 6.3E-04 6.3E-05 
Red Marrow 5.0E-03 2.4E-03 2.7E-03 6.6E-04 7.4E-04 2.5E-04 1.3E-04 1.0E-04 1.0E-05 
Lung  insig. 1.0E-03 4.3E-04 5.2E-02 1.8E-02 9.8E-01 3.5E-01 insig. insig. 
Lower Large Intestine insig. insig. insig. insig. insig. insig. 1.6E-04 1.7E-04 1.7E-04 
Upper Large Intestine insig. insig. insig. insig. insig. insig. insig. insig. 5.4E-04 
(a) To convert to rem/mg, multiply by specific activity of 0.336 nCi/mg. 
 
Table 7.12.  Committed Dose Coefficients for Acute Intakes of 236U (rem/nCi)(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion 
Organ or Tissue  
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=0.02 f1=0.002 
Effective 5.8E-03 2.9E-03 3.2E-03 7.6E-03 3.3E-03 1.3E-01 4.5E-02 1.3E-04 2.6E-05 
Bone Surface 8.0E-02 3.8E-02 4.3E-02 1.0E-02 1.2E-02 4.0E-03 2.1E-03 1.6E-03 1.6E-04 
Kidneys 3.3E-02 1.6E-02 1.8E-02 4.3E-03 4.9E-03 1.7E-03 8.7E-04 6.7E-04 6.7E-05 
Red Marrow 5.1E-03 2.4E-03 2.7E-03 6.6E-04 7.4E-04 2.5E-04 1.3E-04 1.0E-04 1.0E-05 
Lung  insig. 1.1E-03 4.7E-04 5.6E-02 2.0E-02 1.1E+00 3.7E-01 insig. insig. 
Lower Large Intestine insig. insig. insig. insig. insig. insig. insig. 1.7E-04 1.7E-04 
Upper Large Intestine insig. insig. insig. insig. insig. insig. insig. 5.8E-05 5.6E-05 
(a) To convert to rem/mg, multiply by specific activity of 64.7 nCi/mg. 
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Table 7.13.  Committed Dose Coefficients for Acute Intakes of 235U (rem/nCi)(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion 
Organ or Tissue  
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=0.02 f1=0.002 
Effective 5.6E-03 2.8E-03 3.1E-03 7.4E-03 3.2E-03 1.2E-01 4.4E-02 1.3E-04 2.8E-05 
Bone Surface 7.7E-02 3.7E-02 4.2E-02 1.0E-02 1.1E-02 3.9E-03 2.0E-03 1.5E-03 1.5E-04 
Kidneys 3.2E-02 1.5E-02 1.7E-02 4.2E-03 4.7E-03 1.7E-03 8.5E-04 6.5E-04 6.5E-05 
Red Marrow 5.0E-03 2.4E-03 2.7E-03 6.5E-04 7.3E-04 2.6E-04 1.3E-04 1.0E-04 1.0E-05 
Lung  insig. 1.1E-03 4.6E-04 5.5E-02 1.9E-02 1.0E+00 3.6E-01 insig. insig. 
Lower Large Intestine insig. insig. insig. insig. insig. insig. insig. 2.0E-04 2.0E-04 
Upper Large Intestine insig. insig. insig. insig. insig. insig. insig. 6.5E-05 6.2E-05 
(a) To convert to rem/mg, multiply by specific activity of 2.16 nCi/mg. 
 
Table 7.14.  Committed Dose Coefficients for Acute Intakes of 234U (rem/nCi)(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion 
Organ or Tissue  
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=0.02 f1=0.002 
Effective 6.1E-03 3.0E-03 3.3E-03 8.0E-03 3.4E-03 1.3E-01 4.7E-02 1.4E-04 2.7E-05 
Bone Surface 8.4E-02 4.0E-02 4.5E-02 1.1E-02 1.2E-02 4.2E-03 2.2E-03 1.7E-03 1.7E-04 
Kidneys 3.4E-02 1.6E-02 1.9E-02 4.5E-03 5.1E-03 1.8E-03 9.0E-04 6.9E-04 6.9E-05 
Red Marrow 5.4E-03 2.6E-03 2.9E-03 7.0E-04 7.9E-04 2.7E-04 1.4E-04 1.1E-04 1.1E-05 
Lung  insig. 1.2E-03 4.9E-04 5.9E-02 2.1E-02 1.1E+00 3.9E-01 insig. insig. 
Lower Large Intestine insig. insig. insig. insig. insig. insig. insig. 1.8E-04 1.8E-04 
Upper Large Intestine insig. insig. insig. insig. insig. insig. insig. 6.4E-05 6.1E-05 
(a) To convert to rem/mg, multiply by specific activity of 6.25E+03 nCi/mg. 
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Table 7.15.  Dose Coefficients for Recycled Uranium Constituents 
 
 Instant Class D Inhalation Class W Inhalation Class Y Inhalation 
 Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
Mixture  
Committed Effective Dose Coefficients 
U-only (rem/nCi-U) 5.9E-03 2.9E-03 3.2E-03 7.6E-03 3.2E-03 1.3E-01 4.5E-02 
Impurities 
 Pu-alpha (rem/nCi-U)(a) 1.7E-03 2.1E-04 2.2E-04 2.1E-04 2.2E-04 1.5E-04 6.2E-05 
 237Np (rem/nCi-U)(b) 2.0E-03 2.4E-04 2.6E-04 2.4E-04 2.6E-04 1.5E-04 6.6E-05 
 232Th (rem/nCi-U)(c) 7.7E-05 8.8E-06 9.9E-06 8.8E-06 9.9E-06 6.6E-06 2.8E-06 
 99Tc (rem/nCi-U)(c) 5.3E-07 3.5E-07 4.8E-07 1.9E-06 1.0E-06 1.9E-06 1.0E-06 
 106Ru (rem/nCi-U)(c) 4.8E-06 2.6E-06 3.0E-06 5.3E-06 2.9E-06 2.1E-05 8.4E-06 
 95ZrNb (rem/nCi-U)(c) 1.0E-06 5.1E-07 5.9E-07 3.3E-07 2.6E-07 4.8E-07 2.4E-07 
RU-Total (rem/nCi-U) 9.6E-03 3.3E-03 3.7E-03 8.1E-03 3.7E-03 1.3E-01 4.5E-02 
Ratio of RU-total:U-only 1.64 1.16 1.16 1.06 1.15 1.00 1.00 
RU-Total (rem/mg-U) 8.7E-03 3.0E-03 3.3E-03 7.3E-03 3.4E-03 1.2E-01 4.1E-02 
Committed Bone Surface Dose Coefficients 
U-only (rem/nCi-U) 8.1E-02 3.8E-02 4.3E-02 1.1E-02 1.2E-02 4.0E-03 2.1E-03 
Impurities 
 Pu-alpha (rem/nCi-U) (a) 3.1E-02 3.7E-03 4.3E-03 3.7E-03 4.3E-03 1.5E-03 7.9E-04 
 237Np (rem/nCi-U) (b) 4.4E-02 5.3E-03 5.7E-03 5.3E-03 5.7E-03 2.1E-03 1.1E-03 
 232Th (rem/nCi-U)(c) 1.9E-03 2.3E-04 2.5E-04 2.3E-04 2.5E-04 9.9E-05 4.8E-05 
 99Tc (rem/nCi-U) (c) 7.5E-08 4.6E-08 6.4E-08 4.0E-08 5.7E-08 4.0E-08 5.7E-08 
 106Ru (nCi/nCi-U)(c) 5.3E-06 2.6E-06 3.0E-06 7.5E-07 9.2E-07 2.9E-07 3.3E-07 
 95ZrNb (nCi/nCi-U)(c) 1.8E-05 8.6E-06 9.7E-06 1.8E-06 2.2E-06 1.9E-07 2.2E-07 
RU-Total (rem/nCi-U) 1.6E-01 4.8E-02 5.4E-02 2.0E-02 2.2E-02 7.7E-03 4.0E-03 
Ratio of RU-total:U-only 1.96 1.24 1.24 1.88 1.88 1.92 1.90 
RU-Total (rem/mg-U) 1.4E-01 4.3E-02 4.9E-02 1.8E-02 2.0E-02 7.0E-03 3.7E-03 
Committed Lung Dose Coefficients 
U-only (rem/nCi-U) NA 1.1E-03 4.7E-04 5.6E-02 2.0E-02 1.1E+00 3.7E-01 
Impurities 
 Pu-alpha (rem/nCi-U)(a) insig. 2.8E-05 1.0E-05 2.8E-05 1.0E-05 5.3E-04 1.8E-04 
 237Np (rem/nCi-U)(b) insig. 2.6E-05 9.2E-06 2.6E-05 9.2E-06 4.8E-04 1.7E-04 
 232Th (rem/nCi-U)(c) insig. 2.9E-07 1.2E-07 2.9E-07 1.2E-07 1.9E-05 6.6E-06 
 99Tc (rem/nCi-U)(c) insig. 2.9E-07 1.4E-07 1.3E-05 4.8E-06 1.3E-05 4.8E-06 
 106Ru (nCi/nCi-U)(c) insig. 2.9E-06 2.8E-06 3.3E-05 1.2E-05 1.7E-04 5.7E-05 
 95ZrNb (nCi/nCi-U)(c) insig. 1.8E-07 1.7E-07 1.5E-06 5.5E-07 3.3E-06 1.2E-06 
RU-Total (rem/nCi-U) insig. 1.2E-03 4.9E-04 5.6E-02 2.0E-02 1.1E+00 3.7E-01 
Ratio of RU-total:U-only insig. 1.05 1.05 1.00 1.00 1.00 1.00 
RU-Total (rem/mg-U) insig. 1.1E-03 4.4E-04 5.1E-02 1.8E-02 9.6E-01 3.4E-01 
(a) Based on 20-year aged weapons grade plutonium (see Table 8.14). 
(b) Table 10.5 class W values used for class D and W.  Class Y calculated from CINDY. 
(c) Based on closest, most soluble class.  Calculated using CINDY.  No allowance for decay. 
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Table 7.16.  Committed Dose Coefficients for Acute Intakes of Uranium Mixtures (rem/mg-U) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion 
 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=0.02 f1=0.002 
Natural Uranium 
Effective 4.1E-03 2.0E-03 2.2E-03 5.3E-03 2.3E-03 8.8E-02 3.1E-02 9.2E-05 1.8E-05 
Bone Surface 5.6E-02 2.7E-02 3.0E-02 7.4E-03 8.1E-03 8.8E-02 1.5E-03 1.1E-03 1.1E-04 
Lung insig. 7.8E-04 3.3E-04 3.9E-02 1.4E-02 7.3E-01 2.6E-01 insig. insig. 
Depleted Uranium 
Effective 2.1E-03 1.0E-03 1.1E-03 2.6E-03 1.1E-03 4.5E-02 1.6E-02 4.5E-05 9.4E-06 
Bone Surface 2.9E-02 1.4E-02 1.5E-02 3.7E-03 4.1E-03 4.5E-02 7.5E-04 5.6E-04 5.6E-05 
Lung insig. 3.8E-04 1.6E-04 2.0E-02 6.8E-03 3.7E-01 1.3E-01 insig. insig. 
Recycled Uranium (U-Only) 
Effective 5.3E-03 2.6E-03 2.9E-03 6.9E-03 3.0E-03 1.1E-01 4.1E-02 1.2E-04 2.4E-05 
Bone Surface 7.3E-02 3.5E-02 3.9E-02 9.6E-03 1.1E-02 3.7E-03 1.9E-03 1.5E-03 1.5E-04 
Lung insig. 1.0E-03 4.2E-04 5.1E-02 1.8E-02 9.6E-01 3.4E-01 insig. insig. 
Recycled Uranium (U+Impurities) 
Effective 8.7E-03 3.0E-03 3.3E-03 7.3E-03 3.4E-03 1.2E-01 4.1E-02 1.2E-04 2.5E-05 
Bone Surface 1.4E-01 4.3E-02 4.9E-02 1.8E-02 2.0E-02 7.0E-03 3.7E-03 1.5E-03 1.7E-04 
Lung insig. 1.1E-03 4.4E-04 5.1E-02 1.8E-02 9.6E-01 3.4E-01 insig. insig. 
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7.3.3 Comparison of Published Dosimetry Factors  
 
A comparison of dosimetry factors, including committed effective 
dose coefficients, annual limits on intake (ALIs), and derived air 
concentrations (DACs) published in several sources is shown in 
Table 7.17. 
 
7.3.4 Derived Reference Levels  
 
Hanford reference and derived reference levels have been tabulated 
for recycled uranium.  Screening and investigation levels have been 
calculated based on committed effective dose equivalents of 
10-mrem and 100-mrem, respectively.  A dose compliance level has 
been calculated based on 50-rem to the bone surfaces for class D 
inhalations and based on 5-rem committed effective dose equivalent 
for class W and Y intakes.  The chemical toxicity threshold was 
calculated based on a peak kidney concentration of 1.1 mg-U/g-
kidney, giving a total kidney burden of 341-mg and applying the most 
limiting kidney retention fraction. 
 
Reference level inhalation intakes are tabulated for 1-mm and 5-mm 
particle sizes for class D, W, and Y inhalations of recycled uranium 
in Tables 7.18, 7.19, and 7.20, respectively, and in Table 7.21 for 
ingestion intakes.  The derived urine excretion levels shown in 
Table 7.18 through 7.21 represent the excess urinary excretion 
associated with the indicated intake above the natural background.  
To account for the anticipated natural uranium background at 
Hanford, 0.021 mg/d (rounding to 0.02 is appropriate) should be 
added to the tabulated values. 
 
Chest-count-derived reference levels for class W and Y intakes, 
based on recycled uranium, are shown in Tables 7.22 and 7.23 for 
234Th (assumed to be in equilibrium with 238U), and in Tables 7.24 
and 7.25 for 235U. 
 
7.4 Bioassay Monitoring 
 
Bioassay monitoring procedures for uranium include excreta analysis 
and in vivo measurements.  Urinalysis is an indicator of systemically 
deposited uranium; fecal analysis provides an indication of the 
amount of uranium that is being cleared from the lung; and in vivo 
counting provides a direct measurement of the quantity of uranium in 
the lung.  The following sections discuss urine sampling, in vivo 
measurement, fecal excretion, the routine bioassay monitoring 
program, and special bioassay measurements following a potential 
acute intake. 
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Table 7.17.  Comparison of Selected Published Dosimetry Factors for 238U 
 
Reference Class D Inhalation Class W Inhalation Class Y Inhalation 
Effective Dose Coefficients 
CINDY [he,50] 
2.7E-03 rem/nCi (1-mm) 
3.0E-03 rem/nCi (5-mm) 
7.0E-03 rem/nCi (1-mm) 
3.0E-03 rem/nCi (5-mm) 
1.2E-01 rem/nCi (1-mm) 
4.2E-02 rem/nCi (5-mm) 
ICRP 54  (1988) [he,50] 
 
6.4E-07 Sv/Bq (1-mm) 
(2.4E-03 rem/nCi) 
1.7E-06 Sv/Bq (1-mm) 
(6.3E-03 rem/nCi) 
3.2E-05 Sv/Bq (1-mm) 
(1.2E-01 rem/nCi) 
EPA Federal Guidance  
Report No. 11 [he,50] 
6.62E-07 Sv/Bq (1-mm Class W) 
(2.4E-03 rem/nCi) 
1.4E-06 Sv/Bq (1-mm) 
(5.2E-03 rem/nCi) 
3.20E-05 Sv/Bq (1-mm) 
(1.18E-01 rem/nCi) 
ICRP 68 (1994) [e(50)] 
 
4.9E-07 Sv/Bq  (1-mm Type F) 
(1.8E-03 rem/nCi) 
5.8E-07 Sv/Bq (5-um Type F) 
(2.1E-03 rem/nCi) 
2.6E-06 Sv/Bq (1-mm Type M) 
(9.6E-03 rem/nCi) 
1.6E-06 Sv/Bq (5-mm Type M) 
(5.9E-03 rem/nCi) 
7.3E-06 Sv/Bq (1-mm Type S) 
(2.7E-02 rem/nCi) 
5.7E-06 Sv/Bq (5-mm Type S) 
(2.1E-02 rem/nCi) 
Derived Air Concentration (Based on bone surface dose limit) (Based on stochastic limit) (Based on stochastic limit) 
10 CFR 835 Appendix A 6E-10 mCi/ml 
2E+01 Bq/m3 
3E-10 mCi/ml 
1E+01 Bq/m3  
2E-11 mCi/ml 
6E-01 Bq/m3 
EPA Federal Guidance  
Report No. 11  
6E-10 mCi/ml 
2E-05 MBq/m3 
3E-10 mCi/ml 
1E-05 MBq/m3  
2E-11 mCi/ml 
7E-07 MBq/m3 
ICRP 54 2E+01 Bq/m3 1E+01 Bq/m3 7E-01 Bq/m3 
Annual Limit on Intake (Based on bone surface dose) (Based on stochastic limit) (Based on stochastic limit) 
ICRP 54 5E+04 Bq 3E+04 Bq 2E+03 Bq 
EPA Federal Guidance  
Report No. 11 
0.05 MBq 
1 mCi 
0.03 MBq 
0.8 mCi 
0.002 MBq 
0.04 mCi 
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Table 7.18.  Urine Excretion(a) Reference Levels and Derived Reference Levels for Cla ss D Inhalation of Recycled Uranium 
 
10-mrem HE,50 
Screening Level 
100-mrem HE,50 
Investigation Level 
50-rem HT,50 
Compliance Level 
Chemical Toxicity 
Threshold Level 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm(b) 5-mm(c) 
Inhalation  
Intake (mg) 
3.3E+00 3.0E+00 3.3E+01 3.0E+01 1.2E+03 1.0E+03 7.6E+00 6.4E+00 
Derived Screening  
Level (mg/d) 
Derived Investigation 
Level (mg/d) 
Derived Compliance 
Level (mg/d) 
Derived Toxicity  
Level (mg/d) Days Post  
Intake 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 3.3E+02 2.5E+02 3.3E+03 2.5E+03 1.2E+05 8.6E+04 7.6E+02 5.4E+02 
2 1.4E+02 8.5E+01 1.4E+03 8.5E+02 4.8E+04 2.9E+04 3.1E+02 1.8E+02 
5 4.0E+01 3.6E+01 4.0E+02 3.6E+02 1.4E+04 1.2E+04 9.1E+01 7.7E+01 
7 3.1E+01 3.0E+01 3.1E+02 3.0E+02 1.1E+04 1.0E+04 7.1E+01 6.4E+01 
14 1.7E+01 1.7E+01 1.7E+02 1.7E+02 5.8E+03 5.6E+03 3.8E+01 3.5E+01 
30 5.7E+00 5.8E+00 5.7E+01 5.8E+01 2.0E+03 1.9E+03 1.3E+01 1.2E+01 
60 1.5E+00 1.5E+00 1.5E+01 1.5E+01 5.1E+02 5.1E+02 3.3E+00 3.2E+00 
90 5.0E-01 5.2E-01 5.0E+00 5.2E+00 1.7E+02 1.7E+02 1.1E+00 1.1E+00 
180 2.8E-02 2.8E-02 2.8E-01 2.8E-01 9.8E+00 9.6E+00 6.4E-02 6.0E-02 
365 5.7E-03 5.8E-03 5.7E-02 5.8E-02 2.0E+00 1.9E+00 1.3E-02 1.2E-02 
730 5.0E-03 5.2E-03 5.0E-02 5.2E-02 1.7E+00 1.7E+00 1.1E-02 1.1E-02 
1825 4.3E-03 4.5E-03 4.3E-02 4.5E-02 1.5E+00 1.5E+00 9.9E-03 9.6E-03 
3650 3.2E-03 3.3E-03 3.2E-02 3.3E-02 1.1E+00 1.1E+00 7.4E-03 7.0E-03 
7300 1.9E-03 1.9E-03 1.9E-02 1.9E-02 6.5E-01 6.5E-01 4.3E-03 4.1E-03 
18250 4.0E-04 4.2E-04 4.0E-03 4.2E-03 1.4E-01 1.4E-01 9.1E-04 9.0E-04 
(a) Excess excretion above background. 
(b) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 0.045). 
(c) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 0.053). 
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Table 7.19.  Urine Excretion(a) Reference Levels and Derived Reference Levels for Class W Inhalation of Recycled Uranium 
 
10-mrem HE,50 
Screening Level 
100-mrem HE,50 
Investigation Level 
50-rem HE,50 
Compliance Level 
Chemical Toxicity 
Threshold Level 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm(b) 5-mm(c) 
Inhalation  
Intake (mg) 
1.4E+00 2.9E+00 1.4E+01 2.9E+01 6.8E+02 1.5E+03 4.4E+01 2.6E+01 
Derived Screening  
Level (mg/d) 
Derived Investigation 
Level (mg/d) 
Derived Compliance 
Level (mg/d) 
Derived Toxicity  
Level (mg/d) Days Post  
Intake 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 1.6E+01 5.9E+01 1.6E+02 5.9E+02 8.2E+03 2.9E+04 5.3E+02 5.2E+02 
2 5.3E+00 1.8E+01 5.3E+01 1.8E+02 2.7E+03 8.8E+03 1.7E+02 1.6E+02 
5 2.9E+00 8.8E+00 2.9E+01 8.8E+01 1.4E+03 4.4E+03 9.2E+01 7.8E+01 
7 2.5E+00 7.4E+00 2.5E+01 7.4E+01 1.2E+03 3.7E+03 7.9E+01 6.5E+01 
14 1.6E+00 4.1E+00 1.6E+01 4.1E+01 8.2E+02 2.1E+03 5.3E+01 3.6E+01 
30 8.9E-01 1.7E+00 8.9E+00 1.7E+01 4.5E+02 8.4E+02 2.9E+01 1.5E+01 
60 5.2E-01 6.8E-01 5.2E+00 6.8E+00 2.6E+02 3.4E+02 1.7E+01 6.0E+00 
90 3.6E-01 3.5E-01 3.6E+00 3.5E+00 1.8E+02 1.8E+02 1.1E+01 3.1E+00 
180 1.2E-01 1.0E-01 1.2E+00 1.0E+00 6.2E+01 5.0E+01 4.0E+00 8.8E-01 
365 1.5E-02 1.2E-02 1.5E-01 1.2E-01 7.5E+00 6.0E+00 4.8E-01 1.1E-01 
730 7.3E-04 1.5E-03 7.3E-03 1.5E-02 3.6E-01 7.5E-01 2.3E-02 1.3E-02 
1825 4.8E-04 1.2E-03 4.8E-03 1.2E-02 2.4E-01 5.9E-01 1.5E-02 1.0E-02 
3650 3.7E-04 8.8E-04 3.7E-03 8.8E-03 1.8E-01 4.4E-01 1.2E-02 7.8E-03 
7300 2.1E-04 5.0E-04 2.1E-03 5.0E-03 1.0E-01 2.5E-01 6.6E-03 4.4E-03 
18250 4.5E-05 1.1E-04 4.5E-04 1.1E-03 2.3E-02 5.4E-02 1.5E-03 9.6E-04 
(a) Excess excretion above background. 
(b) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 0.0078). 
(c) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 0.013). 
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Table 7.20.  Urine Excretion(a) Reference Levels and Derived Reference Levels for Class Y Inhalation of Recycled Uranium 
 
10-mrem HE,50 
Screening Level 
100-mrem HE,50 
Investigation Level 
5-rem HE,50 
Compliance Level 
Chemical Toxicity 
Threshold Level 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm(b) 5-mm(c) 
Inhalation  
Intake (mg) 
8.3E-02 2.4E-01 8.3E-01 2.4E+00 4.2E+01 1.2E+02 7.3E+02 3.5E+02 
Derived Screening  
Level (mg/d) 
Derived Investigation 
Level (mg/d) 
Derived Compliance 
Level (mg/d) 
Derived Toxicity  
Level (mg/d) Days Post  
Intake 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 6.7E-02 3.9E-01 6.7E-01 3.9E+00 3.3E+01 2.0E+02 5.8E+02 5.6E+02 
2 2.3E-02 1.2E-01 2.3E-01 1.2E+00 1.1E+01 6.1E+01 2.0E+02 1.7E+02 
5 1.0E-02 5.6E-02 1.0E-01 5.6E-01 5.0E+00 2.8E+01 8.7E+01 8.0E+01 
7 8.3E-03 4.6E-02 8.3E-02 4.6E-01 4.2E+00 2.3E+01 7.3E+01 6.6E+01 
14 5.3E-03 2.7E-02 5.3E-02 2.7E-01 2.6E+00 1.3E+01 4.6E+01 3.8E+01 
30 2.7E-03 9.5E-03 2.7E-02 9.5E-02 1.3E+00 4.8E+00 2.3E+01 1.4E+01 
60 1.8E-03 3.7E-03 1.8E-02 3.7E-02 8.8E-01 1.8E+00 1.5E+01 5.2E+00 
90 1.6E-03 2.3E-03 1.6E-02 2.3E-02 7.9E-01 1.1E+00 1.4E+01 3.2E+00 
180 1.5E-03 1.6E-03 1.5E-02 1.6E-02 7.5E-01 7.9E-01 1.3E+01 2.3E+00 
365 1.5E-03 1.6E-03 1.5E-02 1.6E-02 7.5E-01 7.9E-01 1.3E+01 2.3E+00 
730 1.4E-03 1.5E-03 1.4E-02 1.5E-02 7.1E-01 7.4E-01 1.2E+01 2.1E+00 
1825 9.2E-04 9.3E-04 9.2E-03 9.3E-03 4.6E-01 4.6E-01 8.0E+00 1.3E+00 
3650 3.1E-04 3.2E-04 3.1E-03 3.2E-03 1.5E-01 1.6E-01 2.7E+00 4.5E-01 
7300 3.1E-05 3.4E-05 3.1E-04 3.4E-04 1.5E-02 1.7E-02 2.7E-01 4.9E-02 
18250 1.4E-06 2.0E-06 1.4E-05 2.0E-05 7.1E-04 9.8E-04 1.2E-02 2.8E-03 
(a) Excess excretion above background. 
(b) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 4.7E-04). 
(c) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 9.8E-04). 
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Table 7.21.  Urine Excretion(a) Reference Levels and Derived Reference Levels for Ingestion of Recycled Uranium 
 
Compliance Level 
10-mrem HE,50 
Screening Level 
100-mrem HE,50 
Investigation Level 
50-rem 
HT,50 
5-rem  
HE.50 
Chemical Toxicity 
Threshold Level 
Soluble  Insoluble  Soluble  Insoluble  Soluble  Insoluble  Soluble (b) Insoluble (c) 
Inhalation  
Intake (mg) 
8.3E+01 4.0E+02 8.3E+02 4.0E+03 3.3E+04 2.0E+05 1.7E+02 1.7E+03 
Derived Screening  
Level (mg/d) 
Derived Investigation 
Level (mg/d) 
Derived Compliance 
Level (mg/d) 
Derived Toxicity  
Level (mg/d) Days Post  
Intake 
Soluble  Insoluble  Soluble  Insoluble  Soluble  Insoluble  Soluble  Insoluble  
1 3.6E+02 1.7E+02 3.6E+03 1.7E+03 1.4E+05 8.6E+04 7.3E+02 7.3E+02 
2 7.0E+01 3.4E+01 7.0E+02 3.4E+02 2.8E+04 1.7E+04 1.4E+02 1.4E+02 
5 3.8E+01 1.8E+01 3.8E+02 1.8E+02 1.5E+04 9.0E+03 7.7E+01 7.7E+01 
7 3.1E+01 1.5E+01 3.1E+02 1.5E+02 1.2E+04 7.6E+03 6.3E+01 6.5E+01 
14 1.7E+01 8.0E+00 1.7E+02 8.0E+01 6.7E+03 4.0E+03 3.4E+01 3.4E+01 
30 5.8E+00 2.8E+00 5.8E+01 2.8E+01 2.3E+03 1.4E+03 1.2E+01 1.2E+01 
60 1.5E+00 7.2E-01 1.5E+01 7.2E+00 6.0E+02 3.6E+02 3.1E+00 3.1E+00 
90 5.3E-01 2.5E-01 5.3E+00 2.5E+00 2.1E+02 1.3E+02 1.1E+00 1.1E+00 
180 2.9E-02 1.4E-02 2.9E-01 1.4E-01 1.2E+01 7.0E+00 6.0E-02 6.0E-02 
365 5.8E-03 2.8E-03 5.8E-02 2.8E-02 2.3E+00 1.4E+00 1.2E-02 1.2E-02 
730 5.3E-03 2.6E-03 5.3E-02 2.6E-02 2.1E+00 1.3E+00 1.1E-02 1.1E-02 
1825 4.5E-03 2.2E-03 4.5E-02 2.2E-02 1.8E+00 1.1E+00 9.2E-03 9.2E-03 
3650 3.3E-03 1.6E-03 3.3E-02 1.6E-02 1.3E+00 8.0E-01 6.8E-03 6.8E-03 
7300 2.0E-03 9.6E-04 2.0E-02 9.6E-03 8.0E-01 4.8E-01 4.1E-03 4.1E-03 
18250 4.3E-04 2.0E-04 4.3E-03 2.0E-03 1.7E-01 1.0E-01 8.7E-04 8.7E-04 
(a) Excess excretion above background. 
(b) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 2.0E-04). 
(c) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 2.0E-03). 
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Table 7.22.  Chest Count Reference Levels and 234Th(a) Derived Reference Levels for Class W Inhalation of Recycled Uranium 
 
10-mrem HE,50 
Screening Level 
100-mrem HE,50 
Investigation Level 
5-rem HE,50 
Compliance Level 
Chemical Toxicity 
Threshold Level 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm(c) 5-mm(d) 
Inhalation  
Intake  
nCi 238U(b) 
4.6E-01 9.8E-01 4.6E+00 9.8E+00 2.3E+02 4.9E+02 1.5E+01 8.6E+00 
Derived Screening  
Level (nCi 234Th) 
Derived Investigation 
Level (nCi 234Th) 
Derived Compliance 
Level (nCi 234Th) 
Derived Toxicity  
Level (nCi 234Th) 
Days Post  
Intake 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 9.6E-02 7.3E-02 9.6E-01 7.3E-01 4.8E+01 3.7E+01 3.1E+00 6.5E-01 
2 8.2E-02 6.2E-02 8.2E-01 6.2E-01 4.1E+01 3.1E+01 2.6E+00 5.4E-01 
5 6.8E-02 5.0E-02 6.8E-01 5.0E-01 3.4E+01 2.5E+01 2.2E+00 4.4E-01 
7 6.4E-02 4.8E-02 6.4E-01 4.8E-01 3.2E+01 2.4E+01 2.0E+00 4.2E-01 
14 5.9E-02 4.3E-02 5.9E-01 4.3E-01 3.0E+01 2.2E+01 1.9E+00 3.8E-01 
30 4.6E-02 3.5E-02 4.6E-01 3.5E-01 2.3E+01 1.8E+01 1.5E+00 3.1E-01 
60 3.2E-02 2.4E-02 3.2E-01 2.4E-01 1.6E+01 1.2E+01 1.0E+00 2.2E-01 
90 2.2E-02 1.7E-02 2.2E-01 1.7E-01 1.1E+01 8.3E+00 7.0E-01 1.5E-01 
180 6.8E-03 5.2E-03 6.8E-02 5.2E-02 3.4E+00 2.6E+00 2.2E-01 4.6E-02 
365 6.4E-04 4.7E-04 6.4E-03 4.7E-03 3.2E-01 2.3E-01 2.0E-02 4.1E-03 
730 insig. insig. insig. insig. insig. insig. insig. insig. 
(a) Assumes secular equilibrium with 238U. 
(b) Based on 0.3325 nCi 238U/mg-RU. 
(c) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 0.0078). 
(d) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 0.013). 
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Table 7.23.  Chest Count Reference Levels and 234Th(a) Derived Reference Levels for Class Y Inhalation of Recycled Uranium 
 
10-mrem HE,50 
Screening Level 
100-mrem HE,50 
Investigation Level 
5-rem HE,50 
Compliance Level 
Chemical Toxicity 
Threshold Level 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm(c) 5-mm(d) 
Inhalation  
Intake  
nCi 238U(b) 
2.8E-02 8.1E-02 2.8E-01 8.1E-01 1.4E+01 4.1E+01 2.4E+02 1.2E+02 
Derived Screening  
Level (nCi 234Th) 
Derived Investigation 
Level (nCi 234Th) 
Derived Compliance 
Level (nCi 234Th) 
Derived Toxicity  
Level (nCi 234Th) 
Days Post  
Intake 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 5.8E-03 6.2E-03 5.8E-02 6.2E-02 2.9E+00 3.1E+00 5.1E+01 8.9E+00 
2 5.0E-03 5.2E-03 5.0E-02 5.2E-02 2.5E+00 2.6E+00 4.3E+01 7.4E+00 
5 4.2E-03 4.4E-03 4.2E-02 4.4E-02 2.1E+00 2.2E+00 3.6E+01 6.2E+00 
7 4.2E-03 4.3E-03 4.2E-02 4.3E-02 2.1E+00 2.1E+00 3.6E+01 6.1E+00 
14 4.2E-03 4.2E-03 4.2E-02 4.2E-02 2.1E+00 2.1E+00 3.6E+01 6.0E+00 
30 4.2E-03 4.1E-03 4.2E-02 4.1E-02 2.1E+00 2.1E+00 3.6E+01 5.9E+00 
60 3.9E-03 4.1E-03 3.9E-02 4.1E-02 1.9E+00 2.0E+00 3.4E+01 5.8E+00 
90 3.9E-03 3.9E-03 3.9E-02 3.9E-02 1.9E+00 1.9E+00 3.4E+01 5.6E+00 
180 3.3E-03 3.6E-03 3.3E-02 3.6E-02 1.7E+00 1.8E+00 2.9E+01 5.1E+00 
365 2.8E-03 2.9E-03 2.8E-02 2.9E-02 1.4E+00 1.5E+00 2.4E+01 4.2E+00 
730 2.0E-03 2.1E-03 2.0E-02 2.1E-02 1.0E+00 1.1E+00 1.8E+01 3.0E+00 
1825 8.0E-04 8.1E-04 8.0E-03 8.1E-03 4.0E-01 4.1E-01 7.0E+00 1.2E+00 
3650 2.7E-04 2.8E-04 2.7E-03 2.8E-03 1.4E-01 1.4E-01 2.4E+00 4.0E-01 
7300 1.2E-04 1.2E-04 1.2E-03 1.2E-03 5.8E-02 6.1E-02 1.0E+00 1.7E-01 
18250 1.1E-04 1.1E-04 1.1E-03 1.1E-03 5.3E-02 5.3E-02 9.2E-01 1.5E-01 
(a) Assumed secular equilibrium with 238U. 
(b) Based on 0.3325 nCi 238U/mg-RU. 
(c) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 4.7E-04). 
(d) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 9.8E-04). 
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Table 7.24.  Chest Count Reference Levels and 235U Derived Reference Levels for Class W Inhalation of Recycled Uranium 
 
10-mrem HE,50 
Screening Level 
100-mrem HE,50 
Investigation Level 
5-rem HE,50 
Compliance Level 
Chemical Toxicity 
Threshold Level 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm(b) 5-mm(c) 
Inhalation  
Intake  
nCi 235U(a) 
2.9E-02 6.2E-02 2.9E-01 6.2E-01 1.4E+01 3.1E+01 9.2E-01 5.5E-01 
Derived Screening  
Level (nCi 235U) 
Derived Investigation 
Level (nCi 235U) 
Derived Compliance 
Level (nCi 235U) 
Derived Toxicity  
Level (nCi 235U) 
Days Post  
Intake 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 6.0E-03 4.6E-03 6.0E-02 4.6E-02 3.0E+00 2.3E+00 1.9E-01 4.1E-02 
2 5.2E-03 3.9E-03 5.2E-02 3.9E-02 2.6E+00 1.9E+00 1.7E-01 3.4E-02 
5 4.3E-03 3.2E-03 4.3E-02 3.2E-02 2.2E+00 1.6E+00 1.4E-01 2.8E-02 
7 4.0E-03 3.0E-03 4.0E-02 3.0E-02 2.0E+00 1.5E+00 1.3E-01 2.7E-02 
14 3.7E-03 2.7E-03 3.7E-02 2.7E-02 1.9E+00 1.4E+00 1.2E-01 2.4E-02 
30 2.9E-03 2.2E-03 2.9E-02 2.2E-02 1.4E+00 1.1E+00 9.2E-02 2.0E-02 
60 2.0E-03 1.5E-03 2.0E-02 1.5E-02 1.0E+00 7.7E-01 6.5E-02 1.4E-02 
90 1.4E-03 1.1E-03 1.4E-02 1.1E-02 6.9E-01 5.3E-01 4.4E-02 9.3E-03 
180 4.3E-04 3.3E-04 4.3E-03 3.3E-03 2.2E-01 1.6E-01 1.4E-02 2.9E-03 
365 4.0E-05 3.0E-05 4.0E-04 3.0E-04 2.0E-02 1.5E-02 1.3E-03 2.6E-04 
730 insig. insig. insig. insig. insig. insig. insig. insig. 
(a) Based on 0.021 nCi 235U/mg-RU. 
(b) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 0.0078). 
(c) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 0.013). 
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Table 7.25.  Chest Count Reference Levels and 235U Derived Reference Levels for Class Y Inhalation of Recycled Uranium 
 
10-mrem HE,50 
Screening Level 
100-mrem HE,50 
Investigation Level 
5-rem HE,50 
Compliance Level 
Chemical Toxicity 
Threshold Level 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm(b) 5-mm(c) 
Inhalation  
Intake  
nCi 235U(a) 
1.8E-03 5.1E-03 1.8E-02 5.1E-02 8.8E-01 2.6E+00 1.5E+01 7.3E+00 
Derived Screening  
Level (nCi 235U) 
Derived Investigation 
Level (nCi 235U) 
Derived Compliance 
Level (nCi 235U) 
Derived Toxicity  
Level (nCi 235U) 
Days Post  
Intake 
1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 3.7E-04 3.9E-04 3.7E-03 3.9E-03 1.8E-01 2.0E-01 3.2E+00 5.6E-01 
2 3.2E-04 3.3E-04 3.2E-03 3.3E-03 1.6E-01 1.6E-01 2.7E+00 4.7E-01 
5 2.6E-04 2.8E-04 2.6E-03 2.8E-03 1.3E-01 1.4E-01 2.3E+00 3.9E-01 
7 2.6E-04 2.7E-04 2.6E-03 2.7E-03 1.3E-01 1.4E-01 2.3E+00 3.9E-01 
14 2.6E-04 2.7E-04 2.6E-03 2.7E-03 1.3E-01 1.3E-01 2.3E+00 3.8E-01 
30 2.6E-04 2.6E-04 2.6E-03 2.6E-03 1.3E-01 1.3E-01 2.3E+00 3.7E-01 
60 2.5E-04 2.6E-04 2.5E-03 2.6E-03 1.2E-01 1.3E-01 2.1E+00 3.7E-01 
90 2.5E-04 2.5E-04 2.5E-03 2.5E-03 1.2E-01 1.2E-01 2.1E+00 3.5E-01 
180 2.1E-04 2.3E-04 2.1E-03 2.3E-03 1.1E-01 1.1E-01 1.8E+00 3.2E-01 
365 1.8E-04 1.8E-04 1.8E-03 1.8E-03 8.8E-02 9.2E-02 1.5E+00 2.6E-01 
730 1.3E-04 1.3E-04 1.3E-03 1.3E-03 6.4E-02 6.7E-02 1.1E+00 1.9E-01 
1825 5.1E-05 5.1E-05 5.1E-04 5.1E-04 2.5E-02 2.6E-02 4.4E-01 7.3E-02 
3650 1.7E-05 1.8E-05 1.7E-04 1.8E-04 8.7E-03 9.0E-03 1.5E-01 2.6E-02 
7300 7.4E-06 7.7E-06 7.4E-05 7.7E-05 3.7E-03 3.8E-03 6.4E-02 1.1E-02 
18250 6.7E-06 6.7E-06 6.7E-05 6.7E-05 3.3E-03 3.3E-03 5.8E-02 9.5E-03 
(a) Based on 0.021 nCi 235U/mg-RU. 
(b) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 4.7E-04). 
(c) Based on maximum kidney burden of 1.1 mg-U/g-kidneys at 2 days post intake (Rt = 9.8E-04). 
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7.4.1 Urine Sampling and Analysis 
 
The interpretation of urinalysis measurements is highly dependent on 
knowledge of the time and duration of the intake and on assumptions 
regarding the biokinetic transport and excretion of systemically 
absorbed uranium.  Standard biokinetic models provide estimated 
uranium excretion rates in terms of daily output (i.e., micrograms per 
day).  The influence of diurnal variations in urination frequency and 
volume may be lessened if a full 24-hour collection is obtained rather 
than a single grab sample. 
 
According to ICRP 30, studies of the metabolism of uranium in man 
show that a significant amount of uranium entering the circulatory 
system (54%) is not deposited in body tissue but instead passes 
directly to excretion.  The excretion of this unabsorbed fraction can 
result in highly variable urinary levels under conditions of ongoing 
repeated or chronic exposure as depicted in Figure 7.6. 
 
Because of the possible large time variability in uranium excretion 
rates due to this unabsorbed fraction, quantitative interpretation of 
bioassay data is best accomplished by either collecting all of the 
unabsorbed fraction (i.e., that voided during the first several days 
after exposure) or by collecting samples after the unabsorbed fraction 
has been eliminated.  For routine sampling of potentially chronically 
exposed workers, it is desirable to collect the urine sample several  
 
 
 
 Figure 7.6. Daily Variability in Instantaneous Urinary Excretion from Chronic Inhalation of 
1 mg/workday of Class D Uranium (Curve shown is for 52nd week of exposure.) 
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days after any possible exposure.  For the initial evaluation of 
potentially significant uptakes of uranium, a single void sample 
within 3 to 4 hours of the exposure is appropriate. 
 
For the reasons stated above, the optimum urine sample for a routine 
uranium bioassay sampling program is a 24-hour total urine collec-
tion after several days’ absence from any source of intake.  Because 
this is not always practicable to implement on a large scale, an 
approximate 24-hour sample is commonly used, which consists of 
urine voided between one-half hour prior to retiring to bed in the 
evening and one-half hour after rising for two consecutive nights.  
Alternatively, the evaluation of bioassay measurement results may be 
normalized to a single day’s excretion using reference volumes of 
1400 ml/d for males and 1000 ml/d for females if only a partial day’s 
sample (e.g., single void) is obtained. 
 
The sensitivity of urine sampling is limited by the presence of 
environmental levels of uranium.  As discussed in Section 7.1.3, it is 
estimated that environmental levels in urine locally average 
0.021 mg/d and range from non-detection to over 0.2 mg/d.  The net 
occupationally derived uranium in urine can be approximated by 
subtracting 0.02 mg/d (rounded) from the observed total daily 
excretion.  Samples containing less than 0.2 mg/d of uranium are 
generally considered to be within the expected environmental range.  
As such, any result above 0.2 mg/d is initially considered to possibly 
contain occupationally derived uranium and the net amount 
attributed to occupational sources is generally calculated as the total 
observed amount minus the average expected environmental level of 
0.02 mg/d.  Thus, 0.18 mg/d becomes the de facto minimum 
detectable occupational urine excretion rate. 
 
Urine samples can be analyzed using either elemental mass or alpha 
radioactivity measurements.  The above discussion of background 
uranium levels in urine can be converted from elemental uranium 
mass units to isotopic alpha activity units by multiplying by the 
specific activity for each constituent of natural uranium.  Results are 
shown in Table 7.26.  The minimum detectable uranium intakes 
based on the 0.18 mg/d net occupational excretion described above 
are shown in Table 7.27.  The associated minimum detectable doses 
for Table 7.27 values of recycled uranium intakes are shown in 
Table 7.28 and depicted graphically in Figure 7.7.  The doses for 
natural uranium and depleted uranium are lower. 
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Table 7.26. Natural Uranium Background Levels for Hanford 
Bioassay Urinalysis 
 
 
Geometric  
Mean Excretion 
Normal Upper Bound 
Screening Level 
Elemental U (mass) 0.021 mg/d 0.2 mg/d 
238U 0.0070 dpm/d 0.15 dpm/d 
236U negligible negligible 
235U 0.0003 dpm/d 0.003 dpm/d 
234U 0.0075 dpm/d 0.16 dpm/d 
 
In addition to the routine elemental mass and alpha spectroscopy 
analytical methods, an inductively coupled plasma mass spectrom-
etry (ICPMS) method has been developed that is capable of detecting 
the very small levels of 236U associated with Hanford recycled 
uranium (Wyse et al. 1995).  This procedure is not part of the routine 
monitoring program but is occasionally used as an investigational 
tool for high routine analyses (MacLellan 1995).  The method has 
not been submitted for DOELAP accreditation, however an aliquot 
of the same sample analyzed by the normal elemental mass 
procedure can provide independent quality verification on the overall 
results. 
 
Of special importance in the evaluation of bioassay measurement 
capability is the potential for chronic intakes.  Any chronic exposure 
subsequent to an acute intake could significantly affect the interpre-
tation of the urinalysis measurement.  In facilities where uncontained 
uranium is handled, urinalysis as a means for monitoring for acute 
intakes is acceptable, but quantitative assessment of intake or dose 
equivalent based on the results of routine urine samples can be 
subject to large uncertainties.  At present, it is assumed that chronic 
occupational exposure at Hanford is not occurring.  Assessment of 
intakes of poorly transportable uranium using urinalysis should be 
cautiously performed and should consider available in vivo measure-
ment results and other information regarding the exposure. 
 
7.4.2 In Vivo Measurements  
 
Uranium is detectable in the lung using in vivo techniques.  Detec-
tion is achieved by measuring photon emissions from 235U and 234Th.  
Thorium-234 is a decay product of 238U assumed to be in secular 
equilibrium for uranium contamination at Hanford.  The Hanford 
method for in vivo measurement of uranium is chest counting using  
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Table 7.27.  Minimum Detectable Intakes (mg) of Uranium Based on 0.18 mg/d in Urine(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion Days Post  
Intake 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm Soluble  Insoluble  
1 1.5E-02 1.8E-03 2.1E-03 1.5E-02 9.0E-03 2.3E-01 1.1E-01 4.2E-02 4.2E-01 
2 5.1E-03 4.4E-03 6.4E-03 4.6E-02 3.0E-02 6.7E-01 3.6E-01 2.1E-01 2.1E+00 
5 8.2E-03 1.5E-02 1.5E-02 8.6E-02 6.0E-02 1.5E+00 7.8E-01 4.0E-01 4.0E+00 
7 1.0E-02 1.9E-02 1.8E-02 1.0E-01 7.2E-02 1.8E+00 9.5E-01 4.9E-01 4.7E+00 
14 1.8E-02 3.6E-02 3.3E-02 1.5E-01 1.3E-01 2.9E+00 1.6E+00 9.0E-01 9.0E+00 
30 5.3E-02 1.1E-01 9.5E-02 2.8E-01 3.2E-01 5.6E+00 4.6E+00 2.6E+00 2.6E+01 
60 2.0E-01 4.1E-01 3.6E-01 4.7E-01 7.8E-01 8.6E+00 1.2E+01 1.0E+01 1.0E+02 
90 5.8E-01 1.2E+00 1.1E+00 6.9E-01 1.5E+00 9.5E+00 1.9E+01 2.9E+01 2.9E+02 
180 1.1E+01 2.1E+01 1.9E+01 2.0E+00 5.3E+00 1.0E+01 2.8E+01 5.1E+02 5.1E+03 
365 5.1E+01 1.1E+02 9.5E+01 1.6E+01 4.4E+01 1.0E+01 2.8E+01 2.6E+03 2.6E+04 
730 5.6E+01 1.2E+02 1.1E+02 3.4E+02 3.5E+02 1.1E+01 3.0E+01 2.8E+03 2.8E+04 
1,825 6.7E+01 1.4E+02 1.2E+02 5.1E+02 4.5E+02 1.6E+01 4.7E+01 3.3E+03 3.3E+04 
3,600 9.0E+01 1.9E+02 1.6E+02 6.7E+02 6.0E+02 4.9E+01 1.4E+02 4.5E+03 4.5E+04 
7,300 1.5E+02 3.2E+02 2.8E+02 1.2E+03 1.1E+03 4.9E+02 1.3E+03 7.5E+03 7.5E+04 
18,250 7.2E+02 1.5E+03 1.3E+03 5.5E+03 4.9E+03 1.1E+04 2.3E+04 3.5E+04 3.5E+05 
(a) Assumes 0.2 mg/d screening level with 0.02 mg/d mean background excretion subtracted. 
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 Table 7.28. Minimum Detectable Committed Effective Dose Equivalents (rem) for Recycled Uranium 
Based on 0.18 mg/d in Urine(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion Days 
Post 
Intake 1-mm 5-um 1-mm 5-mm 1-mm 5-mm 
Instantaneous
Uptake Soluble Insoluble 
1 5.4E-06 7.1E-06 1.1E-04 3.1E-05 2.7E-02 4.6E-03 1.3E-04 5.0E-06 1.0E-05 
2 1.32E-05 2.1E-05 3.4E-04 1.0E-04 8.0E-02 1.5E-02 4.5E-05 2.6E-05 5.4E-05 
5 4.5E-05 5.0E-05 6.3E-04 2.0E-04 1.8E-01 3.2E-02 7.1E-05 4.8E-05 1.0E-04 
7 5.8E-05 5.9E-05 7.3E-04 2.4E-04 2.2E-01 3.9E-02 8.7E-05 5.8E-05 1.2E-04 
14 1.1E-04 1.1E-04 1.1E-03 4.4E-04 3.4E-01 6.7E-02 1.6E-04 1.1E-04 2.3E-04 
30 3.2E-04 3.1E-04 2.0E-03 1.1E-03 6.8E-01 1.9E-01 4.6E-04 3.1E-04 6.5E-04 
60 1.2E-03 1.2E-03 3.5E-03 2.7E-03 1.0E+00 4.9E-01 1.7E-03 1.2E-03 2.5E-03 
90 3.6E-03 3.5E-03 5.1E-03 5.1E-03 1.1E+00 7.9E-01 5.1E-03 3.4E-03 7.1E-03 
180 6.4E-02 6.3E-02 1.5E-02 1.8E-02 1.2E+00 1.1E+00 9.2E-02 6.2E-02 1.3E-01 
365 3.2E-01 3.1E-01 1.2E-01 1.5E-01 1.2E+00 1.1E+00 4.5E-01 3.1E-01 6.5E-01 
730 3.6E-01 3.5E-01 2.5E+00 1.2E+00 1.3E+00 1.2E+00 4.9E-01 3.4E-01 7.0E-01 
1,825 4.2E-01 4.0E-01 3.8E+00 1.5E+00 2.0E+00 1.9E+00 5.8E-01 4.0E-01 8.3E-01 
3,600 5.6E-01 5.4E-01 4.9E+00 2.0E+00 5.8E+00 5.7E+00 7.8E-01 5.4E-01 1.1E+00 
7,300 9.6E-01 9.3E-01 8.8E+00 3.6E+00 5.8E+01 5.3E+01 1.3E+00 9.0E-01 1.9E+00 
18,250 4.5E+00 4.2E+00 4.0E+01 1.7E+01 1.3E+03 9.2E+02 6.3E+00 4.2E+00 8.8E+00 
(a) Assumes 0.2 mg/d screening level with 0.02 mg/d mean background excretion subtracted. 
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Figure 7.7.  Minimum Detectable Dose for Recycled Uranium Based on 0.18 mg/d Net Urine Excretion 
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the low-energy planar germanium detectors, as described in the In 
Vivo Monitoring Project Manual (PNL-MA-574)(a).  Current 
measurement protocols provide a nominal minimum detectable 
activity of 1.5 nCi for 234Th and 0.09 nCi for 235U. 
 
Table 7.29 shows the minimum detectable intakes of recycled 
uranium implied by the detection of 1.5 nCi of 234Th in the lung.  The 
associated minimum detectable committed effective dose equivalents 
are shown in Table  7.30 and Figure 7.8.  Tables 7.31, 7.32, and 
Figure 7.9 provide similar information based on the detection of 
0.09 nCi of 235U in the lung.  Collectively, these presentations show 
that routine in vivo measurements do not meet the bioassay 
monitoring goal of a 100-mrem committed effective dose equivalent 
as a minimum detectable dose.  Their ability to demonstrate 
compliance with dose limits is dependent on the frequency of 
measurement.  They are a valuable tool as special measurements 
following suspected intakes of class W or class Y material. 
 
 Table 7.29. Minimum Detectable Intakes (mg) of Recycled Uranium Based on  
1.5 nCi 234Th in Chest Count(a, b) 
 
Class D Inhalation Class W Inhalation Class Y InhalationDays Post 
Intake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 5.6E+01 1.6E+02 2.1E+01 6.0E+01 2.1E+01 5.9E+01 
2 1.9E+02 5.2E+02 2.5E+01 7.2E+01 2.5E+01 7.0E+01 
5 7.8E+03 2.1E+04 3.0E+01 8.8E+01 3.0E+01 8.4E+01 
7 1.0E+05 2.8E+05 3.2E+01 9.2E+01 3.0E+01 8.5E+01 
14 NA NA 3.5E+01 1.0E+02 3.0E+01 8.7E+01 
30 NA NA 4.5E+01 1.3E+02 3.0E+01 8.8E+01 
60 NA NA 6.4E+01 1.8E+02 3.2E+01 9.0E+01 
90 NA NA 9.4E+01 2.7E+02 3.2E+01 9.4E+01 
180 NA NA 3.0E+02 8.5E+02 3.8E+01 1.0E+02 
365 NA NA 3.2E+03 9.4E+03 4.5E+01 1.3E+02 
730 NA NA 4.1E+05 1.2E+06 6.2E+01 1.7E+02 
1,825 NA NA NA NA 1.6E+02 4.5E+02 
3,600 NA NA NA NA 4.6E+02 1.3E+03 
7,300 NA NA NA NA 1.1E+03 3.0E+03 
18,250 NA NA NA NA 1.2E+03 3.5E+03 
(a) Assumes secular equilibrium with 238U. 
(b) Implies an MDA of 4.5-mg recycled uranium, based on Table  7.3 
isotopic composition. 
NA = not applicable. 
 
                                                 
(a) Pacific Northwest National Laboratory (PNNL).  In Vivo Monitoring Project Manual.  PNNL-MA-
574, Richland, Washington.  (Internal manual.) 
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 Table 7.30. Minimum Detectable Committed Effective Dose Equivalents (rem) for Recycled 
Uranium Based on 1.5 nCi 234Th in Chest Count(a, b) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 1.7E-01 5.3E-01 1.6E-01 2.0E-01 2.6E+00 2.4E+00 
2 5.6E-01 1.7E+00 1.8E-01 2.4E-01 3.0E+00 2.9E+00 
5 2.3E+01 7.1E+01 2.2E-01 3.0E-01 3.6E+00 3.4E+00 
7 3.0E+02 9.3E+02 2.4E-01 3.1E-01 3.6E+00 3.5E+00 
14 NA NA 2.5E-01 3.5E-01 3.6E+00 3.6E+00 
30 NA NA 3.3E-01 4.3E-01 3.6E+00 3.6E+00 
60 NA NA 4.7E-01 6.1E-01 3.9E+00 3.7E+00 
90 NA NA 6.9E-01 9.0E-01 3.9E+00 3.9E+00 
180 NA NA 2.2E+00 2.9E+00 4.5E+00 4.2E+00 
365 NA NA 2.4E+01 3.2E+01 5.4E+00 5.1E+00 
730 NA NA 3.0E+03 3.9E+03 7.4E+00 7.1E+00 
1,825 NA NA NA NA 1.9E+01 1.8E+01 
3,600 NA NA NA NA 5.5E+01 5.3E+01 
7,300 NA NA NA NA 1.3E+02 1.2E+02 
18,250 NA NA NA NA 1.4E+02 1.4E+02 
(a) Assumes secular equilibrium with 238U. 
(b) Implies an MDA of 4.5-mg recycled uranium, based on Table  7.3 
isotopic composition. 
NA = not applicable. 
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Figure 7.8.  Minimum Detectable Dose for Recycled Uranium Based on 1.5 nCi 234Th in Chest 
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Table 7.31. Minimum Detectable Intakes (mg) of  Recycled Uranium Based on 0.09 nCi 235U  
in Chest Count(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 5.4E+01 1.5E+02 2.0E+01 5.7E+01 2.0E+01 5.6E+01 
2 1.8E+02 5.0E+02 2.4E+01 6.8E+01 2.4E+01 6.7E+01 
5 7.4E+03 2.0E+04 2.9E+01 8.4E+01 2.9E+01 7.9E+01 
7 NA NA 3.1E+01 8.7E+01 2.9E+01 8.1E+01 
14 NA NA 3.3E+01 9.7E+01 2.9E+01 8.2E+01 
30 NA NA 4.3E+01 1.2E+02 2.9E+01 8.4E+01 
60 NA NA 6.1E+01 1.7E+02 3.1E+01 8.6E+01 
90 NA NA 8.9E+01 2.5E+02 3.1E+01 8.9E+01 
180 NA NA 2.9E+02 8.1E+02 3.6E+01 9.7E+01 
365 NA NA 3.1E+03 8.9E+03 4.3E+01 1.2E+02 
730 NA NA 3.9E+05 1.1E+06 5.9E+01 1.6E+02 
1,825 NA NA NA NA 1.5E+02 4.3E+02 
3,600 NA NA NA NA 4.3E+02 1.2E+03 
7,300 NA NA NA NA 1.0E+03 2.9E+03 
18,250 NA NA NA NA 1.1E+03 3.3E+03 
(a) Implies an MDA of 4.3-mg recycled uranium, based on Table  7.3 
isotopic composition. 
 
 Table 7.32. Minimum Detectable Committed Effective Dose Equivalents (rem) for Recycled 
Uranium Based on 0.09 nCi 235U in Chest Count(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 1.6E-01 5.1E-01 1.5E-01 1.9E-01 2.4E+00 2.3E+00 
2 5.4E-01 1.6E+00 1.7E-01 2.3E-01 2.9E+00 2.7E+00 
5 2.2E+01 6.7E+01 2.1E-01 2.9E-01 3.4E+00 3.3E+00 
7 2.9E+02 8.8E+02 2.2E-01 3.0E-01 3.4E+00 3.3E+00 
14 NA NA 2.4E-01 3.3E-01 3.4E+00 3.4E+00 
30 NA NA 3.1E-01 4.0E-01 3.4E+00 3.4E+00 
60 NA NA 4.5E-01 5.8E-01 3.7E+00 3.5E+00 
90 NA NA 6.5E-01 8.6E-01 3.7E+00 3.7E+00 
180 NA NA 2.1E+00 2.7E+00 4.3E+00 4.0E+00 
365 NA NA 2.2E+01 3.0E+01 5.1E+00 4.9E+00 
730 NA NA 2.8E+03 3.7E+03 7.0E+00 6.8E+00 
1,825 NA NA NA NA 1.8E+01 1.8E+01 
3,600 NA NA NA NA 5.2E+01 5.0E+01 
7,300 NA NA NA NA 1.2E+02 1.2E+02 
18,250 NA NA NA NA 1.4E+02 1.4E+02 
(a) Implies an MDA of 4.3-mg recycled uranium, based on Table  7.3 
isotopic composition. 
NA = not applicable. 
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Figure 7.9.  Minimum Detectable Dose for Recycled Uranium Based on 0.09 nCi 235U in Chest Count 
 
In vivo measurements of 235U and 234Th are used as co-indicators of 
natural and recycled uranium based on the isotopic compositions 
shown in Table 7.3.  These compositions and the MDDs of Tables 
7.30 and 7.32 show that 234Th and 235U are roughly comparable 
indicators of recycled uranium.  For depleted and natural uranium 
mixtures, the 234Th measurement will be more sensitive.  These two 
results, obtained from a single in vivo chest measurement, can be 
used as independent verification of the presence of uranium, or 
alternatively as a method of identifying potential false-positive 
detections.  For example, the relative isotopic activity abundance of 
238U to 235U for a mixture can be multiplied by the detected amount 
of 235U.  This result (the 238U implied by the 235U measurement) can 
then be compared with the 234Th (assumed to be in equilibrium with 
the 238U) to determine if the measurements reasonably agree. 
 
7.4.3 Fecal Sample Measurements 
 
Fecal samples are useful for confirming and evaluating inhalation 
and ingestion intakes, particularly where insoluble material is 
involved.  The sample results can be used in conjunction with the 
ICRP 30 respiratory tract model to estimate the magnitude of intakes 
and initial lung depositions as a basis for dose assessment.  Clear-
ance of uranium via feces can be divided into two components:  that 
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which represents rapid clearance from the respiratory tract and that 
which represents longer-term clearance from the pulmonary region 
and systemic circulation.  For evaluation of an inhalation of slowly 
transportable uranium, the measurement of the quantity of uranium 
excreted via feces during the first few days following the intake can 
provide a basis for estimating the significance of the intake, when 
levels are below that detectable using in vivo techniques. 
 
Because the quantity of uranium ingested daily through food is 
assumed to be about 2 mg, it is generally not practicable to use fecal 
sampling as a routine bioassay monitoring technique.  However, it 
can be used effectively following incidents or for monitoring of 
potential intakes of enriched or depleted uranium.  Table 7.33 lists 
minimum detectable intakes of uranium based on the detection of a 
net excretion of 2-mg/d uranium above the background level. 
 
Table 7.33.  Minimum Detectable Intakes (mg) of Uranium Based on 2 mg/d in Feces(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm Soluble  Insoluble  
1 2.9E-02 1.2E-02 2.0E-02 9.5E-03 1.5E-02 8.0E-03 4.3E-03 4.3E-03 
2 4.5E-02 1.8E-02 1.5E-02 8.0E-03 1.3E-02 6.9E-03 7.1E-03 7.1E-03 
5 7.1E-01 3.0E-01 8.7E-02 6.7E-02 8.3E-02 5.9E-02 1.1E-01 1.1E-01 
7 5.3E+00 2.2E+00 3.3E-01 3.7E-01 3.7E-01 3.6E-01 8.3E-01 8.0E-01 
14 5.7E+03 2.4E+03 1.7E+00 4.8E+00 1.2E+01 3.2E+01 9.1E+02 8.7E+02 
30 NA NA 2.2E+00 6.3E+00 1.5E+01 4.3E+01 NA NA 
60 NA NA 3.3E+00 9.5E+00 1.5E+01 4.4E+01 NA NA 
90 NA NA 5.0E+00 1.4E+01 1.7E+01 4.7E+01 NA NA 
180 NA NA 1.7E+01 4.9E+01 1.8E+01 5.3E+01 NA NA 
365 NA NA 2.2E+02 6.5E+02 2.4E+01 6.9E+01 NA NA 
730 NA NA 3.6E+04 1.0E+05 4.0E+01 1.1E+02 NA NA 
1,825 NA NA NA NA 1.8E+02 5.1E+02 NA NA 
3,600 NA NA NA NA 2.1E+03 6.1E+03 NA NA 
(a) Assumed net excretion when corrected for nominal background 1.4 to 1.8 mg/d. 
NA = not applicable. 
 
Table 7.34 and Figure 7.10 show the minimum detectable doses 
associated with the Table 7.33 values for recycled uranium.  The 
associated doses for natural and depleted uranium are lower. 
 
7.4.4 Routine Bioassay Monitoring Program 
 
Because of the high variability in background uranium excretion in 
urine, all workers involved in uranium bioassay should have a 
baseline bioassay prior to commencing uranium work.  In addition,  
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 Table 7.34. Minimum Detectable Committed Effective Dose Equivalents (rem) for Recycled 
Uranium Based on 2-mg/d in Feces(a) 
 
Class D Inhalation Class W Inhalation Class Y Inhalation Ingestion Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm Soluble  Insoluble  
1 8.6E-05 3.9E-05 1.5E-04 3.2E-05 1.8E-03 3.3E-04 5.2E-07 1.1E-07 
2 1.4E-04 6.0E-05 1.1E-04 2.7E-05 1.5E-03 2.8E-04 8.6E-07 1.8E-07 
5 2.1E-03 9.9E-04 6.3E-04 2.3E-04 1.0E-02 2.4E-03 1.3E-05 2.8E-06 
7 1.6E-02 7.2E-03 2.4E-03 1.3E-03 4.4E-02 1.5E-02 1.0E-04 2.0E-05 
14 1.7E+01 7.9E+00 1.2E-02 1.6E-02 1.4E+00 1.3E+00 1.1E-01 2.2E-02 
30 1.4E+07 3.7E+06 1.6E-02 2.1E-02 1.8E+00 1.7E+00 4.5E+04 6.5E+04 
60 NA NA 2.4E-02 3.2E-02 1.8E+00 1.8E+00 NA NA 
90 NA NA 3.7E-02 4.9E-02 2.0E+00 1.9E+00 NA NA 
180 NA NA 1.2E-01 1.7E-01 2.2E+00 2.2E+00 NA NA 
365 NA NA 1.6E+00 2.2E+00 2.9E+00 2.8E+00 NA NA 
730 NA NA 2.6E+02 3.4E+02 4.8E+00 4.6E+00 NA NA 
1,825 NA NA 8.6E+07 8.2E+08 2.2E+01 2.1E+01 NA NA 
3,600 NA NA NA NA 2.6E+02 2.5E+02 NA NA 
7,300 NA NA NA NA 4.3E+04 4.1E+04 NA NA 
18,250 NA NA NA NA 1.6E+11 1.3E+11 NA NA 
(a) Assumed net excretion when corrected for nominal background 1.4 to 1.8 mg/d. 
NA = not applicable. 
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Figure 7.10.  Minimum Detectable Dose for Recycled Uranium Based on 2-mg/d Net Fecal Excretion 
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significant changes in geographic location (e.g., moving from a 
private groundwater well water supply to a surface water supply, or 
vice versa) may warrant reestablishing a baseline excretion. 
 
A contractor request urinalysis may be obtained as a non-periodic 
measurement following completion of a specific task involving 
potential uranium exposure.  This approach may provide a cost-
effective monitoring program for workers with infrequent potential 
for occupational uranium intakes, and may permit higher 
supplemental screening levels based on the time following the 
potential for intake. 
 
The interpretation of routine urinalysis measurements is highly 
dependent on the nature of the intake, i.e., low-level chronic 
exposure conditions significantly affect the interpretation of bioassay 
measurements.  Chronic exposures to uranium have occurred in the 
UO3 Plant, 300 Area Fuel Production Facilities, and the 306-W 
Building, but are no longer normal conditions, and thus bioassay 
protocols for chronic exposure have been terminated.  Chronic 
exposure bioassay programs for these facilities were most recently 
described in Technical Basis for Internal Dosimetry at Hanford  
(Sula, Carbaugh, and Bihl 1991).  If such exposure conditions return, 
the current bioassay program recommendations will be reconsidered.  
The discussion below addresses bioassay monitoring for acute 
intakes, which are now considered to be the most likely intake 
scenarios. 
 
Class D Routine Monitoring 
 
Routine bioassay monitoring for acute inhalations of highly soluble 
uranium (class D) should consist of a minimum of quarterly 
urinalyses using a dose assessment screening level of 0.5-mg/d, based 
on Table 7.18.  Such a program provides adequate assurance that 
potentially significant doses do not go undetected and that the 
chemical toxicity threshold level has not been exceeded.  Results 
between the upper bound of normal background (0.2-mg/d) and 
0.5-mg/d may indicate that slight intakes have occurred but do not 
require individual dose assessment.  Results above 0.5-mg/d should 
be investigated.  Results above 1-mg/d suggest that the transient 
chemical toxicity level might have been exceeded, however a more 
recent intake or chronic low-level nonoccupational ingestion could 
significantly affect interpretation.  More frequent sampling (e.g., 
monthly) allows for the use of substantially higher screening levels 
(e.g., 5-mg/d as a screening level for investigation and dose 
assessment, and 12-mg/d as a screening level for transient chemical 
toxicity). 
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Chest counting is not warranted as periodic bioassay for acute class 
D uranium monitoring. 
 
Class W Routine Monitoring 
 
Annual urinalysis for class W recycled uranium comes sufficiently 
close to the bioassay goal of 100-mrem committed effective dose 
equivalent to be considered adequate for routine monitoring.  Semi-
annual (twice yearly) urinalyses can easily demonstrate compliance 
with the 100-mrem-bioassay goal.  In both cases, any result 
exceeding the 0.2-mg/d environmental screening level should be 
investigated for potential occupational intake resulting in a 
committed effective dose equivalent exceeding 10-mrem. 
 
Semi-annual chest counting can be useful as a supplemental bioassay 
for class W uranium intakes, and is capable of independently 
demonstrating compliance with dose limits. 
 
Class Y Routine Monitoring 
 
Routine bioassay monitoring programs are inherently not capable of 
meeting the 100-mrem committed effective dose equivalent bioassay 
goal due to the normal presence of uranium in the environment.  
Thus, reliance must be placed on good workplace surveillance 
practices to detect potential intake conditions in a timely manner so 
that special bioassay may be initiated. 
 
The recommended routine monitoring program for class Y 
inhalations of uranium is an annual urinalysis combined with an 
annual chest count.  This protocol provides the capability of 
demonstrating compliance with the annual dose limits. 
 
As shown in Table 7.28, quarterly urinalyses do not significantly 
improve the sensitivity of bioassay with respect to the 100-mrem 
goal, however monthly samples would, albeit at a cost 12 times 
higher than annual measurements.  Likewise, as demonstrated in 
Tables 7.30 and 7.32, the shift from annual to more frequent (e.g., 
semiannual or quarterly) chest counts is of some technical benefit for 
dose limit compliance monitoring, but must be weighed against the 
added cost of such programs.   
 
7.4.5 Special Monitoring for Suspected Intakes 
 
Bioassay monitoring should be initiated promptly upon indication 
that a potential acute intake has occurred.  The primary consideration 
in determining the appropriate measurements is the mode of intake 
and the clearance rate of the material from the initial deposition site.   
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For readily transportable materials, urine sampling to determine 
kidney burden is required.  For slowly transportable material, in vivo 
measurements and collection of early fecal excretion are necessary.  
 
For unknown forms or mixtures with a range of transportabilities, 
both urine and fecal samples are recommended in addition to lung 
counts. 
 
For intakes of readily transportable forms of uranium with potential 
significance relative to the threshold for chemical toxicity, a urine 
sample should be collected and analyzed within 12 hours of the 
intake.  If preliminary information indicates that a significant intake 
was likely, the contractor should be advised to contact HEHF 
Occupational Medicine promptly for medical support.  (See also 
Section 7.6.) 
 
Investigations of high routine uranium urinalysis measurements are 
often problematic due to the potential for elevated background from 
natural environmental sources.  Verification and confirmation of the 
initial measurement is important.  If the worker is potentially 
exposed to recycled uranium, analysis for 236U by the specia l ICPMS 
method can be an effective tool to identify occupational intake from 
environmental exposure.  Comparison of isotopic ratios in a urine or 
fecal result with the potential workplace source can be useful, 
provided that the workplace source is significantly different from 
natural environmental uranium.  In some cases, investigation of 
potential nonoccupational sources (e.g., drinking water or 
comparison with a family member) might be beneficial to the 
investigation. 
 
7.5 Assessment of Internal Dose 
 
Internal dose assessment can be performed using the methods 
described in Section 7.5.1 for acute intakes and Section 7.5.2 for 
chronic intakes.  The kidney burden and potential chemical toxicity 
associated with uranium intakes are discussed in Section 7.5.3. 
 
Assessment of internal dose equivalents from intakes of uranium is 
preferably based on evaluation of bioassay measurements.  The 
choice of bioassay measurement depends on consideration of the 
transportability of the inhaled material and the nature of the 
exposure.  Generally, urinalysis measurements are most indicative of 
systemically deposited uranium, and in vivo measurements provide a 
measure of lung burden.  The potential for mixed chronic and acute 
intakes (i.e., acute occupational exposure on top of a low-level  
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chronic natural background exposure) complicates the interpretation 
of available data and must be carefully considered during the 
evaluation process. 
 
Experience has shown that actual uranium exposures may involve 
varying mixtures of inhalation classes and particle sizes that may not 
be adequately represented by a single classification.  If there is no 
basis for establishing the inhalation class and particle size character-
istics of the intake, then it is prudent to assume a class Y material 
with a particle AMAD of 5 mm for evaluation of dose equivalent.  
Evaluations of potential for renal damage, based on urinalysis, are 
relatively insensitive to transportability and particle variations.  If 
either the threshold for toxicity or a committed effective dose 
equivalent of 100 mrem is exceeded, simplifying assumptions should 
be reviewed for their appropriateness and additional bioassay and 
other measurements should be performed, as necessary, to improve 
the quality of the assessment. 
 
Special care should be taken in to account for the isotopic composi-
tion of the uranium.  For example, the dose equivalent for an intake 
of class Y recycled uranium, such as is present at the Fuel Production 
Facilities, will exceed the dose equivalent from an equal mass of 
natural uranium, or depleted uranium (from 306-W Building) 
because of the higher specific alpha activity.  Impurity radionuclides 
present in the recycled uranium can also increase the magnitude of 
the internal dose received, particularly for soluble forms of uranium.  
The default assumption of recycled uranium used for bioassay 
program design may not be appropriate for dose assessment. 
 
Tables and graphs provided in this chapter have been constructed 
using the ICRP 30 model for uranium biokinetics and thus can be 
used to convert bioassay measurement results to intake and 
committed effective dose equivalent.  Although the tables and figures 
are sufficient for evaluating lower-level intakes and those that are 
relatively straightforward, additional computing capability may be 
necessary for more complex evaluations, particularly when bioassay 
data indicate that distribution and retention patterns deviate from the 
standard model.  In this case, evaluations are performed using the 
computer code CINDY (see Appendix D).  CINDY parameters are 
set up according to the ICRP 30 biokinetic model for uranium; 
however, the code provides the capability to change model param-
eters based on bioassay measurement results.  Deviations from the 
standard ICRP model are documented in the assessment. 
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7.5.1 Acute Intake Assessment 
 
Acute intakes are best assessed through the performance of bioassay 
measurements beginning shortly after the intake.  It is important that 
any additional exposure to uranium, even low-level chronic intakes, 
be avoided to the extent practicable during the period of bioassay 
monitoring following an acute intake.  Interpretation of excreta data 
is highly susceptible to errors introduced by even minor subsequent 
intakes and thus, if the possibility of continued exposure cannot be 
ruled out, all excreta sample data collected following an acute intake 
must be considered to be potentially biased. 
 
Acute intakes of readily transportable forms of uranium are best 
evaluated through collection and analysis of follow-up urine 
samples.  Samples collected after the unabsorbed fraction is 
eliminated from the body (i.e., after the first day post intake) provide 
the best estimate of systemically deposited material.  Table  7.8 lists 
urine excretion fractions that may be used as default values for 
selected times following an acute intake. 
 
In vivo measurements of lung activity provide the most direct basis 
for the assessment of internal dose equivalent for moderately or 
poorly transportable forms of uranium, however they are insensitive 
to small intakes.  They do provide a useful tool for estimating the 
upper bound of an intake immediately following exposure.  Multiple 
measurements of internal activity can provide a measure of the 
pulmonary retention for the specific exposure case; however, the 
initial assessment of intake, based on a single in vivo measurement 
can be made using the retention factors of Table  7.7 
 
Although intakes of poorly transportable uranium are preferably 
assessed using direct (in vivo) bioassay measurements, most acute 
intakes of such material will be below the sensitivity of in vivo 
measurement techniques.  The collection and analysis of fecal 
samples within the first week provides an alternative, and the most 
sensitive, indicator of activity deposited in the respiratory tract.  It is 
difficult to obtain all fecal matter representing the rapidly clearing 
component from the lung to the GI tract, and normalizing available 
fecal sample data to account for partial collection may be required.  
Table 7.9 provides fecal excretion rates at various times post intakes, 
and additional information on the collection and evaluation of fecal 
samples is provided in Appendix C. 
 
7.5.2 Chronic Intake Assessment 
 
Urinalysis is the preferred bioassay measurement technique for 
monitoring chronic exposures to readily transportable forms of 
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uranium.  For predominantly moderately or poorly transportable 
forms of uranium, the lung is the primary contributor to effective 
dose equivalent and in vivo chest measurements are the most direct 
indicator of internal dose.  Because of the relatively poor sensitivity 
of in vivo techniques for low-enrichment uranium, the results of 
periodic urinalysis measurements may provide a means for 
estimating the magnitude of dose equivalent from chronic exposures 
below the sensitivity of the in vivo measurements. 
 
Chronic exposures to moderately or poorly transportable forms of 
uranium will result in accumulations of uranium activity in the lung.  
Use of in vivo chest activity measurements provides a direct means 
for assessing the magnitude of the chronic exposure and the resulting 
dose equivalents.  Urinalysis and air monitoring data can be used to 
help characterize the nature of the exposures.  The computer code 
CINDY can be used to estimate intakes yielding the observed 
bioassay measurement results and to calculate resulting dose 
equivalents.  Distribution and retention parameters in CINDY may 
be modified to better reflect bioassay measurement results. 
 
In cases where urinalysis data indicate chronic exposures, but in vivo 
measurements do not detect internal activity, the urinalysis data can 
be used to provide an estimate of intake; however, the uncertainty 
associated with such estimates is quite high and should be modified 
as necessary to be consistent with in vivo measurement results.  
Intake rate and dose equivalents from chronic exposure to uranium, 
based on urinalysis, can be computed using CINDY.  
 
Alternatively, if multiple small, intermittent intakes are assumed 
throughout the year, each sample can be assumed to be independent 
of (i.e., unaffected by) the others.  Under this scenario, an effective 
chronic intake rate can be approximated using the geometric mean 
(mg) of the daily urinary excretion rate [Mu(t)] based on analysis of 
urine samples (n) collected during the period of exposure, as follows: 
 
 ]
n
)t(Mlog[logAnti ug
S=m  
 
This effective daily excretion rate can then be used to calculate an 
effective daily intake rate for the period of exposure.  (CINDY 
provides a simple tool for converting the effective daily excretion 
rate to a daily intake rate.)  Multiplying the effective daily intake rate 
by the duration of the exposure will give the total intake, from which 
committed doses can be calculated using the appropriate dose 
coefficient.  CINDY can also be used to calculate doses. 
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The historical use of the above method for evaluating routine 
bioassay program data for the UO3 Plant, the 300 Area Fuel 
Production Facilities, and 306-W Building was described more fully 
in Technical Basis for Internal Dosimetry at Hanford  (Sula, 
Carbaugh, and Bihl 1991). 
 
7.5.3 Assessment of Kidney Burden and Potential Chemical Toxicity 
 
The maximum kidney burden from an acute exposure can be 
assessed from urinalysis data in the following manner.  First 
calculate the total uranium intake using one of the methods described 
above.  Then multiply the intake by the maximum kidney retention 
fraction from Table 7.10 (or as calculated for a specific intake 
scenario using CINDY).  As long as the total maximum kidney 
retention does not exceed 341-mg, the threshold for chemical toxicity 
(based on 1.1-mg-U/g-kidney, as described in Section 7.2.4) has not 
been exceeded and the uranium intake is below that considered 
potentially harmful.  Exceeding the threshold does not necessarily 
imply serious harm, however potential impact should be considered 
in light of the discussion in Section 7.2.4. 
 
The average daily urinary excretion for continuous intake is related 
to the kidney burden.  This ratio varies with time, but is independent 
of inhalation class and particle size.  For continuous exposures 
lasting longer than about 5 years, the ratio of the kidney burden to 
the average daily excretion is about 2.  Thus, assuming a kidney 
burden of 341 mg (i.e., 1.1 mg-U/g-kidney; the assumed threshold 
level at which a chronic kidney burden may result in renal damage), 
the average daily excretion would be about 341/2 = 170 mg/d.  If 
exposure were halted for 2 days (such as during a weekend), the 
daily excretion would drop to about 85 mg/d.  For class D uranium, 
the 341-mg kidney burden would result from prolonged intakes of 
about 320 mg/d. 
 
If preliminary information indicates that an intake at the threshold 
for chemical toxicity was possible, investigation of the potential 
intake should be performed.  If evidence suggests that a significant 
intake was likely, follow-up samples should be promptly collected 
and analyzed, and HEHF Occupational Medicine should be notified.  
Because acute damage of the kidneys is the primary consideration, 
kidney function tests provide the most direct and useful means of 
assessing the impact of the exposure.  Sensitive tests for kidney 
damage include beta-2-microglobulin and catalase relative to 
creatinine (Fisher 1985).  Albuminuria is also an indicator of kidney 
damage.  Leggett (1989) and Fisher, Swint, and Kathren (1990) have 
identified a number of other potentially useful tests.  The decision to 
perform such tests is made by HEHF Occupational Medicine. 
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7.6 Management of Internal Contamination Cases 
 
Acute intakes of uranium pose both radiological and nephrotoxicity 
concerns.  Renal damage results in failure of the proximal tubules to 
reabsorb constituents filtered from the blood.  Laboratory abnormal-
ities include proteinuria, glucosuria, and increased urine output.  
Clinical symptoms of severe uranium poisoning may include nausea, 
vomiting, abdominal cramps, and diarrhea. 
 
Urine samples should be collected within 3 to 4 hours following any 
uranium uptake with potential chemical toxicity concerns.  As a 
general rule, biological indicators of kidney damage should be 
checked if urine concentrations exceed 2 mg/l.  Clinical indicators of 
kidney damage include albuminuria, glucose, catalase, and beta-2 
microglobulin.  Urine concentrations on the order of 20 mg/l indicate 
serious exposure with potential life-threatening consequences and are 
cause for immediate medical attention (Rich et al. 1988). 
 
Antidotal therapy for uranium poisoning includes oral administration 
of GI tract adsorbents and oral or intravenous infusion of sodium 
bicarbonate (Bhattacharyya et al. 1992; NCRP 1980).  The 
bicarbonate promotes formation of the uranyl-bicarbonate complex, 
which is more rapidly excreted in urine (Fisher 1985).  Ethylene 
diamine tetraacetic acid (EDTA) and DTPA have been used in 
experimental animals to increase the excretion of uranium; however, 
chelation therapy appears to have no beneficial effect more than 
4 hours after exposure (NCRP 1980).  Therapeutic actions such as 
described above require prescription by appropriate medical 
authority (e.g., HEHF Occupational Medicine). 
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8.0 Plutonium 
 
 
This chapter provides information on the sources, characteristics, and 
biokinetics of plutonium and ingrown americium and summarizes 
the technical basis for their internal dosimetry at Hanford. 
 
Prior to 1989, the general approach to plutonium internal dosimetry 
at Hanford was to evaluate the systemic deposition based on urine 
data, and compare the result with a referenced maximum permissible 
body burden (MPBB) such as those contained in ICRP publication 2 
(1959).  The assessed systemic deposition was a “committed” 
systemic deposition, i.e., an estimate of the total amount of activity 
that would eventually reach systemic compartments.  The calculated 
depositions did not address the time post intake at which the 
maximum systemic deposition might be expected, nor the amount of 
activity that might be retained in the body at various times post 
intake.  Once the committed systemic deposition was calculated, its 
value was assumed to remain constant for the worker’s life.  The 
percentage of the MPBB was used to indicate the degree of 
compliance (or noncompliance) with Atomic Energy Commission, 
Energy Research and Development Agency, and DOE standards for 
radiation protection.  Initially, systemic depositions below 5% 
MPBB were not reported as confirmed depositions.  This cutoff for 
recording and reporting was lowered to 1% MPBB in the 1970s. 
 
Lung dose equivalents were assessed prior to 1989 in cases where 
in vivo measurements had observed activity in the lung.  The 
approach used for assessment was documented on a case-by-case 
basis in the specific case evaluation.  Generally, the approach was to 
use the best available information regarding isotope ratios and 
estimates of lung clearance rates based on 241Am in vivo 
measurements, urine data, and fecal data when they were available.  
Lacking such data, default assumptions were used and documented 
in evaluations.  The techniques for calculating dose were similar to 
those used in ICRP 2 and ICRP 10 (1969) and applied a quality 
factor of 10 for alpha particle emissions.  The results of those lung 
dose estimates were compared with the long-standing 15-rem/yr 
limit of ICRP 2. 
 
In late 1988, the technical approach to plutonium dosimetry at 
Hanford changed to the dosimetry approach of ICRP 26/30 
(1977/1979), incorporating the concepts of organ and tissue 
weighting factors to give an effective dose equivalent from specific 
organ doses.  The alpha particle quality factor was also changed from 
10 to 20, and the concepts of stochastic and deterministic 
(nonstochastic) dose limits were adopted.  In addition, advances in 
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measurement technology and modeling improved the capabilities for 
plutonium dosimetry.  The concept of “presystemic deposition” was 
introduced by Sula, Carbaugh, and Bihl (1989) for the purpose of 
simulating biokinetic behavior in estimating internal doses.  The 
presystemic deposition was defined as the component(s) of an initial 
deposition that would ultimately translocate to the blood, regardless 
of the time required to translocate.  A transfer rate from the initial 
deposition into the systemic compartment was linked with each 
component of the presystemic deposition.  Once material from the 
presystemic deposition reached the systemic compartment, it was 
assumed to behave in accordance with the applicable biokinetic 
model.  The presystemic deposition specifically excluded material 
permanently retained at the entry site or in lymphatic tissues. 
 
A further shift in internal dosimetry for plutonium occurred in 1992 
with requirements to report intake magnitude in addition to dose 
equivalents (10 CFR 835, DOE 1992).  This resulted in a shift away 
from presystemic deposition assessments (which ignored intake 
fractions not retained, such as the material exhaled immediately 
following inhalation) to the total intake assessment.  The adoption of 
the CINDY computer code (Strenge et al. 1992) as the principal 
calculational tool for Hanford internal dosimetry facilitated this shift 
to intake assessment. 
 
8.1 Sources and Characteristics 
 
This section provides general information on the isotopes, mixtures, 
and forms of plutonium that are commonly found at Hanford.  The 
physical data were taken directly from, or calculated based on, 
information in ICRP 30 and ICRP 38 (1983). 
 
8.1.1 Sources of Plutonium 
 
Production of plutonium was the original mission for Hanford.  It 
was produced by irradiation of uranium fuel elements in reactors in 
the 100 Areas, then separated and purified in the 200 Area chemical 
processing facilities.  After purification, it underwent conversion to 
final metallic form at the Plutonium Finishing Plant (PFP [234-5Z 
Building]) in the 200-West Area, where it was stored until it was 
shipped to other DOE sites for component fabrication.  Plutonium-
contaminated waste is buried or stored in a variety of waste 
management facilities.  Trace plutonium and americium levels can be 
found in some of the high-level waste storage facilities (e.g., 100-K 
Spent Fuel Storage Basins, 200 Area tank farms and associated 
facilities). 
 
 
Issued:  January 31, 2003  PNNL-MA-860 Chapter 8.0 
  Page 8.3 
Plutonium can also be found at Hanford as a result of research 
projects that involved spent fuel associated with nuclear power 
plants, breeder reactor applications, and radioisotope applications.  
Many of these research projects were in 300 Area facilities.  
Analytical chemistry laboratories may contain plutonium standard 
solutions. 
 
Plutonium has also been distributed in the worldwide environment at 
very low levels as a result of atmospheric testing of nuclear devices.  
Wrenn, Singh, and Xue (1994) indicated that persons living in the 
northern hemisphere have accumulated about 3 pCi of 239+240Pu from 
fallout from the weapons tests of the 1950s, and reported a 
background mean urine excretion of 3 to 8 H 10-5 dpm/day resulting 
from that body burden.  Similar levels of body burden have been 
reported by McInroy et al. (1979); McInroy, Boyd, and Eutsler 
(1981); and Nelson, Thomas, and Kathren (1993).  Ibrahim et al. 
(1999) reported a mean 239Pu urine excretion rate of 1.1 mBq/d 
(9.2H10-5 dpm/d) in a group of long-term residents near the Rocky 
Flats Site.  These body burdens and the urine results suggest that 
normal background urinary excretion levels of plutonium are far 
below the nominal 0.02 dpm minimum detectable activity routinely 
available for Hanford urine bioassay measurements. 
 
8.1.2 Isotope Decay Data 
 
The plutonium and plutonium decay product isotopes of concern at 
Hanford and selected decay data are listed in Table 8.1.  The 
radiological constants given in Table 8.1 are taken or calculated from 
data in ICRP 30 and 38. 
 
Table 8.1.  Plutonium and Americium Decay Data 
 
 Half-Life Decay Constant 
Specific 
Activity 
Isotope Decay Mode Years Days Year-1 Day-1 Ci/g 
238Pu Alpha 87.7 3.20E+04 7.90E-03 2.16E-05 1.71E+01 
239Pu Alpha 24,065 8.78E+06 2.88E-05 7.89E-08 6.21E-02 
240Pu Alpha 6,537 2.39E+06 1.06E-04 2.90E-07 2.27E-01 
241Pu Beta 14.4 5.26E+03 4.81E-02 1.32E-04 1.03E+02 
242Pu Alpha 376,300 1.37E+08 1.84E-06 5.05E-09 3.92E-03 
241Am Alpha 432.2 1.58E+05 1.60E-03 4.39E-06 3.43E+00 
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8.1.3 Reference Isotope Mixtures 
 
Pure isotopes of plutonium are seldom encountered at Hanford 
facilities.  Instead, plutonium is usually encountered as a mixture of 
isotopes.  For specific exposure situations where the isotopic 
composition of a mixture is known, that composition should be used 
for dosimetry purposes.  In situations where mixtures are unknown, 
or for bioassay planning purposes, assumptions regarding the 
mixture should be made. 
 
The isotopic composition of a plutonium mixture is related to several 
variables, including the following: 
 
· the length of time fuel was irradiated (fuel exposure or burn-up 
time) 
 
· the time since irradiation (cooling time) 
 
· the time since processing of fuel or purification of plutonium. 
 
Typically, plutonium at Hanford falls into one of two generic 
mixtures.  These mixtures are defined by the weight percent (wt%) of 
240Pu.  Thus, 6% plutonium has a nominal 240Pu content of 6 wt% and 
12% plutonium has a nominal 240Pu content of 12 wt%.  The 6% 
plutonium mixture is commonly referred to as “weapons grade” 
because that was the nominal target mixture for nuclear weapons 
components.  Weapons-grade plutonium had a relatively short reactor 
exposure time.  The 12% plutonium mixture is commonly referred to 
at Hanford as “fuel grade,” and resulted from lengthier reactor 
exposure for research or power production purposes. 
 
Plutonium mixtures are also associated with the much longer fuel 
cycle of large-scale power production reactors.  The spent fuel from 
the power reactor fuel cycle demonstrates a significant buildup of 
240Pu, e.g., 25 wt% would not be an unusual number.  This form of 
plutonium can be associated with Hanford research projects 
involving commercial fuel, such as the Nuclear Waste Vitrification 
Project (NWVP), circa 1970s. 
 
Other isotopic compositions may be encountered and should be 
addressed as needed.  In a discussion of the manufacture of 
plutonium, the DOE Standard Guide of Good Practices for 
Occupational Radiological Protection in Plutonium Facilities (DOE 
1998) identified isotopic mixtures for heat source, weapons-grade 
and reactor-grade plutonium mixtures.  The weapons-grade mixture 
is similar to the Hanford weapons-grade mixture, and the 
reactor-grade mixture is similar to the NWVP mixture described 
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above.  In the internal dosimetry section of that standard, the 
Hanford weapons grade and fuel-grade mixtures are specifically 
listed as example mixtures.  The heat-source mixture refers to 
material used for radioisotope thermal generators, which are 
primarily 238Pu.  Heat-source plutonium is not a typical Hanford 
mixture. 
 
Reference Hanford plutonium mixtures, prior to any 241Am ingrowth, 
are provided in Table 8.2.  These reference mixtures are approxima-
tions based on the isotopic composition of a number of batches of 
freshly processed plutonium and are not intended to represent any 
specific batch.  Actual exposures may or may not reflect these 
compositions.  When the actual composition of a mixture to which a 
worker has been exposed can be obtained, such data should be used. 
 
Table 8.2.  Reference Hanford Plutonium Mixtures Prior to Aging (wt%) 
 
Isotope Weapons Grade Fuels Grade Commercial Power Grade 
238Pu 0.05 0.10 1 
239Pu 93.1 84.8 55 
240Pu 6.0 12.0 26 
241Pu 0.8 3.0 13 
242Pu 0.05 0.1 5 
241Am 0.0 0.0 0.0 
 
In the typical plutonium mixture, the plutonium-alpha activity is 
relatively constant over time due to the long decay half-life of the 
alpha emitters.  The plutonium-beta activity (241Pu) decays with a 
14-year half-life into 241Am.  Thus, over a period of years, 
plutonium-beta activity in a mixture will decrease while at the same 
time the 241Am activity and the total alpha activity of the mixture will 
increase.  Serial decay relationships can be used to estimate the 
activity of each isotope for any decay time.  A hand-calculator 
program developed at Hanford by Rittman (1984) and written into a 
computer utility for personal computers (PCs)(a) is used to solve these 
decay relationships, which can also be solved using computer 
spreadsheet application software.  Tables 8.3, 8.4, and 8.5 provide 
the specific activities of each isotope in the reference mixtures and 
isotope ratios relative to 239+240Pu and 241Am.  These tables clearly 
show that 242Pu is an insignificant contributor to the specific activity 
of the reference mixtures, and may be ignored for purposes of 
dosimetry. 
                                                   
(a) Personal correspondence between P. D. Rittman and E. H. Carbaugh, 1993, Pacific Northwest 
National Laboratory. 
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Table 8.3.  Activity Composition of Hanford Reference Weapons-Grade Plutonium Mixture 
 
Mixture Designation: Fresh 5-Year 10-Year 15-Year 20-Year 25-Year 30-Year 40-Year 50-Year 
Years of Aging: 0 5 10 15 20 25 30 40 50 
          
Specific Activity          
in Mixture (Ci/g)          
238Pu 8.56E-03 8.23E-03 7.91E-03 7.60E-03 7.31E-03 7.03E-03 6.75E-03 6.24E-03 5.77E-03 
239Pu 5.77E-02 5.77E-02 5.77E-02 5.77E-02 5.77E-02 5.77E-02 5.77E-02 5.76E-02 5.76E-02 
240Pu 1.36E-02 1.36E-02 1.36E-02 1.36E-02 1.36E-02 1.36E-02 1.36E-02 1.35E-02 1.35E-02 
241Pu 8.24E-01 6.48E-01 5.09E-01 4.00E-01 3.15E-01 2.48E-01 1.95E-01 1.20E-01 7.44E-02 
242Pu 1.97E-06 1.97E-06 1.97E-06 1.97E-06 1.97E-06 1.97E-06 1.97E-06 1.97E-06 1.97E-06 
241Am 0 5.83E-03 1.04E-02 1.39E-02 1.66E-02 1.87E-02 2.03E-02 2.25E-02 2.36E-02 
239+240Pu 7.13E-02 7.13E-02 7.13E-02 7.13E-02 7.12E-02 7.12E-02 7.12E-02 7.12E-02 7.11E-02 
Pu-alpha 7.99E-02 7.95E-02 7.92E-02 7.89E-02 7.85E-02 7.83E-02 7.80E-02 7.74E-02 7.69E-02 
Total alpha 7.99E-02 8.53E-02 8.96E-02 9.28E-02 9.52E-02 9.70E-02 9.83E-02 9.99E-02 1.01E-01 
          
Activity Ratios          
239+240Pu:241Am NA 1.22E+01 6.87E+00 5.13E+00 4.28E+00 3.80E+00 3.50E+00 3.17E+00 3.01E+00 
241Am:238Pu NA 7.09E-01 1.31E+00 1.83E+00 2.27E+00 2.66E+00 3.01E+00 3.60E+00 4.09E+00 
241Pu:239+240Pu 1.16E+01 9.09E+00 7.15E+00 5.62E+00 4.42E+00 3.48E+00 2.73E+00 1.69E+00 1.05E+00 
Total alpha:239+240Pu 1.12E+00 1.20E+00 1.26E+00 1.30E+00 1.34E+00 1.36E+00 1.38E+00 1.40E+00 1.41E+00 
Total alpha:241Am NA 1.46E+01 8.63E+00 6.67E+00 5.72E+00 5.18E+00 4.84E+00 4.45E+00 4.26E+00 
NA = not applicable 
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Table 8.4.  Activity Composition of Hanford Reference Fuel-Grade Plutonium Mixture 
 
Mixture Designation: Fresh 5-Year 10-Year 15-Year 20-Year 25-Year 30-Year 40-Year 50-Year 
Years of Aging: 0 5 10 15 20 25 30 40 50 
          
Specific Activity          
in Mixture (Ci/g)          
238Pu 1.71E-02 1.64E-02 1.58E-02 1.52E-02 1.46E-02 1.40E-02 1.35E-02 1.25E-02 1.15E-02 
239Pu 5.26E-02 5.26E-02 5.26E-02 5.26E-02 5.26E-02 5.26E-02 5.25E-02 5.25E-02 5.25E-02 
240Pu 2.72E-02 2.72E-02 2.72E-02 2.72E-02 2.72E-02 2.71E-02 2.71E-02 2.71E-02 2.71E-02 
241Pu 3.09E+00 2.43E+00 1.91E+00 1.50E+00 1.18E+00 9.29E-01 7.30E-01 4.51E-01 2.79E-01 
242Pu 3.93E-06 3.93E-06 3.93E-06 3.93E-06 3.93E-06 3.93E-06 3.93E-06 3.93E-06 3.93E-06 
241Am 0 2.19E-02 3.89E-02 5.22E-02 6.24E-02 7.03E-02 7.63E-02 8.43E-02 8.86E-02 
239+240Pu 7.98E-02 7.98E-02 7.98E-02 7.97E-02 7.97E-02 7.97E-02 7.97E-02 7.96E-02 7.96E-02 
Pu-alpha 9.69E-02 9.62E-02 9.56E-02 9.49E-02 9.43E-02 9.37E-02 9.32E-02 9.21E-02 9.11E-02 
Total alpha 9.69E-02 1.18E-01 1.35E-01 1.47E-01 1.57E-01 1.64E-01 1.69E-01 1.76E-01 1.80E-01 
          
Activity Ratios          
239+240Pu:241Am NA 3.64E+00 2.05E+00 1.53E+00 1.28E+00 1.13E+00 1.04E+00 9.45E-01 8.98E-01 
241Am:238Pu NA 1.33E+00 2.46E+00 3.43E+00 4.27E+00 5.01E+00 5.65E+00 6.76E+00 7.69E+00 
241Pu:239+240Pu 3.87E+01 3.05E+01 2.40E+01 1.88E+01 1.48E+01 1.17E+01 9.17E+00 5.67E+00 3.51E+00 
Total alpha:239+240Pu 1.21E+00 1.48E+00 1.69E+00 1.84E+00 1.97E+00 2.06E+00 2.13E+00 2.21E+00 2.26E+00 
Total alpha:241Am NA 5.40E+00 3.45E+00 2.82E+00 2.51E+00 2.33E+00 2.22E+00 2.09E+00 2.03E+00 
NA = not applicable 
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Table 8.5.  Activity Composition of Hanford Reference Commercial Power-Grade Plutonium Mixture 
 
Mixture Designation: Fresh 5-Year 10-Year 15-Year 20-Year 25-Year 30-Year 40-Year 50-Year 
Years of Aging: 0 5 10 15 20 25 30 40 50 
          
Specific Activity          
in Mixture (Ci/g)          
238Pu 1.71E-01 1.65E-01 1.58E-01 1.52E-01 1.46E-01 1.41E-01 1.35E-01 1.25E-01 1.15E-01 
239Pu 3.41E-02 3.41E-02 3.41E-02 3.41E-02 3.41E-02 3.41E-02 3.41E-02 3.41E-02 3.41E-02 
240Pu 5.90E-02 5.89E-02 5.89E-02 5.89E-02 5.89E-02 5.88E-02 5.88E-02 5.87E-02 5.87E-02 
241Pu 1.34E+01 1.05E+01 8.28E+00 6.51E+00 5.12E+00 4.03E+00 3.17E+00 1.96E+00 1.21E+00 
242Pu 1.97E-04 1.97E-04 1.97E-04 1.97E-04 1.97E-04 1.97E-04 1.97E-04 1.97E-04 1.97E-04 
241Am 0 9.49E-02 1.69E-01 2.26E-01 2.70E-01 3.04E-01 3.31E-01 3.65E-01 3.84E-01 
239+240Pu 9.31E-02 9.31E-02 9.30E-02 9.30E-02 9.29E-02 9.29E-02 9.29E-02 9.28E-02 9.27E-02 
Pu-alpha 2.65E-01 2.58E-01 2.52E-01 2.45E-01 2.39E-01 2.34E-01 2.28E-01 2.18E-01 2.08E-01 
Total alpha 2.65E-01 3.53E-01 4.20E-01 4.71E-01 5.10E-01 5.38E-01 5.59E-01 5.83E-01 5.92E-01 
          
Activity Ratios          
239+240Pu:241Am NA 9.81E-01 5.51E-01 4.11E-01 3.44E-01 3.05E-01 2.81E-01 2.54E-01 2.41E-01 
241Am:238Pu NA 5.76E-01 1.07E+00 1.49E+00 1.85E+00 2.17E+00 2.45E+00 2.92E+00 3.33E+00 
241Pu:239+240Pu 1.44E+02 1.13E+02 8.91E+01 7.00E+01 5.51E+01 4.33E+01 3.41E+01 2.11E+01 1.30E+01 
Total alpha:239+240Pu 2.84E+00 3.79E+00 4.52E+00 5.07E+00 5.48E+00 5.79E+00 6.02E+00 6.28E+00 6.39E+00 
Total alpha:241Am NA 3.72E+00 2.49E+00 2.09E+00 1.89E+00 1.77E+00 1.69E+00 1.60E+00 1.54E+00 
NA = not applicable 
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For each reference mixture, a family of curves can be developed to 
describe the changing activity relationships between isotopes (see 
Figures 8.1 through 8.4).  These curves can then be used to identify, 
for dosimetry purposes, the plutonium mixture and its approximate 
age after processing or purification.  When information about 
isotopic composition or activity ratios is lacking, assumptions must 
be made for dose assessment.  Hanford internal dosimetry 
applications of these curves were developed by Sula, Carbaugh, and 
Bihl (1989; 1991) for freshly separated and 5-year aged conditions of 
6% Pu and 12% Pu.  Since that time, production of plutonium at 
Hanford has ceased and mixtures have continued to age.  Thus, 
presentations of such relationships for freshly irradiated or separated 
plutonium mixtures are no longer needed, while the need for data 
about additional mixture ages has presented itself.  Consequently, 
this manual now uses, as the basis for bioassay program design and 
interpretation, reference mixtures of 10-, 20-, and 40-year-old 
weapons- and fuel-grade plutonium.  The primary use for these 
reference mixtures is in the planning of bioassay monitoring 
frequencies and methods, and for defining the capability of the 
internal dosimetry program. 
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Figure 8.1.  239+240Pu/241Am Activity Ratio for Hanford Reference Plutonium Mixtures 
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Figure 8.2.  Total Alpha/241Am Activity Ratio for Hanford Reference Plutonium Mixtures 
 
 
Figure 8.3.  Total Alpha/239+240Pu Activity Ratio for Hanford Reference Plutonium Mixtures 
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Figure 8.4.  241Am/Total Alpha Activity Ratio for Hanford Reference Plutonium Mixtures 
 
8.2 Biokinetic Behavior 
 
This section discusses the inhalation transportability class, internal 
distribution and retention, and the urinary and fecal excretion of 
plutonium. 
 
8.2.1 Transportability Class 
 
The transportability classes for plutonium are similar to those used in 
the ICRP 30 respiratory tract model and are sometimes referred to as 
solubility or inhalation classes.  The class designation represents the 
relative speed at which material is solubilized and translocated into 
the transfer compartment from the deep pulmonary (or alveolar) 
region of the lung.  Classes D, W, and Y as used in this technical 
basis are identical to the ICRP 30 classes of the same name.  The 
term “instantaneous uptake” is used in this technical basis to refer to 
the material that is essentially immediately taken up by the transfer 
compartment upon intake, and is typically applied to wound 
scenarios. 
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The new respiratory tract model presented in ICRP publication 66 
(1994a), replaced the ICRP 30 concepts of inhalation class D, W, and 
Y, with absorption types F, M, and S.  Whereas the ICRP 30 
inhalation classes described overall clearance (i.e., absorption and 
mechanical clearance), the ICRP 66 type refers only to the absorption 
characteristics (i.e., dissolution and absorption into blood).  With 
regard to the dissolution and absorption rates, the ICRP 30 classes D, 
W, and Y correspond to the characteristics of ICRP 66 types F, M, 
and S, respectively.  Although Hanford has not adopted the ICRP 66 
respiratory tract model, the use of the absorption types as a 
supplemental concept to the ICRP 30 inhalation classes may be 
useful, particularly with the application of newly published solubility 
studies or animal study data.  Unless specifically indicated, the 
chemical forms assigned to the ICRP 30 classes can be assumed to 
be assigned to the corresponding ICRP 66 absorption types (and vice 
versa). 
 
The transportability of plutonium varies greatly depending on the 
chemical form.  In ICRP publication 19 (1972), plutonium oxides 
were identified as belonging to class Y, and other forms of plutonium 
(e.g., nitrates, carbonates, carbides, fluorides) were identified as most 
appropriately belonging to class W.  It was specifically noted that no 
plutonium compounds were assigned to class D.  This approach was 
essentially endorsed by ICRP publication 68 (1994b), which 
assigned insoluble plutonium oxides to absorption type S and 
unspecified compounds to type M.  Caution should be used in 
applying these categorizations, because significant variations have 
been observed, as discussed below. 
 
Plutonium nitrate, as might be found in chemistry lab solutions and 
the early phases of plutonium finishing, was identified by ICRP 30 as 
class W.  However, work by Moody, Stradling, and Britcher (1994) 
concluded that plutonium nitrate behavior was something between 
class W and Y, with aged nitrate residues being very simil ar to 
class Y. 
 
Stradling and Stather (1989) indicated that residual plutonium that 
has been subject to air oxidation for several years at normal room 
temperature and humidity may best be characterized as class Y 
material.  Stradling and Stather studied the behavior of two dusts in 
rat lungs.  One dust was a plutonium dioxide corrosion product of 
plutonium metal oxidized in air under ambient conditions (20° to 
25°C and relative humidity of 60 to 70%) over a period of about 
15 years.  The second dust was a dry powder, process line residue 
consisting of an atmospherically degraded mixture of plutonium and 
uranium nitrates (originally 1.2M HNO3) intimately mixed and 
highly diluted with inactive debris, resulting from the corrosion of an 
experimental rig over 15 years (i.e., rust).  The plutonium oxide 
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powder was found to exhibit very definite class Y behavior 
characteristics.  The translocation rate for plutonium in the nitrate-
bearing residues was about 3 times faster than for a class Y 
compound, but about 10 times slower than for a class W compound; 
i.e., the nitrate-bearing residue came closer to being class Y than 
class W in behavior.  These findings imply that dry, residual 
plutonium contamination within facilities and gloveboxes should be 
treated as class Y material regardless of its original chemical form.  
Designation of plutonium as a class W material should be limited to 
current processes generating nitrates or residuals from recent runs of 
such processes.  Plutonium worker bioassay programs should 
consider the potential for exposure to aged plutonium oxides if there 
is any source of old residual contamination. 
 
La Bone et al. (1992) identified a circumstance in which a 
238Pu-oxide inhalation case appeared to exhibit biokinetic behavior 
more characteristic of a class D material.  This characteristic for 
238Pu has been informally discussed among internal dosimetrists and 
radiation protection staff for years.  One explanation for it is that the 
alpha particle recoil from decay of the very high specific activity 
238Pu may serve to break down the matrix to forms readily absorbed 
by blood. 
 
In addition to classes D, W, and Y, the possibility of a super class Y 
(super Y) form has been identified.  Super Y was defined by the 
HIDP in 1988 to describe highly nontransportable forms of 
plutonium based on some actual observed cases at Hanford (Bihl et 
al. 1988; Carbaugh, Bihl, and Sula 1991).  For general discussion of 
inhalation exposures, super Y material has been defined as being 
similar to class Y material with respect to compartment deposition 
fractions in the ICRP 30 respiratory tract model.  However, retention 
half-lives for the transport from the lung to the blood (ICRP 30 lung 
compartments a, c, e, and i) have been adjusted from 500 days to 
10,000 days, representing the highly insoluble (i.e., very slow 
dissolution rate) of the super class Y material.  The 500-day 
clearance half-time of ICRP 30 lung compartment g was left 
unchanged, representing particle clearance from the pulmonary 
region by mechanical processes not affected by the highly insoluble 
nature of super class Y material.  The precise nature of super class Y 
material is not known, although it appears to have been associated 
with processes involving high-fired plutonium oxides.  The 
phenomenon has been informally verified by dosimetry personnel at 
Rocky Flats, Savannah River, and Los Alamos sites, and is supported 
in the literature by Foster (1991). 
 
When combinations of transportability classes may exist in a matrix, 
the transportability of the mixture is assumed to be that of the 
predominant material.  For example, in a plutonium oxide matrix  
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containing americium oxide as an ingrown impurity, the transport-
ability of the americium oxide is assumed to be the same as that of 
the major mass constituent of the matrix (Eidson 1980).  Thus, the 
americium is assumed to exhibit the class Y behavior of the host 
matrix (plutonium oxide), rather than the class W behavior normally 
expected of americium oxide.  The above-described behavior would 
not be the case if the mixture were merely a blend of the two oxide 
powders.  In this latter case, each element would be expected to 
exhibit its own characteristic behavior.  These assumptions are also 
consistent with the observations by Stradling and Stather (1989). 
 
The wide range of transportability for plutonium compounds, and its 
variability from the standard ICRP recommendations, emphasizes the 
importance of addressing the uniqueness of individual workers and 
exposure circumstances when dealing with known intakes.  When 
limited information is available, the Hanford practice is to use class 
W for exposure to plutonium nitrate solutions (e.g., wet solutions, 
trace contaminants in high-level waste tanks) and class Y for oxides 
involving either high-firing or room temperature oxidation processes.  
Super class Y is not routinely used as a default program design form.  
Based on personal communication with a Hanford soil chemist,(a) 
plutonium in soil is assumed to be class Y unless the plutonium came 
from a recent release of plutonium nitrate (class W).  Plutonium 
nitrate converts to the hydroxide form in the soil and oxides of 
plutonium are stable unless the soil is acidified (pH<5). 
 
8.2.2 Gastrointestinal Uptake to Blood (f1 Factor) 
 
The uptake of plutonium from the gastrointestinal (GI) tract is quite 
small and is dependent on its chemical form.  The fraction of 
material taken up by the blood from the total in the GI tract is called 
the f1 factor.  In ICRP 30 Part 4 (1988), the ICRP recommended that 
10-5 be used for oxides of plutonium, 10-4 for nitrates, and 10-3 for 
other compounds.  In ICRP 56 (1989), the 10-3 value was used for 
adult members of the public.  Based on additional published studies, 
ICRP 67 (1993) recommended a value of 5 ´ 10-4 for unknown forms.  
This recommendation was adopted in ICRP 68 (1994b) for 
occupational exposures to all other compounds of plutonium except 
nitrate (10-4) and oxide (10-5).  However, the tabulated plutonium 
dose coefficients in ICRP 68 showed the use of 5 ´ 10-4 for type M, 
rather than the nitrate value.  For application to worker monitoring 
programs, ICRP 78 (1997) retained the ICRP 68 values for ingestion, 
and used 10-5 for inhalation of type S compounds (insoluble oxides) 
and used 5´ 10-4 for inhalation of Type M compounds (unspecified 
compounds).  No specific f1 factor was identified for nitrates. 
                                                   
(a) Conversation between D. A. Cataldo and D. E. Bihl, 1995. 
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For Hanford plutonium internal dose applications, the f1 factors of 
ICRP 78 are preferred, unless otherwise specified.  The type M factor 
(5´ 10-4) is applied to inhalation class W material, and the type S 
factor (1´ 10-5) is applied to class Y forms.  Ingestion intakes will 
use the f1 factors specified in ICRP 78, namely, 1 ´ 10-4 for nitrates, 
1´ 10-5 for oxides, and 5´ 10-4 for other compounds. 
 
8.2.3 Distribution and Retention in Systemic Organs and Tissues 
 
The ICRP 30 Part 4 model is used for calculating the distribution and 
retention of plutonium in the body.  For dissolved (ionic form) 
plutonium reaching the transfer compartment (i.e., the blood stream), 
this ICRP model distributes 45% to the bone surfaces from which it 
clears with a biological half-time of 50 years, and 45% to the liver 
from which it clears with a biological half-time of 20 years.  The 
activity deposited in bone is assumed to be deposited uniformly over 
bone surfaces of both cortical and trabecular bone, where it remains 
until it decays or is excreted.  A small fraction is permanently 
retained in the gonads (0.035% for testes and 0.011% for ovaries).  
Although the translocated fractions for testes and ovaries differ, the 
gonadal dose equivalent for males and females is identical.  This is 
attributed to the substantially differing masses of the two organs, 
with the result that the alpha activity concentration within the tissues, 
and therefore the tissue doses, are the same. 
 
The remaining 10% is assumed to go directly to excretion and any 
short-term holdup in the tissues of the circulatory or urinary systems.  
For purposes of dosimetry, this fraction is considered to be an 
insignificant contributor to effective dose equivalent (relative to 
bone, red marrow, liver, and gonad dose contributors), and is 
ignored. 
 
The shift to the ICRP 30 Part 4 model from the ICRP 48 (1986) 
model used since 1988 is based on the better agreement with human 
autopsy data, as initially reported by Sula et al. (1987) and addressed 
in greater depth by Kathren (1993).  Consideration was given to 
newer models such as the USTUR model presented by Kathren, and 
the recycling models used in ICRP publications 56 (1989) and 67 
(1993).  The USTUR plutonium model is thought by HIDP staff to 
be a more technically correct model, however it could not be fully 
implemented using the standard resources currently available to the 
HIDP (notably, the CINDY computer code).  Comparison of dose 
estimates based on the ICRP 30 Part 4 model and the USTUR model 
were performed by the HIDP as part of this technical basis 
development, and showed that the USTUR model resulted in 
committed doses ranging up to 20% lower than those provided using  
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the ICRP 30 Part 4 model.  The recycling models could not be 
implemented at all using the current standard tools of the HIDP and 
thus were not considered to be viable options. 
 
8.2.4 Urinary Excretion 
 
The NCRP, in its Report 84 (NCRP 1985), states that, “interpretation 
of excretion data for purposes of body burden estimation should be 
based on models derived with that application primarily in mind.  
The models of ICRP 30 and ICRP 48 (1986) were derived for the 
estimation of organ dose and were not necessarily intended to 
account for excretion.”  In recognition of this, the HIDP has selected 
the Jones function (Jones 1985) to relate the urine excretion of 
plutonium to systemic uptake. 
 
The Jones function is based on human injection studies originally 
reported by Langham et al. (1950) and Langham (1956), and 
follow-up work by Rundo et al. (1976) and Moss and Gautier (1985).  
The studies involved direct intravenous injection of plutonium 
citrate.  The application of the function to observed excretion data 
results in an estimate of the uptake of plutonium by systemic 
circulation. 
 
The Jones function models urinary excretion of plutonium following 
systemic uptake as a four-component exponential function.  Jones 
emphasized that his function was an empirical fit to human data and 
should not be interpreted as modeling retention in specifically 
identifiable compartments.  Thus, its application at Hanford is 
limited to estimating uptake and predicting excretion based on 
uptake.  It is specifically not being used for organ dose calculations. 
 
The Jones function is a four-component exponential sum, 
mathematically defined as 
 
 
( )
t0000284.05t00380.05
t0442.04t558.03
u
e1042.1e1055.8
e1039.2e1075.4te
----
----
´+´
+´+´=
 (8.1) 
 
where eu(t) is the fraction of uptake to blood excreted in urine on 
day t, and t is the days post uptake (note:  t = 0 is time of uptake; 
t = 1 represents the first 24 hours following uptake; t = 2 represents 
the second day post uptake; etc.). 
 
The Jones excretion function described above replaced the Langham 
and Healy (Healy 1957) functions for evaluating plutonium 
depositions at Hanford.  Further discussion of this change can be  
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found in the Hanford Radiation Protection Historical Files of the 
Radiation Records Library.(a)  The effective date for this change was 
November 1986. 
 
The Jones excretion function has also been applied to material that is 
not readily transportable to the systemic compartment through the 
use of one or more isolated presystemic compartments, initially 
containing all of the material that will ultimately become systemic 
uptake.  Each presystemic compartment clears to the systemic 
compartment by an associated fractional transfer rate using simple 
first-order kinetics.  The PUCALC computer program was developed 
by the HIDP to calculate presystemic depositions and urinary 
excretion based on a single pre-systemic-to-systemic uptake transfer 
rate.  The program allows for fits of various combinations of transfer 
rate and presystemic deposition estimates to urine data and is 
particularly useful in cases involving substantial excretion data, 
where multiple presystemic components may be identifiable.  The 
evaluation process is described in Section 8.5. 
 
8.2.5 Fecal Excretion 
 
The excretion of bile to the GI tract provides a pathway for systemic 
excretion of plutonium to feces from the liver.  Few data are 
available to quantify this pathway relative to urine, however the 
assumption of an equal amount excreted from the systemic 
compartment by way of feces and urine is not uncommon.  For 
inhalation intakes, the fecal excretion is typically dominated by 
clearance from the respiratory tract, even at long-times post intake 
for class Y forms. 
 
8.3 Internal Dosimetry Factors 
 
This section contains factors that are useful in making internal 
dosimetry calculations.  The factors included in this section are 
derived from the CINDY computer code and incorporate the models 
and assumptions described in the preceding section.  Their 
application is intended for those circumstances where such 
assumptions are appropriate or more specific information is lacking.  
Variation from these factors is appropriate if sufficient data are 
available. 
 
                                                   
(a) Carbaugh, E. H., and M. J. Sula.  1986.  Proposed Change to Plutonium Excretion Function Used for 
Hanford Internal Dosimetry.  Letter Report to the Hanford Radiation Protection Historical Files, 
December 11, 1986, Pacific Northwest Laboratory, Richland, Washington. 
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8.3.1 Intake Retention and Excretion Fractions 
 
The intake retention (or excretion) fraction expresses the fraction of 
intake retained in a particular compartment or excreted by a 
particular pathway (urine or feces) at a given time post intake.  
Although excretion implies elimination rather than retention, 
conventional models include excretion compartments under the 
general term retention and use the term “intake retention fraction” 
(IRF) to describe both.  IRFs for various times post intake are 
tabulated as described below for 239Pu.  These values are also suitable 
for other isotopes of plutonium, with appropriate correction for 
different radiological half-lives. 
 
Lung retention fractions for the class W, class Y, and super class Y 
inhalations of 1-mm and 5-mm AMAD particles of 239Pu are tabulated 
in Table 8.6 and plotted in Figure 8.5.  Urine excretion fractions for 
an instantaneous uptake, acute inhalations, and acute ingestions of 
239Pu are shown in Table 8.7 and Figure 8.6.  Tabulated values for 
fecal excretion factors are shown in Table 8.8 and Figure 8.7.  Values 
for days other than those tabulated here can be obtained by 
interpolation between the tabulated data, or by obtaining the values 
directly from the CINDY computer code.  The ratio of fecal to 
urinary excretion is shown for these same intakes in Table 8.9 and 
Figure 8.8.  This latter table may be useful for identifying the 
appropriate type of intake for unknown circumstances, if sufficient 
data are obtained. 
 
8.3.2 Dose Coefficients 
 
Dose coefficients, expressed as committed dose equivalent per unit 
activity of intake (rem per nanocurie of acute intake or rem per 
nanocurie per day of chronic intake), are a convenient shortcut to 
estimating doses based on standard assumptions when the magnitude 
of an intake is known or assumed.  Acute intake dose coefficients 
have been tabulated in this section for instantaneous uptake, class W, 
Y, and super class Y inhalations (for both 1-mm and 5-mm-AMAD 
particle sizes) and for ingestion.  These dose coefficients were all 
derived using the CINDY computer code. 
 
Dose coefficients for single isotopes are shown in Tables 8.10 
through 8.13.  In the case of 241Pu, the 241Am ingrown from the time 
of intake is included in Table 8.12.  The 241Am values tabulated in 
Table 8.13 assume that behavior is characteristic of plutonium; i.e., 
the plutonium biokinetic model is used for americium because the 
americium is considered trapped in a plutonium matrix, which limits 
its behavior to that of the predominant matrix.  Dose coefficients 
have been derived for intakes of some mixtures representing the  
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 Table 8.6. Lung Retention for 1-mm and 5-mm-AMAD Particles Plutonium Inhalation 
 Intake (fraction of intake) 
 
Class W Class Y Super Class Y Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
0 0.33 0.17 0.33 0.17 0.33 0.17 
1 0.21 0.075 0.21 0.077 0.21 0.078 
2 0.18 0.063 0.18 0.064 0.18 0.065 
5 0.15 0.051 0.15 0.054 0.15 0.055 
7 0.14 0.049 0.15 0.053 0.15 0.054 
14 0.13 0.044 0.15 0.052 0.15 0.053 
30 0.10 0.036 0.15 0.051 0.15 0.052 
60 0.070 0.025 0.14 0.050 0.14 0.051 
90 0.048 0.017 0.14 0.048 0.14 0.049 
180 0.015 0.0053 0.12 0.044 0.13 0.046 
365 0.0014 4.80E-04 0.10 0.036 0.11 0.039 
730 1.10E-05 3.90E-06 0.073 0.026 0.086 0.031 
1,825 insig. insig. 0.029 0.010 0.057 0.020 
3,600 insig. insig. 0.0096 0.0034 0.048 0.017 
7,300 insig. insig. 0.0042 0.0015 0.042 0.015 
18,250 insig. insig. 0.0037 0.0013 0.029 0.010 
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Figure 8.5.  239Pu Lung Retention 
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Table 8.7.  239Pu Urine Excretion Fractions for Instantaneous Uptake, Inhalation, and Ingestion Intakes 
 
Class W Inhalation Class Y Inhalation 
Super Class Y 
Inhalation Ingestion 
Days 
Post 
Intake 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=5E-04 f1=1E-05 
1 3.0E-03 2.2E-04 3.5E-04 1.2E-05 2.5E-05 1.7E-08 2.8E-08 1.7E-06 3.4E-08 
2 1.9E-03 1.4E-04 2.2E-04 7.3E-06 1.6E-05 1.9E-08 2.7E-08 1.0E-06 2.1E-08 
5 5.8E-04 4.6E-05 6.9E-05 2.4E-06 4.9E-06 1.5E-08 1.5E-08 3.1E-07 6.2E-09 
7 3.7E-04 3.1E-05 4.4E-05 1.6E-06 3.1E-06 1.4E-08 1.3E-08 1.9E-07 3.8E-09 
14 2.3E-04 2.2E-05 2.8E-05 1.1E-06 1.9E-06 1.5E-08 1.3E-08 1.1E-07 2.3E-09 
30 1.5E-04 1.7E-05 2.0E-05 8.5E-07 1.4E-06 1.8E-08 1.5E-08 7.7E-08 1.5E-09 
60 9.9E-05 1.3E-05 1.4E-05 7.1E-07 9.3E-07 2.2E-08 1.7E-08 5.0E-08 9.9E-10 
90 7.9E-05 1.1E-05 1.1E-05 6.9E-07 7.9E-07 2.5E-08 2.0E-08 4.0E-08 8.0E-10 
180 5.7E-05 8.3E-06 8.1E-06 7.2E-07 6.5E-07 3.2E-08 2.5E-08 2.9E-08 5.8E-10 
365 3.5E-05 4.8E-06 4.9E-06 8.0E-07 5.2E-07 4.2E-08 3.2E-08 1.8E-08 3.5E-10 
730 1.9E-05 2.5E-06 2.6E-06 8.9E-07 4.4E-07 5.3E-08 4.0E-08 9.6E-09 2.0E-10 
1,825 1.4E-05 1.6E-06 1.8E-06 8.8E-07 4.0E-07 7.6E-08 5.3E-08 6.8E-09 1.3E-10 
3,600 1.3E-05 1.5E-06 1.7E-06 7.4E-07 3.5E-07 1.1E-07 7.3E-08 6.4E-09 1.3E-10 
7,300 1.2E-05 1.4E-06 1.5E-06 6.1E-07 2.9E-07 1.7E-07 1.1E-07 5.8E-09 1.2E-10 
18,250 8.4E-06 1.0E-06 1.1E-06 4.4E-07 2.1E-07 3.1E-07 1.6E-07 4.2E-09 8.4E-11 
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Figure 8.6.  239Pu Urinary Excretion 
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Table 8.8.  239Pu Fecal Excretion Fractions for Instantaneous Uptake, Inhalation, and Ingestion Intakes 
 
Class W Inhalation Class Y Inhalation 
Super Class Y 
Inhalation Ingestion 
Days 
Post 
Intake 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=5E-04 f1=1E-05 
1 3.0E-03 1.1E-01 2.2E-01 1.3E-01 2.5E-01 1.3E-01 2.5E-01 4.7E-01 4.7E-01 
2 1.9E-03 1.3E-01 2.6E-01 1.6E-01 2.9E-01 1.6E-01 2.9E-01 2.8E-01 2.8E-01 
5 5.8E-04 2.3E-02 3.1E-02 2.4E-02 3.4E-02 2.4E-02 3.4E-02 1.8E-02 1.8E-02 
7 3.7E-04 6.3E-03 5.6E-03 5.4E-03 5.7E-03 5.4E-03 5.7E-03 2.5E-03 2.5E-03 
14 2.3E-04 1.2E-03 4.6E-04 1.7E-04 6.5E-05 1.7E-04 6.3E-05 2.4E-06 2.3E-06 
30 1.5E-04 9.6E-04 3.5E-04 1.3E-04 4.8E-05 1.3E-04 4.7E-05 7.7E-08 1.5E-09 
60 9.9E-05 6.3E-04 2.3E-04 1.3E-04 4.6E-05 1.3E-04 4.5E-05 5.0E-08 9.9E-10 
90 7.9E-05 4.2E-04 1.6E-04 1.2E-04 4.4E-05 1.2E-04 4.3E-05 4.0E-08 8.0E-10 
180 5.7E-05 1.3E-04 4.9E-05 1.1E-04 3.9E-05 1.1E-04 3.8E-05 2.9E-08 5.8E-10 
365 3.5E-05 1.4E-05 8.1E-06 8.5E-05 3.0E-05 8.4E-05 3.0E-05 1.8E-08 3.5E-10 
730 1.9E-05 2.5E-06 2.6E-06 5.1E-05 1.8E-05 5.1E-05 1.8E-05 9.6E-09 2.0E-10 
1,825 1.4E-05 1.6E-06 1.8E-06 1.2E-05 4.3E-06 1.1E-05 4.0E-06 6.8E-09 1.3E-10 
3,600 1.3E-05 1.5E-06 1.7E-06 1.6E-06 6.6E-07 9.9E-07 3.8E-07 6.4E-09 1.3E-10 
7,300 1.2E-05 1.5E-06 1.5E-06 6.2E-07 3.0E-07 1.8E-07 1.1E-07 5.8E-09 1.2E-10 
18,250 8.4E-06 1.0E-06 1.1E-06 4.4E-07 2.1E-07 3.1E-07 1.6E-07 4.2E-09 8.4E-11 
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Figure 8.7.  239Pu Fecal Excretion 
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Table 8.9.  Fecal-to-Urine Ratios for 239Pu Intakes 
 
Class W Inhalation Class Y Inhalation 
Super Class Y 
Inhalation Ingestion 
Days 
Post 
Intake 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=5E-4 f1=1E-5 
1 1.0E+00 5.0E+02 6.3E+02 1.1E+04 1.0E+04 7.6E+06 8.9E+06 2.8E+05 1.4E+07 
2 1.0E+00 9.3E+02 1.2E+03 2.2E+04 1.8E+04 8.4E+06 1.1E+07 2.8E+05 1.3E+07 
5 1.0E+00 5.0E+02 4.5E+02 1.0E+04 6.9E+03 1.6E+06 2.3E+06 5.8E+04 2.9E+06 
7 1.0E+00 2.0E+02 1.3E+02 3.4E+03 1.8E+03 3.9E+05 4.4E+05 1.3E+04 6.6E+05 
14 1.0E+00 5.5E+01 1.6E+01 1.5E+02 3.4E+01 1.1E+04 4.8E+03 2.2E+01 1.0E+03 
30 1.0E+00 5.6E+01 1.8E+01 1.5E+02 3.4E+01 7.2E+03 3.1E+03 1.0E+00 1.0E+00 
60 1.0E+00 4.8E+01 1.6E+01 1.8E+02 4.9E+01 5.9E+03 2.6E+03 1.0E+00 1.0E+00 
90 1.0E+00 3.8E+01 1.5E+01 1.7E+02 5.6E+01 4.8E+03 2.2E+03 1.0E+00 1.0E+00 
180 1.0E+00 1.6E+01 6.0E+00 1.5E+02 6.0E+01 3.4E+03 1.5E+03 1.0E+00 1.0E+00 
365 1.0E+00 2.9E+00 1.7E+00 1.1E+02 5.8E+01 2.0E+03 9.4E+02 1.0E+00 1.0E+00 
730 1.0E+00 1.0E+00 1.0E+00 5.7E+01 4.1E+01 9.6E+02 4.5E+02 1.0E+00 1.0E+00 
1,825 1.0E+00 1.0E+00 1.0E+00 1.4E+01 1.1E+01 1.4E+02 7.5E+01 1.0E+00 1.0E+00 
3,600 1.0E+00 1.0E+00 1.0E+00 2.1E+00 1.9E+00 9.0E+00 5.2E+00 1.0E+00 1.0E+00 
7,300 1.0E+00 1.0E+00 1.0E+00 1.0E+00 1.0E+00 1.1E+00 1.0E+00 1.0E+00 1.0E+00 
18,250 1.0E+00 1.0E+00 1.0E+00 1.0E+00 1.0E+00 1.0E+00 1.0E+00 1.0E+00 1.0E+00 
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Figure 8.8.  Feces-to-Urine Excretion Ratios for 239Pu Intakes 
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Table 8.10.  Committed Dose Coefficients for Acute Intakes of 238Pu (rem/nCi) 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Ingestion 
Organ or Tissue 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=5E-04 f1=1E-05 
Effective 3.2E+00 4.0E-01 4.3E-01 2.9E-01 1.2E-01 5.1E-01 1.9E-01 1.6E-03 5.0E-05 
Bone Surface 5.9E+01 7.1E+00 7.8E+00 2.7E+00 1.4E+00 7.3E-01 4.4E-01 2.9E-02 5.9E-04 
Red Marrow 4.7E+00 5.7E-01 6.3E-01 2.2E-01 1.1E-01 5.9E-02 3.5E-02 2.4E-03 4.7E-05 
Liver 1.1E+01 1.3E+00 1.4E+00 5.1E-01 2.5E-01 1.5E-01 8.8E-02 5.4E-03 1.1E-04 
Lung  3.2E-05 6.7E-02 2.4E-02 1.2E+00 4.1E-01 3.9E+00 1.4E+00 1.6E-08 3.2E-10 
Gonads 8.6E-01 1.0E-01 1.1E-01 3.9E-02 2.0E-02 9.7E-03 5.8E-03 4.3E-04 8.6E-06 
Lower Large Intestine insig. insig. insig. insig. insig. insig. insig. 2.1E-04 2.1E-04 
 
Table 8.11.  Committed Dose Coefficients for Acute Intakes of 239Pu and/or 240Pu (rem/nCi)(a) 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Ingestion 
Organ or Tissue 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=5E-04 f1=1E-05 
Effective 3.6E+00 4.4E-01 4.8E-01 3.1E-01 1.3E-01 5.5E-01 2.1E-01 1.8E-03 5.2E-05 
Bone Surface 6.7E+01 8.0E+00 8.8E+00 3.1E+00 1.6E+00 9.0E-01 5.3E-01 3.3E-02 6.7E-04 
Red Marrow 5.2E+00 6.2E-01 6.8E-01 2.4E-01 1.2E-01 6.9E-02 4.1E-02 2.6E-03 5.2E-05 
Liver 1.2E+01 1.4E+00 1.5E+00 5.6E-01 2.8E-01 1.8E-01 1.0E-01 5.8E-03 1.2E-04 
Lung  2.9E-05 6.1E-02 2.2E-02 1.1E+00 4.0E-01 4.1E+00 1.5E+00 1.4E-08 2.9E-10 
Gonads 9.8E-01 1.2E-01 1.3E-01 4.5E-02 2.5E-02 1.2E-02 7.1E-03 4.9E-04 9.8E-06 
Lower Large Intestine insig. insig. insig. insig. insig. insig. insig. 1.9E-04 1.9E-04 
(a) 239Pu and 240Pu are dosimetrically equivalent. 
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Table 8.12.  Committed Dose Coefficients for Acute Intakes of 241Pu (rem/nCi) 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Ingestion 
Organ or Tissue 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=5E-04 f1=1E-05 
Effective 6.9E-02 8.3E-03 9.1E-03 5.0E-03 2.2E-03 1.1E-02 4.2E-03 3.5E-05 7.7E-07 
Bone Surface 1.3E+00 1.6E-01 1.7E-01 6.6E-02 3.2E-02 2.3E-02 1.3E-02 6.5E-04 1.3E-05 
Red Marrow 1.0E-01 1.2E-02 1.3E-02 5.2E-03 2.5E-03 1.8E-03 1.0E-03 5.1E-05 1.0E-06 
Liver 2.0E-01 2.4E-02 2.7E-02 1.1E-02 5.3E-03 4.5E-03 2.6E-03 1.0E-04 2.0E-06 
Lung  1.7E-06 2.7E-05 9.7E-06 1.2E-02 4.1E-03 7.9E-02 2.8E-02 8.3E-10 1.7E-11 
Gonads 2.1E-02 2.5E-03 2.8E-03 1.0E-03 5.0E-04 3.1E-04 1.8E-04 1.1E-05 2.1E-07 
Lower Large Intestine insig. insig. insig. insig. insig. insig. insig. 9.7E-07 9.8E-07 
 
Table 8.13.  Committed Dose Coefficients for Acute Intakes of 241Am in a Plutonium Matrix (rem/nCi) 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Ingestion 
Organ or Tissue 
Instantaneous 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm f1=5E-04 f1=1E-05 
Effective 3.7E+00 4.5E-01 4.9E-01 3.2E-01 1.4E-01 5.8E-01 2.2E-01 1.9E-03 5.5E-05 
Bone Surface 6.7E+01 8.1E+00 8.9E+00 3.1E+00 1.6E+00 8.9E-01 5.3E-01 3.4E-02 6.7E-04 
Red Marrow 5.3E+00 6.3E-01 7.0E-01 2.5E-01 1.2E-01 7.0E-02 4.1E-02 2.6E-03 5.3E-05 
Liver 1.2E+01 1.4E+00 1.6E+00 5.8E-01 2.9E-01 1.8E-01 1.1E-01 6.0E-03 1.2E-04 
Lung  1.2E-04 6.7E-02 2.4E-02 1.2E+00 4.4E-01 4.4E+00 1.6E+00 6.3E-08 2.8E-10 
Gonads 1.0E+00 1.2E-01 1.3E-01 4.6E-02 2.3E-02 1.2E-02 7.2E-03 5.0E-04 1.0E-05 
Lower Large Intestine insig. insig. insig. insig. insig. insig. insig. 2.2E-04 2.2E-04 
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types of plutonium most typically encountered at Hanford.  The dose 
coefficients are tabulated in Table 8.14 for weapons-grade plutonium 
and in Table 8.15 for fuel-grade plutonium.  The mixtures are 
weapons-grade and fuel-grade plutonium aged 10 years, 20 years, 
and 40 years.  For each of these mixtures, dose coefficients have 
been tabulated for instantaneous uptake, and class W, Y, and super 
class Y inhalations of 1-mm- and 5-mm-AMAD particles.  Previous 
HIDP documentation (Sula, Carbaugh, and Bihl 1989; 1991) 
provided dose coefficients for fresh and 5-year aged weapons and 
fuel-grade mixtures for instantaneous uptake and inhalation of 1-mm-
AMAD particles.  As discussed in Section 8.2, the retention model 
used for the super class Y form is highly speculative and subject to 
great uncertainty.  The super class Y dose coefficients are intended 
for comparison with other more widely accepted models, rather than 
confident dosimetry.  Reference mixture dose coefficients have not 
been provided for ingestion intakes, because ingestion has not 
historically been considered a significant mode of occupational 
exposure, due to extremely low GI tract uptake of plutonium.  If an 
ingestion intake occurs, the dose to significant organs can be 
calculated using the CINDY computer code, or using the individual 
nuclide dose coefficients for ingestion listed in Tables 8.10 through 
8.13. 
 
8.3.3 Cumulative Dose Equivalents 
 
The cumulative dose equivalent from an intake through various times 
post intake is sometimes of interest with regard to tenaciously 
retained radionuclides.  The most commonly referenced cumulative 
dose for occupational exposure is the committed dose equivalent 
through a 50-year period following an intake.  The cumulative 
effective dose equivalents (expressed as a percentage of the 50-year 
committed effective dose equivalent) through various times post 
intake are shown in Table 8.16 for 239Pu class W, Y, and super Y 
inhalation intakes of 1-mm-AMAD particles.  Cumulative dose 
equivalents for other forms of plutonium or other time intervals can 
be readily obtained from the CINDY computer code.  Cumulative 
doses are of principal interest with regard to potential biological 
effects, because they represent the dose received through a time 
interval, as opposed to a projected dose expected to be received in 
the future from an intake. 
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Table 8.14.  Committed Dose Coefficients for Acute Intakes of Weapons-Grade Plutonium (rem/nCi)(a) 
 
Class W Inhalation Class Y Inhalation 
Super Class Y 
Inhalation 
Organ or Tissue 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
10-Year Aged Weapons-Grade Mixture 
Effective 4.0E+00 4.8E-01 5.0E-01 3.4E-01 1.4E-01 6.1E-01 2.3E-01 
Bone Surface 7.4E+01 8.8E+00 9.7E+00 3.4E+00 1.8E+00 1.0E+00 6.0E-01 
Red Marrow 5.7E+00 6.8E-01 6.8E-01 2.7E-01 1.3E-01 7.8E-02 4.6E-02 
Liver 1.3E+01 1.5E+00 1.7E+00 6.2E-01 3.1E-01 2.0E-01 1.1E-01 
Lung insig. 6.2E-02 2.2E-02 1.2E+00 4.3E-01 4.6E+00 1.7E+00 
Gonads 1.1E+00 1.3E-01 1.4E-01 5.0E-02 3.0E-02 1.4E-02 8.6E-03 
        
20-Year Aged Weapons-Grade Mixture 
Effective 3.8E+00 4.7E-01 4.8E-01 3.3E-01 1.4E-01 5.9E-01 2.2E-01 
Bone Surface 7.1E+01 8.5E+00 9.3E+00 3.3E+00 1.7E+00 9.6E-01 5.7E-01 
Red Marrow 5.5E+00 6.6E-01 6.1E-01 2.6E-01 1.3E-01 7.4E-02 4.4E-02 
Liver 1.3E+01 1.5E+00 1.6E+00 6.0E-01 3.0E-01 1.9E-01 1.1E-01 
Lung insig. 6.3E-02 2.3E-02 1.2E+00 4.2E-01 4.4E+00 1.6E+00 
Gonads 1.0E+00 1.3E-01 1.4E-01 4.8E-02 2.9E-02 1.3E-02 8.5E-03 
        
40-Year Aged Weapons-Grade Mixture 
Effective 3.7E+00 4.5E-01 4.6E-01 3.2E-01 1.3E-01 5.7E-01 2.2E-01 
Bone Surface 6.8E+01 8.2E+00 9.0E+00 3.2E+00 1.6E+00 9.1E-01 5.4E-01 
Red Marrow 5.3E+00 6.3E-01 5.6E-01 2.5E-01 1.2E-01 7.1E-02 4.2E-02 
Liver 1.2E+01 1.4E+00 1.5E+00 5.7E-01 2.9E-01 1.8E-01 1.0E-01 
Lung insig. 6.3E-02 2.3E-02 1.1E+00 4.1E-01 4.3E+00 1.5E+00 
Gonads 1.0E+00 1.2E-01 1.3E-01 4.6E-02 2.8E-02 1.2E-02 8.3E-03 
(a) nCi of total alpha activity in mixture. 
 
8.3.4 Comparison of Published Dosimetry Factors 
 
A comparison of dosimetry factors, including dose coefficients, 
annual limits on intake (ALIs), and derived air concentrations 
(DACs) published in several sources is shown in Table 8.17.  For 
Hanford applications, the DAC values of 10 CFR 835 Appendix A 
are typically used to control facility operations. 
 
8.3.5 Derived Reference Levels 
 
Unlike other radionuclides, such as 137Cs or 90Sr, derived bioassay 
reference levels are of little value for plutonium.  The 239Pu intake 
that would correspond to a 10-mrem screening level is only 0.02 nCi 
for a class W inhalation, and a 0.2 nCi intake would correspond to an  
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 Table 8.15. Committed Dose Coefficients for Acute Intakes of Hanford Fuel-Grade  
 Plutonium Mixtures (rem/nCi)(a) 
 
Class W Inhalation Class Y Inhalation 
Super Class Y 
Inhalation 
Organ or Tissue 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
10-Year Aged Fuel-Grade Mixture 
Effective 4.6E+00 5.6E-01 6.1E-01 3.8E-01 1.6E-01 7.1E-01 2.7E-01 
Bone Surface 8.5E+01 1.0E+01 1.1E+01 4.0E+00 2.0E+00 1.2E+00 7.0E-01 
Red Marrow 6.6E+00 7.9E-01 8.6E-01 3.1E-01 1.5E-01 9.4E-02 5.5E-02 
Liver 1.5E+01 1.8E+00 1.9E+00 7.2E-01 3.5E-01 2.4E-01 1.4E-01 
Lung insig. 6.4E-02 2.3E-02 1.3E+00 4.7E-01 5.3E+00 1.9E+00 
Gonads 1.3E+00 1.5E-01 1.7E-01 5.9E-02 2.9E-02 1.6E-02 9.5E-03 
        
20-Year Aged Fuel-Grade Mixture 
Effective 4.1E+00 5.0E-01 5.5E-01 3.5E-01 1.5E-01 6.4E-01 2.4E-01 
Bone Surface 7.6E+01 9.2E+00 1.0E+01 3.6E+00 1.8E+00 1.1E+00 6.2E-01 
Red Marrow 5.9E+00 7.1E-01 7.8E-01 2.8E-01 1.4E-01 8.2E-02 4.8E-02 
Liver 1.3E+01 1.6E+00 1.7E+00 6.5E-01 3.2E-01 2.1E-01 1.2E-01 
Lung insig. 6.4E-02 2.3E-02 1.2E+00 4.5E-01 4.8E+00 1.7E+00 
Gonads 1.1E+00 1.4E-01 1.5E-01 5.2E-02 2.6E-02 1.4E-02 8.4E-03 
        
40-Year Aged Fuel-Grade Mixture 
Effective 3.8E+00 4.6E-01 5.0E-01 3.3E-01 1.4E-01 5.9E-01 2.2E-01 
Bone Surface 7.0E+01 8.4E+00 9.2E+00 3.2E+00 1.7E+00 9.4E-01 5.6E-01 
Red Marrow 5.5E+00 6.5E-01 7.2E-01 2.6E-01 1.3E-01 7.3E-02 4.3E-02 
Liver 1.2E+01 1.5E+00 1.6E+00 5.9E-01 3.0E-01 1.9E-01 1.1E-01 
Lung insig. 6.4E-02 2.3E-02 1.2E+00 4.3E-01 4.4E+00 1.6E+00 
Gonads 1.0E+00 1.2E-01 1.4E-01 4.8E-02 2.4E-02 1.3E-02 7.5E-03 
(a) nCi of total alpha activity in mixture. 
 
Table 8.16.  Cumulative Effective Dose Equivalent for 239Pu Intakes 
 
Cumulative Time 
Post Intake 
Inhalation Intake (expressed as percentage 
of 50-year committed dose) 
Days Years Class W Class Y Super Y 
90 0.25 1.7% 2.8% 1.7% 
180 0.5 2.7% 5.2% 3.3% 
365 1 4.3% 10% 6.1% 
730 2 7.1% 17% 11% 
1825 5 15% 30% 20% 
3650 10 28% 43% 32% 
7300 20 50% 60% 53% 
18,250 50 100% 100% 100% 
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Table 8.17.  Comparison of Selected Published Dosimetry Factors for 239Pu 
 
Reference  Soluble Inhalation Insoluble Inhalation 
Dose Coefficients 
Effective Dose   
CINDY (he,50) 0.44 rem/nCi (1-mm class W) 
0.48 rem/nCi (5-mm class W) 
0.31 rem/nCi (1-mm class Y) 
0.13 rem/nCi (5-mm class Y) 
ICRP 30 Part 4 and ICRP 
54 (1988) (he,50) 
1.1E-04 Sv/Bq (1-mm class W) 
(0.41 rem/nCi) 
8.1E-05 Sv/Bq (1-mm class Y) 
(.30 rem/nCi) 
EPA Federal Guidance 
Report No. 11 (he,50) 
1.16E-04 Sv/Bq (1-mm class W) 
(0.43 rem/nCi) 
8.33E-05 Sv/Bq (1-mm class Y) 
(0.31 rem/nCi) 
ICRP 68 (1994) [e(50)] 4.7E-05 Sv/Bq (1-mm type M) 
(0.17 rem/nCi) 
3.2E-05 Sv/Bq (5-mm type M) 
(0.12 rem/nCi) 
1.5E-05 Sv/Bq (1-mm type S) 
(0.055 rem/nCi) 
8.3E-06 Sv/Bq (5-mm type S) 
(0.030 rem/nCi) 
Bone Surfaces Dose   
CINDY (ht,50) 8.0 rem/nCi  (1-mm class W) 
8.8 rem/nCi (5-mm class W) 
3.1 rem/nCi (1-mm class Y) 
1.6 rem/nCi  (5-mm class Y) 
ICRP 30 Part 4 and ICRP 
54 (1988) (he,50) 
2.1E-03 Sv/Bq (1-mm class W) 
(7.8 rem/nCi) 
8.2E-04 Sv/Bq (1-mm class Y) 
(3.0 rem/nCi) 
EPA Federal Guidance 
Report No. 11 (ht,50) 
2.11E-03 Sv/Bq (1-mm class W) 
(7.8 rem/nCi) 
8.21E-04 Sv/Bq (1-mm class Y) 
(3.0 rem/nCi) 
Derived Air 
Concentration (based on 
bone surface dose) 
  
10 CFR 835 Appendix A 2E-12 mCi/ml (class W) 
8E-02 Bq/m3 (class W) 
6E-12 mCi/ml (class Y) 
2E-01 Bq/m3 (class Y) 
EPA Federal Guidance 
Report No. 11 
3E-12 mCi/ml (class W) 
1E-07 MBq/m3 (class W) 
7E-12 mCi/ml (class Y) 
3E-07 MBq/m3 (class Y) 
ICRP 30 Part 4 1E-01 Bq/m3 (class W) 3E-01 Bq/m3 (class Y) 
Annual Limit on Intake 
(based on bone surface 
dose) 
  
ICRP 30 Part 4 2E+02 Bq (class W) 6E+02 Bq (class Y) 
EPA Federal Guidance 
Report No. 11 
2E-4 MBq (class W) 
0.006 mCi (class Y) 
6E-4 Bq (class Y) 
0.02 mCi (class Y) 
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investigation level of 100 mrem.  The associated urine excretion 
from these intakes is sufficiently low that a derived screening or 
investigation level has no practical value for routine monitoring.  
Likewise, a derived bioassay level for medical referral is not of 
practical value for routine bioassay monitoring, because such 
monitoring is typically done on an annual basis.  Medical referral 
criteria have been established based on workplace indicators of 
potential intake, and are contained in the Hanford Internal Dosimetry 
Project Manual, PNL-MA-552, Chapter 7.(a)  Those criteria were 
established based on historical Hanford experience as a good practice 
and not on a rigid set of technical conditions or models. 
 
The Hanford practice is to investigate all routine (periodic) urine or 
in vivo measurements that show indications of potential plutonium 
intake and to calculate doses for any confirmed intake.  Thus the 
derived screening and investigation level concepts of calculated 
bioassay results against which actual measurements are compared 
are not applicable. 
 
8.4 Bioassay Monitoring 
 
This section discusses the general techniques and applicability of 
bioassay monitoring and describes the capabilities of excreta sample 
bioassay and in vivo measurements.  General recommendations are 
also provided for routine bioassay monitoring for plutonium. 
 
8.4.1 General Techniques and Applicability 
 
Bioassay monitoring for plutonium can be provided by both 
radiochemistry analysis of excreta and direct in vivo measurements.  
The application of these techniques, and the interpretation of the 
resulting data, are highly dependent upon the type of plutonium to 
which a worker may be exposed. 
 
Although the ICRP considers plutonium to be an inhalation class W 
or Y compound, substantially more and less transportable forms have 
been observed in past Hanford cases.  For this reason, bioassay 
guidance has been developed for instantaneous uptake, class W, Y, 
and super class Y compounds.  The instantaneous uptake form is 
assumed to behave as a direct injection of plutonium into the transfer 
compartment.  The class W and Y forms are assumed to behave 
according to the ICRP 30 respiratory tract model.  The super Y form 
is defined as being identical to class Y with respect to compartment 
                                                   
(a) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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deposition fractions, however the transport rate from lung to blood 
(lung compartments a, c, e, and i) have been adjusted for a retention 
half-time of 10,000 days. 
 
8.4.2 Urine Sampling and Analysis 
 
Urine sample analysis is the standard technique for confirming and 
evaluating the magnitude of systemic uptakes.  Uptake is required in 
order for material to be excreted by the urine pathway.  It can also be 
used for estimating inhalation intakes and initial lung burdens of 
slowly transportable compounds; however, fecal samples and in vivo 
measurements are usually the preferred techniques.  To reach the 
urine, plutonium must first reach the transfer compartment (blood) in 
a soluble (dissolved) form, from which it can then be removed by the 
kidneys through normal metabolic processes.  Insoluble material in 
the transfer compartment is assumed not to be excreted by the urine 
pathway until it has been dissolved. 
 
In reviewing urine sample results, anomalous results could be 
indicative of urine contamination from external sources (hands, 
sample container, and clothing).  Caution needs to be exercised when 
samples are obtained from workers who have recently had external 
contamination.  The extreme sensitivity of urine sample analysis 
lends itself to the possibility of the sample being contaminated by 
trace particles well below the level that can be observed by standard 
personal survey and workplace control practices.  This was one of 
the reasons why at-home sampling was originally selected for the 
Hanford Site in lieu of obtaining a sample at work. 
 
The typical urine sampling practice is to collect a urine sample over 
a specified time interval and perform a chemical separation for 
plutonium.  This technique is followed by electroplating and 
quantitative alpha spectrometry.  The final results are reported as 
238Pu and 239Pu.  The reported 239Pu result is actually the sum of the 
measured 239+240Pu, because alpha spectrometry systems do not have 
the capability to differentiate between the alpha energies for 239Pu 
and 240Pu decay emissions.  This does not pose a significant problem 
because the dosimetry for the two isotopes is essentially the same.  
When considering the total plutonium-alpha activity of a sample, it is 
important to combine the 238Pu with the 239Pu results. 
 
Prior to October 1983, the Hanford radiochemistry bioassay 
laboratory used an autoradiography procedure instead of the 
electroplating/alpha spectrometry procedure.  This autoradiography 
procedure actually measured the total plutonium-alpha activity, 
which was reported as 239Pu.  This point should be remembered when  
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comparing sample results analyzed by autoradiography with sample 
results obtained from alpha spectrometry, and may help account for 
potential shifts in long-term data trends. 
 
The reported detection levels for historical urine sample analysis 
procedures at various times are shown in Table 8.18.  The method 
used to define the detection level has changed over time, so the 
values in Table 8.18 are not strictly comparable with each other. 
 
 Table 8.18. Detection Limits for Routine Hanford 
  Analyses of Plutonium in Urine 
 
Time Period 
Detection Limit, 
dpm/routine sample 
Prior to June 1949 0.66 
June 1949 to Dec. 1952 0.33 
Dec. 1952 to 01/28/53 0.18 
01/28/53 to 03/27/53 0.15 
03/27/53 to 11/07/53 0.05 
11/07/53 to 12/04/53 0.07 
12/53 to 05/55 0.057 
05/55 to 09/55 0.027 
09/55 to 10/55 0.04 
10/55 to 10/01/83 0.05(a) 
10/01/83 to 12/31/83 0.035 
12/31/83 to 05/90 0.02 
06/90 to 11/91 0.03 
11/91 to present 0.02 
(a) During part of this period, results that were less 
than the detection limit were reported as 0.025. 
 
Special rapid analytical procedures are available for special 
circumstances.  These procedures can be executed and results 
obtained in substantially shorter times than the routine procedure, but 
they are less sensitive.  Their use is primarily for diagnostic bioassay 
of suspected internal contamination related to unplanned exposures 
(incidents).  The decision to use such procedures involves consider-
ing the probability and potential magnitude of the exposure.  The 
contractual detection limit for plutonium in urine can be found in the 
radiochemistry bioassay laboratory statement of work available from 
the HIDP) and in the Hanford Internal Dosimetry Project Manual 
(PNL-MA-552).(a) 
                                                   
(a) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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8.4.3 Fecal Sampling and Analysis 
 
Fecal samples are useful for confirming and evaluating suspected 
inhalation and ingestion exposures.  The sample results can be used 
in conjunction with the ICRP 30 respiratory tract model to estimate 
the magnitudes of intakes and initial lung depositions as a basis for 
lung dose assessment.  They can also be used as checks on urine- or 
in vivo-based estimates of intake.  In addition, fecal samples can 
provide radionuclide identification data and isotope ratios.  Fecal 
samples are of primary value immediately following a suspected 
intake, when material is rapidly clearing the respiratory and GI 
tracts.  Long-term sampling following intake can be useful for 
differentiating ingestion from inhalation, and class W from class Y 
inhalation.  It may also be of value at long times post intake as an aid 
to estimating residual lung burdens and isotope ratios; however 
substantial uncertainties exist for such applications. 
 
Most fecal excretion following an intake occurs shortly after the 
intake.  According to the ICRP 30 respiratory tract model, 
approximately one-half (48%) of an intake of class Y plutonium 
(1-mm-AMAD particle size) would be excreted in the first 5 days 
following intake.  Additional long-term clearance from the lung by 
the fecal pathway would total approximately 10% of the intake, 
excreted at the fractional biological clearance rate of 0.0014/day.  
For a 5-mm particle size, the early fecal excretion is a higher fraction 
of intake. 
 
Additional fecal excretion comes via the biliary pathway.  This 
pathway represents fecal excretion from systemic deposition.  While 
the magnitude of this pathway relative to the urine pathway has been 
investigated, it is not recommended that fecal excretion be used for 
evaluating systemic deposition.  The primary reason for this is the 
interference that can be caused by very slight acute or chronic 
inhalation or ingestion exposures and the uncertainty of the 
magnitude of the biliary excretion relative to urinary excretion.  
There is no way to differentiate the source of fecal excretion (lung 
clearance, ingestion, or bile) when interpreting fecal sample results.  
For the purpose of modeling systemic excretion, it is assumed that 
systemic excretion is evenly distributed between the urine and biliary 
excretion pathways. 
 
The complications of interpreting long-term fecal excretions do not 
rule out their potential value, particularly if certain conditions can be 
met regarding their collection; notably, lack of potential additional 
exposure immediately prior to collection of the sample and collection 
of more than one sample. 
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Multiple fecal samples are recommended if the data are critical for 
an evaluation.  Normal daily fecal excretion rates vary greatly from 
the 135 g/d of ICRP 23 (1974) Reference Man and can be offset to 
some extent by collecting consecutive samples and averaging the 
results. 
 
The laboratory plutonium analysis procedure for fecal samples 
involves wet ashing and dry ashing to destroy organic elements, 
redissolution to a standard volume using nitric acid, extraction of an 
aliquot representing 25% of the sample, additional dissolution using 
hydrofluoric acid, chemical separation of plutonium, followed by 
electroplating and alpha spectrometry.  A 242Pu tracer is used for 
determining chemical yields. 
 
Contractual detection levels are established in the radiochemical 
bioassay laboratory statement of work, as approximations for the 
minimum detectable activity (MDA) desired for the analysis. 
 
8.4.4 In Vivo Measurements 
 
In vivo measurement techniques suitable for plutonium applications 
and routinely performed at the Hanford In Vivo Radioassay and 
Research Facility (IVRRF) include chest counting, skeleton 
measurement by head counting, liver counting, and wound counting.  
Less common measurements include upper extremity lymph node 
counting (e.g., axillary lymph nodes), and a scanning lung count to 
identify the likelihood of a nonuniform distribution of activity in the 
lung (e.g., a hot particle).  Most of these procedures involve 
measurement of the 60-keV photons from the 241Am present as an 
ingrown impurity in a plutonium mixture.  Direct measurement of 
the 17-keV plutonium L x-rays is possible, but the sensitivity of the 
measurement is not adequate to detect most internal organ 
depositions.  Direct measurement of plutonium in wounds can also 
be performed.  Minimum detectable activities for these 
measurements are described in the In Vivo Monitoring Project 
Manual (PNL-MA-574)(a) and the Hanford Internal Dosimetry 
Program Manual (PNL-MA-552).(b) 
 
Because of the relative insensitivity of direct in vivo plutonium 
measurement techniques at low levels (other than for wounds), the 
presence of plutonium is often inferred by detection of 241Am.  
                                                   
(a) Pacific Northwest National Laboratory (PNNL).  In Vivo Monitoring Project Manual.  
PNNL-MA-574, Richland, Washington.  (Internal manual.) 
(b) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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Estimation of the amount of plutonium must be made using known 
or assumed isotope ratios.  Such ratios may be obtained from 
workplace data (smear samples, air samples, etc.), inferred from 
excreta data (recognizing that fecal or urine samples may be biased 
by different clearance rates from the body), or from assumptions 
regarding material composition based on the facility and process 
involved. 
 
The following paragraphs briefly describe the types of in vivo 
measurements available at the Hanford IVRRF.  Further discussion 
of these measurement techniques can be found in the In Vivo 
Monitoring Program Manual (PNL-MA-574). 
 
Chest counting is a standard measurement technique used for 
monitoring plutonium workers.  A count is performed by placing 
planar germanium detectors over the subject’s chest.  Because of the 
potential impact of chest wall thickness on measurement sensitivity, 
measurement corrections are made on all workers based on a height-
to-weight ratio.  In addition, measurements on workers with known 
depositions will usually be corrected based on direct measurement of 
chest wall thickness using ultrasound techniques.  Chest measure-
ment results may not represent actual lung burdens unless they have 
been corrected for interference from activity deposited in other 
organs (notably the skeleton and, to a lesser extent, the liver).  When 
such a correction has been made the result is more correctly referred 
to as a lung burden estimate rather than a chest count result.  Lacking 
such corrections, chest measurement results may conservatively be 
assumed to represent lung burdens, especially at short times after 
intake. 
 
Head counts (also called skull counts) will usually be performed 
when chest counts confirm detectable activity to determine if 
modification for skeleton activity is needed.  The results of the head 
count are extrapolated to an estimate of the total quantity retained in 
the skeleton using a human skeleton calibration phantom.  Head 
counts can also be used as an approximate check on urine-based 
systemic deposition estimates, recognizing that ionic americium in 
the blood may not behave the same as plutonium. 
 
Liver counts provide a direct estimate of activity in the liver based 
on the Livermore calibration phantom (Griffith et al. 1978).  These 
counts are used to correct chest counts for interference from activity 
deposited in the liver and are primarily used for long-term follow-up 
and as an approximate check on urine-based systemic deposition 
estimates.  They can also provide a check on the assumptions used in 
the computer codes for calculating committed dose equivalents. 
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Wound counts using a single planar germanium detector can 
directly measure plutonium and americium.  Wound counts can be 
performed either at the Emergency Decontamination Facility (EDF) 
or at the IVRRF.  The detection equipment is similar at both 
facilities, however MDAs are substantially better at the IVRRF due 
to the use of shielded counting rooms.  The 239Pu results (based on 
the 17 keV L x-rays) can be significantly underestimated if the 
activity is deeply embedded in tissue. 
 
Upper extremity lymph node counts are used to identify potential 
deposition sites for non-transportable or slowly transportable 
material deposited in extremity wounds.  These nodes include the 
supratracular lymph nodes located near the elbow and the axillary 
lymph nodes located near the armpit.  The nodes are counted by 
placing planar germanium detectors in the lymph node region.  
Activity deposited in the axillary lymph nodes has the potential for 
interfering with chest count results.  Precise calibrations for these 
counts are not available. 
 
Scanning lung counts are used to determine the distribution of 
activity deposited in the lung.  By a series of counts, the extent to 
which activity is deposited in the tracheal-bronchial region (include-
ing the lymph nodes) and the left and right pulmonary regions can be 
reasonably determined.  The results of these counts are not likely to 
affect lung dose estimates, except to the extent that they shed light on 
the nature of the retention and potential lung dynamics.  The 
calibration for these counts is still under development.  Results may 
be expressed as the percentage of total lung activity in a given 
counting region. 
 
8.4.5 Bioassay Monitoring Capability 
 
The bioassay monitoring capability for plutonium can be discussed 
as the minimum detectable intake (MDI) or minimum detectable 
dose (MDD) associated with a bioassay measurement at the 
minimum detectable activity (MDA) at some time post intake.  
Analyses of the MDIs and MDDs (committed effective dose 
equivalents and committed bone surface dose equivalent for cases 
where the bone surface dose was more limiting than the effective 
dose) have been performed for three bioassay methods (239Pu in 
urine, 239Pu in feces, and in vivo 241Am lung counting).  These 
analyses included instant uptake, and class W, Y, and super class Y 
inhalations (1-mm and 5-mm-AMAD particles) for both weapons-
grade and fuel-grade reference plutonium mixtures, aged 10, 20, and 
40 years.  The analyses assumed MDAs for the bioassay measure- 
ments to be slightly higher than those that have been observed for  
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most Hanford bioassay measurements.  Thus, the stated MDIs and 
MDDs in the following tables are slightly higher than those expected 
to be achieved by routine worker monitoring. 
 
To determine the capability of bioassay of plutonium by urine 
analysis, the intakes of 239Pu associated with minimum detectable 
urine analysis results were calculated for transportable injection, and 
class W, Y, and super Y inhalations.  These intakes are given in 
Table 8.19.  Based on the activity ratios described in Section 8.1, the 
total-alpha intake was estimated for the mixtures, and the committed 
dose equivalents were calculated using the dose coefficients of 
Tables 8.14 and 8.15.  The results are summarized in Tables 8.20 
through 8.31 and graphically presented in Figures 8.9 through 8.20. 
 
The minimum detectable committed doses associated with 241Am 
detection by chest counting are shown in Tables 8.32 through 8.43 
and Figures 8.21 through 8.32. 
 
The capability for plutonium fecal bioassay is addressed in a similar 
manner, with the 239Pu intakes compiled in Table 8.44.  The 
corresponding minimum detectable committed effective dose 
equivalents are shown in Tables 8.45 through 8.56 and in 
Figures 8.33 through 8.44. 
 
Table 8.19.  Minimum Detectable Intakes (nCi) of 239Pu Based on Detection of 0.02 dpm/d in Urine 
 
Class W Inhalation Class Y Inhalation 
Super Class Y 
Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 3.0E-03 4.1E-02 2.6E-02 7.5E-01 3.6E-01 5.3E+02 3.2E+02 
2 4.7E-03 6.4E-02 4.1E-02 1.2E+00 5.6E-01 4.7E+02 3.3E+02 
5 1.6E-02 2.0E-01 1.3E-01 3.8E+00 1.8E+00 6.0E+02 6.0E+02 
7 2.4E-02 2.9E-01 2.0E-01 5.6E+00 2.9E+00 6.4E+02 6.9E+02 
14 3.9E-02 4.1E-01 3.2E-01 8.2E+00 4.7E+00 6.0E+02 6.9E+02 
30 6.0E-02 5.3E-01 4.5E-01 1.1E+01 6.4E+00 5.0E+02 6.0E+02 
60 9.1E-02 6.9E-01 6.4E-01 1.3E+01 9.7E+00 4.1E+02 5.3E+02 
90 1.1E-01 8.2E-01 8.2E-01 1.3E+01 1.1E+01 3.6E+02 4.5E+02 
180 1.6E-01 1.1E+00 1.1E+00 1.3E+01 1.4E+01 2.8E+02 3.6E+02 
365 2.6E-01 1.9E+00 1.8E+00 1.1E+01 1.7E+01 2.1E+02 2.8E+02 
730 4.7E-01 3.6E+00 3.5E+00 1.0E+01 2.0E+01 1.7E+02 2.3E+02 
1,825 6.4E-01 5.6E+00 5.0E+00 1.0E+01 2.3E+01 1.2E+02 1.7E+02 
3,600 6.9E-01 6.0E+00 5.3E+00 1.2E+01 2.6E+01 8.2E+01 1.2E+02 
7,300 7.5E-01 6.4E+00 6.0E+00 1.5E+01 3.1E+01 5.3E+01 8.2E+01 
18,250 1.1E+00 9.0E+00 8.2E+00 2.0E+01 4.3E+01 2.9E+01 5.6E+01 
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 Table 8.20. Minimum Detectable Committed Effective Dose Equivalent (rem) for 10-Year Aged  
 Weapons-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 1.5E-02 2.5E-02 1.6E-02 3.2E-01 6.3E-02 4.1E+02 9.3E+01 
2 2.4E-02 3.9E-02 2.6E-02 5.3E-01 9.9E-02 3.6E+02 9.6E+01 
5 7.8E-02 1.2E-01 8.2E-02 1.6E+00 3.2E-01 4.6E+02 1.7E+02 
7 1.2E-01 1.8E-01 1.3E-01 2.4E+00 5.1E-01 4.9E+02 2.0E+02 
14 2.0E-01 2.5E-01 2.0E-01 3.5E+00 8.3E-01 4.6E+02 2.0E+02 
30 3.0E-01 3.2E-01 2.8E-01 4.5E+00 1.1E+00 3.8E+02 1.7E+02 
60 4.6E-01 4.2E-01 4.0E-01 5.4E+00 1.7E+00 3.1E+02 1.5E+02 
90 5.7E-01 4.9E-01 5.1E-01 5.6E+00 2.0E+00 2.8E+02 1.3E+02 
180 7.9E-01 6.5E-01 7.0E-01 5.3E+00 2.4E+00 2.2E+02 1.0E+02 
365 1.3E+00 1.1E+00 1.2E+00 4.8E+00 3.0E+00 1.6E+02 8.1E+01 
730 2.4E+00 2.2E+00 2.2E+00 4.3E+00 3.6E+00 1.3E+02 6.5E+01 
1,825 3.2E+00 3.4E+00 3.1E+00 4.4E+00 4.0E+00 9.1E+01 4.9E+01 
3,600 3.5E+00 3.6E+00 3.3E+00 5.2E+00 4.5E+00 6.3E+01 3.6E+01 
7,300 3.8E+00 3.9E+00 3.8E+00 6.3E+00 5.5E+00 4.1E+01 2.4E+01 
18,250 5.4E+00 5.4E+00 5.1E+00 8.7E+00 7.5E+00 2.2E+01 1.6E+01 
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 Figure 8.9. Minimum Detectable Committed Effective Doses for 10-Year Aged Weapons-Grade 
 Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
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 Table 8.21. Minimum Detectable Committed Effective Dose Equivalent (rem) for 20-Year Aged  
 Weapons-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 1.5E-02 2.6E-02 1.7E-02 3.3E-01 6.8E-02 4.2E+02 9.5E+01 
2 2.4E-02 4.1E-02 2.6E-02 5.5E-01 1.1E-01 3.7E+02 9.8E+01 
5 7.9E-02 1.2E-01 8.4E-02 1.7E+00 3.4E-01 4.7E+02 1.8E+02 
7 1.2E-01 1.8E-01 1.3E-01 2.5E+00 5.5E-01 5.1E+02 2.0E+02 
14 2.0E-01 2.6E-01 2.1E-01 3.6E+00 8.9E-01 4.7E+02 2.0E+02 
30 3.1E-01 3.3E-01 2.9E-01 4.7E+00 1.2E+00 4.0E+02 1.8E+02 
60 4.6E-01 4.4E-01 4.1E-01 5.6E+00 1.8E+00 3.2E+02 1.6E+02 
90 5.8E-01 5.2E-01 5.3E-01 5.8E+00 2.1E+00 2.8E+02 1.3E+02 
180 8.0E-01 6.8E-01 7.2E-01 5.5E+00 2.6E+00 2.2E+02 1.1E+02 
365 1.3E+00 1.2E+00 1.2E+00 5.0E+00 3.3E+00 1.7E+02 8.3E+01 
730 2.4E+00 2.3E+00 2.2E+00 4.5E+00 3.8E+00 1.3E+02 6.6E+01 
1,825 3.3E+00 3.5E+00 3.2E+00 4.5E+00 4.2E+00 9.4E+01 5.0E+01 
3,600 3.5E+00 3.8E+00 3.4E+00 5.3E+00 4.8E+00 6.5E+01 3.6E+01 
7,300 3.8E+00 4.1E+00 3.9E+00 6.5E+00 5.8E+00 4.2E+01 2.4E+01 
18,250 5.5E+00 5.7E+00 5.3E+00 9.1E+00 8.0E+00 2.3E+01 1.7E+01 
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 Figure 8.10. Minimum Detectable Committed Effective Doses for 20-Year Aged Weapons-Grade 
 Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
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 Table 8.22. Minimum Detectable Committed Effective Dose Equivalent (rem) for 40-Year Aged  
 Weapons-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 1.6E-02 2.6E-02 1.7E-02 3.4E-01 6.6E-02 4.2E+02 9.9E+01 
2 2.5E-02 4.1E-02 2.6E-02 5.5E-01 1.0E-01 3.8E+02 1.0E+02 
5 8.0E-02 1.2E-01 8.4E-02 1.7E+00 3.3E-01 4.8E+02 1.8E+02 
7 1.3E-01 1.8E-01 1.3E-01 2.5E+00 5.3E-01 5.1E+02 2.1E+02 
14 2.0E-01 2.6E-01 2.1E-01 3.7E+00 8.6E-01 4.8E+02 2.1E+02 
30 3.1E-01 3.3E-01 2.9E-01 4.7E+00 1.2E+00 4.0E+02 1.8E+02 
60 4.7E-01 4.4E-01 4.1E-01 5.7E+00 1.8E+00 3.3E+02 1.6E+02 
90 5.9E-01 5.2E-01 5.3E-01 5.8E+00 2.1E+00 2.9E+02 1.4E+02 
180 8.2E-01 6.8E-01 7.2E-01 5.6E+00 2.5E+00 2.2E+02 1.1E+02 
365 1.3E+00 1.2E+00 1.2E+00 5.0E+00 3.2E+00 1.7E+02 8.7E+01 
730 2.5E+00 2.3E+00 2.2E+00 4.5E+00 3.7E+00 1.4E+02 6.9E+01 
1,825 3.3E+00 3.5E+00 3.2E+00 4.6E+00 4.1E+00 9.5E+01 5.2E+01 
3,600 3.6E+00 3.8E+00 3.4E+00 5.4E+00 4.7E+00 6.5E+01 3.8E+01 
7,300 3.9E+00 4.1E+00 3.9E+00 6.6E+00 5.7E+00 4.2E+01 2.5E+01 
18,250 5.6E+00 5.7E+00 5.3E+00 9.2E+00 7.8E+00 2.3E+01 1.7E+01 
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 Figure 8.11. Minimum Detectable Committed Effective Doses for 40-Year Aged Weapons-Grade  
 Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
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 Table 8.23. Minimum Detectable Committed Effective Dose Equivalent (rem) for 10-Year Aged  
 Fuel-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 2.3E-02 3.9E-02 2.7E-02 4.8E-01 9.7E-02 6.4E+02 1.5E+02 
2 3.7E-02 6.1E-02 4.2E-02 7.9E-01 1.5E-01 5.7E+02 1.5E+02 
5 1.2E-01 1.9E-01 1.3E-01 2.4E+00 5.0E-01 7.2E+02 2.7E+02 
7 1.9E-01 2.8E-01 2.1E-01 3.6E+00 7.9E-01 7.7E+02 3.2E+02 
14 3.0E-01 3.9E-01 3.3E-01 5.3E+00 1.3E+00 7.2E+02 3.2E+02 
30 4.7E-01 5.0E-01 4.6E-01 6.8E+00 1.7E+00 6.0E+02 2.7E+02 
60 7.1E-01 6.6E-01 6.6E-01 8.1E+00 2.6E+00 4.9E+02 2.4E+02 
90 8.9E-01 7.8E-01 8.4E-01 8.4E+00 3.1E+00 4.3E+02 2.1E+02 
180 1.2E+00 1.0E+00 1.1E+00 8.0E+00 3.7E+00 3.4E+02 1.6E+02 
365 2.0E+00 1.8E+00 1.9E+00 7.2E+00 4.7E+00 2.6E+02 1.3E+02 
730 3.7E+00 3.4E+00 3.6E+00 6.5E+00 5.5E+00 2.0E+02 1.0E+02 
1,825 5.0E+00 5.3E+00 5.2E+00 6.6E+00 6.1E+00 1.4E+02 7.8E+01 
3,600 5.4E+00 5.7E+00 5.5E+00 7.7E+00 7.0E+00 9.8E+01 5.6E+01 
7,300 5.8E+00 6.1E+00 6.2E+00 9.5E+00 8.4E+00 6.4E+01 3.7E+01 
18,250 8.3E+00 8.5E+00 8.4E+00 1.3E+01 1.2E+01 3.5E+01 2.6E+01 
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 Figure 8.12. Minimum Detectable Committed Effective Doses for 10-Year Aged Fuel-Grade  
 Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
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 Table 8.24. Minimum Detectable Committed Effective Dose Equivalent (rem) for 20-Year Aged  
 Fuel-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 2.4E-02 4.0E-02 2.8E-02 5.2E-01 1.1E-01 6.7E+02 1.5E+02 
2 3.8E-02 6.3E-02 4.4E-02 8.5E-01 1.7E-01 6.0E+02 1.6E+02 
5 1.3E-01 1.9E-01 1.4E-01 2.6E+00 5.4E-01 7.6E+02 2.8E+02 
7 2.0E-01 2.9E-01 2.2E-01 3.9E+00 8.6E-01 8.1E+02 3.3E+02 
14 3.2E-01 4.0E-01 3.5E-01 5.6E+00 1.4E+00 7.6E+02 3.3E+02 
30 4.9E-01 5.2E-01 4.9E-01 7.3E+00 1.9E+00 6.3E+02 2.8E+02 
60 7.4E-01 6.8E-01 7.0E-01 8.7E+00 2.9E+00 5.2E+02 2.5E+02 
90 9.2E-01 8.1E-01 8.9E-01 9.0E+00 3.4E+00 4.5E+02 2.1E+02 
180 1.3E+00 1.1E+00 1.2E+00 8.6E+00 4.1E+00 3.5E+02 1.7E+02 
365 2.1E+00 1.8E+00 2.0E+00 7.8E+00 5.1E+00 2.7E+02 1.3E+02 
730 3.8E+00 3.5E+00 3.8E+00 7.0E+00 6.1E+00 2.1E+02 1.1E+02 
1,825 5.2E+00 5.5E+00 5.4E+00 7.1E+00 6.7E+00 1.5E+02 8.0E+01 
3,600 5.6E+00 5.9E+00 5.7E+00 8.3E+00 7.6E+00 1.0E+02 5.8E+01 
7,300 6.1E+00 6.3E+00 6.5E+00 1.0E+01 9.2E+00 6.7E+01 3.9E+01 
18,250 8.7E+00 8.9E+00 8.9E+00 1.4E+01 1.3E+01 3.7E+01 2.7E+01 
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 Table 8.25. Minimum Detectable Committed Effective Dose Equivalent (rem) for 40-Year Aged  
 Fuel-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 2.5E-02 4.2E-02 2.8E-02 5.5E-01 1.1E-01 6.9E+02 1.6E+02 
2 4.0E-02 6.5E-02 4.5E-02 9.0E-01 1.7E-01 6.2E+02 1.6E+02 
5 1.3E-01 2.0E-01 1.4E-01 2.7E+00 5.7E-01 7.8E+02 2.9E+02 
7 2.0E-01 3.0E-01 2.3E-01 4.1E+00 9.0E-01 8.4E+02 3.4E+02 
14 3.3E-01 4.2E-01 3.6E-01 6.0E+00 1.5E+00 7.8E+02 3.4E+02 
30 5.0E-01 5.4E-01 5.0E-01 7.7E+00 2.0E+00 6.5E+02 2.9E+02 
60 7.6E-01 7.0E-01 7.1E-01 9.3E+00 3.0E+00 5.3E+02 2.6E+02 
90 9.6E-01 8.3E-01 9.0E-01 9.5E+00 3.5E+00 4.7E+02 2.2E+02 
180 1.3E+00 1.1E+00 1.2E+00 9.1E+00 4.3E+00 3.7E+02 1.8E+02 
365 2.2E+00 1.9E+00 2.0E+00 8.2E+00 5.4E+00 2.8E+02 1.4E+02 
730 4.0E+00 3.7E+00 3.8E+00 7.4E+00 6.3E+00 2.2E+02 1.1E+02 
1,825 5.4E+00 5.7E+00 5.5E+00 7.5E+00 7.0E+00 1.5E+02 8.3E+01 
3,600 5.8E+00 6.1E+00 5.9E+00 8.8E+00 8.0E+00 1.1E+02 6.0E+01 
7,300 6.3E+00 6.5E+00 6.6E+00 1.1E+01 9.6E+00 6.9E+01 4.0E+01 
18,250 9.0E+00 9.2E+00 9.0E+00 1.5E+01 1.3E+01 3.8E+01 2.7E+01 
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 Figure 8.14. Minimum Detectable Committed Effective Doses for 40-Year Aged Fuel-Grade  
 Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
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 Table 8.26. Minimum Detectable Committed Bone Surfaces Dose Equivalent (rem) for 10-Year  
 Aged Weapons-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 2.8E-01 4.5E-01 3.1E-01 3.2E+00 8.2E-01 
2 4.4E-01 7.1E-01 5.0E-01 5.3E+00 1.3E+00 
5 1.4E+00 2.2E+00 1.6E+00 1.6E+01 4.2E+00 
7 2.3E+00 3.2E+00 2.5E+00 2.4E+01 6.6E+00 
14 3.6E+00 4.5E+00 3.9E+00 3.5E+01 1.1E+01 
30 5.6E+00 5.9E+00 5.5E+00 4.5E+01 1.5E+01 
60 8.5E+00 7.7E+00 7.8E+00 5.4E+01 2.2E+01 
90 1.1E+01 9.1E+00 1.0E+01 5.6E+01 2.6E+01 
180 1.5E+01 1.2E+01 1.4E+01 5.3E+01 3.1E+01 
365 2.4E+01 2.1E+01 2.2E+01 4.8E+01 3.9E+01 
730 4.4E+01 4.0E+01 4.2E+01 4.3E+01 4.6E+01 
1,825 6.0E+01 6.2E+01 6.1E+01 4.4E+01 5.1E+01 
3,600 6.4E+01 6.6E+01 6.5E+01 5.2E+01 5.8E+01 
7,300 7.0E+01 7.1E+01 7.3E+01 6.3E+01 7.0E+01 
18,250 1.0E+02 1.0E+02 1.0E+02 8.7E+01 9.7E+01 
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 Figure 8.15. Minimum Detectable Bone Surface Dose for 10-Year Aged Weapons-Grade  
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 Table 8.27. Minimum Detectable Committed Bone Surfaces Dose Equivalent (rem) for 20-Year  
 Aged Weapons-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 2.9E-01 4.7E-01 3.2E-01 3.3E+00 8.2E-01 
2 4.5E-01 7.3E-01 5.1E-01 5.5E+00 1.3E+00 
5 1.5E+00 2.2E+00 1.6E+00 1.7E+01 4.2E+00 
7 2.3E+00 3.3E+00 2.6E+00 2.5E+01 6.6E+00 
14 3.7E+00 4.7E+00 4.0E+00 3.6E+01 1.1E+01 
30 5.7E+00 6.0E+00 5.6E+00 4.7E+01 1.5E+01 
60 8.7E+00 7.9E+00 8.0E+00 5.6E+01 2.2E+01 
90 1.1E+01 9.3E+00 1.0E+01 5.8E+01 2.6E+01 
180 1.5E+01 1.2E+01 1.4E+01 5.5E+01 3.2E+01 
365 2.4E+01 2.1E+01 2.3E+01 5.0E+01 3.9E+01 
730 4.5E+01 4.1E+01 4.3E+01 4.5E+01 4.7E+01 
1,825 6.1E+01 6.4E+01 6.2E+01 4.5E+01 5.1E+01 
3,600 6.6E+01 6.8E+01 6.6E+01 5.3E+01 5.9E+01 
7,300 7.1E+01 7.3E+01 7.5E+01 6.5E+01 7.1E+01 
18,250 1.0E+02 1.0E+02 1.0E+02 9.1E+01 9.8E+01 
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 Figure 8.16. Minimum Detectable Bone Surface Dose for 20-Year Aged Weapons-Grade  
  Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
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 Table 8.28. Minimum Detectable Committed Bone Surfaces Dose Equivalent (rem) for 40-Year  
 Aged Weapons-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 2.9E-01 4.7E-01 3.2E-01 3.4E+00 8.1E-01 
2 4.5E-01 7.4E-01 5.2E-01 5.5E+00 1.3E+00 
5 1.5E+00 2.2E+00 1.6E+00 1.7E+01 4.1E+00 
7 2.3E+00 3.3E+00 2.6E+00 2.5E+01 6.5E+00 
14 3.7E+00 4.7E+00 4.1E+00 3.7E+01 1.1E+01 
30 5.7E+00 6.1E+00 5.7E+00 4.7E+01 1.4E+01 
60 8.7E+00 8.0E+00 8.1E+00 5.7E+01 2.2E+01 
90 1.1E+01 9.4E+00 1.0E+01 5.8E+01 2.6E+01 
180 1.5E+01 1.2E+01 1.4E+01 5.6E+01 3.1E+01 
365 2.5E+01 2.2E+01 2.3E+01 5.0E+01 3.9E+01 
730 4.5E+01 4.1E+01 4.4E+01 4.5E+01 4.6E+01 
1,825 6.1E+01 6.5E+01 6.3E+01 4.6E+01 5.0E+01 
3,600 6.6E+01 6.9E+01 6.7E+01 5.4E+01 5.8E+01 
7,300 7.1E+01 7.4E+01 7.6E+01 6.6E+01 7.0E+01 
18,250 1.0E+02 1.0E+02 1.0E+02 9.2E+01 9.6E+01 
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 Table 8.29. Minimum Detectable Committed Bone Surfaces Dose Equivalent (rem) for 10-Year  
 Aged Fuel-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 4.3E-01 6.9E-01 4.8E-01 5.1E+00 1.2E+00 
2 6.8E-01 1.1E+00 7.6E-01 8.3E+00 1.9E+00 
5 2.2E+00 3.3E+00 2.4E+00 2.5E+01 6.2E+00 
7 3.5E+00 4.9E+00 3.8E+00 3.8E+01 9.8E+00 
14 5.6E+00 6.9E+00 6.0E+00 5.5E+01 1.6E+01 
30 8.6E+00 9.0E+00 8.4E+00 7.2E+01 2.2E+01 
60 1.3E+01 1.2E+01 1.2E+01 8.6E+01 3.3E+01 
90 1.6E+01 1.4E+01 1.5E+01 8.8E+01 3.9E+01 
180 2.3E+01 1.8E+01 2.1E+01 8.5E+01 4.7E+01 
365 3.7E+01 3.2E+01 3.4E+01 7.6E+01 5.9E+01 
730 6.8E+01 6.1E+01 6.4E+01 6.8E+01 6.9E+01 
1,825 9.2E+01 9.5E+01 9.3E+01 6.9E+01 7.6E+01 
3,600 1.0E+02 1.0E+02 9.9E+01 8.2E+01 8.7E+01 
7,300 1.1E+02 1.1E+02 1.1E+02 1.0E+02 1.1E+02 
18,250 1.5E+02 1.5E+02 1.5E+02 1.4E+02 1.5E+02 
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 Figure 8.18. Minimum Detectable Bone Surface Dose for 10-Year Aged Fuel-Grade 
  Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
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 Table 8.30. Minimum Detectable Committed Bone Surfaces Dose Equivalent (rem) for 20-Year  
 Aged Fuel-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 4.5E-01 7.4E-01 5.1E-01 5.3E+00 1.3E+00 
2 7.1E-01 1.2E+00 8.1E-01 8.8E+00 2.0E+00 
5 2.3E+00 3.5E+00 2.6E+00 2.7E+01 6.5E+00 
7 3.6E+00 5.3E+00 4.0E+00 4.0E+01 1.0E+01 
14 5.9E+00 7.4E+00 6.3E+00 5.8E+01 1.7E+01 
30 9.0E+00 9.6E+00 8.9E+00 7.5E+01 2.3E+01 
60 1.4E+01 1.3E+01 1.3E+01 9.0E+01 3.4E+01 
90 1.7E+01 1.5E+01 1.6E+01 9.3E+01 4.0E+01 
180 2.4E+01 2.0E+01 2.2E+01 8.9E+01 4.9E+01 
365 3.9E+01 3.4E+01 3.6E+01 8.0E+01 6.1E+01 
730 7.1E+01 6.5E+01 6.8E+01 7.2E+01 7.3E+01 
1,825 9.6E+01 1.0E+02 9.9E+01 7.3E+01 8.0E+01 
3,600 1.0E+02 1.1E+02 1.0E+02 8.6E+01 9.1E+01 
7,300 1.1E+02 1.2E+02 1.2E+02 1.0E+02 1.1E+02 
18,250 1.6E+02 1.6E+02 1.6E+02 1.5E+02 1.5E+02 
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 Figure 8.19. Minimum Detectable Bone Surface Dose for 20-Year Aged Fuel-Grade 
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 Table 8.31. Minimum Detectable Committed Bone Surfaces Dose Equivalent (rem) for 40-Year  
 Aged Fuel-Grade Plutonium Based on Detection of 0.02 dpm/d 239Pu in Urine 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 4.6E-01 7.6E-01 5.2E-01 5.3E+00 1.4E+00 
2 7.3E-01 1.2E+00 8.3E-01 8.7E+00 2.1E+00 
5 2.4E+00 3.6E+00 2.7E+00 2.7E+01 6.9E+00 
7 3.8E+00 5.4E+00 4.2E+00 4.0E+01 1.1E+01 
14 6.1E+00 7.6E+00 6.5E+00 5.8E+01 1.8E+01 
30 9.3E+00 9.8E+00 9.2E+00 7.5E+01 2.4E+01 
60 1.4E+01 1.3E+01 1.3E+01 9.0E+01 3.6E+01 
90 1.8E+01 1.5E+01 1.7E+01 9.2E+01 4.3E+01 
180 2.4E+01 2.0E+01 2.3E+01 8.8E+01 5.2E+01 
365 4.0E+01 3.5E+01 3.7E+01 8.0E+01 6.5E+01 
730 7.3E+01 6.7E+01 7.0E+01 7.2E+01 7.7E+01 
1,825 1.0E+02 1.0E+02 1.0E+02 7.2E+01 8.5E+01 
3,600 1.1E+02 1.1E+02 1.1E+02 8.5E+01 9.7E+01 
7,300 1.2E+02 1.2E+02 1.2E+02 1.0E+02 1.2E+02 
18,250 1.7E+02 1.7E+02 1.7E+02 1.4E+02 1.6E+02 
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 Figure 8.20. Minimum Detectable Bone Surface Dose for 40-Year Aged Fuel-Grade 
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 Table 8.32. Minimum Detectable Committed Effective Dose Equivalent (rem) for 10-Year Aged  
 Weapons-Grade Plutonium Based on Detection of 0.16 nCi  241Am in the Lungs 
 
Days Post Class W Inhalation Class Y Inhalation Super Class Y Inhalation 
Intake 1-um  5-um  1-um  5-um  1-um  5-um  
0 2.0E+00 4.2E+00 1.4E+00 1.2E+00 2.6E+00 1.9E+00 
1 3.1E+00 9.2E+00 2.2E+00 2.5E+00 3.9E+00 4.1E+00 
2 3.7E+00 1.1E+01 2.6E+00 3.0E+00 4.6E+00 4.9E+00 
5 4.5E+00 1.4E+01 3.0E+00 3.6E+00 5.4E+00 5.8E+00 
7 4.8E+00 1.4E+01 3.2E+00 3.7E+00 5.4E+00 5.9E+00 
14 5.1E+00 1.5E+01 3.2E+00 3.7E+00 5.7E+00 5.9E+00 
30 6.4E+00 1.9E+01 3.2E+00 3.7E+00 5.7E+00 6.0E+00 
60 9.4E+00 2.8E+01 3.2E+00 3.9E+00 5.7E+00 6.1E+00 
90 1.4E+01 4.0E+01 3.4E+00 3.9E+00 6.1E+00 6.3E+00 
180 4.3E+01 1.3E+02 3.6E+00 4.2E+00 6.5E+00 6.7E+00 
365 4.5E+02 1.3E+03 4.2E+00 5.0E+00 7.0E+00 7.5E+00 
730 5.1E+04 1.5E+05 5.6E+00 6.6E+00 8.9E+00 9.0E+00 
1,825 8.3E+09 2.1E+10 1.2E+01 1.4E+01 1.1E+01 1.2E+01 
3,600 1.9E+10 1.2E+12 3.0E+01 3.5E+01 1.1E+01 1.2E+01 
7,300 2.6E+11 2.5E+11 5.7E+01 6.8E+01 1.0E+01 1.1E+01 
18,250 5.1E+12 1.0E+12 5.4E+01 6.2E+01 1.2E+01 1.3E+01 
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 Table 8.33. Minimum Detectable Committed Effective Dose Equivalent (rem) for 20-Year Aged  
 Weapons-Grade Plutonium Based on Detection of 0.16 nCi  241Am in the Lungs 
 
Days 
Post Class W Inhalation Class Y Inhalation Super Class Y Inhalation 
Intake 1-um  5-um  1-um  5-um  1-um  5-um  
0 1.3E+00 2.6E+00 9.1E-01 7.7E-01 1.6E+00 1.2E+00 
1 2.0E+00 5.9E+00 1.4E+00 1.7E+00 2.5E+00 2.5E+00 
2 2.4E+00 7.0E+00 1.7E+00 2.0E+00 3.0E+00 3.2E+00 
5 3.0E+00 8.6E+00 2.0E+00 2.4E+00 3.5E+00 3.7E+00 
7 3.1E+00 9.0E+00 2.0E+00 2.4E+00 3.6E+00 3.7E+00 
14 3.4E+00 9.8E+00 2.0E+00 2.5E+00 3.6E+00 3.8E+00 
30 4.2E+00 1.2E+01 2.0E+00 2.5E+00 3.6E+00 3.8E+00 
60 6.3E+00 1.8E+01 2.1E+00 2.6E+00 3.8E+00 4.0E+00 
90 9.0E+00 2.6E+01 2.2E+00 2.6E+00 3.9E+00 4.0E+00 
180 2.8E+01 8.2E+01 2.4E+00 2.9E+00 4.1E+00 4.3E+00 
365 3.1E+02 8.9E+02 2.8E+00 3.4E+00 4.7E+00 5.0E+00 
730 3.6E+04 1.1E+05 4.1E+00 4.8E+00 5.9E+00 6.2E+00 
1,825 1.7E+10 2.8E+08 9.3E+00 1.1E+01 8.6E+00 8.8E+00 
3,600 4.4E+11 4.5E+09 2.5E+01 3.0E+01 9.4E+00 9.5E+00 
7,300 6.3E+12 2.6E+11 5.3E+01 6.4E+01 9.4E+00 9.8E+00 
18,250 1.0E+13 2.1E+13 5.5E+01 6.6E+01 1.3E+01 1.3E+01 
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 Table 8.34. Minimum Detectable Committed Effective Dose Equivalent (rem) for 40-Year Aged  
 Weapons-Grade Plutonium Based on Detection of 0.16 nCi  241Am in the Lungs 
 
Days 
Post Class W Inhalation Class Y Inhalation 
Super Class Y 
Inhalation 
Intake 1-um  5-um  1-um  5-um  1-um  5-um  
0 9.7E-01 1.9E+00 6.9E-01 5.5E-01 1.2E+00 9.3E-01 
1 1.5E+00 4.3E+00 1.1E+00 1.2E+00 1.9E+00 2.1E+00 
2 1.8E+00 5.3E+00 1.2E+00 1.5E+00 2.2E+00 2.3E+00 
5 2.2E+00 6.7E+00 1.5E+00 1.7E+00 2.6E+00 2.9E+00 
7 2.3E+00 6.7E+00 1.5E+00 1.7E+00 2.7E+00 2.9E+00 
14 2.6E+00 7.4E+00 1.6E+00 1.7E+00 2.7E+00 2.9E+00 
30 3.1E+00 9.1E+00 1.6E+00 1.7E+00 2.8E+00 2.9E+00 
60 4.5E+00 1.3E+01 1.6E+00 1.9E+00 2.9E+00 3.2E+00 
90 6.5E+00 1.9E+01 1.7E+00 1.9E+00 2.9E+00 3.2E+00 
180 2.1E+01 6.1E+01 1.8E+00 2.1E+00 3.1E+00 3.5E+00 
365 2.3E+02 6.7E+02 2.2E+00 2.5E+00 3.6E+00 4.0E+00 
730 2.9E+04 8.2E+04 3.0E+00 3.5E+00 4.6E+00 5.0E+00 
1,825 2.3E+09 1.9E+09 7.6E+00 8.7E+00 7.0E+00 7.3E+00 
3,600 1.1E+10 3.2E+11 2.2E+01 2.5E+01 8.3E+00 8.6E+00 
7,300 1.0E+12 3.7E+12 5.1E+01 5.8E+01 9.1E+00 9.5E+00 
18,250 2.2E+12 6.7E+14 5.6E+01 6.5E+01 1.3E+01 1.4E+01 
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 Table 8.35. Minimum Detectable Committed Effective Dose Equivalent (rem) for 10-Year Aged 
 Fuel-Grade Plutonium Based on Detection of 0.16 nCi  241Am in the Lungs 
 
Days 
Post Class W Inhalation Class Y Inhalation Super Class Y Inhalation 
Intake 1-um  5-um  1-um  5-um  1-um  5-um  
0 9.3E-01 2.0E+00 6.3E-01 5.2E-01 1.2E+00 8.8E-01 
1 1.5E+00 4.4E+00 9.8E-01 1.2E+00 1.8E+00 1.9E+00 
2 1.7E+00 5.4E+00 1.1E+00 1.3E+00 2.1E+00 2.3E+00 
5 2.1E+00 6.5E+00 1.4E+00 1.6E+00 2.5E+00 2.7E+00 
7 2.2E+00 7.0E+00 1.4E+00 1.7E+00 2.6E+00 2.7E+00 
14 2.4E+00 7.5E+00 1.4E+00 1.7E+00 2.6E+00 2.9E+00 
30 3.0E+00 8.9E+00 1.4E+00 1.7E+00 2.6E+00 2.9E+00 
60 4.3E+00 1.4E+01 1.5E+00 1.7E+00 2.7E+00 2.9E+00 
90 6.4E+00 2.0E+01 1.5E+00 1.8E+00 2.8E+00 2.9E+00 
180 2.0E+01 6.1E+01 1.6E+00 2.0E+00 2.9E+00 3.1E+00 
365 2.1E+02 6.5E+02 1.9E+00 2.3E+00 3.2E+00 3.6E+00 
730 2.4E+04 7.5E+04 2.5E+00 3.0E+00 3.9E+00 4.3E+00 
1,825 6.9E+09 8.1E+09 5.5E+00 6.4E+00 5.2E+00 5.5E+00 
3,600 1.2E+12 2.2E+10 1.4E+01 1.6E+01 5.2E+00 5.5E+00 
7,300 9.0E+12 7.0E+10 2.5E+01 3.1E+01 4.7E+00 5.0E+00 
18,250 1.4E+14 1.6E+13 2.4E+01 2.9E+01 5.7E+00 6.2E+00 
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 Table 8.36. Minimum Detectable Committed Effective Dose Equivalent (rem) for 20-Year Aged  
 Fuel-Grade Plutonium Based on Detection of 0.16 nCi  241Am in the Lungs 
 
Days 
Post Class W Inhalation Class Y Inhalation Super Class Y Inhalation 
Intake 1-um  5-um  1-um  5-um  1-um  5-um  
0 6.2E-01 1.3E+00 4.3E-01 3.6E-01 7.9E-01 5.7E-01 
1 9.5E-01 2.9E+00 6.6E-01 7.7E-01 1.2E+00 1.2E+00 
2 1.1E+00 3.5E+00 7.8E-01 9.6E-01 1.4E+00 1.5E+00 
5 1.4E+00 4.4E+00 9.2E-01 1.1E+00 1.7E+00 1.7E+00 
7 1.5E+00 4.6E+00 9.3E-01 1.1E+00 1.7E+00 1.8E+00 
14 1.6E+00 4.9E+00 9.5E-01 1.1E+00 1.7E+00 1.8E+00 
30 2.0E+00 6.3E+00 9.7E-01 1.2E+00 1.7E+00 1.8E+00 
60 2.9E+00 8.9E+00 1.0E+00 1.2E+00 1.8E+00 1.9E+00 
90 4.2E+00 1.3E+01 1.0E+00 1.3E+00 1.8E+00 1.9E+00 
180 1.3E+01 4.2E+01 1.1E+00 1.3E+00 2.0E+00 2.1E+00 
365 1.5E+02 4.4E+02 1.3E+00 1.6E+00 2.3E+00 2.4E+00 
730 1.7E+04 5.5E+04 1.8E+00 2.2E+00 2.8E+00 3.0E+00 
1,825 2.1E+09 4.9E+09 4.3E+00 5.2E+00 3.9E+00 4.2E+00 
3,600 7.3E+09 2.6E+10 1.2E+01 1.4E+01 4.5E+00 4.6E+00 
7,300 8.0E+10 3.1E+11 2.5E+01 3.0E+01 4.5E+00 4.7E+00 
18,250 3.1E+12 1.4E+12 2.5E+01 3.1E+01 6.0E+00 6.3E+00 
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 Table 8.37. Minimum Detectable Committed Effective Dose Equivalent (rem) for 40-Year Aged 
 Fuel-Grade Plutonium Based on Detection of 0.16 nCi  241Am in the Lungs 
 
Days 
Post Class W Inhalation Class Y Inhalation 
Super Class Y 
Inhalation 
Intake 1-um  5-um  1-um  5-um  1-um  5-um  
0 4.6E-01 1.0E+00 3.3E-01 2.8E-01 5.9E-01 4.4E-01 
1 7.4E-01 2.2E+00 5.3E-01 6.1E-01 9.4E-01 9.5E-01 
2 8.7E-01 2.7E+00 6.1E-01 7.5E-01 1.1E+00 1.1E+00 
5 1.1E+00 3.3E+00 7.2E-01 8.6E-01 1.3E+00 1.4E+00 
7 1.1E+00 3.5E+00 7.3E-01 9.0E-01 1.3E+00 1.4E+00 
14 1.2E+00 3.8E+00 7.4E-01 9.0E-01 1.3E+00 1.4E+00 
30 1.5E+00 4.7E+00 7.5E-01 9.3E-01 1.3E+00 1.4E+00 
60 2.3E+00 6.7E+00 7.9E-01 9.3E-01 1.4E+00 1.5E+00 
90 3.2E+00 1.0E+01 8.1E-01 9.7E-01 1.4E+00 1.5E+00 
180 1.0E+01 3.2E+01 8.8E-01 1.1E+00 1.5E+00 1.6E+00 
365 1.1E+02 3.5E+02 1.1E+00 1.2E+00 1.8E+00 1.9E+00 
730 1.4E+04 4.2E+04 1.5E+00 1.9E+00 2.2E+00 2.3E+00 
1,825 6.1E+09 1.8E+10 3.8E+00 4.5E+00 3.4E+00 3.5E+00 
3,600 9.7E+09 3.6E+11 1.1E+01 1.3E+01 3.9E+00 4.1E+00 
7,300 3.9E+10 1.7E+13 2.4E+01 2.9E+01 4.3E+00 4.5E+00 
18,250 4.6E+11 5.0E+14 2.8E+01 3.3E+01 6.3E+00 6.6E+00 
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 Table 8.38. Minimum Detectable Committed Bone Surface Doses for 10-Year  
Aged Weapons-Grade Plutonium Based on Detection of 0.16 nCi  
241Am in the Lungs 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 
0 3.7E+01 8.2E+01 1.4E+01 1.5E+01 
1 5.6E+01 1.8E+02 2.2E+01 3.2E+01 
2 6.7E+01 2.1E+02 2.6E+01 3.9E+01 
5 8.3E+01 2.6E+02 3.0E+01 4.6E+01 
7 8.8E+01 2.7E+02 3.2E+01 4.7E+01 
14 9.4E+01 3.0E+02 3.2E+01 4.7E+01 
30 1.2E+02 3.7E+02 3.2E+01 4.8E+01 
60 1.7E+02 5.4E+02 3.2E+01 5.0E+01 
90 2.5E+02 7.8E+02 3.4E+01 5.1E+01 
180 7.8E+02 2.5E+03 3.6E+01 5.4E+01 
365 8.3E+03 2.6E+04 4.2E+01 6.4E+01 
730 9.4E+05 3.0E+06 5.6E+01 8.5E+01 
1,825 1.5E+11 4.1E+11 1.2E+02 1.8E+02 
3,600 3.4E+11 2.2E+13 3.0E+02 4.5E+02 
7,300 3.6E+12 4.9E+12 5.7E+02 8.7E+02 
18,250 9.4E+13 2.0E+13 5.4E+02 8.0E+02 
NA = not applicable 
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 Table 8.39. Minimum Detectable Committed Bone Surface Doses for 20-Year  
Aged Weapons-Grade Plutonium Based on Detection of 0.16 nCi  
241Am in the Lungs 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 
0 2.3E+01 5.1E+01 9.1E+00 9.4E+00 
1 3.7E+01 1.1E+02 1.4E+01 2.1E+01 
2 4.4E+01 1.4E+02 1.7E+01 2.5E+01 
5 5.4E+01 1.7E+02 2.0E+01 2.9E+01 
7 5.7E+01 1.8E+02 2.0E+01 3.0E+01 
14 6.2E+01 1.9E+02 2.0E+01 3.0E+01 
30 7.6E+01 2.4E+02 2.0E+01 3.0E+01 
60 1.1E+02 3.5E+02 2.1E+01 3.1E+01 
90 1.6E+02 5.0E+02 2.2E+01 3.2E+01 
180 5.0E+02 1.6E+03 2.4E+01 3.5E+01 
365 5.7E+02 1.7E+04 2.8E+01 4.1E+01 
730 6.5E+05 2.1E+06 4.1E+01 5.8E+01 
1,825 3.2E+11 5.5E+09 9.3E+01 1.4E+02 
3,600 8.0E+12 8.8E+10 2.5E+02 3.7E+02 
7,300 1.1E+14 5.1E+12 5.3E+02 7.8E+02 
18,250 1.9E+14 4.1E+14 5.5E+02 7.8E+02 
NA = not applicable 
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 Table 8.40. Minimum Detectable Committed Bone Surface Doses for 40-Year  
Aged Weapons-Grade Plutonium Based on Detection of 0.16 nCi  
241Am in the Lungs 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 
0 1.8E+01 3.8E+01 6.9E+00 6.7E+00 
1 2.7E+01 8.5E+01 1.1E+01 1.5E+01 
2 3.3E+01 1.0E+02 1.2E+01 1.8E+01 
5 4.0E+01 1.3E+02 1.5E+01 2.1E+01 
7 4.2E+01 1.3E+02 1.5E+01 2.1E+01 
14 4.7E+01 1.4E+02 1.6E+01 2.1E+01 
30 5.7E+01 1.8E+02 1.6E+01 2.1E+01 
60 8.2E+01 2.6E+02 1.6E+01 2.3E+01 
90 1.2E+02 3.8E+02 1.7E+01 2.3E+01 
180 3.9E+02 1.2E+03 1.8E+01 2.6E+01 
365 4.2E+03 1.3E+04 2.2E+01 3.1E+01 
730 5.2E+05 1.6E+06 3.0E+01 4.3E+01 
1,825 4.2E+10 3.7E+10 7.6E+01 1.1E+02 
3,600 2.0E+11 6.3E+12 2.2E+02 3.1E+02 
7,300 1.8E+13 7.2E+13 5.1E+02 7.1E+02 
18,250 4.0E+13 1.3E+16 5.6E+02 8.0E+02 
NA = not applicable 
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 Table 8.41.  Minimum Detectable Committed Bone Surface Dose Equivalent  
(rem) for 10-Year Aged Fuel-Grade Plutonium Based on  
Detection of 0.16 nCi 241Am in the Lungs 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 
0 1.7E+01 3.6E+01 6.7E+00 6.5E+00 
1 2.6E+01 8.0E+01 1.0E+01 1.5E+01 
2 3.1E+01 9.8E+01 1.2E+01 1.7E+01 
5 3.8E+01 1.2E+02 1.5E+01 2.0E+01 
7 4.0E+01 1.3E+02 1.5E+01 2.1E+01 
14 4.3E+01 1.4E+02 1.5E+01 2.1E+01 
30 5.3E+01 1.6E+02 1.5E+01 2.1E+01 
60 7.6E+01 2.4E+02 1.6E+01 2.1E+01 
90 1.1E+02 3.5E+02 1.6E+01 2.3E+01 
180 3.6E+02 1.1E+03 1.7E+01 2.5E+01 
365 3.8E+03 1.2E+04 2.0E+01 2.9E+01 
730 4.3E+05 1.4E+06 2.7E+01 3.8E+01 
1,825 1.2E+11 1.5E+11 5.8E+01 8.0E+01 
3,600 2.2E+13 4.0E+11 1.4E+02 2.0E+02 
7,300 1.6E+14 1.3E+12 2.7E+02 3.9E+02 
18,250 2.6E+15 2.9E+14 2.6E+02 3.6E+02 
NA = not applicable 
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 Table 8.42. Minimum Detectable Committed Bone Surface Dose Equivalent  
(rem) for 20-Year Aged Fuel-Grade Plutonium Based on  
Detection of 0.16 nCi  241Am in the Lungs 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 
0 1.1E+01 2.4E+01 4.4E+00 4.3E+00 
1 1.8E+01 5.3E+01 6.8E+00 9.3E+00 
2 2.1E+01 6.4E+01 8.0E+00 1.2E+01 
5 2.5E+01 8.0E+01 9.4E+00 1.4E+01 
7 2.7E+01 8.4E+01 9.6E+00 1.4E+01 
14 2.9E+01 8.9E+01 9.8E+00 1.4E+01 
30 3.6E+01 1.1E+02 9.9E+00 1.4E+01 
60 5.3E+01 1.6E+02 1.0E+01 1.4E+01 
90 7.7E+01 2.4E+02 1.0E+01 1.5E+01 
180 2.5E+02 7.6E+02 1.2E+01 1.6E+01 
365 2.7E+03 8.0E+03 1.4E+01 1.9E+01 
730 3.1E+05 1.0E+06 1.9E+01 2.6E+01 
1,825 3.9E+10 8.9E+10 4.4E+01 6.3E+01 
3,600 1.3E+11 4.7E+11 1.2E+02 1.7E+02 
7,300 1.5E+12 5.7E+12 2.6E+02 3.6E+02 
18,250 5.7E+13 2.6E+13 2.6E+02 3.7E+02 
NA = not applicable 
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 Table 8.43. Minimum Detectable Committed Bone Surface Dose Equivalent  
(rem) for 40-Year Aged Fuel-Grade Plutonium Based on  
Detection of 0.16 nCi 241Am in the Lungs 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 1-mm 5-mm 1-mm 5-mm 
0 8.4E+00 1.8E+01 3.2E+00 3.4E+00 
1 1.3E+01 4.1E+01 5.1E+00 7.4E+00 
2 1.6E+01 4.9E+01 5.9E+00 9.1E+00 
5 1.9E+01 6.1E+01 7.0E+00 1.0E+01 
7 2.0E+01 6.4E+01 7.1E+00 1.1E+01 
14 2.2E+01 7.0E+01 7.2E+00 1.1E+01 
30 2.7E+01 8.7E+01 7.3E+00 1.1E+01 
60 4.1E+01 1.2E+02 7.6E+00 1.1E+01 
90 5.8E+01 1.8E+02 7.9E+00 1.2E+01 
180 1.9E+02 5.9E+02 8.5E+00 1.3E+01 
365 2.1E+03 6.4E+03 1.0E+01 1.5E+01 
730 2.5E+05 7.7E+05 1.5E+01 2.3E+01 
1,825 1.1E+11 3.3E+11 3.7E+01 5.4E+01 
3,600 1.8E+11 6.7E+12 1.0E+02 1.6E+02 
7,300 7.1E+11 3.1E+14 2.3E+02 3.6E+02 
18,250 8.4E+12 9.2E+15 2.7E+02 4.0E+02 
NA = not applicable 
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 Figure 8.32. Minimum Detectable Bone Surface Doses for 40-Year Aged Fuel-Grade 
 Plutonium Based on Detection of 0.16 nCi 241Am in the Lungs 
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Table 8.44.  Minimum Detectable Intakes (nCi) of 239Pu Based on Detection of 0.2 dpm/d in Feces 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 3.0E-02 8.2E-04 4.1E-04 6.9E-04 3.6E-04 6.9E-04 3.6E-04 
2 4.7E-02 6.9E-04 3.5E-04 5.6E-04 3.1E-04 5.6E-04 3.1E-04 
5 1.6E-01 3.9E-03 2.9E-03 3.8E-03 2.6E-03 3.8E-03 2.6E-03 
7 2.4E-01 1.4E-02 1.6E-02 1.7E-02 1.6E-02 1.7E-02 1.6E-02 
14 3.9E-01 7.5E-02 2.0E-01 5.3E-01 1.4E+00 5.3E-01 1.4E+00 
30 6.0E-01 9.4E-02 2.6E-01 6.9E-01 1.9E+00 6.9E-01 1.9E+00 
60 9.1E-01 1.4E-01 3.9E-01 6.9E-01 2.0E+00 6.9E-01 2.0E+00 
90 1.1E+00 2.1E-01 5.6E-01 7.5E-01 2.0E+00 7.5E-01 2.1E+00 
180 1.6E+00 6.9E-01 1.8E+00 8.2E-01 2.3E+00 8.2E-01 2.4E+00 
365 2.6E+00 1.9E+01 1.1E+01 1.1E+00 3.0E+00 1.1E+00 3.0E+00 
730 4.7E+00 3.6E+01 3.5E+01 1.8E+00 5.0E+00 1.8E+00 5.0E+00 
1,825 6.4E+00 5.6E+01 5.0E+01 7.5E+00 2.1E+01 8.2E+00 2.3E+01 
3,600 6.9E+00 6.0E+01 5.3E+01 5.6E+01 1.4E+02 9.1E+01 2.4E+02 
7,300 7.5E+00 6.0E+01 6.0E+01 1.5E+02 3.0E+02 5.0E+02 8.2E+02 
18,250 1.1E+01 9.0E+01 8.2E+01 2.0E+02 4.3E+02 2.9E+02 5.6E+02 
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 Table 8.45. Minimum Detectable Committed Effective Dose Equivalent (rem) for 10-Year Aged 
Weapons-Grade Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 1.5E-01 4.9E-04 2.6E-04 3.0E-04 6.3E-05 5.3E-04 1.0E-04 
2 2.4E-01 4.2E-04 2.2E-04 2.4E-04 5.5E-05 4.3E-04 9.0E-05 
5 7.8E-01 2.4E-03 1.8E-03 1.6E-03 4.7E-04 2.9E-03 7.7E-04 
7 1.2E+00 8.6E-03 1.0E-02 7.1E-03 2.8E-03 1.3E-02 4.6E-03 
14 2.0E+00 4.5E-02 1.2E-01 2.3E-01 2.4E-01 4.1E-01 4.1E-01 
30 3.0E+00 5.7E-02 1.6E-01 3.0E-01 3.3E-01 5.3E-01 5.5E-01 
60 4.6E+00 8.6E-02 2.5E-01 3.0E-01 3.4E-01 5.3E-01 5.8E-01 
90 5.7E+00 1.3E-01 3.5E-01 3.2E-01 3.6E-01 5.8E-01 6.1E-01 
180 7.9E+00 4.2E-01 1.2E+00 3.5E-01 4.1E-01 6.3E-01 6.9E-01 
365 1.3E+01 1.1E+01 7.0E+00 4.5E-01 5.3E-01 8.2E-01 8.7E-01 
730 2.4E+01 2.2E+01 2.2E+01 7.5E-01 8.8E-01 1.4E+00 1.4E+00 
1,825 3.2E+01 3.4E+01 3.1E+01 3.2E+00 3.7E+00 6.3E+00 6.5E+00 
3,600 3.5E+01 3.6E+01 3.3E+01 2.4E+01 2.4E+01 7.0E+01 6.9E+01 
7,300 3.8E+01 3.6E+01 3.8E+01 6.2E+01 5.3E+01 3.8E+02 2.4E+02 
18,250 5.4E+01 5.4E+01 5.1E+01 8.7E+01 7.5E+01 2.2E+02 1.6E+02 
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 Figure 8.33. Minimum Detectable Committed Effective Doses for 10-Year Aged Weapons-Grade 
 Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.46. Minimum Detectable Committed Effective Dose Equivalent (rem) for 20-Year Aged 
Weapons-Grade Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 1.5E-01 5.2E-04 2.6E-04 3.1E-04 6.8E-05 5.5E-04 1.1E-04 
2 2.4E-01 4.4E-04 2.2E-04 2.5E-04 5.8E-05 4.5E-04 9.2E-05 
5 7.9E-01 2.5E-03 1.9E-03 1.7E-03 5.0E-04 3.0E-03 7.8E-04 
7 1.2E+00 9.0E-03 1.0E-02 7.4E-03 3.0E-03 1.3E-02 4.7E-03 
14 2.0E+00 4.7E-02 1.3E-01 2.3E-01 2.6E-01 4.2E-01 4.2E-01 
30 3.1E+00 5.9E-02 1.7E-01 3.1E-01 3.5E-01 5.5E-01 5.7E-01 
60 4.6E+00 9.0E-02 2.5E-01 3.1E-01 3.7E-01 5.5E-01 5.9E-01 
90 5.8E+00 1.4E-01 3.6E-01 3.3E-01 3.8E-01 5.9E-01 6.2E-01 
180 8.0E+00 4.4E-01 1.2E+00 3.6E-01 4.3E-01 6.5E-01 7.0E-01 
365 1.3E+01 1.2E+01 7.2E+00 4.7E-01 5.6E-01 8.5E-01 8.9E-01 
730 2.4E+01 2.3E+01 2.2E+01 7.8E-01 9.4E-01 1.4E+00 1.5E+00 
1,825 3.3E+01 3.5E+01 3.2E+01 3.3E+00 3.9E+00 6.5E+00 6.6E+00 
3,600 3.5E+01 3.8E+01 3.4E+01 2.5E+01 2.6E+01 7.2E+01 7.0E+01 
7,300 3.8E+01 3.8E+01 3.9E+01 6.4E+01 5.6E+01 4.0E+02 2.4E+02 
18,250 5.5E+01 5.7E+01 5.3E+01 9.1E+01 8.0E+01 2.3E+02 1.7E+02 
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 Figure 8.34. Minimum Detectable Committed Effective Doses for 20-Year Aged Weapons-Grade  
 Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.47. Minimum Detectable Committed Effective Dose Equivalent (rem) for 40-Year Aged 
Weapons-Grade Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 1.6E-01 5.2E-04 2.6E-04 3.1E-04 6.6E-05 5.5E-04 1.1E-04 
2 2.5E-01 4.4E-04 2.2E-04 2.5E-04 5.7E-05 4.5E-04 9.6E-05 
5 8.0E-01 2.5E-03 1.9E-03 1.7E-03 4.8E-04 3.0E-03 8.2E-04 
7 1.3E+00 9.0E-03 1.0E-02 7.5E-03 2.9E-03 1.3E-02 4.9E-03 
14 2.0E+00 4.7E-02 1.3E-01 2.4E-01 2.5E-01 4.2E-01 4.4E-01 
30 3.1E+00 5.9E-02 1.7E-01 3.1E-01 3.4E-01 5.5E-01 5.9E-01 
60 4.7E+00 9.0E-02 2.5E-01 3.1E-01 3.6E-01 5.5E-01 6.2E-01 
90 5.9E+00 1.4E-01 3.6E-01 3.4E-01 3.7E-01 6.0E-01 6.5E-01 
180 8.2E+00 4.4E-01 1.2E+00 3.7E-01 4.2E-01 6.5E-01 7.3E-01 
365 1.3E+01 1.2E+01 7.2E+00 4.7E-01 5.5E-01 8.6E-01 9.2E-01 
730 2.5E+01 2.3E+01 2.2E+01 7.9E-01 9.1E-01 1.4E+00 1.5E+00 
1,825 3.3E+01 3.5E+01 3.2E+01 3.4E+00 3.8E+00 6.5E+00 6.9E+00 
3,600 3.6E+01 3.8E+01 3.4E+01 2.5E+01 2.5E+01 7.3E+01 7.3E+01 
7,300 3.9E+01 3.8E+01 3.9E+01 6.5E+01 5.5E+01 4.0E+02 2.5E+02 
18,250 5.6E+01 5.7E+01 5.3E+01 9.2E+01 7.8E+01 2.3E+02 1.7E+02 
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 Figure 8.35. Minimum Detectable Committed Effective Doses for 40-Year Aged Weapons-Grade  
 Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.48. Minimum Detectable Committed Effective Dose Equivalent (rem) for 10-Year Aged 
Fuel-Grade Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 2.3E-01 7.8E-04 4.2E-04 4.5E-04 9.7E-05 8.3E-04 1.6E-04 
2 3.7E-01 6.6E-04 3.6E-04 3.6E-04 8.4E-05 6.8E-04 1.4E-04 
5 1.2E+00 3.7E-03 3.0E-03 2.4E-03 7.2E-04 4.5E-03 1.2E-03 
7 1.9E+00 1.4E-02 1.7E-02 1.1E-02 4.3E-03 2.0E-02 7.2E-03 
14 3.0E+00 7.1E-02 2.0E-01 3.4E-01 3.7E-01 6.4E-01 6.5E-01 
30 4.7E+00 8.9E-02 2.7E-01 4.5E-01 5.1E-01 8.3E-01 8.7E-01 
60 7.1E+00 1.4E-01 4.0E-01 4.5E-01 5.3E-01 8.3E-01 9.1E-01 
90 8.9E+00 2.0E-01 5.8E-01 4.8E-01 5.5E-01 9.0E-01 9.6E-01 
180 1.2E+01 6.6E-01 1.9E+00 5.3E-01 6.2E-01 9.8E-01 1.1E+00 
365 2.0E+01 1.8E+01 1.1E+01 6.8E-01 8.1E-01 1.3E+00 1.4E+00 
730 3.7E+01 3.4E+01 3.6E+01 1.1E+00 1.4E+00 2.1E+00 2.3E+00 
1,825 5.0E+01 5.3E+01 5.2E+01 4.8E+00 5.7E+00 9.8E+00 1.0E+01 
3,600 5.4E+01 5.7E+01 5.5E+01 3.6E+01 3.7E+01 1.1E+02 1.1E+02 
7,300 5.8E+01 5.7E+01 6.2E+01 9.3E+01 8.1E+01 6.0E+02 3.7E+02 
18,250 8.3E+01 8.5E+01 8.4E+01 1.3E+02 1.2E+02 3.5E+02 2.6E+02 
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 Figure 8.36. Minimum Detectable Committed Effective Doses for 10-Year Aged Fuel-Grade  
 Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.49. Minimum Detectable Committed Effective Dose Equivalent (rem) for 20-Year Aged 
Fuel-Grade Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 2.4E-01 8.1E-04 4.4E-04 4.8E-04 1.1E-04 8.7E-04 1.7E-04 
2 3.8E-01 6.8E-04 3.8E-04 3.9E-04 9.2E-05 7.1E-04 1.5E-04 
5 1.3E+00 3.9E-03 3.1E-03 2.6E-03 7.8E-04 4.7E-03 1.3E-03 
7 2.0E+00 1.4E-02 1.7E-02 1.2E-02 4.7E-03 2.1E-02 7.5E-03 
14 3.2E+00 7.4E-02 2.1E-01 3.7E-01 4.1E-01 6.7E-01 6.8E-01 
30 4.9E+00 9.2E-02 2.8E-01 4.8E-01 5.5E-01 8.7E-01 9.1E-01 
60 7.4E+00 1.4E-01 4.2E-01 4.8E-01 5.8E-01 8.7E-01 9.5E-01 
90 9.2E+00 2.1E-01 6.1E-01 5.2E-01 6.1E-01 9.5E-01 9.9E-01 
180 1.3E+01 6.8E-01 2.0E+00 5.6E-01 6.8E-01 1.0E+00 1.1E+00 
365 2.1E+01 1.8E+01 1.2E+01 7.3E-01 8.9E-01 1.4E+00 1.4E+00 
730 3.8E+01 3.5E+01 3.8E+01 1.2E+00 1.5E+00 2.2E+00 2.4E+00 
1,825 5.2E+01 5.5E+01 5.4E+01 5.2E+00 6.2E+00 1.0E+01 1.1E+01 
3,600 5.6E+01 5.9E+01 5.7E+01 3.9E+01 4.0E+01 1.1E+02 1.1E+02 
7,300 6.1E+01 5.9E+01 6.5E+01 1.0E+02 8.9E+01 6.3E+02 3.9E+02 
18,250 8.7E+01 8.9E+01 8.9E+01 1.4E+02 1.3E+02 3.7E+02 2.7E+02 
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 Figure 8.37. Minimum Detectable Committed Effective Doses for 20-Year Aged Fuel-Grade  
 Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
  
Issued:  January 31, 2003  PNNL-MA-860 Chapter 8.0 
  Page 8.67 
 Table 8.50. Minimum Detectable Committed Effective Dose Equivalent (rem) for 40-Year Aged 
Fuel-Grade Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Super Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 1-mm 5-mm 
1 2.5E-01 8.3E-04 4.5E-04 5.1E-04 1.1E-04 9.0E-04 1.8E-04 
2 4.0E-01 7.0E-04 3.8E-04 4.1E-04 9.6E-05 7.3E-04 1.5E-04 
5 1.3E+00 4.0E-03 3.2E-03 2.7E-03 8.2E-04 4.9E-03 1.3E-03 
7 2.0E+00 1.5E-02 1.8E-02 1.2E-02 4.9E-03 2.2E-02 7.7E-03 
14 3.3E+00 7.6E-02 2.2E-01 3.9E-01 4.3E-01 6.9E-01 7.0E-01 
30 5.0E+00 9.5E-02 2.8E-01 5.1E-01 5.8E-01 9.0E-01 9.3E-01 
60 7.6E+00 1.5E-01 4.3E-01 5.1E-01 6.1E-01 9.0E-01 9.7E-01 
90 9.6E+00 2.2E-01 6.2E-01 5.5E-01 6.3E-01 9.8E-01 1.0E+00 
180 1.3E+01 7.0E-01 2.0E+00 6.0E-01 7.1E-01 1.1E+00 1.2E+00 
365 2.2E+01 1.9E+01 1.2E+01 7.7E-01 9.3E-01 1.4E+00 1.5E+00 
730 4.0E+01 3.7E+01 3.8E+01 1.3E+00 1.5E+00 2.3E+00 2.4E+00 
1,825 5.4E+01 5.7E+01 5.5E+01 5.5E+00 6.5E+00 1.1E+01 1.1E+01 
3,600 5.8E+01 6.1E+01 5.9E+01 4.1E+01 4.2E+01 1.2E+02 1.2E+02 
7,300 6.3E+01 6.1E+01 6.6E+01 1.1E+02 9.3E+01 6.5E+02 4.0E+02 
18,250 9.0E+01 9.2E+01 9.0E+01 1.5E+02 1.3E+02 3.8E+02 2.7E+02 
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 Figure 8.38. Minimum Detectable Committed Effective Doses for 40-Year Aged Fuel-Grade  
 Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.51. Minimum Detectable Committed Bone Surface Dose Equivalent (rem) for 10-Year 
Aged Weapons-Grade Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 2.8E+00 9.1E-03 5.0E-03 3.0E-03 8.2E-04 
2 4.4E+00 7.7E-03 4.2E-03 2.4E-03 7.0E-04 
5 1.4E+01 4.3E-02 3.5E-02 1.6E-02 6.0E-03 
7 2.3E+01 1.6E-01 2.0E-01 7.1E-02 3.6E-02 
14 3.6E+01 8.3E-01 2.4E+00 2.3E+00 3.1E+00 
30 5.6E+01 1.0E+00 3.1E+00 3.0E+00 4.2E+00 
60 8.5E+01 1.6E+00 4.8E+00 3.0E+00 4.4E+00 
90 1.1E+02 2.4E+00 6.9E+00 3.2E+00 4.6E+00 
180 1.5E+02 7.7E+00 2.2E+01 3.5E+00 5.2E+00 
365 2.4E+02 2.1E+02 1.4E+02 4.5E+00 6.8E+00 
730 4.4E+02 4.0E+02 4.2E+02 7.5E+00 1.1E+01 
1,825 6.0E+02 6.2E+02 6.1E+02 3.2E+01 4.7E+01 
3,600 6.4E+02 6.6E+02 6.5E+02 2.4E+02 3.1E+02 
7,300 7.0E+02 6.6E+02 7.3E+02 6.2E+02 6.8E+02 
18,250 1.0E+03 1.0E+03 1.0E+03 8.7E+02 9.7E+02 
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 Figure 8.39. Minimum Detectable Bone Surface Doses for 10-Year Aged Weapons-Grade 
  Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.52. Minimum Detectable Committed Bone Surface Dose Equivalent (rem) for 20-Year 
Aged Weapons-Grade Plutonium Based on Detection of 0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 2.9E+00 9.3E-03 5.1E-03 3.1E-03 8.2E-04 
2 4.5E+00 7.9E-03 4.3E-03 2.5E-03 7.1E-04 
5 1.5E+01 4.5E-02 3.6E-02 1.7E-02 6.0E-03 
7 2.3E+01 1.6E-01 2.0E-01 7.4E-02 3.6E-02 
14 3.7E+01 8.6E-01 2.4E+00 2.3E+00 3.2E+00 
30 5.7E+01 1.1E+00 3.2E+00 3.1E+00 4.3E+00 
60 8.7E+01 1.6E+00 4.9E+00 3.1E+00 4.5E+00 
90 1.1E+02 2.4E+00 7.0E+00 3.3E+00 4.7E+00 
180 1.5E+02 7.9E+00 2.3E+01 3.6E+00 5.3E+00 
365 2.4E+02 2.1E+02 1.4E+02 4.7E+00 6.8E+00 
730 4.5E+02 4.1E+02 4.3E+02 7.8E+00 1.1E+01 
1,825 6.1E+02 6.4E+02 6.2E+02 3.3E+01 4.8E+01 
3,600 6.6E+02 6.8E+02 6.6E+02 2.5E+02 3.1E+02 
7,300 7.1E+02 6.8E+02 7.5E+02 6.4E+02 6.8E+02 
18,250 1.0E+03 1.0E+03 1.0E+03 9.1E+02 9.8E+02 
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 Figure 8.40. Minimum Detectable Bone Surface Doses for 20-Year Aged Weapons-Grade Plutonium 
 Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.53. Minimum Detectable Committed Bone Surface Dose Equivalent (rem)  
for 40-Year Aged Weapons-Grade Plutonium Based on Detection of  
0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 2.9E+00 9.4E-03 5.2E-03 3.1E-03 8.1E-04 
2 4.5E+00 8.0E-03 4.4E-03 2.5E-03 7.0E-04 
5 1.5E+01 4.5E-02 3.7E-02 1.7E-02 5.9E-03 
7 2.3E+01 1.6E-01 2.0E-01 7.5E-02 3.5E-02 
14 3.7E+01 8.6E-01 2.5E+00 2.4E+00 3.1E+00 
30 5.7E+01 1.1E+00 3.2E+00 3.1E+00 4.2E+00 
60 8.7E+01 1.6E+00 4.9E+00 3.1E+00 4.4E+00 
90 1.1E+02 2.5E+00 7.1E+00 3.4E+00 4.6E+00 
180 1.5E+02 8.0E+00 2.3E+01 3.7E+00 5.2E+00 
365 2.5E+02 2.2E+02 1.4E+02 4.7E+00 6.7E+00 
730 4.5E+02 4.1E+02 4.4E+02 7.9E+00 1.1E+01 
1,825 6.1E+02 6.5E+02 6.3E+02 3.4E+01 4.7E+01 
3,600 6.6E+02 6.9E+02 6.7E+02 2.5E+02 3.1E+02 
7,300 7.1E+02 6.9E+02 7.6E+02 6.5E+02 6.7E+02 
18,250 1.0E+03 1.0E+03 1.0E+03 9.2E+02 9.6E+02 
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 Figure 8.41. Minimum Detectable Bone Surface Doses for 40-Year Aged Weapons-Grade Plutonium 
 Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.54. Minimum Detectable Committed Bone Surface Dose Equivalent (rem) 
for 10-Year Aged Fuel-Grade Plutonium Based on Detection of  
0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 4.3E+00 1.4E-02 7.6E-03 4.7E-03 1.2E-03 
2 6.8E+00 1.2E-02 6.4E-03 3.8E-03 1.1E-03 
5 2.2E+01 6.6E-02 5.4E-02 2.5E-02 9.0E-03 
7 3.5E+01 2.4E-01 3.0E-01 1.1E-01 5.3E-02 
14 5.6E+01 1.3E+00 3.6E+00 3.6E+00 4.7E+00 
30 8.6E+01 1.6E+00 4.8E+00 4.7E+00 6.3E+00 
60 1.3E+02 2.4E+00 7.3E+00 4.7E+00 6.6E+00 
90 1.6E+02 3.6E+00 1.0E+01 5.1E+00 6.9E+00 
180 2.3E+02 1.2E+01 3.4E+01 5.5E+00 7.8E+00 
365 3.7E+02 3.2E+02 2.1E+02 7.2E+00 1.0E+01 
730 6.8E+02 6.1E+02 6.4E+02 1.2E+01 1.7E+01 
1,825 9.2E+02 9.5E+02 9.3E+02 5.1E+01 7.1E+01 
3,600 1.0E+03 1.0E+03 9.9E+02 3.8E+02 4.6E+02 
7,300 1.1E+03 1.0E+03 1.1E+03 9.8E+02 1.0E+03 
18,250 1.5E+03 1.5E+03 1.5E+03 1.4E+03 1.5E+03 
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 Figure 8.42. Minimum Detectable Bone Surface Doses for 10-Year Aged Fuel-Grade Plutonium 
 Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.55. Minimum Detectable Committed Bone Surface Dose Equivalent (rem)  
for 20-Year Aged Fuel-Grade Plutonium Based on Detection of  
0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 4.5E+00 1.5E-02 8.1E-03 4.9E-03 1.3E-03 
2 7.1E+00 1.3E-02 6.8E-03 4.0E-03 1.1E-03 
5 2.3E+01 7.1E-02 5.7E-02 2.7E-02 9.4E-03 
7 3.6E+01 2.6E-01 3.2E-01 1.2E-01 5.6E-02 
14 5.9E+01 1.4E+00 3.9E+00 3.8E+00 4.9E+00 
30 9.0E+01 1.7E+00 5.1E+00 4.9E+00 6.7E+00 
60 1.4E+02 2.6E+00 7.7E+00 4.9E+00 6.9E+00 
90 1.7E+02 3.9E+00 1.1E+01 5.3E+00 7.3E+00 
180 2.4E+02 1.3E+01 3.6E+01 5.8E+00 8.2E+00 
365 3.9E+02 3.4E+02 2.2E+02 7.5E+00 1.1E+01 
730 7.1E+02 6.5E+02 6.8E+02 1.3E+01 1.8E+01 
1,825 9.6E+02 1.0E+03 9.9E+02 5.3E+01 7.4E+01 
3,600 1.0E+03 1.1E+03 1.0E+03 4.0E+02 4.8E+02 
7,300 1.1E+03 1.1E+03 1.2E+03 1.0E+03 1.1E+03 
18,250 1.6E+03 1.6E+03 1.6E+03 1.5E+03 1.5E+03 
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 Figure 8.43. Minimum Detectable Bone Surface Doses for 20-Year Aged Fuel-Grade Plutonium 
 Based on Detection of 0.2 dpm/d 239Pu in Feces 
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 Table 8.56. Minimum Detectable Committed Bone Surface Dose Equivalent (rem)  
for 40-Year Aged Fuel-Grade Plutonium Based on Detection of  
0.2 dpm/d 239Pu in Feces 
 
Class W Inhalation Class Y Inhalation Days Post 
Intake 
Instant 
Uptake 1-mm 5-mm 1-mm 5-mm 
1 4.6E+00 1.5E-02 8.3E-03 4.9E-03 1.4E-03 
2 7.3E+00 1.3E-02 7.0E-03 4.0E-03 1.2E-03 
5 2.4E+01 7.3E-02 5.9E-02 2.7E-02 1.0E-02 
7 3.8E+01 2.7E-01 3.3E-01 1.2E-01 5.9E-02 
14 6.1E+01 1.4E+00 4.0E+00 3.7E+00 5.2E+00 
30 9.3E+01 1.7E+00 5.2E+00 4.9E+00 7.1E+00 
60 1.4E+02 2.7E+00 8.0E+00 4.9E+00 7.4E+00 
90 1.8E+02 4.0E+00 1.1E+01 5.3E+00 7.7E+00 
180 2.4E+02 1.3E+01 3.7E+01 5.8E+00 8.7E+00 
365 4.0E+02 3.5E+02 2.3E+02 7.5E+00 1.1E+01 
730 7.3E+02 6.7E+02 7.0E+02 1.2E+01 1.9E+01 
1,825 1.0E+03 1.0E+03 1.0E+03 5.3E+01 7.9E+01 
3,600 1.1E+03 1.1E+03 1.1E+03 4.0E+02 5.1E+02 
7,300 1.2E+03 1.1E+03 1.2E+03 1.0E+03 1.1E+03 
18,250 1.7E+03 1.7E+03 1.7E+03 1.4E+03 1.6E+03 
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 Figure 8.44. Minimum Detectable Bone Surface Doses for 40-Year Aged Fuel-Grade Plutonium 
 Based on Detection of 0.2 dpm/d 239Pu in Feces 
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8.4.6 Recommended Bioassay Monitoring Program 
 
The recommended periodic bioassay-monitoring program for 
plutonium is to perform annual in vivo lung measurements and 
annual plutonium-in-urine assessments.  Annual chest counts provide 
a reasonable capability of demonstrating compliance with the 50-rem 
deterministic dose limit for the bone surfaces as the most limiting 
intake condition for class Y inhalations, and also are likely to be 
capable of demonstrating compliance for inhalation of super class Y 
based on the effective dose equivalent as the most restrictive dose 
limit.  More frequent chest counting is not particularly effective in 
lowering the MDD unless it is performed immediately after an 
intake.  Annual urine sampling provides capability for demonstrating 
compliance with both deterministic and stochastic dose limits for 
instantaneous uptake and inhalations of class W material.  
Substantially more frequent urine sampling can lower the MDD for 
instantaneous uptakes or class W inhalations; however, the 
improvement in sensitivity is not necessarily commensurate with the 
added cost (e.g., going from annual to quarterly urine samples 
quadruples the cost but only improves the MDD by a little over a 
factor of 2).  Routine fecal sampling could provide some 
improvements for class Y inhalation monitoring, however the 
attendant difficulties with collection (worker inconvenience), 
analysis (a very difficult matrix to analyze), and interpretation 
(potential interference from minor ingestion) suggest that fecal 
sampling is best applied to special investigations. 
 
These recommendations do not provide the high degree of sensitivity 
for internal dose estimation available for fission products.  The lack 
of sensitivity is due to the much higher dose per unit intake 
associated with tenaciously retained alpha-emitting radionuclides as 
compared with beta- and gamma-emitting fission products. 
 
Because of the lack of sensitivity of periodic bioassay, special 
bioassay monitoring as a supplement to the routine program should 
be promptly initiated by workplace indications of potential internal 
exposure to plutonium.  When adequate measurements are made 
promptly after a suspected intake, good sensitivity to potential dose 
can be obtained. 
 
8.4.7 Special Bioassay Monitoring 
 
If a potential intake of plutonium is suspected, special bioassay 
monitoring should be quickly initiated.  Typically this monitoring 
should include same-day in vivo measurements, overnight or first-
day urine collection, and early fecal sample collection.  The early 
fecal samples are particularly important for relatively insoluble 
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forms of plutonium (class Y and super Y) because in vivo and urine 
sample measurements are relatively insensitive to these intakes.  An 
early single voiding urine sample may also be warranted for 
determining the need for potential dose-reduction therapy.  If DTPA 
chelation therapy was administered, then a total urine sample 
collection is recommended to reduce any uncertainties associated 
with sample normalization.  Total urine sample collection should be 
continued until the excretion pattern is established. 
 
How many special bioassay measurements to obtain is a matter of 
professional judgment, factoring in the potential significance of the 
exposure, the appropriate types of measurements, worker 
inconvenience, cost, and the degree of confidence required in the 
assessment.  Generally, if an initial chest count shows detectable 
lung activity, a next-day follow-up chest count should be performed 
to monitor early lung clearance.  Additional counts are warranted if 
detection continues.  Total fecal sample collections for the first week 
allow for complete observation of the early fecal clearance pattern 
and permit a higher degree of confidence in the intake estimate than 
does a single sample.  Because the general early fecal clearance 
pattern is not significantly different for inhalation class W or Y, the 
fecal-based intake estimate needs to be coupled with at least one 
early urine sample representing a period concurrent with at least one 
fecal sample to allow for a determination of inhalation class based on 
the ratio of fecal to urine excretion.  The extent of this collection 
protocol can pose substantial inconvenience to the worker and can be 
costly.  Such inconvenience and cost may be justified when doses are 
considered relatively high (e.g., greater than 500- to 1000-mrem 
committed effective dose equivalent).  At lower doses, reliance on 
more limited measurements (e.g., one or two fecal samples and a 
urine sample) and standard assumptions of the source material and 
ICRP Reference Man biokinetic behavior may be appropriate. 
 
8.4.8 Bioassay Monitoring Capability for Workers with Known Plutonium Depositions 
 
The capability of a bioassay program is directly dependent upon the 
magnitude of an identifiable increase in a bioassay measurement.  
When a worker has a positive baseline bioassay level due to a 
previous intake, the ability to detect a subsequent increase in the 
bioassay level from an additional intake is more dependent on the 
variability of current bioassay levels and less dependent on analytical 
capability.  In other words, to be detected, subsequent intakes must 
result in increases in bioassay measurements that exceed the baseline 
“noise” level.  Guidance concerning the minimum detectable dose 
from potential additional intakes must be developed on a case-by-
case basis.  Appropriate adjustments to measurement frequencies can 
then be determined based on the potential undetected dose.  As an 
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approximate rule-of-thumb, a single bioassay measurement will 
probably have to be at least twice the baseline level to be readily 
recognized, due to the substantial variability in single bioassay 
measurements on individual people.  For many situations, this may 
imply that a normally detectable intake may not be detectable on top 
of a pre-existing internal plutonium deposition.  Like most rules-of-
thumb, this is only a rough suggestion; cases of significance must be 
addressed individually. 
 
8.5 Assessment of Internal Dose 
 
The following subsections discuss two general approaches to internal 
dosimetry and highlight some applications and caveats associated 
with different types of bioassay data.  The most typical method used 
for plutonium internal dosimetry is intake assessment using fecal, 
urine, and in vivo data, as available.  This method has been used for 
most Hanford assessments since the early 1990s.  Prior to that the 
predominant method was a deposition assessment based primarily on 
urine data.  It is a good practice to compare estimates based on 
different bioassay data sets for the same intake. 
 
8.5.1 Intake Assessment 
 
An intake of plutonium can be estimated by fitting the bioassay data 
to the appropriate retention or excretion function, using manual or 
computerized techniques.  For a single data point, the intake can be 
estimated by dividing the measured excretion by the value of the 
retention function for the appropriate day after intake represented by 
the sample in a manner similar to Equation 2.5.  Values for the 
retention function can be obtained from those tabulated in this 
chapter, or directly from running the CINDY computer code.  For 
multiple data points, the CINDY code provides a choice of fitting 
routines, or a manually determined fit of the data to the expected 
function can be performed.  Once the intake is calculated, 
appropriate internal doses may be calculated by applying the dose 
coefficients of this chapter to Equation 2.10 or 2.11.  The CINDY 
computer code may also be used to directly calculate internal doses, 
and is particularly appropriate for complex cases. 
 
In addition to their use for dose calculations, intakes calculated by 
the above techniques may also be compared with intake estimates 
based on air sample results.  When bioassay data are not available or 
not sufficiently sensitive, air sample results may be the basis for 
estimating intake. 
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8.5.2 Deposition Assessment 
 
Deposition assessment involves determining the amount of material 
deposited in a body or tissue compartment of interest.  Whereas the 
term intake includes all material taken into the body regardless of its 
subsequent fate, deposition is a more limited quantity that excludes 
material not retained (e.g., that immediately exhaled) and material 
not systemically absorbed (e.g., material cleared to the GI tract and 
excreted in feces without absorption).  The HIDP coined the term 
presystemic deposition in the mid-1980s to precisely define what 
was being evaluated and avoid terms that had developed generic, 
nebulous, or varied meanings (e.g., deposition, uptake, burden).  In 
addition, the term deposition was gaining preference in the field of 
internal dosimetry as a process term associated with the respiratory 
tract, rather than a retained quantity.  The HIDP defined presystemic 
deposition as the total radioactivity that will ultimately translocate 
into the transfer compartment from a metabolically isolated pool; in 
other words, the activity ultimately reaching the blood.  Historically 
at Hanford, this was the quantity compared with the maximum 
permissible body burden (MPBB) of 0.04 mCi (239Pu) listed in 
National Bureau of Standards Handbook 69 (NBS 1959), NCRP 22 
(1959), and ICRP 2 (1959).  It is related to, but significantly different 
from intake, lung deposition, long-term lung burden, and 
instantaneous body burden (or retained quantity). 
 
Activity is deposited in presystemic compartments at the time of 
intake.  From there, systemic uptake may be essentially 
instantaneous (as with a readily transportable wound intake), or it 
may occur gradually over an extended period of time (as in the case 
of an inhalation of class Y material).  Transfer from the presystemic 
compartment into systemic circulation is assumed to be governed by 
linear first-order kinetics, and can be described in terms of a transfer 
rate constant. 
 
The computer program PUCALC was written to evaluate alternate 
values of the transfer rate and presystemic deposition, based on the 
urinary excretion data.  The program describes the urinary excretion 
of plutonium for user-selected values for the transfer rate and 
presystemic deposition.  Additional information on PUCALC is 
available from the HIDP and the Hanford Radiation Records 
Historical File. 
 
It must be remembered that the presystemic deposition may be only 
part of the initial deposition in the body.  In the case of the lung, the 
ICRP 30-lung model predicts that the presystemic deposition 
represents about one-third of the total deposition in the slowly 
clearing compartments of the lung.  The total long-term lung 
  
PNNL-MA-860 Chapter 8.0  Issued:  January 31, 2003 
Page 8.78 
deposition must be considered when assessing lung doses.  
Experience with wounds has shown that a significant fraction of 
slowly transportable activity can become bound up in tissue at the 
wound site or captured by lymph nodes and is essentially walled-off 
or permanently isolated from the transfer compartment.  Whether 
this might represent a true isolation, or merely an extremely slow 
transfer rate, is a matter of some speculation.  The need to determine 
localized tissue deposits for potentially small wound areas from 
slowly transportable plutonium must be decided on a case-by-case 
basis. 
 
8.5.3 Applications of Fecal Data 
 
Fecal data can be used in two ways for plutonium assessments.  First, 
it can provide isotopic composition information for use with other 
bioassay and monitoring data.  Secondly, it can be used in 
conjunction with a biokinetic model to estimate intake or initial 
depositions in various compartments of the respiratory tract.  Caution 
must be exercised in interpreting fecal data because a slight ingestion 
intake can significantly bias inhalation intake estimates.  There is no 
way to differentiate inhalation from ingestion intakes by early fecal 
data.  Follow-up fecal samples somewhat removed in time from the 
intake (2 to 4 weeks or more) may be helpful in determining if 
observed fecal activity is from lung clearance or ingestion clearance.  
Fecal excretion is also highly dependent on particle size, with larger 
sizes being more readily excreted in feces.  Early fecal sampling is 
typically the most sensitive bioassay indicator of plutonium intake.  
Experience with Hanford cases suggests that the first fecal sample 
following an intake is likely to bias inhalation intake estimates high 
due to possible concurrent ingestion of large, nonrespirable particles.  
Undue emphasis should not be placed on the first fecal sample when 
other data appear to contradict it.  For this reason, collection of 
multiple fecal samples is a good practice. 
 
8.5.4 Applications of Urine Data 
 
Urine sampling is the simplest and most accepted excreta sampling 
method by workers, however it is not particularly sensitive to 
low-level intakes.  It is most appropriate for instantaneous uptake 
(wound) and class W inhalations, and as a tool to compare with fecal 
samples to determine the inhalation class of an intake. 
 
Urine sample data are generally not considered a good basis for 
estimating initial lung depositions; however, they can be helpful and 
occasionally may be the only data available.  For known inhalation 
exposures, the presystemic deposition estimated using the technique 
described in the preceding section can provide an indication of initial 
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lung deposition.  By using the presystemic deposition estimate as the 
ultimate quantity to be translocated into the transfer compartment, 
the compartment fractions of the ICRP 30 respiratory tract model can 
be used to estimate initial deposition in the various compartments.  
For example, the initial deposition in the long-term pulmonary 
region compartments (ICRP 30 lung model compartments e, g, and 
h) can be estimated by attributing the slowly transportable 
presystemic deposition to pulmonary compartments e and h, and then 
multiplying that value by the ratio of the total long-term 
compartment fractions to the fraction in the presystemic 
compartments as follows: 
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where P0 is the initial long-term pulmonary deposition, U¥(e+h) is 
the slowly transportable presystemic deposition, and Fe, Fg, Fh are 
ICRP 30 lung model compartment deposition fractions. 
 
8.5.5 Applications of In Vivo Data 
 
Chest counting data for plutonium is subject to some significant 
interpretation pitfalls, especially when it shows 241Am detection over 
very long periods.  Evaluations of chest count data must consider the 
potential for interference from activity deposited in other organs 
(particularly the skeleton and liver), as well as the specific chest-wall 
thickness of the individual.  In addition, 241Am ingrowth over time 
can complicate the determination of actual retention.  The HIDP has 
developed the AMERIN computer code to assist with case 
evaluations as a tool to identify an 241Am biological clearance rate 
consistent with observed ingrowth in a single compartment.  This 
tool is particularly applicable to long-term lung retention of 241Pu and 
241Am. 
 
Initial lung depositions can be estimated based on direct in vivo 
measurements, fecal data, urine data, or a combination of such data.  
When there is direct knowledge, or a reasonable assumption, of the 
isotopic composition of a plutonium mixture, direct in vivo 
measurement of 241Am in the lung can be used to evaluate lung 
depositions.  A series of detectable 241Am measurements can be used 
to establish the effective lung clearance rate, and the plutonium 
depositions can be estimated by activity ratios relative to 241Am.  In 
analyzing long-term lung measurement data, consideration must be 
given to the potential impact of the ingrowth of 241Am from 241Pu.  
This requires that the clearance rate of the 241Am relative to that of 
241Pu be known.  Laboratory animal research data have indicated that 
early clearance of plutonium mixtures from the lung may be enriched 
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in 241Am relative to the intake composition.  This has been attributed 
to a more rapidly clearing component of the 241Am that is initially 
deposited in the lung along with the plutonium.  Once this initially 
soluble 241Am has been cleared, the observed clearance rate for the 
remaining 241Am will be similar to that of the host matrix material, 
i.e., plutonium (Eidson 1980). 
 
Lung measurement results are also useful as an appropriate upper 
bound estimate for use with other intake estimates. 
 
8.5.6 Assessing Organ and Effective Dose Equivalents 
 
The organs of primary interest for plutonium dose evaluations are the 
bone surface, red marrow, liver, and gonads.  The lung is also an 
organ of interest for inhalations.  Other organs or tissues may be of 
interest depending on the nature of an intake.  For example, the dose 
to a specific lymph node or small volume of tissue may be of 
academic interest as the result of a wound intake of slowly 
transportable materials, even though doses to such tissues are not 
considered doses of record for compliance purposes.  Such cases can 
be dealt with as they arise and are beyond the general scope of this 
technical basis. 
 
Plutonium reaching the transfer compartment is assumed to be 
distributed to the liver, bone surfaces, and the gonads according to 
the ICRP 30 Part 4 biokinetic model.  Once deposited in these 
tissues, the ICRP 30 Part 4 clearance rates are assumed to apply.  
Thus, for calculating organ doses, the ICRP 30 Part 4 organ-retention 
functions and dosimetry factors are normally used. 
 
Because plutonium cannot be effectively measured in the systemic 
organs, and because plutonium and americium may not behave 
similarly after reaching the systemic organs, caution must be 
exercised in using measurements of americium in systemic organs 
for plutonium dose calculations based on the isotope ratios existing 
at the time of intake.  Isotope ratios can change with time due to the 
different solubility rates and retention characteristics of plutonium 
and americium.  However, americium measurements can be used for 
americium dose calculations. 
 
Once the magnitude of an intake, presystemic deposition, or initial 
lung deposition has been determined, organ dose equivalents and the 
effective dose equivalent can be assessed using hand-calculation 
techniques or computer codes.  The HIDP uses the CINDY computer 
code to aid in dose calculations.  More detailed explanations and a 
copy of the code are maintained in the Hanford Radiation Protection 
Historical Files. 
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8.6 Management of Internal Contamination Cases 
 
This section discusses the diagnostic procedures, therapeutic actions, 
and long-term monitoring of internal depositions. 
 
8.6.1 Diagnostic Procedures 
 
The diagnosis of an intake involves a combination of workplace 
monitoring to identify on-the-job potential intakes and bioassay 
measurements to confirm and quantify internal contamination. 
 
The primary method of identifying potential intakes is by workplace 
monitoring, such as personal contamination surveys, nasal smear 
analyses, air sample results, or workers’ identifications of unusual 
conditions.  These techniques provide qualitative screening to alert 
radiation protection staff to potential internal exposure, rather than 
absolute confirmation that exposure has or has not occurred.  For 
example, activity detected on nasal smears is usually an indication of 
an inhalation intake; however, the absence of activity does not 
necessarily mean that an intake did not occur.  The absence of nasal 
smear activity following an inhalation intake can be explained by a 
sufficient delay between the time of intake and the collection of nasal 
smears to allow for complete clearance of activity from the nares.  
The ICRP 30 respiratory tract model indicates that a delay of as little 
as 30 to 60 minutes may be adequate for this in some cases.  
Alternatively, some individuals are mouth-breathers, whose noses 
are partially or completely bypassed in the respiratory process, hence 
no activity may be deposited in the nares, despite the occurrence of 
an inhalation intake.  Particle size can also significantly affect nasal 
deposition and clearance. 
 
Once a worker has been identified as having incurred a potential 
intake, the initial diagnostic measurements are arranged.  These may 
include a chest count, wound count, single voiding (spot) urine 
sample analysis, first-day fecal sampling, and overnight urine 
sampling.  The purpose of these initial procedures is to provide an 
order-of-magnitude estimate of the potential internal exposure and 
dose.  Initial diagnostic measurements are usually sufficient for final 
evaluations only when all results collectively rule out the possibility 
of an intake.  In reality, initial measurements are not generally 
expected to do this, and follow-up measurements are necessary. 
 
Follow-up diagnostic measurements may include additional urine 
and fecal samples, chest counts, liver counts, head counts, and lymph 
node counts.  These analyses aid in determining the magnitude,  
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location, and retention characteristics of the deposited material.  In 
some cases, blood samples or tissue specimens may also be 
appropriate. 
 
In addition, workplace or clothing contamination analyses, air 
sample analyses, particle size analyses, and/or solubility analyses 
may be performed to more clearly define the physical and 
radiological characteristics of the material to which the worker was 
exposed. 
 
It is the responsibility of the exposure evaluator, working closely 
with contractor radiation protection staff, to determine the 
appropriate diagnostic protocols.  Scheduling of follow-up 
measurements will normally be done by the appropriate contractor 
radiation protection staff. 
 
8.6.2 Therapeutic Actions 
 
Therapeutic actions for potential internal contamination includes the 
use of decorporation agents, catharsis, and surgical excision.  For the 
purposes of this discussion, the normal skin decontamination 
procedures of Hanford contractors are not considered therapeutic 
actions, although it is acknowledged that these procedures can be 
quite effective in preventing the intake of radioactivity.  The decision 
to undertake one or more of these therapeutic actions is the 
responsibility of the participating HEHF Occupational Medicine care 
provider with the concurrence of the patient.  The exposure evaluator 
will provide advice and consultation to the physician and patient 
regarding the potential dose implications and efficacy of alternative 
actions.  Guidance for the methods of therapy can be found in NCRP 
Report 65 (1980) and in the “Guidebook for the Treatment of 
Accidental Internal Radionuclide Contamination of Workers” 
(Bhattacharyya et al. 1992).  Guidance for circumstances under 
which therapy may be warranted is contained in PNL-MA-552,(a) but 
was established as a good practice based on experience rather than a 
detailed technical analysis. 
 
Decorporation therapy, also referred to as chelation therapy, involves 
the chemical removal of radioactivity from the bloodstream through 
drug administration.  The drug DTPA has U.S. Food and Drug 
Administration approval as an investigational new drug for use in 
removing plutonium and other heavy metals from the body.  Under 
the investigational new drug category, the patient must provide 
                                                   
(a) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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informed consent to HEHF before the drug can be administered.  
Other drugs are also available to HEHF Occupational Medicine, but 
none has demonstrated the efficacy of DTPA for plutonium 
chelation.  The decision to administer DTPA is usually made based 
on workplace indicators suggesting the likelihood of a significant 
uptake.  Urinalysis is required to determine the actual efficacy of 
treatment.  When DTPA is indicated, special emergency processing 
of a single void urine sample should be performed to determine if 
additional (i.e., extended) therapy might be warranted.  Professional 
judgment is required on the part of the medical and exposure 
evaluator staff to determine if continued therapy is warranted.  
DTPA chelation therapy can enhance urine excretion of plutonium 
by up to a factor of 100 or more for highly soluble forms of 
plutonium.  For insoluble forms, it is relatively ineffective.  Because 
of this wide range of effectiveness, dosimetric interpretation of the 
urine data of a person undergoing chelation therapy is problematic.  
Bihl (1994) has suggested a dose-averted method for interpreting 
urine data.  The historical practice at Hanford was to base final 
dosimetry on urine samples obtained long after the excretion 
enhancement effect of DTPA had passed (typically 30 to 100 days 
following therapy). 
 
Catharsis involves accelerating the passage of material through the 
GI tract by means of laxative drugs or physical means such as an 
enema.  Catharsis has potential value in reducing the adsorption of 
material into the blood stream from the GI tract and in reducing the 
dose to the GI tract organs from material passing through the GI 
tract.  These measures are not generally considered for occupational 
exposures to plutonium, because the GI tract adsorption of plutonium 
is so slight, and the dose to the GI tract organs is usually an 
insignificant fraction of the total effective dose. 
 
Surgical excision following wounds can be extremely effective in 
reducing the potential uptake, particularly when coupled with 
decorporation therapy.  Minor excisions are usually performed at the 
Emergency Decontamination Facility (EDF) by HEHF Occupational 
Medicine staff, assisted by PNNL exposure evaluation and radiation 
protection personnel. 
 
8.6.3 Long-Term Monitoring of Internal Depositions 
 
Once an internal dosimetry evaluation has been completed, it may be 
recommended that the worker be placed on a specialized long-term 
bioassay monitoring schedule.  The reasons for this are twofold:  
first, long-term follow-up monitoring results that are consistent with 
the projected results verify the conclusions of the evaluation.  
Second, if long-term results are projected to be detectable, and the 
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worker returns to plutonium work, then the capability of a routine 
bioassay monitoring program to detect an additional intake may be 
affected.  This latter point is addressed in greater detail in 
Section 8.4.8. 
 
Specialized bioassay monitoring programs may be required for 
workers with known internal depositions of plutonium.  These 
programs may include head counts, liver counts, periodic chest 
counts, and urine samples.  In some cases fecal sampling may also be 
desired.  It is the responsibility of the HIDP to recommend 
appropriate long-term bioassay monitoring to the contractor 
dosimetry or radiation protection organization that has the 
responsibility for acting on these recommendations. 
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9.0 Americium 
 
 
This chapter provides technical information on the sources and 
characteristics of americium and summarizes the technical basis for its 
internal dosimetry at Hanford.  Dosimetry methods used are based on the 
concepts of ICRP 48 (1986) and ICRP 67 (1993), as implemented using 
the CINDY computer code (Strenge et al. 1992). 
 
9.1 Sources and Characteristics 
 
Americium at Hanford can be found as the ingrown 241Am progeny of 
241Pu in a plutonium mixture or as a separated 241Am isotope that exists 
singly or in combination with other separated isotopes in waste mixtures.  
In addition, 243Am has been used in some PNNL facilities as a research 
isotope. 
 
The 241Am existing as an ingrown progeny in a plutonium mixture is 
typically a small fraction of the mass of the mixture.  Consequently, it is 
assumed to be trapped in a plutonium matrix and exhibits the basic 
solubility and biokinetic characteristics of plutonium, rather than of pure 
americium.  Ingrown 241Am is typically encountered at plutonium 
facilities such as most of the Plutonium Finishing Plant (PFP [234-5Z 
Building]), the Plutonium-Uranium Extraction (PUREX) Plant (202-A), 
the 233-S Building, or research facilities such as the former Critical Mass 
Laboratory (209-E). 
 
Separated 241Am can also be encountered at PFP because chemical 
separation of 241Am from plutonium was a routine process at the 
Plutonium Reclamation Facility (PRF, 236-Z) or the 242-Z facility and 
the 241Am product was handled in PFP.  The 242-Z facility was the site of 
the 1976 americium column explosion, which resulted in extensive 
contamination of the facility and its subsequent physical isolation from 
routine entry. 
 
Separated 241Am is also a trace contaminant in many of the 200-Area tank 
farm waste mixtures.  During routine waste management activities, the 
trace americium was part of an intimately mixed waste slurry from the 
fuel processing facilities that was pumped into the waste tanks.  With 
time, the slurry separated into a sludge at the bottom of the tank and a 
supernate liquid above the sludge.  The trace americium was retained 
primarily in the supernate, along with 137Cs, while the sludge retained the 
majority of the trace plutonium and 90Sr.  Subsequent supernate 
concentration activities produced salt cake that could also retain the trace 
241Am.  It is not likely that tank farm waste would contain separated 241Am 
as a pure isotope; it can be anticipated that it would be accompanied by 
much larger quantities of fission product activity. 
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Pure isotopes of 241Am and 243Am can be found in analytical laboratory 
standard solutions and in pure isotope research applications. 
 
The environmental levels of 241Am from worldwide nuclear weapons 
testing fallout can be considered insignificant with regard to potential 
interferences with worker or workplace monitoring.  The isotope has also 
found significant application as a sealed source for ionization in 
commercially manufactured smoke detectors, with the typical smoke 
detector containing about 1 µCi of 241Am, but there have not been 
indications that loss of containment has occurred with these sources. 
 
Radiological decay data for 241Am and 243Am are shown in Table 9.1.  The 
data were taken directly from, or calculated based on, information 
contained in ICRP 38 (1983). 
 
9.2 Biokinetic Behavior 
 
This section discusses the inhalation transportability class, internal 
distribution and retention, and the urinary and fecal excretion of 
americium.  This discussion relates to pure 241Am compounds or mixtures 
in which the 241Am component represents a predominant fraction of the 
mixture mass (e.g., 50% or more).  Where americium is entrapped within 
a plutonium matrix as an ingrown progeny, it is assumed to behave 
characteristically with the plutonium matrix, and those properties are 
described in Chapter 8.0. 
 
Table 9.1.  Radiological Decay Data for Americium 
 
Physical Half-Life Decay Constant 
Specific 
Activity
Isotope 
Principal Decay Mode, 
Energy, and Yield Years Days Year-1 Day-1 Ci/g 
241Am 
Alpha 
5.486 MeV, 85.2%  
Gamma  
59.54 keV, 35.7% 
432.2 1.58E+05 1.60E-03 4.39E-06 3.43 
243Am 
Alpha 
5.276 MeV, 87.9%  
Gamma  
74.67 keV, 66.0% 
7380 2.69E+06 9.39E-05 2.57E-07 0.181 
 
 
9.2.1 Transportability Class 
 
All compounds of americium are assigned transportability class W by 
ICRP 48 (1986).  The limited number of Hanford cases involving 241Am 
compounds has supported this assignment. 
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The new respiratory tract model of ICRP 66 (1994a) assigned absorption 
type M to all forms of americium (ICRP 68 [1994b]; ICRP 78 [1997]). 
 
9.2.2 Gastrointestinal Uptake to Blood (f1 Factor) 
 
The fractional uptake to blood from the GI tract is assumed to be 5×10-4, 
as recommended in ICRP publications 67 (1993) and 78 (1997).  This 
value was reduced from the 10-3 value used in earlier ICRP publications 
based on human studies discussed in ICRP 67, which became available in 
the late 1980s and early 1990s.  The 5×10-4 value applies to both 
inhalation and ingestion intakes. 
 
9.2.3 Distribution and Retention in Systemic Organs and Tissues 
 
The choice of models for use by the HIDP is constrained somewhat by the 
tools routinely used by the program.  For internal dose calculations, the 
main computer code used by the HIDP is the CINDY computer code 
(Strenge et al. 1992).  It uses the ICRP 30 and ICRP 48 format for its 
models (simple first-order kinetics) for defining metabolically significant 
organs and tissues.  CINDY allows for adjustment of the organ partition 
fractions and clearance half-times for those organs and tissues, but does 
not accommodate the addition of new organs and tissues or alternate 
model forms, such as the recycling models used in more recent ICRP 
publications (e.g., ICRP 67, [1993]).  Thus, the HIDP has examined the 
ICRP recommendations as well as other published models and adopted a 
modified ICRP 48 (1986) model to approximate the dose to the liver, 
which would be calculated using the ICRP 67 recycling model. 
 
The basic ICRP 48 model for distribution and retention of americium in 
the body is described as follows.  For dissolved (ionic form) americium 
reaching the transfer compartment (i.e., the blood stream), this ICRP 
model distributes 50% to the bone with a clearance half-time of 50 years, 
and 30% to the liver with a clearance half-time of 20 years.  The activity 
deposited in bone is assumed to be deposited uniformly over bone 
surfaces of both cortical and trabecular bone, where it remains until 
decayed or excreted.  A small fraction is permanently retained in the 
gonads (0.035% for testes and 0.011% for ovaries).  The remaining 20% 
are assumed to go directly to excretion or short-term holdup in other body 
tissues. 
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The Hanford adaptation of this model to americium is identical to the 
ICRP 48 description with the exception that the liver clearance half-time 
is reduced to 9 years.  The logic for this modification is described in the 
following paragraphs. 
 
The ICRP 48 model for americium metabolic distribution and retention 
was identical to that for plutonium, but the report noted that limited 
human data suggested an americium deposition in liver smaller than 
plutonium and with a shorter liver half-time.  It concluded that for 
purposes of radiation protection, it was reasonable to use the same model.  
That position was retained in ICRP 30 Part 4 (1988a) but the partitioning 
between skeleton and liver was changed to 45% in each, consistent with 
ICRP 30 Part 1 (1979) and ICRP 19 (1972). 
 
A departure from the simple first-order kinetics form of modeling (sum of 
single exponentials) to a recycling form of model occurred with ICRP 56 
(1989).  Two significant changes with regard to americium also occurred 
with that model shift.  First, the skeleton-to-liver partition was changed to 
30:50 (reversed from the ICRP 48 partition).  Secondly, it was noted that 
an apparent (i.e., externally viewed) liver half-time of 2 to 8 years was 
appropriate.  In ICRP 67 (1993) the recycling model was refined, with 
some additional significant differences between the plutonium and 
americium retention.  Notably, the liver model demonstrated substantially 
faster clearance of 2 to 3 years as an “externally viewed half-time” for the 
first few years, then stabilizing to a relatively constant liver burden at 
decades post uptake due to the skeleton feedback to blood.  The rapid 
clearance from the liver in the early years, combined with subsequent 
absorption by the skeleton of the early liver clearance to the blood 
resulted in an effective skeleton buildup in the first 5 years to a level 
approximating 50% of the initial uptake.  Based on this shift, the HIDP 
concluded that the original partition of 50% skeleton and 30% liver was a 
reasonable model approximation. 
 
The United States Transuranium and Uranium Registries (USTUR) is a 
DOE-funded research entity chartered to collect human data for the 
verification, refinement, or development of radiation protection standards.  
Data obtained and analyzed by the Registries suggested much smaller 
retention in liver than ICRP 30 Part 4, and an additional muscle 
component.  Kathren (1994) published a USTUR model for americium 
that split the initial uptake fraction as follows:  45% to the skeleton (half-
time of 50 years), 25% to the liver (half-time of 2.5 years), 20% to the 
muscle (half-time of 10 years), and 10% to the rest of the body and direct 
excretion (half-time of 10 years). 
Both the ICRP 67 and the USTUR models for the bone surfaces showed 
long retention, comparable to that of ICRP 30 Part 4 and ICRP 48.  The 
use of the ICRP 48 uptake fraction of 50% to the bone with a 50-year 
clearance half-time was consistent with the ICRP 67 and USTUR models 
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and was retained for Hanford applications.  This was also consistent with 
Hanford practices since 1988.  The ambiguity in the data discussions and 
interpretations by ICRP 48, ICRP 30 Part 4, ICRP 56, and ICRP 67 
suggests that either a 45% or 50% fraction can adequately represent the 
bone uptake. 
 
Because the recent modeling efforts of both the ICRP and the USTUR 
suggested substantially less retention in the liver than predicted by ICRP 
48 and ICRP 30 Part 4, the HIDP sought to incorporate these conclusions 
into this technical basis.  As a benchmark, the HIDP obtained the results 
of the integrated retention of the ICRP 67 liver model using 
Matlab/Simulink™(a) and then iteratively solved several single exponential 
component models to approximate the integrated retention.  Thus, by 
using the single exponential liver model in the CINDY computer code, 
committed liver dose equivalents calculated by CINDY would be similar 
to those calculated using the ICRP 67 recycling model.  The result of this 
analysis was the choice of a liver uptake fraction of 30% having a 
clearance half-time of 9 years. 
 
Figure 9.1 illustrates the differences in these models with regard to liver 
retention.  The curve showing a two-component Matlab™ fit to ICRP 67 
represents a close approximation to the americium liver retention 
illustrated in ICRP 67 that was developed using the actual recycling 
model.  By comparison, the ICRP 30 Part 4 and ICRP 48 curves show 
significantly greater retention, and the USTUR model shows significantly 
less retention.  The ICRP 67 integral equivalent curve demonstrates 
retention both greater and less than ICRP 67 depending on the time post 
uptake; however, the ICRP 67 integral equivalent curve represents the 
same number of transformations over 50 years (i.e., the retention function 
integrated over 50 years) as the ICRP 67 recycling model, approximated 
in the figure by the Matlab™ fit curve. 
 
In summary, the distribution and retention model used by the HIDP for 
intakes of americium is a modified ICRP 48 model.  It assumes that for 
americium reaching the bloodstream, 50% is taken up by the bone 
surfaces from which it clears with a 50-year half-time, and 30% is taken 
up by the liver from which it clears with a 9-year half-time.  A small 
fraction is permanently retained in the gonads (0.035% for testes and 
0.011% for ovaries).  The remaining 20% is assumed to  
                                                     
(a) Matlab and Simulink are registered trademarks of The MathWorks, Inc., Natick, Massachusetts. 
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Figure 9.1.  Liver Retention for Americium - Model Comparison 
 
go directly to excretion or short-term holdup in other body tissues.  For 
the purposes of dosimetry, this fraction is considered to be an insignificant 
contributor to effective dose equivalent (relative to bone marrow, liver, 
and gonadal contributions). 
 
9.2.4 Urinary Excretion 
 
In ICRP publication 54 (1988b), it was noted that there were few reports 
of americium excretion in humans.  For that report, americium excretion 
used the same excretion function as for plutonium.  Based on that 
recommendation, the HIDP uses the Jones excretion function for 
plutonium, as implemented using the CINDY computer code.  The Jones 
function models urinary excretion of plutonium following systemic uptake 
as a four-component exponential function.  Jones emphasized that his 
function was an empirical fit to human data and should not be interpreted 
as modeling retention in specifically identifiable compartments.  Thus, its 
application at Hanford is limited to estimating uptake and predicting 
excretion based on uptake.  Further discussion on the Jones function can 
be found in Section 8.2.4 of the Plutonium Chapter of this manual. 
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The Jones function is a four-component exponential sum, mathematically 
defined as follows: 
 
  (9.1) 
( )
t0000284.05t00380.05
t0442.04t558.03
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−−−−
−−−−
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+×+×=
 
where eu(t) is the fraction of uptake to blood excreted in urine, and t is the 
days post uptake (note:  t = 0 is time of uptake; t = 1 represents the first 24 
hours following uptake; t = 2 represents the second day post uptake; etc.). 
 
As a possible alternative to the Jones function, a historical model used at 
Hanford is described here.  The 1976 americium column explosion at the 
Hanford 242-Z facility resulted in several workers incurring acute 
inhalation exposures to americium nitrate.   An excretion model 
developed by Rosen, Cohen, and Wrenn (1972) from baboon data was 
applied by Hanford internal dosimetrists to the workers exposed in this 
case, although only the most highly exposed worker was reported in the 
open literature (Robinson et al. 1983). The Rosen model is described by 
the following power function: 
 
t036.0qEu 3.10
−×=  (9.2) 
 
where Eu = 241Am excretion via urine on day t, q0 is the initial systemic 
burden, and t is the day post intake. 
 
The HIDP will use the Jones function for americium intakes and bioassay 
projection unless data suggest the Rosen model or another model provides 
a better fit for specific cases. 
 
9.2.5 Fecal Excretion 
 
The excretion of bile to the GI tract provides a pathway for systemic 
excretion of americium to feces from the liver.  Few data are available to 
quantify this pathway relative to urine, however the assumption of an 
equal amount excreted from the systemic compartment by way of feces 
and urine is not uncommon and is assumed at Hanford.  For inhalation 
intakes, the fecal excretion is dominated by clearance from the respiratory 
tract for the first year. 
 
9.3 Internal Dosimetry Factors 
 
This section contains factors that are useful in making internal dosimetry 
calculations.  The factors included in this section are derived from 
CINDY and incorporate the models and assumptions described in the 
preceding section.  Their application is intended for those circumstances 
where such assumptions are appropriate or more specific information is 
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lacking.  Variation from these factors is appropriate if sufficient data are 
available.  The factors shown are for 241Am, however there is no 
significant dosimetric difference between 241Am and 243Am. 
 
9.3.1 Intake Retention and Excretion Fractions 
 
The intake retention (or excretion) fraction expresses the fraction of intake 
retained in a particular compartment or excreted by a particular pathway 
(urine or feces) at a given time post intake.  Although excretion implies 
elimination rather than retention, conventional models include excretion 
compartments under the general term retention and use the term “intake 
retention fraction” (IRF) to describe both.  IRFs for various times post 
intake are tabulated as described below for 241Am. 
 
Lung retention fractions for the class W inhalations of 1-µm and 5-µm-
AMAD particles of 241Am are listed in Table 9.2 and plotted in Figure 9.2.  
Urine excretion fractions for an instantaneous uptake, acute inhalations, 
and acute ingestions of 241Am are listed in Table 9.3 and plotted in Figure 
9.3.  Corresponding values for fecal excretion are listed in Table 9.4 and 
plotted in Figure 9.4.  Values for days other than those tabulated here can 
be obtained by interpolation between the tabulated data, or by obtaining 
the values directly from CINDY. 
 
9.3.2 Dose Coefficients 
 
Dose coefficients, expressed as committed dose equivalent per unit 
activity of intake (rem per nanocurie of acute intake) are a convenient 
shortcut to estimating doses based on standard assumptions when the 
magnitude of an intake is known or assumed.  Acute intake dose 
coefficients have been tabulated for instantaneous uptake, class W 
inhalation (for both 1-µm and 5-µm-AMAD particle sizes), and for 
ingestion.  The dose coefficients shown in Table 9.5 were derived by the 
CINDY computer code using the previously described models. 
 
9.3.3 Comparison of Published Dosimetry Factors 
 
A comparison of dosimetry factors, including dose coefficients, ALIs, and 
DACs published in several sources is shown in Table 9.6.  For Hanford 
applications, the DAC values of 10 CFR 835 Appendix A, are required for 
use to control facility operations. 
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Table 9.2.  Lung Retention Fractions for Class W Inhalation of 241Am 
 
Days Post 
Intake 1-µm AMAD 5-µm AMAD 
0 3.3E-01 1.7E-01 
1 2.1E-01 7.5E-02 
2 1.8E-01 6.3E-02 
5 1.5E-01 5.1E-02 
7 1.4E-01 4.9E-02 
14 1.3E-01 4.4E-02 
30 1.0E-01 3.6E-02 
60 7.0E-02 2.5E-02 
90 4.8E-02 1.7E-02 
180 1.5E-02 5.3E-03 
365 1.4E-03 4.8E-04 
730 1.1E-05 3.9E-06 
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Figure 9.2.  241Am Lung Retention 
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Table 9.3.  Urine Excretion Fractions for 241Am Intakes 
 
Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm Class W 5-µm Class W 
1 3.1E-03 1.7E-06 2.2E-04 3.5E-04 
2 1.9E-03 1.0E-06 1.4E-04 2.2E-04 
5 5.8E-04 3.1E-07 4.6E-05 6.9E-05 
7 3.7E-04 1.9E-07 3.1E-05 4.4E-05 
14 2.3E-04 1.1E-07 2.2E-05 2.8E-05 
30 1.5E-04 7.7E-08 1.7E-05 2.0E-05 
60 9.9E-05 5.0E-08 1.3E-05 1.4E-05 
90 7.9E-05 4.0E-08 1.1E-05 1.1E-05 
180 5.7E-05 2.9E-08 8.3E-06 8.1E-06 
365 3.5E-05 1.8E-08 4.8E-06 4.9E-06 
730 1.9E-05 9.6E-09 2.4E-06 2.6E-06 
1,825 1.3E-05 6.7E-09 1.6E-06 1.8E-06 
3,650 1.3E-05 6.3E-09 1.5E-06 1.7E-06 
7,300 1.1E-05 5.6E-09 1.3E-06 1.5E-06 
18,250 7.8E-06 3.9E-09 9.4E-07 1.0E-06 
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Figure 9.3.  241Am Urine Excretion Fractions 
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Table 9.4.  Fecal Excretion Fractions for 241Am Intakes 
 
Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm Class W 5-µm Class W 
1 3.1E-03 4.7E-01 1.1E-01 2.2E-01 
2 1.9E-03 2.8E-01 1.3E-01 2.6E-01 
5 5.8E-04 1.8E-02 2.3E-02 3.1E-02 
7 3.7E-04 2.5E-03 6.3E-03 5.6E-03 
14 2.3E-04 2.4E-06 1.2E-03 4.6E-04 
30 1.5E-04 7.7E-08 9.6E-04 3.5E-04 
60 9.9E-05 5.0E-08 6.3E-04 2.3E-04 
90 7.9E-05 4.0E-08 4.2E-04 1.6E-04 
180 5.7E-05 2.9E-08 1.3E-04 4.9E-05 
365 3.5E-05 1.8E-08 1.4E-05 8.1E-06 
730 1.9E-05 9.6E-09 2.5E-06 2.6E-06 
1,825 1.3E-05 6.7E-09 1.6E-06 1.8E-06 
3,650 1.3E-05 6.3E-09 1.5E-06 1.7E-06 
7,300 1.1E-05 5.6E-09 1.3E-06 1.5E-06 
18,250 7.8E-06 3.9E-09 9.4E-07 1.0E-06 
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Figure 9.4.  241Am Fecal Excretion Fractions 
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Table 9.5.  Committed Dose Coefficients for Acute Intakes of 241Am (rem/nCi) 
 
Class W Inhalation Organ or 
Tissue 
Instantaneous 
Uptake 
Ingestion 
f1 = 5E-04 1-µm 5-µm 
Effective 3.5E+00 1.8E-03 4.3E-01 4.6E-01 
Bone Surface 7.5E+01 3.7E-02 9.0E+00 9.9E+00 
Red Marrow 5.9E+00 2.9E-03 7.0E-01 7.7E-01 
Liver 4.3E+00 2.2E-03 5.2E-01 5.7E-01 
Lung 8.5E-05 4.4E-08 6.7E-02 2.4E-02 
Gonads 1.0E+00 5.0E-04 1.2E-01 1.3E-01 
 
Table 9.6.  Comparison of Dosimetric Factors for 241Am 
 
Reference Source 
Class W  
Inhalation 1-µm 
AMAD 
Class W 
Inhalation 5-µm 
AMAD Soluble Ingestion 
Dose Coefficients 
CINDY (hE,50) 
0.43 rem/nCi  
1.2E-04 Sv/Bq 
0.46 rem/nCi 
1.2E-04 Sv/Bq 
0.0018 rem/nCi 
4.9E-07 Sv/Bq 
ICRP 54 (hE,50) 
1.2E-04 Sv/Bq 
(0.44 rem/nCi) NA NA 
EPA Federal 
Guidance Report 
No. 11 (hE,50) 
1.20E-04 Sv/Bq 
(0.44 rem/nCi) NA 
9.84E-07 Sv/Bq 
(3.64E-03 rem/nCi) 
ICRP 68 [e(50)] 3.9E-05 Sv/Bq (0.14 rem/nCi) 
2.7E-05 Sv/Bq 
(0.10 rem/nCi) 
2.0E-07 Sv/Bq 
(7.4E-04 rem/nCi) 
Bone Surface DAC 
10 CFR 835, App. A 2E-12 µCi/ml 
and 8E-02 Bq/m3
NA NA 
EPA Federal 
Guidance Report 
No. 11 
3E-12 µCi/ml 
and 1E-07 Bq/m3
NA NA 
ICRP 30, ICRP 54 1E-01 Bq/m3 NA NA 
Annual Limit on Intake, ALI (Bone Surface) 
Calculated from 10 
CFR 835 DAC 
4.8E-03 µCi/ml 
and 190 Bq 
NA NA 
ICRP 30, ICRP 54 2E+02 Bq NA 3E+04 Bq 
EPA Federal 
Guidance Report 
No. 11 
2.0E-04 MBq 
and 0.006 µCi NA 
0.03 MBq 
and 0.8 µCi 
NA = not applicable 
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9.3.4 Derived Reference Levels 
 
Derived screening, investigation, and compliance levels (based on 
committed effective dose equivalents of 10-mrem, 100-mrem, and a 
committed bone surface dose equivalent of 50,000 mrem, respectively) 
have been calculated for 1-µm and 5-µm class W inhalations of pure 
241Am.  The urine excretion levels are shown in Table 9.7 and chest count 
levels are shown in Table 9.8.  These levels are sufficiently low that, from 
a practical standpoint, any detected result is likely to result in 
investigation and dose assessment.  This is particularly the case because 
241Am at Hanford is usually used as an indicator of potential plutonium 
intake. 
 
9.4 Bioassay for Americium 
 
This section discusses the general techniques and applicability of bioassay 
monitoring and describes the capabilities of excreta sample bioassay and 
in vivo measurements.  General recommendations are also provided for 
routine bioassay monitoring for americium.  Techniques are similar for 
both 241Am and 243Am. 
 
9.4.1 Excreta Bioassay Techniques for Americium 
 
The typical urine sampling practice is to collect a urine sample over a 
specified time interval and perform a chemical separation for americium 
using an added tracer to determine the chemical yield of the process.  This 
technique is followed by electroplating and quantitative alpha 
spectrometry.  Where the analyte is 241Am, the tracer added to the 
chemical process is 243Am.  If the analyte is 243Am, a 241Am tracer is 
added.  Because of the tracers used, if a worker is to be monitored for both 
241Am and 243Am, two samples will have to be collected and analyzed (or 
alternatively, a single sample must be split prior to adding the tracer and 
two different analyses performed.)  
 
Fecal sample analysis follows a process similar to urine sample analysis. 
 
Less sensitive, rapid analytical procedures are available for special 
circumstances.  These procedures can be executed and results obtained in 
substantially shorter times than the routine procedure, but they are less 
sensitive.  Their use is primarily for diagnostic bioassay of suspected 
internal contamination related to unplanned exposures (incidents).  The 
decision to use such procedures involves considering the probability and 
potential magnitude of the exposure.  Of particular interest as an 
alternative to the electroplating and alpha spectrometry procedure is direct 
counting of the low-energy 241Am  
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 Table 9.7. 241Am Reference Levels and Urine Excretion Derived Reference Levels for 
Class W Inhalation 
 
10-mrem HE,50
Screening Level 
100-mrem HE,50
Investigation Level 
50-rem HT,50
Compliance Level 
 1-µm 5-µm 1-µm 5-µm 1-µm 5-µm 
Intake (nCi) 2.3E-02 2.2E-02 2.3E-01 2.2E-01 5.6E+00 5.1E+00 
 
Derived Screening Level 
(dpm/d) 
Derived Investigation Level
(dpm/d) 
Derived Compliance Level
(dpm/d) 
Days Post Intake 1-µm 5-µm 1-µm 5-µm 1-µm 5-µm 
1 1.1E-02 1.7E-02 1.1E-01 1.7E-01 2.7E+00 3.9E+00 
2 7.2E-03 1.1E-02 7.2E-02 1.1E-01 1.7E+00 2.5E+00 
5 2.4E-03 3.3E-03 2.4E-02 3.3E-02 5.7E-01 7.7E-01 
7 1.6E-03 2.1E-03 1.6E-02 2.1E-02 3.8E-01 4.9E-01 
14 1.1E-03 1.4E-03 1.1E-02 1.4E-02 2.7E-01 3.1E-01 
30 8.8E-04 9.7E-04 8.8E-03 9.7E-03 2.1E-01 2.2E-01 
60 6.7E-04 6.8E-04 6.7E-03 6.8E-03 1.6E-01 1.6E-01 
90 5.7E-04 5.3E-04 5.7E-03 5.3E-03 1.4E-01 1.2E-01 
180 4.3E-04 3.9E-04 4.3E-03 3.9E-03 1.0E-01 9.1E-02 
365 2.5E-04 2.4E-04 2.5E-03 2.4E-03 5.9E-02 5.5E-02 
730 1.2E-04 1.3E-04 1.2E-03 1.3E-03 3.0E-02 2.9E-02 
1825 8.3E-05 8.7E-05 8.3E-04 8.7E-04 2.0E-02 2.0E-02 
3650 7.7E-05 8.2E-05 7.7E-04 8.2E-04 1.9E-02 1.9E-02 
7300 6.7E-05 7.2E-05 6.7E-04 7.2E-04 1.6E-02 1.7E-02 
18250 4.9E-05 4.8E-05 4.9E-04 4.8E-04 1.2E-02 1.1E-02 
 
 Table 9.8. 241Am Reference Levels and Chest Count Derived Reference Levels for Class W 
Inhalation 
 
10-mrem HE,50
Screening Level 
100-mrem HE,50 
Investigation Level 
50-rem HT,50 
Compliance Level 
 1-µm 5-µm 1-µm 5-µm 1-µm 5-µm 
Intake (nCi) 2.3E-02 2.2E-02 2.3E-01 2.2E-01 5.6E+00 5.1E+00 
 
Derived Screening Level 
(nCi) 
Derived Investigation Level
(nCi) 
Derived Compliance Level
(nCi) 
Days Post Intake 1-µm 5-µm 1-µm 5-µm 1-µm 5-µm 
0 7.7E-03 3.7E-03 7.7E-02 3.7E-02 1.8E+00 8.6E-01 
1 4.9E-03 1.6E-03 4.9E-02 1.6E-02 1.2E+00 3.8E-01 
2 4.2E-03 1.4E-03 4.2E-02 1.4E-02 1.0E+00 3.2E-01 
5 3.5E-03 1.1E-03 3.5E-02 1.1E-02 8.3E-01 2.6E-01 
7 3.3E-03 1.1E-03 3.3E-02 1.1E-02 7.8E-01 2.5E-01 
14 3.0E-03 9.6E-04 3.0E-02 9.6E-03 7.2E-01 2.2E-01 
30 2.3E-03 7.8E-04 2.3E-02 7.8E-03 5.6E-01 1.8E-01 
60 1.6E-03 5.4E-04 1.6E-02 5.4E-03 3.9E-01 1.3E-01 
90 1.1E-03 3.7E-04 1.1E-02 3.7E-03 2.7E-01 8.6E-02 
180 3.5E-04 1.2E-04 3.5E-03 1.2E-03 8.3E-02 2.7E-02 
365 3.3E-05 1.0E-05 3.3E-04 1.0E-04 7.8E-03 2.4E-03 
730 2.6E-07 8.5E-08 2.6E-06 8.5E-07 6.1E-05 2.0E-05 
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photon using a germanium detector.  This protocol is substantially less 
sensitive than the alpha spectrometry, but is not subject to the difficulties 
associated with americium chemical separation.  This analysis is an 
appropriate quick-turnaround emergency analysis procedure that could be 
used as an indicator for a plutonium intake based on fecal sampling and 
reasonable knowledge of the americium-to-plutonium ratio. 
 
The contractual detection limits for americium in urine or feces can be 
found in the radiochemistry bioassay laboratory statement of work 
(available from the HIDP) and in the Hanford Internal Dosimetry Project 
Manual (PNL-MA-552).(a)
 
The minimum detectable intakes based on a 0.02 dpm/d urinalysis 
sensitivity are shown in Table 9.9.  The committed effective and bone 
surface dose equivalents associated with those intakes are shown in 
Tables 9.10 and 9.11, respectively.  Figures 9.5 and 9.6 show graphical 
presentations of the minimum detectable doses.  Corresponding data 
based on a 0.8 dpm/d fecal analysis sensitivity, are shown in Tables 9.12 
through 9.14 and Figures 9.7 and 9.8.  
 
Table 9.9. Minimum Detectable Intakes (nCi) for 241Am Based on 
Detection of 0.02 dpm/d 241Am in Urine 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 2.9E-03 5.3E+00 4.1E-02 2.6E-02 
2 4.7E-03 9.0E+00 6.4E-02 4.1E-02 
5 1.6E-02 2.9E+01 2.0E-01 1.3E-01 
7 2.4E-02 4.7E+01 2.9E-01 2.0E-01 
14 3.9E-02 8.2E+01 4.1E-01 3.2E-01 
30 6.0E-02 1.2E+02 5.3E-01 4.5E-01 
60 9.1E-02 1.8E+02 6.9E-01 6.4E-01 
90 1.1E-01 2.3E+02 8.2E-01 8.2E-01 
180 1.6E-01 3.1E+02 1.1E+00 1.1E+00 
365 2.6E-01 5.0E+02 1.9E+00 1.8E+00 
730 4.7E-01 9.4E+02 3.8E+00 3.5E+00 
1825 6.9E-01 1.3E+03 5.6E+00 5.0E+00 
3650 6.9E-01 1.4E+03 6.0E+00 5.3E+00 
7300 8.2E-01 1.6E+03 6.9E+00 6.0E+00 
18250 1.2E+00 2.3E+03 9.6E+00 9.0E+00 
 
                                                     
(a) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  PNNL-
MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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 Table 9.10. Minimum Detectable Committed Effective Dose Equivalent (rem) for 241Am Based on 
Detection of 0.02 dpm/d 241Am in Urine 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 1.0E-02 9.5E-03 1.8E-02 1.2E-02 
2 1.7E-02 1.6E-02 2.8E-02 1.9E-02 
5 5.4E-02 5.2E-02 8.4E-02 6.0E-02 
7 8.5E-02 8.5E-02 1.2E-01 9.4E-02 
14 1.4E-01 1.5E-01 1.8E-01 1.5E-01 
30 2.1E-01 2.1E-01 2.3E-01 2.1E-01 
60 3.2E-01 3.2E-01 3.0E-01 3.0E-01 
90 4.0E-01 4.1E-01 3.5E-01 3.8E-01 
180 5.5E-01 5.6E-01 4.7E-01 5.1E-01 
365 9.0E-01 9.0E-01 8.1E-01 8.5E-01 
730 1.7E+00 1.7E+00 1.6E+00 1.6E+00 
1825 2.4E+00 2.4E+00 2.4E+00 2.3E+00 
3650 2.4E+00 2.6E+00 2.6E+00 2.4E+00 
7300 2.9E+00 2.9E+00 3.0E+00 2.8E+00 
18250 4.0E+00 4.2E+00 4.1E+00 4.1E+00 
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 Figure 9.5. Minimum Detectable Committed Effective Dose Equivalent (rem) for 241Am Based on 
Detection of 0.02 dpm/d 241Am in Urine 
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 Table 9.11. Minimum Detectable Bone Surfaces Dose Equivalent (rem) for 241Am 
Based on Detection of 0.02 dpm/d 241Am in Urine 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 2.2E-01 2.0E-01 3.7E-01 2.5E-01 
2 3.6E-01 3.3E-01 5.8E-01 4.1E-01 
5 1.2E+00 1.1E+00 1.8E+00 1.3E+00 
7 1.8E+00 1.8E+00 2.6E+00 2.0E+00 
14 2.9E+00 3.0E+00 3.7E+00 3.2E+00 
30 4.5E+00 4.3E+00 4.8E+00 4.5E+00 
60 6.8E+00 6.7E+00 6.2E+00 6.4E+00 
90 8.6E+00 8.3E+00 7.4E+00 8.1E+00 
180 1.2E+01 1.1E+01 9.8E+00 1.1E+01 
365 1.9E+01 1.9E+01 1.7E+01 1.8E+01 
730 3.6E+01 3.5E+01 3.4E+01 3.4E+01 
1825 5.2E+01 5.0E+01 5.1E+01 5.0E+01 
3650 5.2E+01 5.3E+01 5.4E+01 5.2E+01 
7300 6.1E+01 6.0E+01 6.2E+01 5.9E+01 
18250 8.7E+01 8.5E+01 8.6E+01 8.9E+01 
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 Figure 9.6. Minimum Detectable Bone Surfaces Dose Equivalent (rem) for 241Am 
Based on Detection of 0.02 dpm/d 241Am in Urine 
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 Table 9.12. Minimum Detectable Intakes (nCi) for 241Am Based on Detection of 0.8 dpm/d 241Am 
in Feces 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 1.2E-01 7.7E-04 3.3E-03 1.6E-03 
2 1.9E-01 1.3E-03 2.8E-03 1.4E-03 
5 6.2E-01 2.0E-02 1.6E-02 1.2E-02 
7 9.7E-01 1.4E-01 5.7E-02 6.4E-02 
14 1.6E+00 1.5E+02 3.0E-01 7.8E-01 
30 2.4E+00 4.7E+03 3.8E-01 1.0E+00 
60 3.6E+00 7.2E+03 5.7E-01 1.6E+00 
90 4.6E+00 9.0E+03 8.6E-01 2.3E+00 
180 6.3E+00 1.2E+04 2.8E+00 7.4E+00 
365 1.0E+01 2.0E+04 2.6E+01 4.4E+01 
730 1.9E+01 3.8E+04 1.4E+02 1.4E+02 
1825 2.8E+01 5.4E+04 2.3E+02 2.0E+02 
3650 2.8E+01 5.7E+04 2.4E+02 2.1E+02 
7300 3.3E+01 6.4E+04 2.8E+02 2.4E+02 
18250 4.6E+01 9.2E+04 3.8E+02 3.6E+02 
 
9.4.2 In Vivo Bioassay Techniques for Americium 
 
In vivo measurement of americium is available for both 241Am and 243Am, 
though it is not routinely performed for 243Am.  Hanford in vivo 
measurements for americium include chest counts, skeleton measurements 
by head counting, liver counts, and wound counts.  Brief descriptions of 
the measurements are contained in Section 8.4.3 of the Plutonium Chapter 
of this manual.  Minimum detectable activities for these measurements are 
described in the Hanford In Vivo Monitoring Program Manual (PNL-
MA-574)(a) and the Hanford Internal Dosimetry Program Manual (PNL-
MA-552).(b)
 
The minimum detectable intakes of 241Am and associated committed 
doses as determined by detection of 0.16 nCi 241Am by chest counting are 
described in Table 9.15 and illustrated in Figure 9.9. 
                                                     
(a) Pacific Northwest National Laboratory (PNNL).  Hanford In Vivo Monitoring Program Manual.  PNNL-
MA-574, Richland, Washington.  (Internal manual.) 
(b) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  PNNL-
MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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 Table 9.13. Minimum Detectable Committed Effective Dose Equivalent (rem) for 241Am Based on 
Detection of 0.8 dpm/d 241 Am in Feces 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 4.1E-01 1.4E-06 1.4E-03 7.5E-04 
2 6.6E-01 2.3E-06 1.2E-03 6.4E-04 
5 2.2E+00 3.6E-05 6.7E-03 5.3E-03 
7 3.4E+00 2.6E-04 2.5E-02 3.0E-02 
14 5.5E+00 2.7E-01 1.3E-01 3.6E-01 
30 8.4E+00 8.4E+00 1.6E-01 4.7E-01 
60 1.3E+01 1.3E+01 2.5E-01 7.2E-01 
90 1.6E+01 1.6E+01 3.7E-01 1.0E+00 
180 2.2E+01 2.2E+01 1.2E+00 3.4E+00 
365 3.6E+01 3.6E+01 1.1E+01 2.0E+01 
730 6.6E+01 6.8E+01 6.2E+01 6.4E+01 
1825 9.7E+01 9.7E+01 9.7E+01 9.2E+01 
3650 9.7E+01 1.0E+02 1.0E+02 9.8E+01 
7300 1.1E+02 1.2E+02 1.2E+02 1.1E+02 
18250 1.6E+02 1.7E+02 1.6E+02 1.7E+02 
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 Figure 9.7. Minimum Detectable Committed Effective Doses for 241Am Based on Detection 
of 0.8 dpm/d 241Am in Feces 
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 Table 9.14. Minimum Detectable Committed Bone Surface Dose Equivalents (rem) for 241Am Based on 
Detection of 0.8 dpm/d 241Am in Feces 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 8.7E+00 2.8E-05 2.9E-02 1.6E-02 
2 1.4E+01 4.8E-05 2.5E-02 1.4E-02 
5 4.7E+01 7.4E-04 1.4E-01 1.2E-01 
7 7.3E+01 5.3E-03 5.1E-01 6.4E-01 
14 1.2E+02 5.6E+00 2.7E+00 7.8E+00 
30 1.8E+02 1.7E+02 3.4E+00 1.0E+01 
60 2.7E+02 2.7E+02 5.1E+00 1.6E+01 
90 3.4E+02 3.3E+02 7.7E+00 2.2E+01 
180 4.7E+02 4.6E+02 2.5E+01 7.3E+01 
365 7.7E+02 7.4E+02 2.3E+02 4.4E+02 
730 1.4E+03 1.4E+03 1.3E+03 1.4E+03 
1825 2.1E+03 2.0E+03 2.0E+03 2.0E+03 
3650 2.1E+03 2.1E+03 2.2E+03 2.1E+03 
7300 2.5E+03 2.4E+03 2.5E+03 2.4E+03 
18250 3.5E+03 3.4E+03 3.5E+03 3.6E+03 
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 Figure 9.8. Minimum Detectable Committed Bone Surface Doses for 241Am 
Based on Detection of 0.8 dpm/d 241Am in Feces 
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 Table 9.15. Minimum Detectable Intakes and Committed Doses for Class W Inhalation of 241Am Based 
on Detection of 0.16 nCi 241Am by Chest Counting 
 
Minimum Detectable Values for 1-µm AMAD 
Particles 
Minimum Detectable Values for 5-µm 
AMAD Particles 
Days Post 
Intake 
Intake 
(nCi) 
Effective Dose 
(rem) 
Bone Surface 
Dose (rem) 
Intake 
(nCi) 
Effective Dose 
(rem) 
Bone Surface 
Dose (rem) 
0 4.8E-01 2.1E-01 4.4E+00 9.4E-01 4.3E-01 9.3E+00 
1 7.6E-01 3.3E-01 6.9E+00 2.1E+00 9.8E-01 2.1E+01 
2 8.9E-01 3.8E-01 8.0E+00 2.5E+00 1.2E+00 2.5E+01 
5 1.1E+00 4.6E-01 9.6E+00 3.1E+00 1.4E+00 3.1E+01 
7 1.1E+00 4.9E-01 1.0E+01 3.3E+00 1.5E+00 3.2E+01 
14 1.2E+00 5.3E-01 1.1E+01 3.6E+00 1.7E+00 3.6E+01 
30 1.6E+00 6.9E-01 1.4E+01 4.4E+00 2.0E+00 4.4E+01 
60 2.3E+00 9.8E-01 2.1E+01 6.4E+00 2.9E+00 6.3E+01 
90 3.3E+00 1.4E+00 3.0E+01 9.4E+00 4.3E+00 9.3E+01 
180 1.1E+01 4.6E+00 9.6E+01 3.0E+01 1.4E+01 3.0E+02 
365 1.1E+02 4.9E+01 1.0E+03 3.3E+02 1.5E+02 3.3E+03 
730 1.5E+04 6.3E+03 1.3E+05 4.1E+04 1.9E+04 4.1E+05 
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 Figure 9.9. Minimum Detectable Committed Doses for 241Am Based on  
Detection of 0.16 nCi 241Am in the Lung 
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9.4.3 Recommended Periodic Bioassay Monitoring Protocol 
 
Based on Tables 9.10 and 9.11, an annual urine-sampling program is 
recommended for monitoring intakes of pure 241Am.  Such a program is 
capable of demonstrating regulatory compliance with both stochastic and 
deterministic dose limits, but is not capable of demonstrating compliance 
with administrative control levels of 500-mrem committed effective dose 
equivalent or lower.  More frequent urinalysis can provide some 
improvement in sensitivity, but primary reliance must be placed on 
prompt detection of potential intakes by workplace indicators and special 
bioassay monitoring to provide low-level dosimetry. 
 
Annual chest counting is appropriate as an augmentation, particularly 
when 241Am is used as an indicator for plutonium. 
 
9.4.4 Special Monitoring for Suspected Intakes 
 
Special bioassay monitoring for suspected inhalation or ingestion intakes 
should include a chest count, urine sample, and at least one (preferably 
two or more) fecal samples.  If these measurements are obtained within 
the first 3 to 5 days, committed effective dose equivalents in the range of a 
few millirem can be detected. 
 
For potential wound intakes, special bioassay should consist of a wound 
count and a urine sample.  Fecal sampling is not necessary for wound 
dosimetry, however data on the fecal excretion following a wound can 
provide information that may be valuable for improving americium 
metabolic models. 
 
9.4.5 Bioassay Monitoring Capability for Workers with Known Americium Depositions 
 
The capability of a bioassay program is directly dependent upon the 
magnitude of an identifiable increase in a bioassay measurement.  When a 
worker has a detectable baseline bioassay level due to a previous intake, 
the ability to detect a subsequent increase in the bioassay level from an 
additional intake is more dependent on the variability of current bioassay 
levels and less dependent on analytical capability.  In other words, to be 
detected, subsequent intakes must result in increases in bioassay 
measurements that exceed the  baseline or background “noise” level.  
Guidance concerning the potential dose from potentially undetected 
intakes must be developed on a case-by-case basis.  Appropriate 
adjustments to measurement frequencies can then be determined based on 
the potential undetected dose.  As an approximate rule-of-thumb, a single 
bioassay measurement will probably have to be at least twice the baseline 
level to be readily recognized, due to the substantial variability in single 
bioassay measurements on individual people.  For many situations, this 
may imply that a normally detectable intake may not be detectable on top 
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of a pre-existing internal plutonium deposition.  Like most rules-of-
thumb, this is only a rough suggestion; cases of significance must be 
addressed individually. 
 
9.5 Assessment of Internal Dose 
 
Assessments of internal dose for americium rely on evaluations of intake 
or deposition.  Current practice for such evaluations is to perform an 
intake assessment.  Prior to 1988, the common Hanford approach was a 
deposition assessment based on urine data.  For significant cases, it may 
be possible to directly measure americium retention in the organ or tissue 
of interest using in vivo monitoring.  In such cases, individual-specific 
retention parameters are appropriate for dosimetry. 
 
9.5.1 Intake Assessment 
 
An americium intake can be estimated by fitting the bioassay data to the 
appropriate retention or excretion function, using manual or computerized 
techniques.  For a single data point, the intake can be estimated by 
dividing the measured excretion by the value of the retention function for 
the appropriate day after intake represented by the sample in a manner 
similar to Equation 2.5.  Values for the retention function can be obtained 
from those tabulated in this chapter, or directly from running the CINDY 
computer code.  For multiple data points, the CINDY code provides a 
choice of fitting routines, or a manually determined fit of the data to the 
expected function can be performed.  Once the intake is calculated, 
appropriate internal doses may be calculated by applying the dose 
coefficients of this chapter to Equations 2.10 or 2.11.  The CINDY 
computer code may also be used to directly calculate internal doses, and is 
particularly appropriate for complex cases. 
 
9.5.2 Deposition Assessment 
 
Deposition assessment involves determining the amount of material 
deposited in a body or tissue compartment of interest.  Whereas the term 
“intake” includes all material taken into the body regardless of its 
subsequent fate, “deposition” is a more limited quantity that excludes 
material not retained (e.g., material that is immediately exhaled) and 
material not systemically absorbed (e.g., material cleared to the GI tract 
and excreted in feces without absorption).  The HIDP coined the term 
“presystemic deposition” in the mid-1980s to precisely define what was 
being evaluated and avoid terms that had developed generic, ill-defined, 
or varied meanings (e.g., deposition, uptake, burden).  In addition, the 
term “deposition” was gaining preference in the field of internal 
dosimetry as a process term associated with the respiratory tract, rather 
than a retained quantity.  The HIDP defined presystemic deposition as the 
total radioactivity that will ultimately translocate into the transfer 
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compartment from a metabolically isolated pool; in other words, the 
activity ultimately reaching the blood.  Historically at Hanford, this was 
the quantity compared with the MPBB of 0.05 µCi (241Am) as listed in 
ICRP 2 (1959).  It is related to, but significantly different from intake, 
lung deposition, long-term lung burden, and instantaneous body burden 
(or retained quantity). 
 
Activity is deposited in presystemic compartments at the time of intake.  
From there, systemic uptake may be essentially instantaneous or it may 
occur gradually over an extended period of time.  Transfer from the 
presystemic compartment into systemic circulation is assumed to be 
governed by linear first-order kinetics, and can be described in terms of a 
transfer rate constant.  A urine excretion function such as described in 
Section 9.2.4 is typically used to estimate the presystemic deposition. 
 
9.5.3 Assessing Organ and Effective Dose Equivalents 
 
The organs of primary interest for americium dose evaluations are the 
bone surface, red marrow, liver, and gonads.  The lung is also an organ of 
general interest for inhalations, even though its contribution to effective 
dose for class W intakes is relatively insignificant.  Other organs or tissues 
may be of interest depending on the nature of an intake.  For example, the 
dose to a specific lymph node or small volume of tissue as the result of a 
wound intake of slowly transportable materials may be of academic 
interest, but is not a regulatory concern.  Such cases can be dealt with as 
they arise and are beyond the general scope of this technical basis. 
 
Once the magnitude of an intake, presystemic deposition, or initial lung 
deposition has been determined, organ dose equivalents and the effective 
dose equivalent can be assessed using hand-calculation techniques or 
computer codes.  The HIDP uses the CINDY computer code to aid in dose 
calculations.  More detailed explanations and copies of the code are 
maintained in the Hanford Radiation Protection Historical Files.  The 
tabulated dose coefficients of Section 9.3 are useful for hand calculations. 
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9.6 Management of Internal Contamination Cases 
 
This section discusses the diagnostic procedures, therapeutic actions, and 
long-term monitoring of internal depositions. 
 
9.6.1 Diagnostic Procedures 
 
The diagnosis of an intake involves a combination of workplace 
monitoring to identify on-the-job potential intakes and bioassay 
measurements to confirm and quantify internal contamination. 
 
The primary method of identifying potential intakes is by workplace 
monitoring, such as personal contamination surveys, nasal smear analyses, 
air sample results, or workers’ identifications of unusual conditions.  
These techniques provide qualitative screening to alert radiation 
protection staff about potential internal exposure, rather than absolute 
confirmation that exposure has or has not occurred.  For example, activity 
detected on nasal smears is usually an indication of an inhalation intake; 
however, the absence of activity does not necessarily mean that an intake 
did not occur.  The absence of nasal smear activity following an inhalation 
intake can be explained by a sufficient delay between the time of intake 
and the collection of nasal smears to allow for complete clearance of 
activity from the nares.  The ICRP 30 (1979) respiratory tract model 
indicates that a delay of as little as 30 to 60 minutes may be adequate for 
this in some cases.  Alternatively, some individuals are mouth-breathers, 
whose noses are partially or completely bypassed in the respiratory 
process, hence no activity may be deposited in the nares, despite the 
occurrence of an inhalation intake.  Particle size can also significantly 
affect nasal deposition and clearance. 
 
Once a worker has been identified as having incurred a potential intake, 
the initial diagnostic measurements are arranged.  These may include a 
chest count, wound count, single voiding (spot) urine sample analysis, 
first-day fecal sampling, and overnight urine sampling.  The purpose of 
these initial procedures is to provide an order-of-magnitude estimate of 
the potential internal exposure and dose.  Initial diagnostic measurements 
are usually sufficient for final evaluations only when all results 
collectively rule out the possibility of an intake.  In reality, initial 
measurements are not generally expected to do this, and follow-up 
measurements are necessary. 
 
Follow-up diagnostic measurements may include additional urine and 
fecal samples, chest counts, liver counts, head counts, and lymph node 
counts.  These analyses aid in determining the magnitude, location, and 
retention characteristics of the deposited material.  In some cases, blood 
samples or tissue specimens may also be appropriate.  In addition, 
workplace or clothing contamination analyses, air sample analyses, 
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particle size analyses, and/or solubility analyses may be performed to 
more clearly define the physical and radiological characteristics of the 
material to which the worker was exposed. 
 
It is the responsibility of the exposure evaluator, working closely with 
contractor radiation protection staff, to determine the appropriate 
diagnostic protocols.  Scheduling of follow-up measurements will 
normally be done by the appropriate contractor radiation protection staff. 
9.6.2 Therapeutic Actions 
 
Therapeutic actions for potential internal contamination include the use of 
decorporation agents, catharsis, and surgical excision.  For the purposes of 
this discussion, the normal skin decontamination procedures of Hanford 
contractors are not considered therapeutic actions, although it is 
acknowledged that these procedures can be quite effective in preventing 
the intake of radioactivity.  The decision to undertake one or more of 
these therapeutic actions is the responsibility of the participating HEHF 
Occupational Medicine care provider with the concurrence of the patient.  
The exposure evaluator will provide advice and consultation to the 
physician and patient regarding the potential dose implications and 
efficacy of alternative actions.  Guidance for the methods of therapy can 
be found in NCRP Report No. 65 (1980) and in the “Guidebook for the 
Treatment of Accidental Internal Radionuclid Contamination of Workers” 
(Bhattacharyya et al. 1992).  Guidance for circumstances under which 
therapy may be warranted is contained in PNL-MA-552, but was 
established as a good practice based on experience rather than a detailed 
technical analysis. 
 
Decorporation therapy is also referred to as chelation therapy, and 
involves the chemical removal of radioactivity from the bloodstream 
through drug administration.  The drug diethylenetriaminepenta-acetic 
acid (DTPA) has U.S. Food and Drug Administration approval as an 
investigational new drug for use in removing americium.  Under the 
investigational new drug category, the patient must provide informed 
consent to HEHF before the drug may be administered.  Decorporation 
therapy significantly enhances urinary excretion of americium, a point 
that must be considered when interpreting urine samples affected by 
therapy.  ICRP 78 (1997) suggests that urinary excretion may be increased 
by as much as a factor of 50. 
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Following the 1976 americium column explosion at the 242-Z facility, the 
most exposed worker received extensive therapy using DTPA 
(Breitenstein 1983; Robinson et al. 1983).  This therapy is generally 
recognized as having been life-saving, owing to the dose to the liver that 
was averted by the DTPA.  Without the DTPA therapy it is generally 
considered that doses would have been sufficiently high as to ultimately 
result in liver failure.  There was no evidence of liver disorder either 
during or following the DTPA therapy. 
 
Catharsis involves accelerating the passage of material through the GI 
tract by means of laxative drugs or physical means such as an enema.  
Catharsis has potential value in reducing the adsorption of material into 
the bloodstream from the GI tract and in reducing the dose to the GI tract 
organs from material passing through the GI tract.  These measures are 
not generally considered for occupational exposures to americium, 
because the GI tract adsorption of americium is slight, and the dose to the 
GI tract organs is an insignificant fraction of the total effective dose. 
 
Surgical excision following wounds can be extremely effective in 
reducing the potential uptake, particularly when coupled with 
decorporation therapy.  Minor excisions are usually performed at the 
Emergency Decontamination Facility (EDF) by HEHF Occupational 
Medicine staff, assisted by a PNNL exposure evaluation and radiation 
protection personnel. 
 
9.6.3 Long-Term Monitoring of Internal Depositions 
 
Once an internal dosimetry evaluation has been completed, it may be 
recommended that the worker be placed on a specialized long-term 
bioassay monitoring schedule.  The reasons for this are twofold:  first, 
long-term follow-up monitoring results that are consistent with the 
projected results verify the conclusions of the evaluation.  Second, if long-
term results are projected to be detectable, and the worker returns to 
americium work, then the capability of a routine bioassay monitoring 
program to detect an additional intake may be affected.  This issue must 
be addressed on an individual-specific basis. 
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10.0 Other Transuranic Elements 
 
 
This chapter provides technical information on the transuranic 
elements (other than plutonium and americium) that have been 
identified as warranting Hanford technical basis analysis.  Initially, 
neptunium is the only element so identified.  As other elements are 
identified, this chapter will be expanded with subsections devoted to 
each element.  Dosimetry methods used are based on the concepts of 
ICRP 30 (1979), ICRP 48 (1986) and ICRP 67 (1993), as 
implemented using the CINDY computer code (Strenge et al. 1992). 
 
10.1 Neptunium 
 
Neptunium has posed very limited internal dosimetry issues at 
Hanford, due in large part to its very low specific activity relative to 
plutonium.  The slight mass impurities of plutonium typically found 
with neptunium usually are much more dosimetrically significant 
because of their much higher specific activity.  The following 
discussions lead to adoption of an internal dosimetry program for 
neptunium based on ICRP 30 and ICRP 48 concepts.  Compared 
with more recent ICRP publications discussed below, this is a 
program likely to be conservative by a factor of 10 to 100.  However, 
the CINDY code cannot accommodate the newer ICRP models.  The 
lack of significant neptunium exposure at Hanford and the 
conservativeness of the ICRP 30 and 48 models suggest that 
additional Hanford resources need not be allocated to neptunium 
internal dosimetry at this time. 
 
10.1.1 Sources and Characteristics 
 
Neptunium at Hanford might be found at the Redox Plant (202-S), 
233-S, the PUREX Plant (202-A), chemistry labs, or as a trace 
contaminant in waste products or fuel.  The only isotope likely to be 
of significant dosimetric concern as a result of current Hanford 
activities is 237Np. 
 
Radiological decay data for 237Np are shown in Table 10.1.  The data 
were taken directly from, or calculated based on information 
contained in ICRP 38 (1983). 
 
10.1.2 Biokinetic Behavior 
 
This section discusses the inhalation transportability class, internal 
distribution and retention, and the urinary and fecal excretion of 
neptunium. 
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Table 10.1.  Radiological Decay Data for Neptunium 
 
Physical Half-Life Decay Constant 
Specific 
Activity 
Isotope 
Principal Decay 
Mode, 
Energy and Yield Years Days Year-1 Day-1 Ci/g 
237Np 
Alpha 
4.772 MeV, 25% 
4.789 MeV, 47.1% 
Gamma 
86.5 keV, 12.6% 
2.14E+06 7.81E+08 3.24E-07 8.87E-10 7.02E-04
 
Transportability Class 
 
All compounds of neptunium are assigned transportability class W 
by ICRP 48 (1986).  The new respiratory tract model of ICRP 66 
(1994) assigned absorption type M to all forms of neptunium (ICRP 
68 [1994], ICRP 78 [1997]). 
 
Gastrointestinal Uptake to Blood (f1 Factor) 
 
The fractional uptake to blood from the gastrointestinal (GI) tract is 
assumed to be 5Η10-4, as recommended in ICRP publications 67 and 
78.  This value was reduced from the 10-3 value used in earlier ICRP 
publications based on human studies published by Popplewell, 
Harrison, and Ham (1991) and discussed in ICRP 67.  The 5Η10-4 
value applies to both inhalation and ingestion intakes. 
 
Distribution and Retention in Systemic Organs and Tissues 
 
The choice of models for use by the HIDP is constrained somewhat 
by the tools routinely used by the program.  For internal dose 
calculations, the main computer code used by the HIDP is the 
CINDY computer code (Strenge et al. 1992), which uses basic 
ICRP 30 and 48 format models (simple first-order kinetics) for 
defining metabolically significant organs and tissues but allows 
adjustment of the organ partitioning and clearance half-times for 
those organs and tissues.  CINDY does not accommodate the 
addition of new organs and tissues or alternate model forms, such as 
the recycling models used in more recent ICRP publications (e.g., 
ICRP 67). 
 
The basic ICRP 30 Part 4 (1988) model (based on data presented in 
ICRP 48) is used by Hanford for distribution and retention of 
neptunium in the body, and is described as follows.  For dissolved 
(ionic form) neptunium reaching the transfer compartment (i.e., the 
blood stream), this ICRP model distributes 75% to the bone with a 
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clearance half-time of 50 years, and 15% to the liver with a clearance 
half-time of 20 years.  The activity deposited in bone is assumed to 
be deposited uniformly over bone surfaces of both cortical and 
trabecular bone, where it remains until decayed or excreted.  A small 
fraction is permanently retained in the gonads (0.035% for testes and 
0.011% for ovaries).  The remaining 10% is assumed to go directly 
to excretion or short-term holdup in other body tissues. 
 
A departure from the simple first-order kinetics form of modeling 
(sum of single exponentials) to a recycling form of model occurred 
with ICRP 56 (1989), which was further refined in ICRP 67.  Some 
significant changes with regard to neptunium biokinetics also 
occurred with those model shifts.  The skeleton uptake was changed 
from the 75% in ICRP 48 to 50% in ICRP 56, and then to 45% in 
ICRP 67.  The liver uptake fraction was reduced from 15% in 
ICRP 48 to 10% in both ICRP 56 and 67.  The concept of retention 
half-time is somewhat lost with recycling models, however, an 
“externally viewed” or apparent half-time can be stated for some 
applications.  ICRP 56 suggested such a liver half-time of about 3 to 
15 years, which was reinforced in ICRP 67.  This liver half-time is 
much faster than plutonium, and somewhat faster than americium.  
The long apparent skeleton half-time of ICRP 48 did not appear to be 
significantly reduced.  ICRP 56 and 67 also attributed small uptake 
fractions to long-term retention in soft tissues (2% with a 100-year 
half-time), with a total of another 3 to 5% having short-term soft 
tissue retention.  As much as 30 to 35% of the neptunium in 
circulation in the blood may go to direct urinary excretion.  These 
modeling changes, combined with the new tissue weighting factors 
of ICRP 60 (1990), resulted in a much lower effective dose 
coefficient than the one derived using the ICRP 30 and ICRP 48 
models.  These newer recycling models and the associated lower 
dose coefficients are not being adopted by the HIDP at this time due 
to the lack of a routine dosimetry code to implement them, the 
relative insignificance of neptunium to Hanford dosimetry with the 
older, more conservative models, and the mandatory tissue weighting 
factors of 10 CFR 835. 
 
Urinary and Fecal Excretion of Neptunium 
 
Actual data for neptunium excretion are limited and there is 
substantial variation in models.  Neither ICRP 30 Part 4, ICRP 48, 
nor ICRP 54 directly addressed urinary or fecal excretion of 
neptunium.  Lessard et al. (1987) used a fractional split of 0.5 to 
urine and 0.5 to feces for excretion and calculated urine and fecal 
excretion fractions based on ICRP 30 Part 2 (1981).  The CINDY 
computer code incorporates a general ICRP 30 model for excretion,  
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based on the initial fraction going directly to excretion and the long-
term clearance from liver and skeleton going directly to excretion 
with a user-established ratio for the urine-to-fecal paths.  In ICRP 78, 
urine and fecal excretion fractions were tabulated based on the 
ICRP 67 recycling model.  Injection (instant uptake) and ingestion 
fractions were tabulated only for the first 10 days post intake.  
Fractions for 5-µm-AMAD particle inhalation of Type M 237Np 
compounds were tabulated out to 365 days post intake.  The ICRP 67 
model has a much larger fraction (32%) going directly to urine 
excretion from the blood, with fecal excretion representing only a 
few percent.  These models give substantially different results. 
 
Based on the ICRP 67 discussion of urinary excretion, the HIDP 
has adopted a 90% urinary excretion pathway for excretion of 
metabolized neptunium, and incorporates this into a CINDY 
computer code urine-to-fecal split of 90:10.  This modeling results in 
a substantial underestimate of urine excretion fractions compared 
with values tabulated in ICRP 67.  The application of these fractions 
to actual bioassay data would result in substantially higher estimates 
of intake compared with the use of ICRP 67.  The CINDY model 
used by Hanford is considered adequate for basic program design 
and interpretation of early data.  Caution in its application to actual 
intakes is advised because of the relatively large discrepancy 
between the various models and the lack of human data to support 
them. 
 
10.1.3 Internal Dosimetry Factors 
 
This section contains factors that are useful in making internal 
dosimetry calculations.  The factors included in this section are 
derived from the CINDY computer code and incorporate the models 
and assumptions described in the preceding sections.  Their 
application is intended for those circumstances where such 
assumptions are appropriate or more specific information is lacking.  
Variation from these factors is appropriate if sufficient data are 
available. 
 
Intake Retention and Excretion Fractions 
 
The intake retention (or excretion) fraction expresses the fraction of 
intake retained in a particular compartment or excreted by a 
particular pathway (urine or feces) at a given time post intake.  
Although excretion implies elimination rather than retention, 
conventional models include excretion compartments under the 
general term retention and use the term “intake retention fraction” 
(IRF) to describe both.  IRFs for various times post intake are 
tabulated as described below for 237Np. 
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Lung retention fractions for the class W inhalations of 1-µm- and 
5-µm-AMAD particles of 237Np are tabulated in Table 10.2 and 
plotted in Figure 10.1.  Urine excretion fractions for an instantaneous 
uptake, acute inhalations, and acute ingestions of 237Np are shown in 
Table 10.3 and plotted in Figure 10.2.  Corresponding values for 
fecal excretion are shown in Table 10.4 and plotted in Figure 10.3.  
Values for days other than those tabulated here can be obtained by 
interpolation between the tabulated data, or by obtaining the values 
directly from CINDY. 
 
Dose Coefficients 
 
Dose coefficients, expressed as committed dose equivalent per unit 
activity of intake (rem per nanocurie of acute intake), are a conven-
ient shortcut to estimating doses based on standard assumptions 
when the magnitude of an intake is known or assumed.  Acute intake 
dose coefficients have been tabulated for instantaneous uptake, class 
W inhalation (for both 1-µm- and 5-µm-AMAD particle sizes), and 
ingestion.  The dose coefficients shown in Table 10.5 were derived 
by the CINDY computer code using the previously described 
models. 
 
Comparison of Published Dosimetry Factors 
 
A comparison of 237Np dosimetry factors, including dose coeffici-
ents, annual limits on intake (ALIs), and derived air concentrations 
(DACs) published in several sources is shown in Table 10.6.  For 
Hanford applications, the DAC values of 10 CFR 835 Appendix A 
are typically used to control facility operations.  As noted in the 
previous discussion on neptunium biokinetics, the dose coefficients 
used by Hanford are approximately an order of magnitude more 
conservative than the recent recommendations of the ICRP (1993; 
1994b; 1997), due primarily to the significant impact of changing 
from the ICRP 48 metabolic model to that of ICRP 67. 
 
10.1.4 Derived Reference Levels 
 
Derived screening, investigation, and regulatory compliance levels 
(based on committed effective dose equivalents of 10-mrem, 
100-mrem, and committed bone surface dose equivalent of 
50,000 mrem, respectively) have been calculated for 1-µm and 5-µm 
class W inhalations of pure 237Np.  The urine excretion levels are 
shown in Table 10.7 and chest count levels are shown in Table 10.8.  
These levels are sufficiently low that, from a practical standpoint, 
any detected result is likely to result in investigation and dose 
assessment. 
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Table 10.2.  Lung Retention Fractions for Class W Inhalation of 237Np 
 
Days Post Intake 1-µm AMAD 5-µm AMAD
0 3.3E-01 1.7E-01 
1 2.1E-01 7.5E-02 
2 1.8E-01 6.3E-02 
5 1.5E-01 5.1E-02 
7 1.4E-01 4.9E-02 
14 1.3E-01 4.4E-02 
30 1.0E-01 3.6E-02 
60 7.0E-02 2.5E-02 
90 4.8E-02 1.7E-02 
180 1.5E-02 5.3E-03 
365 1.4E-03 4.8E-04 
730 1.1E-05 3.9E-06 
1825 NA NA 
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Figure 10.1.  237Np Lung Retention 
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Table 10.3.  Urine Excretion Fractions for 237Np Intakes 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 1.6E-02 1.6E-05 1.2E-03 1.9E-03 
2 1.0E-03 1.0E-06 1.2E-04 1.4E-04 
5 3.9E-05 1.9E-08 4.8E-05 2.0E-05 
7 3.8E-05 1.9E-08 4.7E-05 2.0E-05 
14 3.8E-05 1.9E-08 4.4E-05 1.9E-05 
30 3.8E-05 1.9E-08 3.8E-05 1.7E-05 
60 3.8E-05 1.9E-08 3.0E-05 1.4E-05 
90 3.8E-05 1.9E-08 2.3E-05 1.1E-05 
180 3.8E-05 1.9E-08 1.1E-05 7.4E-06 
365 3.8E-05 1.9E-08 5.3E-06 5.2E-06 
730 3.7E-05 1.8E-08 4.5E-06 4.9E-06 
1825 3.5E-05 1.7E-08 4.2E-06 4.6E-06 
3650 3.1E-05 1.6E-08 3.8E-06 4.1E-06 
7300 2.6E-05 1.3E-08 3.1E-06 3.4E-06 
18250 1.5E-05 7.5E-09 1.8E-06 2.0E-06 
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Figure 10.2.  237Np Urine Excretion Fractions 
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Table 10.4.  Fecal Excretion Fractions for 237Np Intakes 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 1.8E-03 4.7E-01 1.1E-01 2.2E-01 
2 1.2E-04 2.8E-01 1.3E-01 2.6E-01 
5 4.3E-06 1.8E-02 2.3E-02 3.1E-02 
7 4.3E-06 2.5E-03 6.3E-03 5.6E-03 
14 4.3E-06 2.3E-06 1.2E-03 4.3E-04 
30 4.3E-06 2.1E-09 9.4E-04 3.3E-04 
60 4.3E-06 2.1E-09 6.2E-04 2.2E-04 
90 4.3E-06 2.1E-09 4.1E-04 1.5E-04 
180 4.2E-06 2.1E-09 1.2E-04 4.2E-05 
365 4.2E-06 2.1E-09 9.6E-06 3.8E-06 
730 4.1E-06 2.0E-09 5.5E-07 5.6E-07 
1825 3.9E-06 1.9E-09 4.6E-07 5.1E-07 
3650 3.5E-06 1.7E-09 4.2E-07 4.6E-07 
7300 2.9E-06 1.4E-09 3.5E-07 3.8E-07 
18250 1.7E-06 8.4E-10 2.0E-07 2.2E-07 
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Figure 10.3.  237Np Fecal Excretion Fractions 
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Table 10.5.  Committed Dose Coefficients for Acute Intakes of 237Np (rem/nCi) 
 
Class W Inhalation 
Organ or Tissue 
Instantaneous
Uptake 
Ingestion 
f1=5E-04 1-µm 5-µm 
Effective 4.5E+00 2.3E-03 5.5E-01 6.0E-01 
Bone Surface 1.0E+02 5.1E-02 1.2E+01 1.3E+01 
Red Marrow 8.1E+00 4.1E-03 9.7E-01 1.1E+00 
Liver 3.6E+00 1.8E-03 4.3E-01 4.8E-01 
Lung 5.7E-04 2.8E-07 5.9E-02 2.1E-02 
Gonads 9.2E-01 4.6E-04 1.1E-01 1.2E-01 
 
Table 10.6.  Comparison of Dosimetric Factors for 237Np 
 
Reference Source 
Class W 
Inhalation 
1-µm AMAD 
Class W 
Inhalation 
5-µm AMAD Soluble Ingestion 
Dose Coefficients 
CINDY (hE,50) 0.55 rem/nCi 
1.5E-04 Sv/Bq 
0.60 rem/nCi 
1.6E-04 Sv/Bq 
0.0023 rem/nCi 
6.2E-07Sv/Bq 
ICRP-30 Part 4 (hE,50) 1.3E-04 Sv/Bq NA 1.1E-06 Sv/Bq 
EPA Federal Guidance 
Report No.11 (hE,50) 
1.46E-04 Sv/Bq  
(0.54 rem/nCi) 
NA 1.20E-06 Sv/Bq 
(4.44E-03 rem/nCi 
ICRP-68 [e(50)] 2.1E-05 Sv/Bq 
(0.078 rem/nCi) 
1.5E-05 Sv/Bq 
(0.056 rem/nCi) 
1.1E-07 Sv/Bq 
(4.1E-04 rem/nCi) 
Bone Surface DAC 
10 CFR 835, App. A 2E-12 µCi/ml and 
9E-02 Bq/m3
NA NA 
EPA Federal Guidance 
Report No. 11 
2E-12 µCi/ml and 
6E-08 MBq/m3
NA NA 
ICRP-30 Part 4 6E-02 Bq/ m3 NA NA 
Annual Limit on Intake, ALI (Bone Surface) 
Calculated from  
10 CFR 835 DAC  
4.8E-03 µCi and  
216 Bq 
NA NA 
ICRP-30, ICRP-54 2E+02 Bq NA 2E+04 Bq 
EPA Federal Guidance 
Report No. 11 
2.0E-04 MBq and  
0.004 µCi 
NA 0.02 MBq and  
0.5 µCi 
NA = not applicable 
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 Table 10.7. 237Np Urine Excretion Reference Levels and Derived Reference Levels for 
Class W Inhalation 
 
10-mrem HE,50  
Screening Level 
100-mrem HE,50 
Investigation Level 
50-rem Bone Surface 
Dose Limit  
Compliance Level 
1-µm 5-µm 1-µm 5-µm 1-µm 5-µm Inhalation 
Intake (nCi): 1.8E-02 1.7E-02 1.8E-01 1.7E-01 4.2E+00 3.8E+00 
 
Derived Screening 
Level 
(dpm/d) 
Derived Investigation 
Level 
(dpm/d) 
Derived Compliance 
Level 
(dpm/d) 
Days Post 
Intake 1-µm 5-µm 1-µm 5-µm 1-µm 5-µm 
1 4.8E-02 7.0E-02 4.8E-01 7.0E-01 1.1E+01 1.6E+01 
2 4.8E-03 5.2E-03 4.8E-02 5.2E-02 1.1E+00 1.2E+00 
5 1.9E-03 7.4E-04 1.9E-02 7.4E-03 4.4E-01 1.7E-01 
7 1.9E-03 7.4E-04 1.9E-02 7.4E-03 4.3E-01 1.7E-01 
14 1.8E-03 7.0E-04 1.8E-02 7.0E-03 4.1E-01 1.6E-01 
30 1.5E-03 6.3E-04 1.5E-02 6.3E-03 3.5E-01 1.5E-01 
60 1.2E-03 5.2E-04 1.2E-02 5.2E-03 2.8E-01 1.2E-01 
90 9.3E-04 4.1E-04 9.3E-03 4.1E-03 2.1E-01 9.4E-02 
180 4.4E-04 2.7E-04 4.4E-03 2.7E-03 1.0E-01 6.3E-02 
365 2.1E-04 1.9E-04 2.1E-03 1.9E-03 4.9E-02 4.4E-02 
730 1.8E-04 1.8E-04 1.8E-03 1.8E-03 4.2E-02 4.2E-02 
1825 1.7E-04 1.7E-04 1.7E-03 1.7E-03 3.9E-02 3.9E-02 
3650 1.5E-04 1.5E-04 1.5E-03 1.5E-03 3.5E-02 3.5E-02 
7300 1.3E-04 1.3E-04 1.3E-03 1.3E-03 2.9E-02 2.9E-02 
18250 7.3E-05 7.4E-05 7.3E-04 7.4E-04 1.7E-02 1.7E-02 
 
10.1.5  Bioassay for 237Np 
 
This section discusses the general techniques and applicability of 
bioassay monitoring and describes the capabilities of excreta sample 
bioassay and in vivo measurements.  General recommendations are 
also provided for routine bioassay monitoring for 237Np.  Because 
237Np is rarely found as a truly pure isotope, but usually has trace 
amounts of plutonium in it, the recommended bioassay program 
includes a discussion of the impact of these trace amounts with 
regard to bioassay. 
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Table 10.8.  237Np Chest Count Reference Levels and Derived Reference Levels for Class W Inhalation 
 
10-mrem HE,50  
Screening Level 
100-mrem HE,50 
Investigation Level 
50-rem Bone Surface 
Dose Limit  
Compliance Level 
1-µm 5-µm 1-µm 5-µm 1-µm 5-µm Inhalation 
Intake (nCi): 1.8E-02 1.7E-02 1.8E-01 1.7E-01 4.2E+00 3.8E+00 
 
Derived Screening 
Level 
(nCi) 
Derived Investigation 
Level 
(nCi) 
Derived Compliance 
Level 
(nCi) 
Days Post 
Intake 1-µm 5-µm 1-µm 5-µm 1-µm 5-µm 
0 6.0E-03 2.8E-03 6.0E-02 2.8E-02 1.4E+00 6.5E-01 
1 3.8E-03 1.3E-03 3.8E-02 1.3E-02 8.8E-01 2.9E-01 
2 3.3E-03 1.1E-03 3.3E-02 1.1E-02 7.5E-01 2.4E-01 
5 2.7E-03 8.5E-04 2.7E-02 8.5E-03 6.3E-01 2.0E-01 
7 2.5E-03 8.2E-04 2.5E-02 8.2E-03 5.8E-01 1.9E-01 
14 2.4E-03 7.3E-04 2.4E-02 7.3E-03 5.4E-01 1.7E-01 
30 1.8E-03 6.0E-04 1.8E-02 6.0E-03 4.2E-01 1.4E-01 
60 1.3E-03 4.2E-04 1.3E-02 4.2E-03 2.9E-01 9.6E-02 
90 8.7E-04 2.8E-04 8.7E-03 2.8E-03 2.0E-01 6.5E-02 
180 2.7E-04 8.8E-05 2.7E-03 8.8E-04 6.3E-02 2.0E-02 
365 2.5E-05 8.0E-06 2.5E-04 8.0E-05 5.8E-03 1.8E-03 
730 2.0E-07 6.5E-08 2.0E-06 6.5E-07 4.6E-05 1.5E-05 
 
Excreta Bioassay Techniques for 237Np 
 
The typical urine sampling practice is to collect a urine sample over 
a specified time interval and perform a chemical separation using an 
added tracer to determine the chemical yield of the process.  This 
technique is followed by electroplating and quantitative alpha 
spectrometry.  Fecal sample analysis follows a process similar to 
urine sample analysis. 
 
Less sensitive, rapid analytical procedures are available for special 
circumstances.  These procedures can be executed and results 
obtained in substantially shorter times than the routine procedure, but 
they are less sensitive.  Their use is primarily for diagnostic bioassay 
of suspected internal contamination related to unplanned exposures 
(incidents).  The decision to use such procedures involves consider-
ing the probability and potential magnitude of the exposure. 
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The contractual detection limits for 237Np in urine or feces can be 
found in the radiochemistry bioassay laboratory statement of work  
(available from the HIDP) and in the Hanford Internal Dosimetry 
Project Manual (PNL-MA-552).(a)
 
The minimum detectable intakes based on a 0.02 dpm/d urinalysis 
sensitivity are shown in Table 10.9.  The committed effective and 
bone surface dose equivalents associated with those intakes are 
shown in Tables 10.10 and 10.11, respectively, and Figures 10.4 and 
10.5 show graphical presentations of the minimum detectable doses.  
Corresponding data based on a 0.1-dpm/d fecal analysis sensitivity, 
are shown in Tables 10.12 through 10.14 and plotted in Figures 10.6 
and 10.7. 
 
 Table 10.9. Minimum Detectable Intakes (nCi) for 237Np Based on 
Detection of 0.02 dpm/d 237Np in Urine 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 5.6E-04 5.6E-01 7.5E-03 4.7E-03 
2 9.0E-03 9.0E+00 7.5E-02 6.4E-02 
5 2.3E-01 4.7E+02 1.9E-01 4.5E-01 
7 2.4E-01 4.7E+02 1.9E-01 4.5E-01 
14 2.4E-01 4.7E+02 2.0E-01 4.7E-01 
30 2.4E-01 4.7E+02 2.4E-01 5.3E-01 
60 2.4E-01 4.7E+02 3.0E-01 6.4E-01 
90 2.4E-01 4.7E+02 3.9E-01 8.2E-01 
180 2.4E-01 4.7E+02 8.2E-01 1.2E+00 
365 2.4E-01 4.7E+02 1.7E+00 1.7E+00 
730 2.4E-01 5.0E+02 2.0E+00 1.8E+00 
1825 2.6E-01 5.3E+02 2.1E+00 2.0E+00 
3650 2.9E-01 5.6E+02 2.4E+00 2.2E+00 
7300 3.5E-01 6.9E+02 2.9E+00 2.6E+00 
18250 6.0E-01 1.2E+03 5.0E+00 4.5E+00 
                                                     
(a) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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 Table 10.10. Minimum Detectable Committed Effective Dose Equivalent (rem) for 237Np 
Based on Detection of 0.02 dpm/d 237Np in Urine 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 2.5E-03 1.3E-03 4.1E-03 2.8E-03 
2 4.1E-02 2.1E-02 4.1E-02 3.9E-02 
5 1.0E+00 1.1E+00 1.0E-01 2.7E-01 
7 1.1E+00 1.1E+00 1.1E-01 2.7E-01 
14 1.1E+00 1.1E+00 1.1E-01 2.8E-01 
30 1.1E+00 1.1E+00 1.3E-01 3.2E-01 
60 1.1E+00 1.1E+00 1.7E-01 3.9E-01 
90 1.1E+00 1.1E+00 2.2E-01 4.9E-01 
180 1.1E+00 1.1E+00 4.5E-01 7.3E-01 
365 1.1E+00 1.1E+00 9.3E-01 1.0E+00 
730 1.1E+00 1.2E+00 1.1E+00 1.1E+00 
1825 1.2E+00 1.2E+00 1.2E+00 1.2E+00 
3650 1.3E+00 1.3E+00 1.3E+00 1.3E+00 
7300 1.6E+00 1.6E+00 1.6E+00 1.6E+00 
18250 2.7E+00 2.8E+00 2.8E+00 2.7E+00 
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 Figure 10.4. Minimum Detectable Committed Effective Doses for 237Np Based on Detection of 
0.02 dpm/d in Urine 
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 Table 10.11. Minimum Detectable Committed Bone Surfaces Dose Equivalent (rem) for 
237Np Based on Detection of 0.02 dpm/d 237Np in Urine 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 5.6E-02 2.9E-02 9.0E-02 6.2E-02 
2 9.0E-01 4.6E-01 9.0E-01 8.4E-01 
5 2.3E+01 2.4E+01 2.3E+00 5.9E+00 
7 2.4E+01 2.4E+01 2.3E+00 5.9E+00 
14 2.4E+01 2.4E+01 2.5E+00 6.2E+00 
30 2.4E+01 2.4E+01 2.8E+00 6.9E+00 
60 2.4E+01 2.4E+01 3.6E+00 8.4E+00 
90 2.4E+01 2.4E+01 4.7E+00 1.1E+01 
180 2.4E+01 2.4E+01 9.8E+00 1.6E+01 
365 2.4E+01 2.4E+01 2.0E+01 2.3E+01 
730 2.4E+01 2.6E+01 2.4E+01 2.4E+01 
1825 2.6E+01 2.7E+01 2.6E+01 2.5E+01 
3650 2.9E+01 2.9E+01 2.8E+01 2.9E+01 
7300 3.5E+01 3.5E+01 3.5E+01 3.4E+01 
18250 6.0E+01 6.1E+01 6.0E+01 5.9E+01 
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 Figure 10.5. Minimum Detectable Committed Bone Surface Doses for 237Np Based on Detection of 
0.02 dpm/d in Urine 
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 Table 10.12. Minimum Detectable Intakes (nCi) for 237Np Based on Detection of 0.1 dpm/d 237Np 
in Feces 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 2.5E-02 9.6E-05 4.1E-04 2.0E-04 
2 3.8E-01 1.6E-04 3.5E-04 1.7E-04 
5 1.0E+01 2.5E-03 2.0E-03 1.5E-03 
7 1.0E+01 1.8E-02 7.2E-03 8.0E-03 
14 1.0E+01 2.0E+01 3.8E-02 1.0E-01 
30 1.0E+01 2.1E+04 4.9E-02 1.4E-01 
60 1.0E+01 2.1E+04 7.3E-02 2.0E-01 
90 1.0E+01 2.1E+04 1.1E-01 3.0E-01 
180 1.1E+01 2.1E+04 3.8E-01 1.1E+00 
365 1.1E+01 2.1E+04 4.7E+00 1.2E+01 
730 1.1E+01 2.3E+04 8.2E+01 8.0E+01 
1825 1.2E+01 2.4E+04 9.8E+01 8.8E+01 
3650 1.3E+01 2.6E+04 1.1E+02 9.8E+01 
7300 1.6E+01 3.2E+04 1.3E+02 1.2E+02 
18250 2.6E+01 5.4E+04 2.3E+02 2.0E+02 
 
In Vivo Bioassay Techniques for 237Np 
 
In vivo measurement of 237Np is not routinely performed at Hanford.  
It can be accomplished by measuring the low-energy x-rays from 
237Np, but is more effectively accomplished by measuring the 233Pa 
progeny of 237Np.  The gamma emissions from 233Pa (e.g., the 
312-keV photon having a 36% intensity) are a reasonable indicator 
for 237Np in secular equilibrium with 233Pa.  The equilibrium 
condition is reached in a few tens of days. 
 
Hanford does not have a ready calibration in place for these in vivo 
measurements, however, chest counting for 233Pa can be 
accomplished if it is required, with a MDA in the range of 0.25 nCi.  
Because routine in vivo measurements for this nuclide are not being 
performed and a formal MDA has not been established, a minimum 
detectable dose analysis is not provided. 
 
Recommended Periodic Bioassay Monitoring Protocol 
 
Based on Tables 10.11 and 10.12, an annual urine sampling program 
is recommended for monitoring intakes of pure 237Np.  Such a 
program is capable of demonstrating regulatory compliance with 
both stochastic and deterministic dose limits, but is not capable of  
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 Table 10.13. Minimum Detectable Committed Effective Dose Equivalent (rem) for 237Np 
Based on Detection of 0.1 dpm/d 237Np in Feces 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 1.1E-01 2.2E-07 2.3E-04 1.2E-04 
2 1.7E+00 3.7E-07 1.9E-04 1.0E-04 
5 4.7E+01 5.8E-06 1.1E-03 8.7E-04 
7 4.7E+01 4.1E-05 3.9E-03 4.8E-03 
14 4.7E+01 4.5E-02 2.1E-02 6.3E-02 
30 4.7E+01 4.9E+01 2.7E-02 8.2E-02 
60 4.7E+01 4.9E+01 4.0E-02 1.2E-01 
90 4.7E+01 4.9E+01 6.0E-02 1.8E-01 
180 4.8E+01 4.9E+01 2.1E-01 6.4E-01 
365 4.8E+01 4.9E+01 2.6E+00 7.1E+00 
730 4.9E+01 5.2E+01 4.5E+01 4.8E+01 
1825 5.2E+01 5.5E+01 5.4E+01 5.3E+01 
3650 5.8E+01 6.1E+01 5.9E+01 5.9E+01 
7300 7.0E+01 7.4E+01 7.1E+01 7.1E+01 
18250 1.2E+02 1.2E+02 1.2E+02 1.2E+02 
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 Figure 10.6. Minimum Detectable Committed Effective Doses for 237Np Based on Detection of 
0.1 dpm/d in Feces 
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 Table 10.14. Minimum Detectable Committed Bone Surface Dose Equivalents (rem) for 237Np 
Based on Detection of 0.1 dpm/d 237Np in Feces 
 
Class W Inhalation Days Post 
Intake 
Instant 
Uptake Ingestion 1-µm 5-µm 
1 2.5E+00 4.9E-06 4.9E-03 2.7E-03 
2 3.8E+01 8.2E-06 4.2E-03 2.3E-03 
5 1.0E+03 1.3E-04 2.4E-02 1.9E-02 
7 1.0E+03 9.2E-04 8.6E-02 1.0E-01 
14 1.0E+03 1.0E+00 4.5E-01 1.4E+00 
30 1.0E+03 1.0E+03 5.9E-01 1.8E+00 
60 1.0E+03 1.0E+03 8.7E-01 2.7E+00 
90 1.0E+03 1.0E+03 1.3E+00 3.9E+00 
180 1.1E+03 1.1E+03 4.5E+00 1.4E+01 
365 1.1E+03 1.1E+03 5.6E+01 1.5E+02 
730 1.1E+03 1.1E+03 9.8E+02 1.0E+03 
1825 1.2E+03 1.2E+03 1.2E+03 1.1E+03 
3650 1.3E+03 1.4E+03 1.3E+03 1.3E+03 
7300 1.6E+03 1.6E+03 1.5E+03 1.5E+03 
18250 2.6E+03 2.7E+03 2.7E+03 2.7E+03 
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 Figure 10.7. Minimum Detectable Committed Bone Surface Doses for 237Np Based on Detection 
of 0.1 dpm/d in Feces 
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demonstrating compliance with administrative control levels of 
500-mrem committed effective dose equivalent or lower.  More 
frequent urinalysis can provide some improvement in sensitivity, but 
primary reliance must be placed on prompt detection of potential 
intakes by workplace indicators and special bioassay monitoring to 
provide low-level dosimetry.  Uncertainties about the appropriate 
urine excretion function for 237Np suggest periodic monitoring 
should not cover periods longer than 1 year. 
 
Actual experience with 237Np facilities at Hanford and Savannah 
River has shown that very slight mass impurities of plutonium in a 
neptunium mixture can eliminate the need for neptunium bioassay.  
The plutonium impurities have a much higher specific activity than 
237Np, and although of little mass significance, they shift the activity 
ratio to that of a plutonium mixture (i.e., by mass the mixture is 
essentially all neptunium, by activity it is essentially all plutonium).  
Hanford practice (as recommended in the Hanford Internal 
Dosimetry Program Manual, PNL-MA-552, Section 5.4)(a) suggests 
that a radionuclide or mixture of nuclides contributing more than 
25% to the 100-mrem committed effective dose equivalent criterion 
for requiring bioassay monitoring should be considered for specific 
bioassay.  Radionuclides do not require specific bioassay if they are 
adequately monitored by indicator nuclides for a reference mixture.  
For 237Np historically found at Hanford, the trace mass of plutonium 
in the mixture resulted in a sufficiently high presence of plutonium 
radionuclides that for bioassay monitoring purposes, plutonium 
bioassay was sufficient.  Conceptually, this can be demonstrated by 
examining the activity and mass ratios for plutonium and 237Np 
resulting in 237Np contributing 25% of the total committed effective 
dose equivalent.  This analysis was performed using the dose 
coefficient for 237Np and several combinations of plutonium (from 
Chapter 8) and results are shown in Table 10.15.  From Table 10.15, 
the summary statements below can be concluded: 
 
• If the Pu alpha-to-237Np activity ratio exceeds 6:1 for 1-µm 
particles (15:1 for 5-µm particles), Np bioassay is not needed. 
 
• If the 237Np mass purity of the mixture exceeds 95% for 1-µm 
particles (90% for 5-µm particles), then Np bioassay should be 
considered.  Alternatively, if the plutonium mass impurity in the 
mixture exceeds 5% by weight for 1-µm particles (10% for 5-µm  
 
                                                     
(a) Pacific Northwest National Laboratory (PNNL).  Hanford Internal Dosimetry Project Manual.  
PNNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.html 
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particles), then Np bioassay is not likely to be needed.  Mixture 
activity or isotopic characterization should be performed at these 
levels to aid in the determination of need for bioassay. 
 
Special Monitoring for Suspected Intakes 
 
Special bioassay monitoring for suspected inhalation or ingestion 
intakes should include a prompt chest count, a urine sample, and at 
least one (preferably two or more) fecal samples.  If these measure-
ments are obtained within the first 3 to 5 days, committed effective 
dose equivalents in the range of a few millirem to tens of mrem 
should be detectable. 
 
 Table 10.15. Activity and Mass Ratios for Plutonium and 237Np Mixtures Resulting in 237Np 
Contributing 25% of the Total Committed Effective Dose Equivalent 
 
 
Pu:Np Alpha  
Activity Ratio Np:Pu Mass Ratio Np Component Wt%
Pu Component 1-µm 5-µm 1-µm 5-µm 1-µm 5-µm 
Class W 238Pu 4.1 4.2 5905 5819 99.98% 99.98% 
Class Y 238Pu 5.7 15.0 4281 1624 99.98% 99.94% 
Class W 239Pu(a) 3.8 3.8 24 24 95.93% 95.93% 
Class Y 239Pu(a) 5.3 13.8 17 6 94.32% 86.47% 
Class W 20-yr Weapons Grade 3.5 3.8 39 36 97.48% 97.31% 
Class Y 20-yr Weapons Grade 4.7 12.9 29 11 96.64% 91.34% 
Class W 20-yr Fuel Grade 3.3 3.4 7 7 87.14% 86.82% 
Class Y 20-yr Fuel Grade 4.7 12.0 5 2 82.59% 65.08% 
(a) For pure 239Pu only.  The presence of 240Pu will increase the mass numbers by approximately 
10-20% 
 
For potential wound intakes, special bioassay should consist of a 
wound count and a urine sample.  Fecal sampling is not necessary for 
wound dosimetry; however, data on the fecal excretion following a 
wound can provide information which may be valuable to improving 
metabolic models. 
 
10.1.6 Assessment of Internal Dose 
 
Assessments of internal dose for neptunium rely on evaluations of 
intake based on urine, fecal, or in vivo data.  For significant cases, it 
may be possible to directly measure neptunium retention in the organ 
or tissue of interest using in vivo monitoring.  In such cases, 
individual-specific retention parameters are appropriate for 
dosimetry. 
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Intake Assessment 
 
An intake can be estimated by fitting the bioassay data to the 
appropriate retention or excretion function, using manual or compu-
terized techniques.  For a single data point, the intake can be 
estimated by dividing the measured excretion by the value of the 
retention function for the appropriate day after intake represented by 
the sample in a manner similar to Equation 2.5.  Values for the 
retention function can be obtained from those tabulated in this 
chapter, or directly from running the CINDY computer code.  For 
multiple data points, the CINDY computer code provides a choice of 
fitting routines, or a manually determined fit of the data to the 
expected function can be performed.  Once the intake is calculated, 
appropriate internal doses may be calculated by applying the dose 
coefficients of this chapter to Equations 2.10 or 2.11.  The CINDY 
computer code may also be used to directly calculate internal doses 
and is particularly appropriate for complex cases. 
 
Assessing Organ and Effective Dose Equivalents 
 
The organs of primary interest for 237Np dose evaluations are the 
bone surface, red marrow, liver, and gonads.  The lung is also an 
organ of general interest for inhalations, even though its contribution 
to effective dose for class W intakes is relatively insignificant.  Other 
organs or tissues may be of interest depending on the nature of an 
intake.  For example, the dose to a specific lymph node or small 
volume of tissue may be of academic interest as the result of a 
wound intake of slowly transportable materials, even though doses to 
such tissues are not of regulatory concern.  Such cases can be dealt 
with as they arise and are beyond the general scope of this technical 
basis. 
 
Once the magnitude of an intake has been determined, organ dose 
equivalents and the effective dose equivalent can be assessed using 
hand-calculation techniques or computer codes.  The HIDP uses the 
CINDY computer codes to aid in dose calculations.  More detailed 
explanations and copies of the codes are maintained in the Hanford 
Radiation Protection Historical Files.  The tabulated dose coefficients 
of Table 10.5 are useful for hand calculations. 
 
10.1.7 Management of Internal Contamination Cases 
 
This section discusses the diagnostic procedures, therapeutic actions, 
and long-term monitoring of internal depositions. 
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Diagnostic Procedures 
 
The diagnosis of an intake involves a combination of workplace 
monitoring to identify on-the-job potential intakes and bioassay 
measurements to confirm and quantify internal contamination. 
 
The primary method of identifying potential intakes is by workplace 
monitoring, such as personal contamination surveys, nasal smear 
analyses, air sample results, or workers' identifications of unusual 
conditions.  These techniques provide qualitative screening to alert 
radiation protection staff to potential internal exposure, rather than 
absolute confirmation that exposure has or has not occurred.  For 
example, activity detected on nasal smears is usually an indication of 
an inhalation intake; however, the absence of activity does not 
necessarily mean that an intake did not occur.  The absence of nasal 
smear activity following an inhalation intake can be explained by a 
sufficient delay between the time of intake and the collection of nasal 
smears to allow for complete clearance of activity from the nares.  
The ICRP 30 (1979) respiratory tract model indicates that a delay of 
as little as 30 to 60 minutes may be adequate for this in some cases.  
Alternatively, some individuals are mouth-breathers, whose noses are 
partially or completely bypassed in the respiratory process, hence no 
activity may be deposited in the nares, despite the occurrence of an 
inhalation intake.  Particle size can also significantly affect nasal 
deposition and clearance. 
 
Once a worker has been identified as having incurred a potential 
intake, the initial diagnostic measurements are arranged.  These may 
include a chest count, wound count, single voiding (spot) urine 
sample analysis, first-day fecal sampling, and overnight urine 
sampling.  The purpose of these initial procedures is to provide an 
order-of-magnitude estimate of the potential internal exposure and 
dose.  Initial diagnostic measurements are usually sufficient for final 
evaluations only when all results collectively rule out the possibility 
of an intake.  In reality, initial measurements are not generally 
expected to do this, and follow-up measurements are necessary.  
Follow-up diagnostic measurements may include additional urine 
and fecal samples, chest counts, liver counts, head counts, and lymph 
node counts.  These analyses aid in determining the magnitude, 
location, and retention characteristics of the deposited material.  In 
some cases, blood samples or tissue specimens may also be appro-
priate.  In addition, workplace or clothing contamination analyses, 
air sample analyses, particle size analyses, and/or solubility analyses 
may also be performed to more clearly define the physical and 
radiological characteristics of the material to which the worker was 
exposed. 
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It is the responsibility of the exposure evaluator, working closely 
with contractor radiation protection staff, to determine the 
appropriate diagnostic protocols.  Scheduling of follow-up 
measurements will normally be done by the appropriate contractor 
radiation protection staff. 
 
Therapeutic Actions 
 
Therapeutic actions for potential internal contamination include the 
use of decorporation agents, catharsis, and surgical excision.  For the 
purposes of this discussion, the normal skin decontamination 
procedures of Hanford contractors are not considered therapeutic 
actions, although it is acknowledged that these procedures can be 
quite effective in preventing the intake of radioactivity.  The decision 
to undertake one or more of these therapeutic actions is the respon-
sibility of the participating HEHF Occupational Medicine care 
provider with the concurrence of the patient.  The exposure evaluator 
will provide advice and consultation to the physician and patient 
regarding the potential dose implications and efficacy of alternative 
actions.  Guidance for the methods of therapy can be found in NCRP 
Report 65 (1980) and in the “Guidebook for the Treatment of 
Accidental Internal Radionuclide Contamination of Workers” 
(Bhattacharyya et al. 1992).  Guidance for circumstances under 
which therapy may be warranted is contained in PNL-MA-552, but 
was established as a good practice based on experience rather than a 
detailed technical analysis. 
 
Decorporation therapy is also referred to as chelation therapy, and 
involves the chemical removal of radioactivity from the bloodstream 
through drug administration.  Both the “Guidebook for the Treatment 
of Accidental Internal Radionuclide Contamination of Workers” and 
NCRP 65 identify DTPA as the principal therapeutic agent, however 
NCRP 65 cautions that it might not be effective.  The drug DTPA has 
U.S. Food and Drug Administration approval as an investigational 
new drug for removal of actinides.  The investigational new drug 
status of DTPA requires that it can only be administered by an 
authorized user (e.g., HEHF) and that the patient must provide 
informed consent prior to its administration.  Decorporation therapy 
may significantly enhance urinary excretion of neptunium, a point 
that must be considered when interpreting urine samples affected by 
therapy.  Human data for chelation enhancement factors for 
neptunium are not available, however, the caution regarding its 
effectiveness suggests that a factor somewhat less than the 50 used 
for americium would be appropriate. 
 
Catharsis involves accelerating the passage of material through the 
GI tract by means of laxative drugs or physical means such as an 
enema.  Catharsis has potential value in reducing the adsorption of 
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material into the bloodstream from the GI tract and in reducing the 
dose to the GI tract organs from material passing through the GI 
tract.  These measures are not generally considered for occupational 
exposures to neptunium, because the GI tract adsorption of neptun-
ium is slight, and the dose to the GI tract organs is an insignificant 
fraction of the total effective dose. 
 
Surgical excision following wounds can be extremely effective in 
reducing the potential internal deposition, particularly when coupled 
with decorporation therapy.  Minor excisions are usually performed 
at the Emergency Decontamination Facility by HEHF Occupational 
Medicine staff, assisted by a PNNL exposure evaluator and radiation 
protection personnel. 
 
Long-Term Monitoring of Internal Depositions 
 
Once an internal dosimetry evaluation has been completed, it may be 
recommended that the worker be placed on a specialized long-term 
bioassay monitoring schedule.  The reasons for this are twofold:  
first, long-term follow-up monitoring results that are consistent with 
the projected results verify the conclusions of the evaluation.  
Second, if long-term results are projected to be detectable, and the 
worker returns to neptunium work, then the capability of a routine 
bioassay monitoring program to detect an additional intake may be 
affected.  This issue must be addressed on an individual-specific 
basis. 
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11.0 Cobalt-60 and Corrosion Products 
 
 
This chapter provides background on the sources, characteristics, and 
biokinetic behavior of 60Co and other corrosion product radionu-
clides and summarizes the technical basis used for their internal 
dosimetry at Hanford. 
 
11.1 Sources and Characteristics of Corrosion Product Radionuclides 
 
Corrosion product radionuclides are created by neutron activation of 
reactor components such as piping or fuel element cladding.  The 
principal sources of corrosion product radionuclides at Hanford are 
the old reactor facilities, such as N Reactor (operated until 1986); 
however, FFTF can also be a source.  In addition, corrosion products 
can be found in workers who have had intakes at other nuclear 
facilities, notably nuclear power plants or naval shipyards servicing 
nuclear-powered vessels.  Corrosion product radionuclides are 
generally high-energy gamma-emitters; therefore, bioassay 
monitoring can be readily accomplished by whole body counting.  
Historically, fresh corrosion product radionuclides, regardless of 
origin, were usually a mixture of several radionuclides.  The 
predominant radionuclide was usually 60Co, with 58Co, 54Mn, and 
59Fe as the other significant constituents in a fresh mixture.  Other 
radionuclides were often present in trace amounts, but they were 
generally of little dosimetric consequence.  The relative abundance 
of the radionuclides varied from facility to facility.  However, given 
the time elapsed since operation of the reactors at Hanford, the short-
lived corrosion products have decayed away, leaving 60Co as the 
nuclide of concern.  Radiological decay data for the common 
corrosion products are shown in Table 11.1. 
 
Table 11.1.  Radiological Data for Common Corrosion Products 
 
Isotope Half-Life Decay Constant Specific Activity (Ci/g) 
60Co 5.27 y 1.31E-01 y-1 1.13E+03 
58Co 70.8 d 9.79E-03 d-1 3.17E+04 
54Mn 313 d 2.21E-03 d-1 7.69E+03 
59Fe 44.5 d 1.56E-02 d-1 4.95E+04 
 
A detailed characterization of these corrosion products during 
N Reactor operations was performed by Weetman and DeHaven 
(1982a; 1982b).  This work indicated that airborne particulates 
containing corrosion product radionuclides could be characterized by 
a lognormal distribution with an AMAD ranging from 0.5 mm to 
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2.5 mm.  Unless specific information is available, the assumption of a 
1-mm-AMAD particulate is recommended for evaluations of internal 
exposure.  This recommendation runs counter to the 5-mm-AMAD 
particle size used elsewhere in this manual. 
 
For mixtures containing corrosion product radionuclides, the 
pulmonary retention of the individual radionuclides is probably 
influenced by the contaminant carrier matrix; thus, pulmonary 
retention for all of the radionuclides within a single carrier matrix 
may be similar.  Oxides characteristically represent the least 
transportable form of an element in the lung.  For purposes of a 
priori calculations of expected dose from intake, the transportability 
class for the oxide form of the radionuclide is assumed.  Neverthe-
less, retrospective assessment of internal dose following an intake 
should be based on actual observed retention in the lung. 
 
11.2 Biokinetic Behavior of Corrosion Product Radionuclides 
 
The biokinetic behavior of corrosion product radionuclides in the 
body is influenced by the physical and chemical properties of the 
host matrix, as well as the individual elements composing the matrix.  
Thus, the actual behavior of the material following intake is 
dependent on numerous complex and competing factors.  Although 
there have been numerous historical cases involving inhalation 
intakes of corrosion products at Hanford, the intakes involved have 
been too small to enable the specific radionuclide versus host matrix 
characteristics to be accurately described.  The approach taken here 
regarding assumptions for distribution and retention of corrosion 
product radionuclides is to assume that the radionuclide behaves 
according to the most insoluble form established for the element in 
ICRP 30 (1979) unless sufficient in vivo data are available and the 
intake is of sufficient magnitude (e.g., potentially above 100 mrem) 
to warrant evaluation of individual-specific retention. 
 
11.2.1 Transportability Class 
 
ICRP 30 establishes default inhalation classes W and Y for cobalt, 
and classes D and W for both manganese and iron.  The CINDY 
computer code (Strenge et al. 1992) implements the biokinetic 
models described in ICRP 30 and is used to assess expected bioassay 
compartment quantities following intakes of the corrosion products.  
The biokinetic parameters of CINDY can also be modified to 
provide a better agreement between observed and expected bioassay 
compartment values. 
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The new ICRP 66 lung model (ICRP 1994a) introduced the concept 
of lung absorption type as a replacement for the ICRP 30 inhalation 
class.  Table 11.2 shows both the ICRP 30 inhalation class and the 
absorption type tabulated in ICRP publications 68 and 78 (ICRP 
1994b; 1997). 
 
Table 11.2.  Lung Absorption and GI Uptake Factors for Corrosion Product Elements 
 
Isotope Chemical Form 
Inhalation 
Class(a) 
Lung Absorption 
Type (b) GI Uptake, f1 (b) 
Oxides, hydroxides, 
halides, nitrates, Y S 0.05 Co 
All other compounds W M 0.1 
Oxides, hydroxides, 
halides, nitrates, W M 0.1 Mn 
All other compounds D F 0.1 
Oxides, hydroxides, 
halides W M 0.1 Fe 
All other compounds D F 0.1 
(a) Based on ICRP 30. 
(b) Based on ICRP 68 and 78. 
 
Because corrosion products are typically oxides, the oxide form of 
these elements is assumed for Hanford internal dosimetry unless 
other information is available.  Consequently, the default inhalation 
classes for Hanford intakes of corrosion products are class Y for 
cobalt and W for manganese and iron. 
 
11.2.2 Gastrointestinal Uptake to Blood (f1 Factor) 
 
The gastrointestinal uptake (f1) factors for the corrosion products 
discussed in this section are shown in Table 11.2.  No changes were 
made in the uptake factors between ICRP publication 30 and 
publications 67 (1993) and 78 for insoluble forms.  The uptake factor 
for moderately insoluble forms of cobalt increased from 0.05 to 0.1.  
The extent of absorption of iron by the GI tract depends on a number 
of factors, including the amount of iron in the diet, its chemical form, 
the body’s iron needs, and the presence of interfering substances in 
the diet. 
 
11.2.3 Biokinetic Models 
 
Cobalt 
 
The ICRP 30 Part 1 (1979) model for cobalt is used by the HIDP.  
This model was also used in ICRP publication 78.  Of the cobalt 
entering the blood stream, half (0.5) is excreted directly with a 
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half-time of 0.5 days, with the remaining half (0.5) distributed in the 
body.  Of the amount distributed in the body, 10% is assumed to go 
to the liver and the remaining 90% is distributed throughout the rest 
of the body.  The material deposited in body organs (other than lung) 
is removed from the organs at several rates.  In the absence of reten-
tion data on a case-specific basis, the ICRP recommends that the 
following retention half-lives be applied to the material in the liver 
and rest of body: 
 
Fraction Retained Biological Half-Life, Days 
0.6 6 
0.2 60 
0.2 800 
 
Because the retention characteristics are considered to be the same 
for the liver as for the rest of the body, the relative distribution can be 
assumed to be constant at 10% in the liver and 90% in all other body 
tissues (except lung).  Excretion from the systemic compartment is 
assumed to be fractionated to urine (0.7) and feces (0.3), as assumed 
by ICRP publication 54 (1988). 
 
Manganese 
The HIDP uses the ICRP 30 Part 1 (1979) model for manganese 
entering the blood stream.  It assumes distribution among bone 
surfaces, liver compartments, and all other soft tissue compartments 
as follows: 
 
Compartment Fraction Retained Biological Half-Life, Days 
Bone Surfaces 0.35 40 
Liver 1 0.10 4 
Liver 2 0.15 40 
Soft Tissue 1 0.2 4 
Soft Tissue 2 0.2 40 
 
ICRP publication 54 noted that there were no reliable data on 
systemic excretion of manganese, thus it is assumed that systemic 
excretion is evenly split between urine and feces. 
 
Iron 
 
The ICRP 30 Part 2 (1980) model for iron entering the blood stream, 
distributes it according to the following fractionation: 
 
Tissue Fraction Biological Half-Life, Days 
Liver 0.08 2,000 
Spleen 0.013 2,000 
Rest of Body 0.907 2,000 
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Regardless of the site of deposition, iron is assumed to have a 
biological half-life of 2000 days, so the above organ distribution can 
be assumed to remain fixed following intake.  ICRP has not provided 
any recommended fractionation for the systemic excretion of iron, 
thus it is assumed that systemic excretion is evenly split between 
urine and feces. 
 
11.3 Internal Dosimetry Factors for Corrosion Products 
 
This section contains factors that are useful in making internal 
dosimetry calculations.  The factors included in this section are 
derived from the CINDY computer code and incorporate the models 
and assumptions of the preceding sections.  Their application is 
intended for circumstances where such assumptions are appropriate 
or more specific information is lacking.  Variation from these factors 
is appropriate if sufficient data are available. 
 
11.3.1 Whole Body Retention for Corrosion Products 
 
The whole body retention fractions for ingestion and inhalation of 
oxides of 60Co, 54Mn, and 59Fe are shown in Table 11.3, 11.4, and 
11.5, respectively.  The fractions are based on inhalation of 1-mm- 
and 5-mm-AMAD particle sizes for class Y 60Co, class W 54Mn, and 
class W 59Fe.  Two particle sizes are addressed because the 1-mm 
particle size is the Hanford default value (based on Hanford facility 
air sample data discussed previously), and the 5-mm particle size is 
now recommended by the ICRP.  Excretion fractions have not been 
provided because whole body counting data are typically used for 
these nuclides and retention can be directly determined.  Retention or 
excretion fractions for other forms of these radionuclides can be 
calculated using the CINDY code. 
 
11.3.2 Dose Coefficients 
 
Dose coefficients, expressed as committed dose equivalent per unit 
activity of intake (e.g., rem/nCi), are a convenient shortcut to 
estimating doses based on standard assumptions when the magnitude 
of an intake is known.  Acute intake dose coefficients have been 
tabulated for selected exposure scenarios.  The scenarios include the 
inhalation of 1-mm- and 5-mm-AMAD particles as the Hanford 
default and ICRP 66 default particle sizes, respectively, and 
ingestion.  Chemical forms tabulated are the oxide forms, considered 
the most likely to be encountered.  For all of these scenario condi-
tions the most limiting dose coefficients are for the committed 
effective dose equivalent.  Those dose coefficients are listed in 
Table 11.6. 
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Table 11.3.  Whole Body Retention for 60Co 
 
Days Post 
Intake 
Inhalation 
1-mm-AMAD 
Class Y 
Inhalation 
5-mm-AMAD 
Class Y 
Ingestion 
f1=0.05 
0 6.3E-01 9.1E-01 1.0E+00 
1 5.8E-01 8.0E-01 7.1E-01 
2 4.2E-01 5.0E-01 3.3E-01 
5 1.9E-01 1.1E-01 3.6E-02 
7 1.7E-01 7.6E-02 1.9E-02 
14 1.5E-01 6.5E-02 1.3E-02 
30 1.5E-01 6.0E-02 8.9E-03 
60 1.4E-01 5.6E-02 7.1E-03 
90 1.4E-01 5.3E-02 6.2E-03 
180 1.2E-01 4.6E-02 4.6E-03 
365 9.4E-02 3.6E-02 3.3E-03 
730 5.9E-02 2.2E-02 2.0E-03 
1825 1.6E-02 6.2E-03 5.3E-04 
3600 3.0E-03 1.1E-03 6.1E-05 
7300 3.1E-04 1.1E-04 6.5E-07 
18250 5.3E-06 1.9E-06 1.2E-12 
 
Table 11.4.  Whole Body Retention for 54Mn 
 
Days Post 
Intake 
Inhalation 
1-mm-AMAD 
Class W 
Inhalation 
5-mm-AMAD 
Class W 
Ingestion 
f1=0.1 
0 6.3E-01 9.1E-01 1.0E+00 
1 5.9E-01 8.2E-01 7.3E-01 
2 4.6E-01 5.7E-01 3.8E-01 
5 2.6E-01 2.3E-01 9.4E-02 
7 2.3E-01 1.9E-01 7.3E-02 
14 1.9E-01 1.5E-01 5.7E-02 
30 1.5E-01 1.1E-01 3.9E-02 
60 9.8E-02 6.7E-02 2.2E-02 
90 6.3E-02 4.1E-02 1.2E-02 
180 1.7E-02 9.2E-03 2.1E-03 
365 1.2E-03 5.0E-04 5.6E-05 
730 5.1E-06 1.9E-06 4.5E-08 
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Table 11.5.  Whole Body Retention for 59Fe 
 
Days Post 
Intake 
Inhalation 
1-mm-AMAD 
Class W 
Inhalation 
5-mm-AMAD 
Class W 
Ingestion 
f1=0.1 
0 6.3E-01 9.1E-01 1.0E+00 
1 5.8E-01 8.2E-01 7.2E-01 
2 4.6E-01 5.7E-01 3.7E-01 
5 2.6E-01 2.5E-01 1.1E-01 
7 2.3E-01 2.2E-01 9.2E-02 
14 2.0E-01 1.9E-01 8.0E-02 
30 1.5E-01 1.4E-01 6.2E-02 
60 8.3E-02 8.7E-02 3.9E-02 
90 4.8E-02 5.3E-02 2.4E-02 
180 1.1E-02 1.2E-02 5.8E-03 
365 5.4E-04 6.6E-04 3.1E-04 
730 1.7E-06 2.1E-06 9.8E-07 
 
Table 11.6.  Dose Coefficients (he,50) for Corrosion Products (rem/nCi) 
 
Radionuclide 
Inhalation 
1-mm-AMAD 
Inhalation 
5-mm-AMAD Ingestion 
60Co 
2.0E-04 
(Class Y) 
7.9E-05 
(Class Y) 
1.0E-05 
(f1=0.05) 
54Mn 
6.0E-06 
(Class W) 
4.2E-06 
(Class W) 
2.1E-06 
(f1=0.1) 
59Fe 
1.2E-05 
(Class W) 
1.0E-05 
(Class W) 
5.9E-06 
(f1=0.1) 
 
Organs of significance (i.e., those contributing greater than 10% of 
the committed effective dose equivalent) can be determined from the 
CINDY code based on actual intake assessment data. 
 
11.3.3 Comparison of Published Dosimetry Factors 
 
A comparison of selected dosimetry factors for 60Co is shown in 
Table 11.7.  Similar comparisons with 54Mn and 59Fe have been 
omitted because of the lack of a Hanford source for these materials at 
this time.  Their potential interest is mainly of a historical nature. 
 
11.3.4 Derived Reference Levels 
 
Derived reporting, investigation, and dose limit compliance levels 
(based on committed effective dose equivalents of 10-mrem, 
100-mrem, and 5,000 mrem, respectively) have been calculated for  
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Table 11.7.  Comparison of Dosimetric Factors for 60Co 
 
Reference Source 
Class Y Inhalation 
1-mm-AMAD 
Class Y Inhalation 
5-mm-AMAD 
Soluble Ingestion 
(f1 = 0.05) 
Dose Coefficients 
CINDY [hE,50] 
2.0E-04 mrem/nCi 
5.4E-08 Sv/Bq 
7.9E-05 rem/nCi 
2.1E-08 Sv/Bq 
1.0E-05 rem/nCi 
2.7E-09 Sv/Bq 
ICRP 54 [hE,50] 
4.1E-08 Sv/Bq 
(1.5E-04 rem/nCi) NA NA 
EPA Federal Guidance 
Report No.11 [hE,50] 
5.91E-08 Sv/Bq 
(2.19E-04 rem/nCi) NA 
7.28E-09 Sv/Bq  
(2.69E-05 rem/nCi) 
ICRP 68 [e(50)] 
2.9E-08 Sv/Bq 
(1.1E-04 rem/nCi) 
Type S 
1.7E-08 Sv/Bq 
(6.3E-05 rem/nCi) 
Type S 
2.5E-09 Sv/Bq 
(9.3E-06 rem/nCi) 
Stochastic DAC 
10 CFR 835, App. A 
1E-08 mCi/ml and 
5E+02 Bq/m3 NA NA 
EPA Federal Guidance 
Report No. 11 
1E-08 mCi/ml and 
5E-04 MBq/m3 NA NA 
ICRP 30, ICRP 54 5E+02 Bq/ m3 NA NA 
Stochastic Annual Limit on Intake, ALI 
Calculated from 
10 CFR 835 DAC  
19 mCi and 
7.2E+05 Bq NA NA 
ICRP 30 1E+06 Bq NA 1E+06 Bq 
ICRP 54 1E+06 Bq NA NA 
EPA Federal Guidance 
Report No. 11 1 MBq and 30 mCi NA 7 MBq and 200 mCi 
NA = not applicable 
 
60Co oxides.  These levels are shown in Table 11.8 for 1-mm-AMAD 
class Y inhalation, Table 11.9 for 5-mm-AMAD class Y inhalation, 
and Table 11.10 for ingestion. 
 
11.4 Bioassay for Corrosion Products 
 
This section discusses the bioassay methods, capabilities, and 
protocols for corrosion products. 
 
11.4.1 Bioassay Methods and Capabilities 
 
In vivo and excreta measurements are the bioassay methods used in 
monitoring for corrosion product radionuclides.  All of the radio-
nuclides included in this section are gamma-emitters and can be 
measured directly using in vivo techniques.  Whole body counting, 
using either sodium-iodide or coaxial germanium detectors, is the in 
vivo technique typically applied for bioassay of these nuclides.   
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Table 11.8.  60Co Whole Body Reference Levels for 1-mm-AMAD Class Y Inhalation 
 
10-mrem HE,50 
Reporting Level 
100-mrem HE,50 
Investigation 
Level 
5-rem HE,50 
Compliance Level 
Inhalation Intake (nCi) 5.0E+01 5.0E+02 2.5E+04 
Days Post Intake 
Derived 
Reporting Level 
(nCi) 
Derived 
Investigation 
Level (nCi) 
Derived 
Compliance Level 
(nCi) 
0 3.2E+01 3.2E+02 1.6E+04 
1 2.9E+01 2.9E+02 1.5E+04 
2 2.1E+01 2.1E+02 1.1E+04 
5 9.5E+00 9.5E+01 4.8E+03 
7 8.5E+00 8.5E+01 4.3E+03 
14 7.5E+00 7.5E+01 3.8E+03 
30 7.5E+00 7.5E+01 3.8E+03 
60 7.0E+00 7.0E+01 3.5E+03 
90 7.0E+00 7.0E+01 3.5E+03 
180 6.0E+00 6.0E+01 3.0E+03 
365 4.7E+00 4.7E+01 2.4E+03 
730 3.0E+00 3.0E+01 1.5E+03 
1825 8.0E-01 8.0E+00 4.0E+02 
3650 1.5E-01 1.5E+00 7.5E+01 
7300 1.6E-02 1.6E-01 7.8E+00 
18250 2.7E-04 2.7E-03 1.3E-01 
 
Table 11.9.  60Co Whole Body Reference Levels for 5-mm-AMAD Class Y Inhalation 
 
10-mrem HE,50 
Reporting Level 
100-mrem HE,50 
Investigation 
Level 
5-rem HE,50 
Compliance Level 
Inhalation Intake (nCi) 1.3E+02 1.3E+03 6.3E+04 
Days Post Intake 
Derived 
Reporting Level 
(nCi) 
Derived 
Investigation 
Level (nCi) 
Derived 
Compliance Level 
(nCi) 
0 1.2E+02 1.2E+03 5.8E+04 
1 1.0E+02 1.0E+03 5.1E+04 
2 6.3E+01 6.3E+02 3.2E+04 
5 1.4E+01 1.4E+02 7.0E+03 
7 9.6E+00 9.6E+01 4.8E+03 
14 8.2E+00 8.2E+01 4.1E+03 
30 7.6E+00 7.6E+01 3.8E+03 
60 7.1E+00 7.1E+01 3.5E+03 
90 6.7E+00 6.7E+01 3.4E+03 
180 5.8E+00 5.8E+01 2.9E+03 
365 4.6E+00 4.6E+01 2.3E+03 
730 2.8E+00 2.8E+01 1.4E+03 
1825 7.8E-01 7.8E+00 3.9E+02 
3650 1.4E-01 1.4E+00 7.0E+01 
7300 1.4E-02 1.4E-01 7.0E+00 
18250 2.4E-04 2.4E-03 1.2E-01 
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Table 11.10.  60Co Whole Body Reference Levels for Ingestion (f1 = 0.05) 
 
10-mrem HE,50 
Reporting Level 
100-mrem HE,50 
Investigation 
Level 
5-rem HE,50 
Compliance Level 
Inhalation Intake (nCi) 1.0E+03 1.0E+04 5.0E+05 
Days Post Intake Whole Body IRF 
Derived 
Reporting Level 
(nCi) 
Derived 
Investigation 
Level (nCi) 
Derived 
Compliance Level 
(nCi) 
0 1.0E+00 1.0E+03 1.0E+04 5.0E+05 
1 7.1E-01 7.1E+02 7.1E+03 3.6E+05 
2 3.3E-01 3.3E+02 3.3E+03 1.7E+05 
5 3.6E-02 3.6E+01 3.6E+02 1.8E+04 
7 1.9E-02 1.9E+01 1.9E+02 9.5E+03 
14 1.3E-02 1.3E+01 1.3E+02 6.5E+03 
30 8.9E-03 8.9E+00 8.9E+01 4.5E+03 
60 7.1E-03 7.1E+00 7.1E+01 3.6E+03 
90 6.2E-03 6.2E+00 6.2E+01 3.1E+03 
180 4.6E-03 4.6E+00 4.6E+01 2.3E+03 
365 3.3E-03 3.3E+00 3.3E+01 1.7E+03 
730 2.0E-03 2.0E+00 2.0E+01 1.0E+03 
1825 5.3E-04 5.3E-01 5.3E+00 2.7E+02 
3650 6.1E-05 6.1E-02 6.1E-01 3.1E+01 
7300 6.5E-07 6.5E-04 6.5E-03 3.3E-01 
18250 1.2E-12 1.2E-09 1.2E-08 6.0E-07 
 
Because the radionuclides are easily detectable using in vivo 
measurement, excreta measurements are not required in most intake 
situations, unless there is concern for other radionuclides such as 
strontium or plutonium, which are not readily measurable by in vivo 
techniques.  Measurement of radionuclides in early fecal excretion 
can be used as a means for establishing the relative radionuclide 
distribution in a corrosion product mixture; however, analysis of a 
nasal or appropriate surface contamination smear sample is preferred 
if the elements present may exhibit different absorption 
characteristics in the GI tract. 
 
Tables 11.11, 11.12, and 11.13 describe the nominal Hanford 
minimum detectable intakes and minimum detectable committed 
effective dose equivalents for class Y inhalations and ingestion of 
60Co.  The MDAs associated with the Hanford bioassay measure-
ments are below those routinely used at many nuclear power plant 
facilities.  Thus, it is possible that corrosion product activity detected 
by baseline Hanford measurements can be related to previously 
undetected intakes performed at facilities with less-sensitive MDAs. 
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Table 11.11.  60Co Minimum Detectable Intakes and Doses (HE,50) for 1-mm-AMAD Class Y Inhalation 
 
NaI System(a) Minimum  
Detectable 
Coax Ge System(b)  
Minimum Detectable 
Days Post Intake Intake (nCi) Dose (mrem)(c) Intake (nCi) Dose (mrem)(c) 
0 2.1 0.4 1.0 0.2 
1 2.2 0.4 1.0 0.2 
2 3.1 0.6 1.4 0.3 
5 6.8 1.4 3.2 0.6 
7 7.6 1.5 3.5 0.7 
14 8.7 1.7 4.0 0.8 
30 8.7 1.7 4.0 0.8 
60 9.3 1.9 4.3 0.9 
90 9.3 1.9 4.3 0.9 
180 11 2.2 5.0 1.0 
365 14 2.8 6.4 1.3 
730 22 4.4 10 2.0 
1825 81 16 37 7.5 
3600 430 87 200 40 
7300 4200 840 1900 390 
(a) Based on MDA of 1.3 nCi 
(b) Based on MDA of 0.6 nCi 
(c) Dose values less than 1 mrem are rounded to the nearest tenth. 
 
Table 11.12.  60Co Minimum Detectable Intakes and Doses (HE,50) for 5-mm-AMAD Class Y Inhalation 
 
NaI System(a) Minimum 
Detectable 
Coax Ge System(b) 
Minimum Detectable 
Days Post Intake Intake (nCi) Dose (mrem)(c) Intake (nCi) Dose (mrem)(c) 
0 1.4 0.1 0.7 0.1 
1 1.6 0.1 0.8 0.1 
2 2.6 0.2 1.2 0.1 
5 12 0.9 5.5 0.4 
7 17 1.4 7.9 0.6 
14 20 1.6 9.2 0.7 
30 22 1.7 10 0.8 
60 23 1.8 11 0.8 
90 25 1.9 11 0.9 
180 28 2.2 13 1.0 
365 36 2.9 17 1.3 
730 59 4.7 27 2.2 
1825 210 17 97 7.6 
3600 1200 93 550 43 
7300 12,000 930 5500 430 
(a) Based on MDA of 1.3 nCi 
(b) Based on MDA of 0.6 nCi 
(c) Dose values less than 1 mrem are rounded to the nearest tenth. 
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Table 11.13.  60Co Minimum Detectable Intakes and Doses (HE,50) for Ingestion(a) 
 
NaI System(b) Minimum  
Detectable 
Coax Ge System(c)  
Minimum Detectable 
Days Post Intake Intake (nCi) Dose (mrem)(d) Intake (nCi) Dose (mrem)(d) 
0 1.3 0.0 0.6 0.0 
1 1.8 0.0 0.8 0.0 
2 3.9 0.0 1.8 0.0 
5 36 0.4 17 0.2 
7 68 0.7 32 0.3 
14 100 1.0 46 0.5 
30 150 1.5 67 0.7 
60 180 1.8 85 0.8 
90 210 2.1 97 1.0 
180 280 2.8 130 1.3 
365 390 3.9 180 1.8 
730 650 6.5 300 3.0 
1825 2500 25 1100 11 
3600 21,000 210 9800 98 
(a) Based on f1 = 0.05. 
(b) Based on MDA of 1.3 nCi. 
(c) Based on MDA of 0.6 nCi. 
(d) Dose values less than 1 mrem are rounded to nearest tenth. 
 
11.4.2 Routine Bioassay Monitoring Protocol 
 
Routine monitoring for gamma-emitting corrosion products is best 
accomplished by periodic whole body counting.  With 60Co as the 
predominant corrosion product, Tables 11.8 through 11.10 show that 
minimum detectable doses of 10 mrem can be achieved with annual 
whole body counts having an MDA of 3 nCi.  Such an MDA is 
readily achievable with the Hanford preview counter—a standup NaI 
detector system.  Definitive measurements using the coaxial 
germanium detector system are preferred for identification and 
quantification of gamma-emitting nuclides due to the much higher 
resolution of that system and a lower MDA.  Consequently, initial 
detection of a gamma-emitter such as 60Co on the NaI system should 
be followed by a verification count on the coaxial germanium 
system, preferably immediately following the initial measurement, 
while the subject is still at the IVRRF. 
 
If, at very low indicated activities, a follow-up measurement is not 
obtained or a contractor wishes to waive the follow-up measurement, 
dose equivalents can be calculated based on the single initial count.  
Although the accuracy of a single count performed using the preview 
counter is somewhat less than that obtained using germanium 
detector systems, this higher uncertainty is not of much significance 
at low doses. 
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11.4.3 Special Monitoring for Suspected Intakes 
 
An in vivo examination should be performed following any indica-
tion of an intake of activated corrosion product radionuclides.  
However, unless the intake appears to be of such a magnitude that 
medical treatment to aid removal of the material from the body is 
considered, the exam may be scheduled as convenient, within several 
days of the intake without significant loss of sensitivity to intake 
detection.  All radionuclides potentially involved in the exposure 
should be considered during the follow-up investigation. 
 
The interpretation of in vivo measurements shortly after intake may 
be complicated by early transport of material through the lung and 
GI tract.  Measurements performed after about 5 days post intake are 
more appropriate for dose evaluation.  Long-term follow-up bioassay 
measurements should be considered to monitor internal radioactivity 
levels and establish individual-specific retention characteristics. 
 
11.5 Assessment of Internal Dose 
 
The assessment of internal dose equivalent from corrosion products 
is accomplished by evaluating in vivo measurement results.  Assess-
ments of internal dose equivalents for intakes of mixtures of 
corrosion product radionuclides must consider the contribution of all 
radionuclides present in the mixture.  The variability of the corrosion 
product mixtures and their change in composition with time due to 
radioactive decay precludes the establishment of a generic mixture. 
 
The committed effective dose equivalent is calculated for any intake 
confirmed by special bioassay measurements, and for periodic 
measurements that exceed the screening levels contained in the 
Hanford Internal Dosimetry Program Manual.(a)  Committed dose 
equivalents to specific organs and tissues are determined based on 
the criteria also presented in the Hanford Internal Dosimetry 
Program Manual.  Several methods exist to evaluate in vivo results 
in order to assess the internal dose equivalent.  The simplest method, 
and the one recommended for initial evaluation of in vivo results, as 
well as for final evaluations when doses are low, involves fitting the 
in vivo measurement data to the expected internal activity using the 
biokinetic model prescribed by the ICRP in publication 30.  This 
model is implemented using CINDY.  Assumptions that are used for 
this evaluation are 1) that the material is in its most insoluble form; 
2) that the intake date, if unknown, is assumed to be the midpoint of 
                                                     
(a) Pacific Northwest National Laboratory.  1999.  Hanford Internal Dosimetry Program Manual.  
PNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.htm 
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the period during which the intake could have occurred; and 3) that 
the intake consisted of inhalation of an aerosol with 1-mm-AMAD 
particles.  Data fitting is performed using CINDY.  Alternatively, a 
hand calculation can be performed using the factors tabulated in this 
chapter. 
 
If the intake could potentially result in a committed effective dose 
equivalent exceeding 100 mrem, then an investigation should be 
performed to determine the radionuclide composition of the involved 
corrosion product mixture and to assess the dose equivalent from all 
radionuclides present in the mixture.  Additional in vivo measure-
ments to confirm the assumed retention function, or to develop a 
case-specific retention function, should also be performed. 
 
Observed in vivo retention of corrosion product radionuclides should 
be used in place of the ICRP biokinetic model for evaluations of 
internal doses that potentially exceed 100 mrem or when sufficient in 
vivo data are available for such an analysis.  This can be accomplish-
ed by modifying distribution and retention parameters in CINDY to 
achieve better agreement between the model and the observed in 
vivo measurement data.  Modifications to default model parameters 
must be documented in the internal dose assessment report. 
 
11.6 Management of Internal Contamination Cases 
 
Historically, during reactor operations, activated corrosion product 
radionuclides were the most common type of internal exposure at 
Hanford.  However, exposures were minor and there is no known 
instance in which special therapeutic measures were applied for 
mitigative purposes.  Various options exist for treatment to remove 
corrosion product radionuclides from the body.  These generally 
involve measures to minimize absorption into the blood, including 
stomach lavage and administration of purgatives, emetics, or 
phytates.  Use of chelating agents may also be considered in signifi-
cant exposure cases.  A primary consideration for all mitigatory 
actions is prompt response because the effectiveness of treatment 
decreases rapidly with time post intake.  Occupational Medicine at 
HEHF should be notified immediately upon indication of a severe 
intake of corrosion product radionuclides. 
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12.0 Iodine 
 
 
Radioiodines generated or used at Hanford have included isotopes 
with half-lives ranging from minutes to millions of years in various 
physical and chemical forms.  With the time that has elapsed since 
operation of Hanford production reactors and the FFTF, the short-
lived radioiodines have all decayed away, leaving only 129I as a waste 
contaminant.  Laboratory use of short-lived radioiodines may still 
occur.  This chapter provides information on the sources, characteris-
tics, and biokinetics of radioiodine and summarizes the technical 
basis used for its internal dosimetry at Hanford. 
 
12.1 Sources and Characteristics of Radioiodine 
 
At Hanford the radioiodines of principal interest are 131I, associated 
with reactor operations, 129I, associated with waste management, and 
125I, associated with biological experimentation.  Radiological decay 
data for these nuclides are shown in Table 12.1. 
 
Table 12.1.  Radiological Data for Radioiodines 
 
Isotope Half-Life 
Decay 
Constant 
Specific 
Activity (Ci/g) 
131I 8.0 d 8.7E-02 d-1 1.24E+05 
129I 1.57E+07 y 4.4E-8 y-1 1.76E-04 
125I 60 d 1.2E-02 d-1 1.73E+04 
 
Historically, radioiodines were generated in large quantities during 
the operation of production and research reactors, however with 
those reactors either permanently shut down or in long-term standby, 
the only current source of onsite fission product radioiodine at 
Hanford is the Energy Northwest power reactor, Columbia 
Generating Station.  Iodine-131 is considered the most significant 
radioiodine from an internal exposure standpoint.  Several other 
radioactive isotopes of iodine are generated by the fission process; 
however, with the exception of the long-lived 129I, the others are 
short-lived and of potential interest only during or within several 
days of reactor operation.  Iodine-129 has, for practical purposes, an 
infinite half-life and is contained in irradiated fuel and associated 
separations and waste management facilities.  However, unless 
concentrated by some means such as in the PUREX air treatment 
system, it is present in negligibly small quantities. 
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The main source for 131I, which has been measured in Hanford 
workers in recent years, has been nonoccupational medical 
administrations for either diagnostic or therapeutic purposes.  
Patients receiving such administrations lose 131I by normal pathways 
including urine excretion and exhalation.  The magnitude of medical 
administrations can easily result in small quantities of 131I being 
absorbed by caregivers, family members, or those in close contact 
with patients, even after patients are released from a hospital. 
 
Iodine-125 is not generated at Hanford, but it is purchased for use in 
various biological research experiments.  Thus, its use is generally 
limited to biology laboratories operated by PNNL.  Quantities of the 
isotope in use at one time are generally limited to amounts that could 
not result in significant internal exposures. 
 
12.2 Biokinetic Behavior 
 
The distribution and retention models described in ICRP 30 (1979) 
and ICRP 54 (1988) are used by Hanford to predict the uptake, 
retention, and resulting doses following an intake of a radioiodine. 
 
12.2.1 Transportability Class 
 
In its publication 30, the ICRP assigned inhalation class D to all 
forms of iodine, and this category is used for Hanford dosimetry. 
 
A new respiratory tract model (ICRP 1994a) established lung 
absorption types as a replacement for the inhalation class of 
ICRP 30.  The more recent ICRP publications 68 (1994b) and 
78 (1997) assign absorption type F to all iodine compounds except 
elemental iodine vapor, which is assigned absorption class SR-1.  
The use of the SR-1 class would result in a 100% respiratory tract 
deposition and uptake of iodine from an inhalation intake instead of 
the 63% described by ICRP 30.  These more recent concepts are not 
adopted at this time, awaiting suitable analytical tools for Hanford 
data analysis. 
 
12.2.2 Gastrointestinal Uptake to Blood (f1 Factor) 
 
The gastrointestinal uptake (f1) factor for all forms of iodine is 1.0.  
This value is the same for ICRP 30 and 54 models, and the more 
recent ICRP 67 (1993), 68, and 78 models. 
 
12.2.3 Biokinetic Model 
 
The ICRP 30 and 54 metabolic model describes the deposition and 
retention of iodine in systemic compartments of the body and is 
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essentially the same model described by Riggs (1952).  Of the iodine 
entering the systemic compartment, a fraction, 0.3, is assumed to be 
translocated to the thyroid, while the remainder (0.7) is assumed to 
go directly to excretion.  Iodine in the thyroid is assumed to be 
retained with a biological half-life of 80 days and to be lost from the 
thyroid in the form of organic iodine.  Organic iodine is assumed to 
be uniformly distributed among all organs and tissues of the body 
other than the thyroid and to be retained there with a biological half-
life of 12 days.  One-tenth of this organic iodine is then assumed to 
go directly to fecal excretion and the rest is assumed to be returned to 
the transfer compartment as inorganic iodine.  This recycling to the 
transfer compartment gives an effective (i.e., apparent) half-life in 
the thyroid of 120 days.  The above model was implemented using 
the computer code CINDY (Strenge et al. 1992). 
 
For simplicity, ICRP 54 (1988) provides a thyroid retention function 
that effectively provides expected thyroid quantities following 
uptake, and that can be easily incorporated into hand calculations: 
 
120/t693.011/t693.024.0/t693.0
thyroid e31.0e018.0e33.0)t(R
--- ++=  (12.1) 
 
where t is in days post uptake. 
 
For class D material, translocation from the lung to the blood is rapid 
and the above equation will provide an accurate thyroid retention 
value for the model after several days following acute inhalation. 
 
12.3 Internal Dosimetry Factors for Radioiodines 
 
This section contains factors that are useful in making internal 
dosimetry calculations.  The factors are derived from the CINDY 
code and incorporate the models and assumptions of the preceding 
sections.  Their application is intended for circumstances where such 
assumptions are appropriate or more specific information is lacking.  
Variation from these factors is appropriate if sufficient data are 
available. 
 
12.3.1 Retention and Excretion of Radioiodine 
 
Retention and excretion fractions can be readily calculated using the 
CINDY code.  Factors for the total body, thyroid, and urine have 
been calculated based on ingestion and inhalation of 1-mm- and 
5-mm-AMAD particles.  These factors are shown in Table 12.2 for 
131I, Table 12.3 for 129I, and Table 12.4 for 125I.  Because the GI tract 
uptake factor is 1.0, the ingestion-based retention and excretion 
fractions can be used to approximate an injection (wound) intake. 
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Table 12.2.  Retention and Excretion for 131I 
 
 
Days Post 
Intake 
Inhalation 
1-mm-AMAD 
Class D 
Inhalation 
5-mm-AMAD 
Class D Ingestion f1=1 
Whole Body Retention 1 2.7E-01 3.2E-01 3.2E-01 
 2 1.9E-01 2.4E-01 2.6E-01 
 5 1.2E-01 1.8E-01 2.0E-01 
 7 1.0E-01 1.5E-01 1.7E-01 
 14 5.8E-02 8.3E-02 9.1E-02 
 30 1.4E-02 2.0E-02 2.2E-02 
 60 9.9E-04 1.4E-03 1.6E-03 
 90 6.8E-05 9.8E-05 1.1E-04 
 180 2.2E-08 3.1E-08 3.5E-08 
 365 3.2E-12 1.3E-12 3.2E-12 
Thyroid 1 1.3E-01 2.2E-01 2.6E-01 
 2 1.5E-01 2.2E-01 2.5E-01 
 5 1.2E-01 1.7E-01 1.9E-01 
 7 1.0E-01 1.4E-01 1.6E-01 
 14 5.3E-02 7.6E-02 8.4E-02 
 30 1.2E-02 1.8E-02 2.0E-02 
 60 8.5E-04 1.2E-03 1.3E-03 
 90 5.8E-05 8.4E-05 9.2E-05 
 180 1.9E-08 2.7E-08 3.0E-08 
 365 4.7E-12 1.1E-12 2.7E-12 
Urine 1 1.3E-01 1.3E-01 1.3E-01 
 2 3.2E-02 1.6E-02 7.4E-03 
 5 7.6E-04 4.3E-04 2.3E-04 
 7 2.1E-04 2.6E-04 2.7E-04 
 14 1.6E-04 2.3E-04 2.6E-04 
 30 6.0E-05 8.7E-05 9.6E-05 
 60 5.0E-06 7.2E-06 7.9E-06 
 90 3.5E-07 5.1E-07 5.6E-07 
 180 1.1E-10 1.6E-10 1.8E-10 
 365 1.7E-14 6.9E-15 1.7E-14 
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Table 12.3.  Retention and Excretion for 129I 
 
 
Days Post 
Intake 
Inhalation 
1-mm-AMAD 
Class D 
Inhalation 
5-mm-AMAD 
Class D Ingestion f1=1 
Whole Body Retention 1 3.0E-01 3.4E-01 3.5E-01 
 2 2.2E-01 2.9E-01 3.0E-01 
 5 1.9E-01 2.7E-01 3.0E-01 
 7 1.9E-01 2.7E-01 3.0E-01 
 14 1.8E-01 2.7E-01 2.9E-01 
 30 1.7E-01 2.5E-01 2.7E-01 
 60 1.5E-01 2.1E-01 2.3E-01 
 90 1.2E-01 1.8E-01 1.9E-01 
 180 7.1E-02 1.0E-01 1.1E-01 
 365 2.3E-02 3.3E-02 3.7E-02 
 730 2.5E-03 3.6E-03 4.0E-03 
Thyroid 1 1.4E-01 2.4E-01 2.8E-01 
 2 1.7E-01 2.6E-01 2.9E-01 
 5 1.8E-01 2.6E-01 2.9E-01 
 7 1.8E-01 2.6E-01 2.8E-01 
 14 1.7E-01 2.4E-01 2.7E-01 
 30 1.5E-01 2.2E-01 2.4E-01 
 60 1.3E-01 1.8E-01 2.0E-01 
 90 1.0E-01 1.5E-01 1.7E-01 
 180 6.2E-02 8.7E-02 9.6E-02 
 365 2.0E-02 2.8E-02 3.1E-02 
 730 2.1E-03 3.1E-03 3.4E-03 
Urine 1 1.3E-01 1.4E-01 1.4E-01 
 2 3.7E-02 1.9E-02 8.7E-03 
 5 1.1E-03 6.5E-04 3.5E-04 
 7 3.7E-04 4.6E-04 4.8E-04 
 14 5.1E-04 7.5E-04 8.3E-04 
 30 7.3E-04 1.1E-03 1.2E-03 
 60 7.4E-04 1.1E-03 1.2E-03 
 90 6.4E-04 9.2E-04 1.0E-03 
 180 3.7E-04 5.3E-04 5.9E-04 
 365 1.2E-04 1.7E-04 1.9E-04 
 730 1.3E-05 1.9E-05 2.1E-05 
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Table 12.4.  Retention and Excretion for 125I 
 
 
Days Post 
Intake 
Inhalation 
1-mm-AMAD 
Class D 
Inhalation 
5-mm-AMAD 
Class D Ingestion f1=1 
Whole Body Retention 1 2.9E-01 3.4E-01 3.5E-01 
 2 2.1E-01 2.8E-01 3.0E-01 
 5 1.8E-01 2.6E-01 2.8E-01 
 7 1.7E-01 2.5E-01 2.8E-01 
 14 1.6E-01 2.3E-01 2.5E-01 
 30 1.2E-01 1.8E-01 1.9E-01 
 60 7.3E-02 1.1E-01 1.2E-01 
 90 4.4E-02 6.3E-02 6.9E-02 
 180 9.0E-03 1.3E-02 1.4E-02 
 365 3.5E-04 5.0E-04 5.6E-04 
Thyroid 1 1.4E-01 2.4E-01 2.7E-01 
 2 1.7E-01 2.6E-01 2.9E-01 
 5 1.7E-01 2.5E-01 2.7E-01 
 7 1.7E-01 2.4E-01 2.6E-01 
 14 1.4E-01 2.1E-01 2.3E-01 
 30 1.1E-01 1.6E-01 1.7E-01 
 60 6.3E-02 9.1E-02 1.0E-01 
 90 3.7E-02 5.4E-02 5.9E-02 
 180 7.7E-03 1.1E-02 1.2E-02 
 365 3.0E-04 4.3E-04 4.7E-04 
Urine 1 1.4E-01 1.4E-01 1.4E-01 
 2 3.6E-02 1.9E-02 8.5E-03 
 5 1.1E-03 6.1E-04 3.3E-04 
 7 3.4E-04 4.3E-04 4.5E-04 
 14 4.4E-04 6.4E-04 7.1E-04 
 30 5.2E-04 7.5E-04 8.3E-04 
 60 3.7E-04 5.3E-04 5.9E-04 
 90 2.3E-04 3.3E-04 3.6E-04 
 180 4.7E-05 6.8E-05 7.2E-05 
 365 1.8E-06 2.6E-06 2.9E-06 
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12.3.2 Dose Coefficients 
 
Dose coefficients, expressed as committed dose equivalent per unit 
activity of intake (e.g., rem/nCi), are a convenient shortcut for 
estimating doses based on standard assumptions when the magnitude 
of an intake is known.  Acute intake dose coefficients have been 
calculated using CINDY and are tabulated for selected exposure 
scenarios in Table 12.5. 
 
Table 12.5.  Committed Dose Coefficients for Radioiodines (rem/nCi) 
 
Class D Inhalation 
Radionuclide Organ 1-mm-AMAD 5-mm-AMAD 
Ingestion 
f1 = 1 
131I Effective 3.1E-05 4.5E-05 4.9E-05 
 Thyroid 1.0E-03 1.5E-03 1.6E-03 
129I Effective 1.6E-04 2.2E-04 2.5E-04 
 Thyroid 5.2E-03 7.5E-03 8.2E-03 
125I Effective 2.2E-05 3.2E-05 3.6E-05 
 Thyroid 7.4E-04 1.1E-03 1.2E-03 
 
The thyroid is the principally exposed organ following an intake of 
radioiodine and can be considered to be the only organ contributing 
to the effective dose equivalent for radioiodines.  Because of the low 
weighting factor for the thyroid (wt = 0.03), the limiting dose from a 
regulatory standpoint is the nonstochastic limit of 50 rem/yr. 
 
12.3.3 Comparison of Published Dosimetry Factors 
 
A comparison of selected dosimetry factors for 131I (as the most 
common radioiodine) is shown in Table 12.6. 
 
12.3.4 Derived Reference Levels 
 
Derived reporting and investigation levels (based on committed 
effective dose equivalents of 10 mrem and 100 mrem, respectively) 
and dose limit compliance levels (based on 50 rem to the thyroid) 
have been derived for inhalation of class D 1-mm- and 5-mm-AMAD 
particles, and for ingestion.  Tabulations are provided in Table 12.7 
for 131I, Table 12.8 for 129I, and Table 12.9 for 125I.  Examination of 
these tables shows that for each of the three nuclides, the value of 
each bioassay considered (whole body, thyroid, urine) is similar after 
a few days, regardless of the type of intake.  Thus, from a practical 
standpoint, the derived reference levels for a 1-mm inhalation, a 
5-mm inhalation, and an ingestion are sufficiently close to suggest 
that a single value can be used for any of them.  For purposes of 
 
PNNL-MA-860 Chapter 12.0  Issued:  September 12, 2000 
Page 12.8 
Table 12.6.  Comparison of Dosimetric Factors for Soluble 131I 
 
Reference Source 
Class D Inhalation 
1-mm-AMAD 
Class D Inhalation 
5-mm-AMAD 
Soluble Ingestion 
f1 = 1 
Dose Coefficients Effective 
CINDY [hE,50] 3.1E-05 rem/nCi 4.5E-05 rem/nCi 4.9E-05 rem/nCi 
ICRP 54 [hE,50] 
8.8E-09 Sv/Bq  
(3.3E-05 rem/nCi) NA NA 
EPA Federal Guidance 
Report No. 11 [hE,50] 
8.89E-09 Sv/Bq 
(3.29E-05 rem/nCi) NA 
1.44E-08 Sv/Bq 
(5.33E-05 rem/nCi) 
ICRP 68 [e(50)] 
7.6E-09 Sv/Bq  
(2.8E-05 rem/nCi) 
1.1E-08 Sv/Bq 
(4.1E-05 rem/nCi) 
2.2E-08 Sv/Bq 
(8.1E-05 rem/nCi) 
Thyroid 
CINDY [hE,50] 1.0E-03 rem/nCi 1.5E-03 rem/nCi 1.6E-03 rem/nCi 
ICRP 54 [hE,50] 
2.9E-07 Sv/Bq 
(1.1E-03 rem/nCi) NA NA 
EPA Federal Guidance 
Report No. 11 [hE,50] 
2.92E-07 Sv/Bq 
(1.08E-03 rem/nCi) NA 
4.76E-07 Sv/Bq 
(1.76E-03 rem/nCi) 
DAC (Thyroid) 
10 CFR 835, App. A 
2E-08 mCi/ml and 
7E+02 Bq/m3 NA NA 
EPA Federal Guidance 
Report No. 11 
2E-08 mCi/ml and 
7E-04 MBq/m3 NA NA 
ICRP 30, ICRP 54 7E+02 Bq/m3 NA NA 
Annual Limit on Intake, ALI (Thyroid) 
Calculated from 
10 CFR 835 DAC 
48 mCi and  
1.7E+06 Bq NA NA 
ICRP 30 2E+06 Bq NA 1E+06 Bq 
EPA Federal Guidance 
Report No. 11 2 MBq and 50 mCi NA 1 MBq and 30 mCi 
NA = not applicable 
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Table 12.7.  Reference Levels and Derived Reference Levels for 131I 
 
10-mrem HE,50 Reporting Level 100-mrem HE,50 Investigation Level 50-mrem Ht,50 Compliance Level 
Days Post Intake 
1-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
1-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
1-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
Intake (nCi) 3.2E+02 2.2E+02 2.0E+02 3.2E+03 2.2E+03 2.0E+03 5.0E+04 3.3E+04 3.1E+04 
Whole Body Count Bioassay (nCi) 
1 8.7E+01 7.1E+01 6.5E+01 8.7E+02 7.1E+02 6.5E+02 1.4E+04 1.1E+04 1.0E+04 
2 6.1E+01 5.3E+01 5.3E+01 6.1E+02 5.3E+02 5.3E+02 9.5E+03 8.0E+03 8.1E+03 
5 3.9E+01 4.0E+01 4.1E+01 3.9E+02 4.0E+02 4.1E+02 6.0E+03 6.0E+03 6.3E+03 
7 3.2E+01 3.3E+01 3.5E+01 3.2E+02 3.3E+02 3.5E+02 5.0E+03 5.0E+03 5.3E+03 
14 1.9E+01 1.8E+01 1.9E+01 1.9E+02 1.8E+02 1.9E+02 2.9E+03 2.8E+03 2.8E+03 
30 4.5E+00 4.4E+00 4.5E+00 4.5E+01 4.4E+01 4.5E+01 7.0E+02 6.7E+02 6.9E+02 
60 3.2E-01 3.1E-01 3.3E-01 3.2E+00 3.1E+00 3.3E+00 5.0E+01 4.7E+01 5.0E+01 
90 2.2E-02 2.2E-02 2.2E-02 2.2E-01 2.2E-01 2.2E-01 3.4E+00 3.3E+00 3.4E+00 
180 7.1E-06 6.9E-06 7.1E-06 7.1E-05 6.9E-05 7.1E-05 1.1E-03 1.0E-03 1.1E-03 
365 1.0E-09 2.9E-10 6.5E-10 1.0E-08 2.9E-09 6.5E-09 1.6E-07 4.3E-08 1.0E-07 
Thyroid Count Bioassay (nCi) 
1 4.2E+01 4.9E+01 5.3E+01 4.2E+02 4.9E+02 5.3E+02 6.5E+03 7.3E+03 8.1E+03 
2 4.8E+01 4.9E+01 5.1E+01 4.8E+02 4.9E+02 5.1E+02 7.5E+03 7.3E+03 7.8E+03 
5 3.9E+01 3.8E+01 3.9E+01 3.9E+02 3.8E+02 3.9E+02 6.0E+03 5.7E+03 5.9E+03 
7 3.2E+01 3.1E+01 3.3E+01 3.2E+02 3.1E+02 3.3E+02 5.0E+03 4.7E+03 5.0E+03 
14 1.7E+01 1.7E+01 1.7E+01 1.7E+02 1.7E+02 1.7E+02 2.7E+03 2.5E+03 2.6E+03 
30 3.9E+00 4.0E+00 4.1E+00 3.9E+01 4.0E+01 4.1E+01 6.0E+02 6.0E+02 6.3E+02 
60 2.7E-01 2.7E-01 2.7E-01 2.7E+00 2.7E+00 2.7E+00 4.3E+01 4.0E+01 4.1E+01 
90 1.9E-02 1.9E-02 1.9E-02 1.9E-01 1.9E-01 1.9E-01 2.9E+00 2.8E+00 2.9E+00 
180 6.1E-06 6.0E-06 6.1E-06 6.1E-05 6.0E-05 6.1E-05 9.5E-04 9.0E-04 9.4E-04 
365 1.5E-09 2.4E-10 5.5E-10 1.5E-08 2.4E-09 5.5E-09 2.4E-07 3.7E-08 8.4E-08 
Urine Bioassay (dmp/d) 
1 9.3E+04 6.4E+04 5.9E+04 9.3E+05 6.4E+05 5.9E+05 1.4E+07 9.6E+06 9.0E+06 
2 2.3E+04 7.9E+03 3.4E+03 2.3E+05 7.9E+04 3.4E+04 3.6E+06 1.2E+06 5.1E+05 
5 5.4E+02 2.1E+02 1.0E+02 5.4E+03 2.1E+03 1.0E+03 8.4E+04 3.2E+04 1.6E+04 
7 1.5E+02 1.3E+02 1.2E+02 1.5E+03 1.3E+03 1.2E+03 2.3E+04 1.9E+04 1.9E+04 
14 1.1E+02 1.1E+02 1.2E+02 1.1E+03 1.1E+03 1.2E+03 1.8E+04 1.7E+04 1.8E+04 
30 4.3E+01 4.3E+01 4.3E+01 4.3E+02 4.3E+02 4.3E+02 6.7E+03 6.4E+03 6.7E+03 
60 3.6E+00 3.6E+00 3.6E+00 3.6E+01 3.6E+01 3.6E+01 5.6E+02 5.3E+02 5.5E+02 
90 2.5E-01 2.5E-01 2.5E-01 2.5E+00 2.5E+00 2.5E+00 3.9E+01 3.8E+01 3.9E+01 
180 7.9E-05 7.9E-05 8.2E-05 7.9E-04 7.9E-04 8.2E-04 1.2E-02 1.2E-02 1.2E-02 
365 1.2E-08 3.4E-09 7.7E-09 1.2E-07 3.4E-08 7.7E-08 1.9E-06 5.1E-07 1.2E-06 
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Table 12.8.  Reference Levels and Derived Reference Levels for 129I 
 
10-mrem HE,50 Reporting Level 100-mrem HE,50 Investigation Level 50-mrem Ht,50 Compliance Level 
Days Post Intake 
1-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
1-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
1-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
Intake (nCi) 6.3E+01 4.5E+01 4.0E+01 6.3E+02 4.5E+02 4.0E+02 9.6E+03 6.7E+03 6.1E+03 
Whole Body Count Bioassay (nCi) 
1 1.9E+01 1.5E+01 1.4E+01 1.9E+02 1.5E+02 1.4E+02 2.9E+03 2.3E+03 2.1E+03 
2 1.4E+01 1.3E+01 1.2E+01 1.4E+02 1.3E+02 1.2E+02 2.1E+03 1.9E+03 1.8E+03 
5 1.2E+01 1.2E+01 1.2E+01 1.2E+02 1.2E+02 1.2E+02 1.8E+03 1.8E+03 1.8E+03 
7 1.2E+01 1.2E+01 1.2E+01 1.2E+02 1.2E+02 1.2E+02 1.8E+03 1.8E+03 1.8E+03 
14 1.1E+01 1.2E+01 1.2E+01 1.1E+02 1.2E+02 1.2E+02 1.7E+03 1.8E+03 1.8E+03 
30 1.1E+01 1.1E+01 1.1E+01 1.1E+02 1.1E+02 1.1E+02 1.6E+03 1.7E+03 1.6E+03 
60 9.4E+00 9.5E+00 9.2E+00 9.4E+01 9.5E+01 9.2E+01 1.4E+03 1.4E+03 1.4E+03 
90 7.5E+00 8.2E+00 7.6E+00 7.5E+01 8.2E+01 7.6E+01 1.2E+03 1.2E+03 1.2E+03 
180 4.4E+00 4.5E+00 4.4E+00 4.4E+01 4.5E+01 4.4E+01 6.8E+02 6.7E+02 6.7E+02 
365 1.4E+00 1.5E+00 1.5E+00 1.4E+01 1.5E+01 1.5E+01 2.2E+02 2.2E+02 2.3E+02 
Thyroid Count Bioassay (nCi) 
1 8.8E+00 1.1E+01 1.1E+01 8.8E+01 1.1E+02 1.1E+02 1.3E+03 1.6E+03 1.7E+03 
2 1.1E+01 1.2E+01 1.2E+01 1.1E+02 1.2E+02 1.2E+02 1.6E+03 1.7E+03 1.8E+03 
5 1.1E+01 1.2E+01 1.2E+01 1.1E+02 1.2E+02 1.2E+02 1.7E+03 1.7E+03 1.8E+03 
7 1.1E+01 1.2E+01 1.1E+01 1.1E+02 1.2E+02 1.1E+02 1.7E+03 1.7E+03 1.7E+03 
14 1.1E+01 1.1E+01 1.1E+01 1.1E+02 1.1E+02 1.1E+02 1.6E+03 1.6E+03 1.6E+03 
30 9.4E+00 1.0E+01 9.6E+00 9.4E+01 1.0E+02 9.6E+01 1.4E+03 1.5E+03 1.5E+03 
60 8.1E+00 8.2E+00 8.0E+00 8.1E+01 8.2E+01 8.0E+01 1.3E+03 1.2E+03 1.2E+03 
90 6.3E+00 6.8E+00 6.8E+00 6.3E+01 6.8E+01 6.8E+01 9.6E+02 1.0E+03 1.0E+03 
180 3.8E+00 4.0E+00 3.8E+00 3.8E+01 4.0E+01 3.8E+01 5.9E+02 5.8E+02 5.9E+02 
365 1.3E+00 1.3E+00 1.2E+00 1.3E+01 1.3E+01 1.2E+01 1.9E+02 1.9E+02 1.9E+02 
Urine Bioassay (dmp/d) 
1 1.9E+04 1.4E+04 1.2E+04 1.9E+05 1.4E+05 1.2E+05 3.0E+06 2.1E+06 1.9E+06 
2 5.1E+03 1.9E+03 7.7E+02 5.1E+04 1.9E+04 7.7E+03 7.9E+05 2.8E+05 1.2E+05 
5 1.5E+02 6.6E+01 3.1E+01 1.5E+03 6.6E+02 3.1E+02 2.3E+04 9.6E+03 4.7E+03 
7 5.1E+01 4.6E+01 4.3E+01 5.1E+02 4.6E+02 4.3E+02 7.9E+03 6.8E+03 6.5E+03 
14 7.1E+01 7.6E+01 7.4E+01 7.1E+02 7.6E+02 7.4E+02 1.1E+04 1.1E+04 1.1E+04 
30 1.0E+02 1.1E+02 1.1E+02 1.0E+03 1.1E+03 1.1E+03 1.6E+04 1.6E+04 1.6E+04 
60 1.0E+02 1.1E+02 1.1E+02 1.0E+03 1.1E+03 1.1E+03 1.6E+04 1.6E+04 1.6E+04 
90 8.9E+01 9.3E+01 8.9E+01 8.9E+02 9.3E+02 8.9E+02 1.4E+04 1.4E+04 1.4E+04 
180 5.1E+01 5.3E+01 5.2E+01 5.1E+02 5.3E+02 5.2E+02 7.9E+03 7.8E+03 8.0E+03 
365 1.7E+01 1.7E+01 1.7E+01 1.7E+02 1.7E+02 1.7E+02 2.6E+03 2.5E+03 2.6E+03 
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Table 12.9.  Reference Levels and Derived Reference Levels for 125I 
 
10-mrem HE,50 Reporting Level 100-mrem HE,50 Investigation Level 50-mrem Ht,50 Compliance Level 
Days Post Intake 
1-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
1-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
1-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
Intake (nCi) 4.5E+02 3.1E+02 2.8E+02 4.5E+03 3.1E+03 2.8E+03 6.8E+04 4.5E+04 4.2E+04 
Whole Body Count Bioassay (nCi) 
1 1.3E+02 1.1E+02 9.7E+01 1.3E+03 1.1E+03 9.7E+02 2.0E+04 1.5E+04 1.5E+04 
2 9.5E+01 8.8E+01 8.3E+01 9.5E+02 8.8E+02 8.3E+02 1.4E+04 1.3E+04 1.3E+04 
5 8.2E+01 8.1E+01 7.8E+01 8.2E+02 8.1E+02 7.8E+02 1.2E+04 1.2E+04 1.2E+04 
7 7.7E+01 7.8E+01 7.8E+01 7.7E+02 7.8E+02 7.8E+02 1.1E+04 1.1E+04 1.2E+04 
14 7.3E+01 7.2E+01 6.9E+01 7.3E+02 7.2E+02 6.9E+02 1.1E+04 1.0E+04 1.0E+04 
30 5.5E+01 5.6E+01 5.3E+01 5.5E+02 5.6E+02 5.3E+02 8.1E+03 8.2E+03 7.9E+03 
60 3.3E+01 3.4E+01 3.3E+01 3.3E+02 3.4E+02 3.3E+02 4.9E+03 5.0E+03 5.0E+03 
90 2.0E+01 2.0E+01 1.9E+01 2.0E+02 2.0E+02 1.9E+02 3.0E+03 2.9E+03 2.9E+03 
180 4.1E+00 4.1E+00 3.9E+00 4.1E+01 4.1E+01 3.9E+01 6.1E+02 5.9E+02 5.8E+02 
365 1.6E-01 1.6E-01 1.6E-01 1.6E+00 1.6E+00 1.6E+00 2.4E+01 2.3E+01 2.3E+01 
Thyroid Count Bioassay (nCi) 
1 6.4E+01 7.5E+01 7.5E+01 6.4E+02 7.5E+02 7.5E+02 9.5E+03 1.1E+04 1.1E+04 
2 7.7E+01 8.1E+01 8.1E+01 7.7E+02 8.1E+02 8.1E+02 1.1E+04 1.2E+04 1.2E+04 
5 7.7E+01 7.8E+01 7.5E+01 7.7E+02 7.8E+02 7.5E+02 1.1E+04 1.1E+04 1.1E+04 
7 7.7E+01 7.5E+01 7.2E+01 7.7E+02 7.5E+02 7.2E+02 1.1E+04 1.1E+04 1.1E+04 
14 6.4E+01 6.6E+01 6.4E+01 6.4E+02 6.6E+02 6.4E+02 9.5E+03 9.5E+03 9.6E+03 
30 5.0E+01 5.0E+01 4.7E+01 5.0E+02 5.0E+02 4.7E+02 7.4E+03 7.3E+03 7.1E+03 
60 2.9E+01 2.8E+01 2.8E+01 2.9E+02 2.8E+02 2.8E+02 4.3E+03 4.1E+03 4.2E+03 
90 1.7E+01 1.7E+01 1.6E+01 1.7E+02 1.7E+02 1.6E+02 2.5E+03 2.5E+03 2.5E+03 
180 3.5E+00 3.4E+00 3.3E+00 3.5E+01 3.4E+01 3.3E+01 5.2E+02 5.0E+02 5.0E+02 
365 1.4E-01 1.3E-01 1.3E-01 1.4E+00 1.3E+00 1.3E+00 2.0E+01 2.0E+01 2.0E+01 
Urine Bioassay (dmp/d) 
1 1.4E+05 9.7E+04 8.6E+04 1.4E+06 9.7E+05 8.6E+05 2.1E+07 1.4E+07 1.3E+07 
2 3.6E+04 1.3E+04 5.2E+03 3.6E+05 1.3E+05 5.2E+04 5.4E+06 1.9E+06 7.9E+05 
5 1.1E+03 4.2E+02 2.0E+02 1.1E+04 4.2E+03 2.0E+03 1.7E+05 6.2E+04 3.1E+04 
7 3.4E+02 3.0E+02 2.8E+02 3.4E+03 3.0E+03 2.8E+03 5.1E+04 4.3E+04 4.2E+04 
14 4.4E+02 4.4E+02 4.4E+02 4.4E+03 4.4E+03 4.4E+03 6.6E+04 6.5E+04 6.6E+04 
30 5.4E+02 5.2E+02 5.1E+02 5.4E+03 5.2E+03 5.1E+03 8.1E+04 7.6E+04 7.7E+04 
60 3.7E+02 3.7E+02 3.6E+02 3.7E+03 3.7E+03 3.6E+03 5.6E+04 5.3E+04 5.5E+04 
90 2.3E+02 2.3E+02 2.2E+02 2.3E+03 2.3E+03 2.2E+03 3.5E+04 3.3E+04 3.3E+04 
180 4.7E+01 4.7E+01 4.4E+01 4.7E+02 4.7E+02 4.4E+02 7.1E+03 6.9E+03 6.7E+03 
365 1.8E+00 1.8E+00 1.8E+00 1.8E+01 1.8E+01 1.8E+01 2.7E+02 2.6E+02 2.7E+02 
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bioassay program design and data evaluation, the 5-mm inhalation-
derived reference levels are used at Hanford as a standard against 
which routine monitoring data can be compared.  The choice of the 
5-mm inhalation was made in large part based on the use of 
5-mm-AMAD particle sizes for most aerosols at Hanford, and as a 
reasonable compromise between values for 1-mm-AMAD particles 
and ingestion. 
 
A point of interest regarding 129I is that the mass of pure 129I 
corresponding to a compliance level intake of 6,100 nCi (i.e., the 
whole body retention at time zero) is 34 mg, which exceeds the 
iodine mass of 12 mg contained in the Reference Man total body 
(ICRP 1975).  Thus, it is likely that a retained intake of 129I, which 
might result in a dose exceeding the 50-rem thyroid dose limit, is 
physiologically impossible.  This does not hold true for the short 
half-life radioiodines. 
 
12.4 Bioassay for Radioiodines 
 
In vivo measurements and a routine monitoring program for 
radioiodine isotopes are the main bioassay considerations. 
 
12.4.1 Bioassay Methods and Capabilities 
 
Radioiodine isotopes can be easily detected by in vivo measure-
ments.  Iodine-131 can be readily detected using the NaI-detector-
based preview counter or the coaxial germanium detector system.  
However, because these are not nuclides in routine use at Hanford, 
they are not part of the standard library of nuclides for which in vivo 
measurement results are routinely calculated.  The spectrum peak 
search routine, performed for each measurement, will find them if 
they are present above the peak search MDA, which is less sensitive 
than the library search MDA.  Nominal 131I MDA values for the peak 
search routine are about 15 nCi for the preview counter and about 
2 nCi for the coaxial system. 
 
Because of their low-energy photon emissions, 125I and 129I can only 
be measured using the intrinsic germanium (IG) detector systems in 
the thyroid-counting configuration.  Nominal MDAs for thyroid 
counting are 0.1 nCi for 131I and 0.8 nCi for 125I and 129I. 
 
The minimum detectable intakes and associated minimum detectable 
doses (committed effective dose equivalents) based on the nominal 
MDAs are shown in Table 12.10 for 131I and Table 12.11 for 129I 
and 125I. 
 
 Issued:  Septem
ber  12, 2000 
 
PN
N
L-M
A
-860 C
hapter 12.0
 
 
Page 12.13 
 
 
Table 12.10.  131I Minimum Detectable Intakes and Doses (HE,50 and Thyroid HT,50) for 5-mm-AMAD Class D Inhalation 
 
NaI System(a) 
Minimum Detectable 
Coax Ge System(b) 
Minimum Detectable 
Planar Ge System(c) 
Minimum Detectable 
Days Post 
Intake Intake (nCi) 
HE,50 
(mrem) 
HT,50 
(mrem) Intake (nCi) 
HE,50 
(mrem) 
HT,50 
(mrem) Intake (nCi) 
HE,50 
(mrem) 
HT,50 
(mrem) 
1 4.7E+01 2.1 70 6.3E+00 0.3 9.4 4.5E-01 0.02 0.7 
2 6.3E+01 2.8 94 8.3E+00 0.4 13 4.5E-01 0.02 0.7 
5 8.3E+01 3.8 130 1.1E+01 0.5 17 5.9E-01 0.03 0.9 
7 1.0E+02 4.5 150 1.3E+01 0.6 20 7.1E-01 0.03 1.1 
14 1.8E+02 8.1 270 2.4E+01 1.1 36 1.3E+00 0.06 2.0 
30 7.5E+02 34 1100 1.0E+02 4.5 150 5.6E+00 0.25 8.3 
60 1.1E+04 4.8E+02 1.6E+04 1.4E+03 64 2100 8.3E+01 3.8 130 
90 1.5E+05 6.9E+03 2.3E+05 2.0E+04 9.2E+02 3.1E+04 1.2E+03 54 1800 
180 4.8E+08 2.2E+07 7.3E+08 6.5E+07 2.9E+06 9.7E+07 3.7E+06 1.7E+05 5.6E+06 
(a) Based on MDA of 15 nCi, whole body count 
(b) Based on MDA of 2 nCi, whole body count 
(c) Based on MDA of 0.1 nCi, thyroid count 
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 Table 12.11. 129I and 125I Minimum Detectable Intakes and Doses (HE,50 and Thyroid HT,50) 
for 5-mm-AMAD Class D Inhalation 
 
Iodine-129 
Minimum Detectable 
Iodine-125 
Minimum Detectable Days Post 
Intake Intake (nCi) HE,50 (mrem) HT,50 (mrem) Intake (nCi) HE,50 (mrem) HT,50 (mrem) 
1 3.3 0.73 25 3.3 0.11 3.7 
2 3.1 0.68 23 3.1 0.10 3.4 
5 3.1 0.68 23 3.2 0.10 3.5 
7 3.1 0.68 23 3.3 0.11 3.7 
14 3.3 0.73 25 3.8 0.12 4.2 
30 3.6 0.80 27 5.0 0.16 5.5 
60 4.4 1.0 33 8.8 0.28 9.7 
90 5.3 1.2 40 15 0.47 16 
180 9 2.0 69 73 2.3 80 
365 29 6.3 210 1900 60 2000 
730 2100 84.0 2900 NA NA NA 
(a) Based on MDA of 0.8 nCi for planar germanium system thyroid count 
NA = not applicable. 
 
Radioiodine bioassay programs at Hanford are based on in vivo 
measurements.  Urine sample analysis using a gamma spectrum 
analysis protocol (Hanford MDA of 10 dpm/l) can also be used for 
radioiodines.  However, the ease and convenience of in vivo 
measurements at Hanford makes urinalysis the less preferred 
method. 
 
12.4.2 Routine Bioassay Monitoring Protocol 
 
It is recommended that routine bioassay measurements be performed 
at intervals not exceeding four to five effective half-lives of the 
radionuclide because of uncertainties associated with the assumed 
retention characteristics.  Based on that recommendation and the 
minimum detectable doses listed in Tables 12.10 and 12.11, the 
measurement frequency for the minimum recommended routine 
monitoring program for workers potentially exposed to 131I, 125I, or 
129I, is monthly, semiannually, and annually, respectively.  If the 
coaxial germanium system is used for 131I bioassay, bimonthly 
measurements (i.e., every 2 months) provide adequate sensitivity. 
 
A supplemental approach to routine bioassay monitoring for 
radioiodines is to perform a workplace thyroid screening measure-
ment shortly after completion of the iodine-related work.  If there is 
any indication of radioiodine detection, then a more timely thyroid 
count can be performed using the high-resolution systems. 
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If a radioiodine isotope is detected in a routine measurement, follow-
up measurements to confirm the intake should be performed.  The 
measurements should preferably be performed immediately 
following the initial measurement while the subject is at the whole 
body counting facility.  The use of the high-resolution germanium 
detectors for follow-up measurements is preferred in order to 
accurately quantify the thyroid deposition. 
 
12.4.3 Special Monitoring for Suspected Intakes 
 
Thyroid counts should be performed to assess the significance of an 
acute intake of radioiodine.  The deposition of iodine in the thyroid 
following an acute intake is not instantaneous; rather, buildup of 
iodine in the thyroid will occur over a period of about 3 days follow-
ing the intake.  Results of thyroid counts obtained within a day or so 
of an intake may thus underestimate the maximum retained quantity 
that will be achieved following the exposure.  Measurements made 2 
to 3 days post intake will likely provide the best indication of the 
maximum retained quantity in the thyroid from the intake. 
 
If significant quantities of short-lived radioiodines are possibly 
associated with an exposure, then in vivo measurements should be 
performed within a day of the intake.  The measurements should be 
made using a germanium detector to achieve optimum resolution.  
Follow-up counts, if needed, should be performed.  Data from 
facility monitoring may be used to identify the relative activities of 
the various radioiodines present at the time of intake.  Caution 
should be exercised when analyzing in vivo data for short-lived 
iodine isotopes to ensure that activity within the thyroid and not 
external contamination is being measured. 
 
12.5 Assessment of Internal Dose 
 
Radioiodines can be detected and quantified in the thyroid using in 
vivo techniques.  Measurement of 125I and 129I requires the use of the 
planar germanium counting system for thyroid counting.  Thyroid 
counts are sufficiently sensitive to enable detection of activity in the 
thyroid at levels below that of any dosimetric consequence (see 
Tables 12.10 and 12.11).  Thus, dose-based screening levels for 
thyroid assessments may be appropriate (e.g., a screening level based 
on 10-mrem committed effective dose equivalent provides assurance 
that significant doses do not go unassessed).  Routine whole body 
counting or thyroid counting can be used for 131I. 
 
Several methods exist to evaluate in vivo results to assess the internal 
dose equivalent.  The simplest method, and one that is recommended 
for initial evaluation of in vivo results as well as for final evaluations 
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when doses are low, involves fitting the in vivo measurement data to 
the expected internal activity using the biokinetic model prescribed 
in this chapter.  Data-fitting is performed using CINDY.  
Alternatively, a hand calculation can be performed using the factors 
tabulated in this chapter. 
 
Assumptions that are used for this evaluation are that 1) the material 
is inhaled in class D form, 2) the intake date, if unknown, is assumed 
to be the midpoint of the period during which the intake could have 
occurred, and 3) the intake consisted of the inhalation of an aerosol 
with an AMAD of 5 mm.  Observed in vivo retention should be used 
in place of the ICRP biokinetic model for evaluations of internal 
doses that potentially exceed a 100-mrem committed effective dose 
equivalent when sufficient in vivo data are available for such an 
analysis. 
 
12.6 Management of Internal Contamination Cases 
 
In an accident exposure situation, iodine will likely be taken in by 
inhalation, ingestion, and absorption through the skin.  If the iodine 
is very soluble, it will reach the thyroid relatively quickly; however, 
maximum thyroid activity may not occur until 2 or 3 days post 
intake.  Thus, thyroid counts performed shortly after intake may 
underestimate the maximum deposition.  Also of concern for in vivo 
measurements made shortly after intake are contributions to the 
count from radioiodine located outside the body or in other regions 
of the body.  However, if thyroid measurements are made with a 
collimated germanium detector, these interferences can most likely 
be reduced to negligible levels. 
 
The adult thyroid gland is considered to be a relatively radioresistant 
organ (weighting factor = 0.03) with respect to the risk of fatal 
malignancies.  However, thyroid nodules, cancer, and hypothyroid-
ism are all associated with radiation exposure to the thyroid.  The 
intervention therapy recommended by both NCRP Report 65 (1980) 
and Bhattacharyya et al. (1992) is immediate administration of 300-
mg KI or NaI tablets, regardless of the route of exposure, and daily 
administrations for 7 to 14 days (to prevent recycling back into the 
thyroid) as a mitigative action following a large intake.  For individ-
uals receiving greater than a 100-rem dose equivalent to the thyroid, 
an estimate of residual thyroid function should be made within 2 or 
3 months after exposure (NCRP 1980).  Occupational Medicine (at 
HEHF) should be immediately notified of a potentially severe intake 
of radioiodine. 
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13.0 Europium 
 
 
This chapter provides technical information on the sources, 
characteristics, biokinetics, and dosimetry of 152Eu, 154Eu, and 155Eu, 
which are the principal europium radionuclides of concern from an 
internal exposure standpoint at Hanford. 
 
13.1 Sources and Characteristics 
 
Europium-154 and 155Eu have been produced historically at Hanford 
by the N Reactor through neutron activation of samarium oxide 
marbles used in the reactor’s safety system.  The samarium oxide 
marbles were replaced in 1978 with marbles made of boron carbide; 
however, a few of the old samarium oxide marbles remained lodged 
in the graphite block moderator and continued to be activated during 
operation of the reactor until its shutdown in 1986. 
 
Europium-152 has been found in coolant pipes of some of the old 
production reactors.  Its exact source has not been determined, but it 
has been speculated that it might result from activation of stable 
151Eu from naturally occurring or fission-product sources.  Data are 
provided for 152Eu, although this has not historically been considered 
a major nuclide of concern in these facilities. 
 
Radiological decay data for these isotopes are given in Table 13.1. 
 
Table 13.1.  Radiological Data for Hanford Europiums 
 
Isotope 
Half-Life 
(y) 
Decay Constant 
(y1) 
Specific 
Activity (Ci/g) 
152Eu 13.33 0.052 176 
154Eu 8.8 0.079 263 
155Eu 4.96 0.14 463 
 
Based on numerous measurements made at various N Reactor 
locations (Weetman and DeHaven 1982), a particle size of 
0.5-mm-AMAD should be assumed, unless specific particle size data 
are available.  This particle size is in contrast to the 1-mm-AMAD 
particle size assumed by ICRP publication 30 (1979) and the 
5-mm-AMAD particle size recommended by ICRP publication 66 
(1994a). 
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The principal locations where exposures to europium radionuclides 
may occur are the 100-N Area and the waste management facilities 
in the 200 Areas where contaminated waste from N Reactor is 
handled. 
 
13.2 Biokinetic Behavior of Europium 
 
The biokinetic behavior of europium is addressed in the following 
sections. 
 
13.2.1 Transportability Class 
 
ICRP 30 Part 3 (1981) recommends that all compounds of europium 
(including nitrates, chlorides, and oxides) be assigned to inhalation 
class W.  Some experience at Hanford has suggested that europium 
oxide may occasionally be more tenaciously retained in the lung than 
would be expected for a class W material.  However, at this time data 
are insufficient to establish a case for class Y europium at Hanford. 
 
The new ICRP 66 lung model (ICRP 1994a) introduced the concept 
of lung absorption type as a replacement for the ICRP 30 inhalation 
class.  Based on data tabulated in ICRP 68 (1994b), all forms of 
europium are assigned absorption type M. 
 
The default assumption for Hanford europium exposures is 
inhalation class W, per the ICRP 30 recommendation. 
 
13.2.2 Gastrointestinal Uptake to Blood (f1 Factor) 
 
Citing a range of 2E-04 to 3E-03, the GI uptake factor (f1) for 
europium was taken by ICRP 30 (1981) to be 1E-03.  More recently, 
ICRP 68 used 5E-04, without highlighting a reason for the change.  
This choice has been promulgated by the International Atomic 
Energy Agency in its Basic Safety Standards (IAEA 1996).  
Although a clear scientific justification for the change has not been 
identified, the HIDP uses the more recent ICRP recommendation of 
5E-04.  This value lies within the range originally cited, and it 
appears to be the current scientific consensus. 
 
13.2.3 Biokinetic Model 
 
According to the ICRP 30 Part 3 (1981) model, europium entering 
the bloodstream is deposited and tenaciously retained in the liver and 
on bone surfaces.  The distribution of europium entering the blood is 
given by ICRP 30 as follows: 
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Organ/Tissue 
Fraction 
Retained Biological Half-Life (days) 
Liver 0.4 3500 
Bone Surfaces 0.4 3500 
Kidney 0.06 10 
Direct Excretion 0.14  
 
13.3 Internal Dosimetry Factors for Europium 
 
This section contains factors that are useful in making internal 
dosimetry calculations.  The factors included are derived from the 
CINDY computer code and incorporate the models and assumptions 
of the preceding sections.  Their application is intended for circum-
stances where such assumptions are appropriate or more specific 
information is lacking.  Variation from these factors is appropriate if 
sufficient data are available. 
 
13.3.1 Retention of Europium 
 
Selected retention fractions for 152Eu and 154Eu in the whole body and 
bone and 155Eu in the lung and bone are listed in Table 13.2 for inhal-
ation intakes and Table 13.3 for ingestion intakes.  Fractions have 
been tabulated for a 0.5-mm-AMAD aerosol class W inhalation as the 
default Hanford assumption based on the previously described char-
acterization work.  Fractions are also tabulated for a 5-mm-AMAD 
aerosol inhalation as the standard ICRP inhalation aerosol.  Although 
the larger particle size is not normally used for Hanford europium 
intakes, particle size growth with time is possible due to oxidation in 
the ambient environment.  The organs and tissues selected for 
tabulation are those of greatest interest to routine and special 
bioassay measurements. 
 
13.3.2 Dose Coefficients 
 
Dose coefficients, expressed as committed dose equivalent per unit 
activity of intake (e.g., rem/nCi of intake), are a convenient shortcut 
to estimating doses based on standard assumptions when the magni-
tude of intake is known.  Acute intake dose coefficients have been 
compiled in Table 13.4 for selected exposure scenarios, based on 
calculations using the CINDY code.  The scenarios include the 
inhalation of class W 0.5-mm- and 5-mm-AMAD particles as the 
Hanford default and ICRP 66 default particle sizes, respectively, and 
ingestion.  For all of these scenarios, the most limiting dose 
coefficients are for the committed effective dose equivalent.  Dose 
coefficients for organs or tissues that contribute approximately 10% 
or more to the committed effective dose equivalent are also shown. 
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Table 13.2.  Fractional Retention of Inhalation Class W Europium 
 
Particle Size:  0.5-mm 
Days Post 
Intake 
152Eu  
Whole Body 
152Eu 
Bone(a) 
154Eu 
Whole Body 
154Eu 
Bone(a) 
155Eu 
Lung 
155Eu 
Bone(a) 
0 5.9E-01 2.1E-03 5.9E-01 2.1E-03 4.1E-01 2.1E-03 
1 5.5E-01 2.1E-02 5.5E-01 2.1E-02 3.0E-01 2.1E-02 
2 4.6E-01 2.3E-02 4.6E-01 2.3E-02 2.5E-01 2.3E-02 
5 2.8E-01 2.4E-02 2.8E-01 2.4E-02 2.0E-01 2.4E-02 
7 2.5E-01 2.4E-02 2.5E-01 2.4E-02 1.9E-01 2.4E-02 
14 2.3E-01 2.6E-02 2.3E-01 2.6E-02 1.8E-01 2.6E-02 
30 2.1E-01 3.0E-02 2.1E-01 3.0E-02 1.4E-01 3.0E-02 
60 1.7E-01 3.5E-02 1.7E-01 3.5E-02 9.6E-02 3.5E-02 
90 1.4E-01 3.9E-02 1.4E-01 3.9E-02 6.4E-02 3.8E-02 
180 1.1E-01 4.4E-02 1.1E-01 4.4E-02 2.0E-02 4.2E-02 
365 9.1E-02 4.5E-02 8.9E-02 4.3E-02 1.7E-03 4.1E-02 
730 8.0E-02 4.0E-02 7.5E-02 3.8E-02 1.2E-05 3.3E-02 
1825 5.5E-02 2.7E-02 4.8E-02 2.4E-02 insig. 1.8E-02 
3650 2.9E-02 1.5E-02 2.3E-02 1.1E-02 insig. 6.1E-03 
7300 8.5E-03 4.3E-03 5.0E-03 2.5E-03 insig. 7.3E-04 
18250 2.0E-04 1.0E-04 5.3E-05 2.7E-05 insig. 1.3E-06 
Particle Size:  5-mm 
Days Post 
Intake 
152Eu  
Whole Body 
152Eu 
Bone(a) 
154Eu 
Whole Body 
154Eu 
Bone(a) 
155Eu 
Lung 
155Eu 
Bone(a) 
0 9.1E-01 4.4E-03 9.1E-01 4.4E-03 1.5E-01 4.4E-03 
1 8.1E-01 4.3E-02 8.1E-01 4.3E-02 7.5E-02 4.3E-02 
2 5.4E-01 4.6E-02 5.4E-01 4.6E-02 6.3E-02 4.6E-02 
5 1.8E-01 4.6E-02 1.8E-01 4.6E-02 5.1E-02 4.6E-02 
7 1.5E-01 4.6E-02 1.5E-01 4.6E-02 4.9E-02 4.6E-02 
14 1.4E-01 4.6E-02 1.4E-01 4.6E-02 4.4E-02 4.6E-02 
30 1.3E-01 4.7E-02 1.3E-01 4.7E-02 3.6E-02 4.7E-02 
60 1.2E-01 4.8E-02 1.2E-01 4.8E-02 2.4E-02 4.7E-02 
90 1.1E-01 4.9E-02 1.1E-01 4.8E-02 1.6E-02 4.8E-02 
180 1.0E-01 4.9E-02 1.0E-01 4.8E-02 4.9E-02 4.7E-02 
365 9.4E-02 4.7E-02 9.1E-02 4.5E-02 4.2E-04 4.3E-02 
730 8.3E-02 4.1E-02 7.8E-02 3.9E-02 3.0E-06 3.5E-02 
1825 5.7E-02 2.8E-02 5.0E-02 2.5E-02 insig. 1.8E-02 
3650 3.1E-02 1.5E-02 2.3E-02 1.2E-02 insig. 6.4E-03 
7300 8.3E-03 4.4E-03 5.2E-03 2.6E-03 insig. 7.6E-04 
18250 2.1E-04 1.1E-04 5.5E-05 2.8E-05 insig. 1.3E-06 
(a) Fractional retention in the liver is the same as the fractional retention in the bone. 
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Table 13.3.  Fractional Retention of Ingested Europium 
 
Days Post 
Intake 
152Eu 
Whole Body 
152Eu 
Bone(a) 
154Eu 
Whole Body 
154Eu 
Bone(a) 
155Eu 
Bone(a) 
0 1.0E+00 2.4E-07 1.0E+00 2.4E-07 2.4E-07 
1 7.1E-01 1.8E-04 7.1E-01 1.8E-04 1.8E-04 
2 3.2E-01 2.0E-04 3.2E-01 2.0E-04 2.0E-04 
5 1.9E-02 2.0E-04 1.9E-02 2.0E-04 2.0E-04 
7 2.9E-03 2.0E-04 2.9E-03 2.0E-04 2.0E-04 
14 4.1E-04 2.0E-04 4.1E-04 2.0E-04 2.0E-04 
30 4.0E-04 2.0E-04 4.0E-04 2.0E-04 2.0E-04 
60 3.9E-04 2.0E-04 3.9E-04 2.0E-04 1.9E-04 
90 3.9E-04 1.9E-04 3.9E-04 1.9E-04 1.9E-04 
180 3.8E-04 1.9E-04 3.7E-04 1.9E-04 1.8E-04 
365 3.5E-04 1.8E-04 3.4E-04 1.7E-04 1.6E-04 
730 3.1E-04 1.6E-04 3.0E-04 1.5E-04 1.3E-04 
1825 2.1E-04 1.1E-04 1.9E-04 9.4E-05 6.9E-05 
3650 1.2E-04 5.8E-05 8.8E-05 4.4E-05 2.4E-05 
7300 3.3E-05 1.7E-05 1.9E-05 9.7E-06 2.9E-06 
18250 8.0E-07 4.0E-07 2.1E-07 1.0E-07 5.0E-09 
(a) Fractional retention in the liver is the same as fractional retention in bone. 
 
Table 13.4.  Committed Dose Coefficients for Europium (rem/nCi acute intake) 
 
Class W Inhalation 
Isotope Organ 0.5-mm-AMAD 5-mm-AMAD 
Ingestion 
f1 = 5E-04 
Instant 
Uptake 
152Eu Effective 2.2E-04 2.1E-04 4.7E-06 1.6E-03 
 Liver 1.3E-03 1.4E-03 insig. 1.0E-02 
 Bone Surface 9.3E-04 9.8E-04 insig. 7.4E-03 
 Red Marrow 3.1E-04 3.2E-04 insig. 2.4E-03 
 Lung 2.7E-04 1.5E-04 insig. insig. 
 Lower Large Intestine insig. insig. 3.7E-05 insig. 
 Upper Large Intestine insig. insig. 1.5E-05 insig. 
154Eu Effective 3.0E-04 2.8E-04 7.5E-06 2.1E-03 
 Liver 1.6E-03 1.7E-03 insig. 1.3E-02 
 Bone Surface 2.0E-03 2.1E-03 insig. 1.6E-02 
 Red Marrow 4.1E-04 4.3E-04 insig. 3.3E-03 
 Lung 3.8E-04 1.7E-04 insig. insig. 
 Lower Large Intestine insig. insig. 6.7E-05 insig. 
155Eu Effective 4.5E-05 4.2E-05 1.3E-06 3.0E-04 
 Liver 1.8E-04 2.0E-04 insig. 1.5E-03 
 Bone Surface 5.7E-04 6.0E-04 insig. 4.6E-03 
 Red Marrow 5.6E-05 5.9E-05 insig. 4.5E-04 
 Lung 6.1E-05 1.9E-05 insig. insig. 
 Lower Large Intestine insig. insig. 1.3E-05 insig. 
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13.3.3 Comparison of Published Dosimetry Factors 
 
A comparison of selected dosimetry factors for 154Eu, the most 
restrictive of the Hanford europium isotopes, is shown in Table 13.5. 
 
Table 13.5.  Comparison of Dosimetric Factors for 154Eu 
 
Reference Source 
Class W Inhalation 
0.5 or 1-mm AMAD 
Class W Inhalation 
5-mm-AMAD 
Ingestion 
(f1 = 5E-04) 
Dose Coefficients 
CINDY (hE,50) 
3.0E-04 rem/nCi 
8.1E-08 Sv/Bq 
(Based on 0.5-mm-
AMAD particles) 
2.8E-04 rem/nCi 
7.6E-08 Sv/Bq 
7.5E-06 rem/nCi 
2.0E-09 Sv/Bq 
EPA Federal 
Guidance Report 
No.11 (hE,50) 
7.73E-08 Sv/Bq 
(2.86E-04 rem/nCi) 
(Based on 1-mm-
AMAD particles) NA 
2.58E-09 Sv/Bq 
(9.55E-06 rem/nCi) 
ICRP 68 [e(50)] 
5.0E-08 Sv/Bq 
(1.8E-04 rem/nCi) 
Type S, based on 
1-mm-AMAD 
particles) 
3.5E-08 Sv/Bq 
(1.3E-04 rem/nCi) 
Type M 
2.0E-09 Sv/Bq 
(7.4E-06 rem/nCi) 
Stochastic DAC 
10 CFR 835, App. A 
8E-09 mCi/ml and 
3E+02 Bq/m3 NA NA 
EPA Federal 
Guidance Report 
No. 11 
8E-09 mCi/ml and 
3E-04 MBq/m3 NA NA 
ICRP 30, ICRP 54 3E+02 Bq/m3 NA NA 
Stochastic Annual Limit on Intake, ALI 
Calculated from 
10 CFR 835 DAC  
19 mCi and 
7.2E+05 Bq NA NA 
ICRP 30 7E+05 Bq NA 2E+07 Bq 
EPA Federal 
Guidance Report 
No. 11 
0.7 MBq and 
20 mCi NA 
20 MBq and 
500 mCi 
NA = not applicable. 
 
13.3.4 Derived Reference Levels 
 
Derived reporting, investigation, and dose limit compliance levels 
(based on committed effective dose equivalents of 10-mrem, 
100-mrem, and 5,000 mrem, respectively) have been calculated for  
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152Eu, 154Eu, and 155Eu, as pure isotopes, for whole body and skeleton 
bioassays.  Derived levels for 152Eu are shown in Table 13.6, for 
154Eu in Table 13.7, and for 155Eu in Table 13.8. 
 
13.4 Bioassay for Europium 
 
This section discusses bioassay methods, capabilities, and protocols 
for europium. 
 
13.4.1 Bioassay Methods and Capabilities 
 
The europium isotopes of concern at Hanford (152Eu, 154Eu, and 
155Eu) are readily measured by in vivo bioassay techniques.  
Europium intakes can also be detected and assessed through 
collection and analysis of urine and fecal samples.  However, 
because in vivo measurements provide a direct and sensitive method 
for assessing internal depositions of europium radionuclides, excreta 
measurements are generally not necessary.  The recommended 
bioassay programs for europium are based on in vivo measurements.  
Nominal minimum detectable activities for in vivo measurements are 
shown in Table 13.9. 
 
Europium-154 is the predominant long-lived europium radioisotope 
in europium mixtures at Hanford.  During the operating lifetime of 
N Reactor, the 154Eu:155Eu activity ratio was about 2.0.  Since the 
1986 shutdown of N Reactor, this ratio should gradually increase due 
to the longer half-life of 154Eu, now that europium is no longer 
produced.  Because 154Eu is also more easily detectable in vivo than 
155Eu, it is the best indicator of an intake of europium radionuclides.  
Whole body counting for 154Eu is conveniently performed using the 
NaI-detector preview counter, however the high-resolution large-
volume coaxial germanium detector system should be used for 
quantitative determinations if detection is indicated on the NaI 
system. 
 
Europium-155 is more difficult to detect in vivo because its 
predominant gamma emission falls in the low-energy noise region of 
the standard whole body count.  It can be detected in the skeleton or 
lungs using the low-energy planar germanium detector systems.  The 
total body content of 155Eu cannot be directly measured with the 
Hanford whole body counter.  It can be estimated by establishing a 
155Eu:154Eu ratio, using chest or skeleton counts, and then applying 
that ratio to the 154Eu whole body count result.  Skeleton counting 
would provide a more sensitive ratio for 155Eu estimation. 
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Table 13.6.  Reference Levels and Derived Reference Levels for 152Eu 
 
10-mrem HE,50 Reporting Level 100-mrem HE,50 Investigation Level 5,000-mrem Ht,50 Compliance Level 
Days Post Intake 
0.5-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
0.5-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
0.5-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
Intake (nCi) 4.5E+01 4.8E+01 2.1E+03 4.5E+02 4.8E+02 2.1E+04 2.3E+04 2.4E+04 1.1E+06 
Whole Body Count Bioassay (nCi) 
0 2.7E+01 4.3E+01 2.1E+03 2.7E+02 4.3E+02 2.1E+04 1.3E+04 2.2E+04 1.1E+06 
1 2.5E+01 3.9E+01 1.5E+03 2.5E+02 3.9E+02 1.5E+04 1.2E+04 1.9E+04 7.5E+05 
2 2.1E+01 2.6E+01 6.8E+02 2.1E+02 2.6E+02 6.8E+03 1.0E+04 1.3E+04 3.4E+05 
5 1.3E+01 8.6E+00 4.0E+01 1.3E+02 8.6E+01 4.0E+02 6.4E+03 4.3E+03 2.0E+04 
7 1.1E+01 7.1E+00 6.2E+00 1.1E+02 7.1E+01 6.2E+01 5.7E+03 3.6E+03 3.1E+03 
14 1.0E+01 6.7E+00 8.7E-01 1.0E+02 6.7E+01 8.7E+00 5.2E+03 3.3E+03 4.3E+02 
30 9.5E+00 6.2E+00 8.5E-01 9.5E+01 6.2E+01 8.5E+00 4.8E+03 3.1E+03 4.2E+02 
60 7.7E+00 5.7E+00 8.3E-01 7.7E+01 5.7E+01 8.3E+00 3.9E+03 2.9E+03 4.1E+02 
90 6.4E+00 5.2E+00 8.3E-01 6.4E+01 5.2E+01 8.3E+00 3.2E+03 2.6E+03 4.1E+02 
180 5.0E+00 4.8E+00 8.1E-01 5.0E+01 4.8E+01 8.1E+00 2.5E+03 2.4E+03 4.0E+02 
365 4.1E+00 4.5E+00 7.4E-01 4.1E+01 4.5E+01 7.4E+00 2.1E+03 2.2E+03 3.7E+02 
730 3.6E+00 4.0E+00 6.6E-01 3.6E+01 4.0E+01 6.6E+00 1.8E+03 2.0E+03 3.3E+02 
Skeleton Bioassay (nCi) 
0 9.5E-02 2.1E-01 5.1E-04 9.5E-01 2.1E+00 5.1E-03 4.8E+01 1.0E+02 2.5E-01 
1 9.5E-01 2.0E+00 3.8E-01 9.5E+00 2.0E+01 3.8E+00 4.8E+02 1.0E+03 1.9E+02 
2 1.0E+00 2.2E+00 4.3E-01 1.0E+01 2.2E+01 4.3E+00 5.2E+02 1.1E+03 2.1E+02 
5 1.1E+00 2.2E+00 4.3E-01 1.1E+01 2.2E+01 4.3E+00 5.4E+02 1.1E+03 2.1E+02 
7 1.1E+00 2.2E+00 4.3E-01 1.1E+01 2.2E+01 4.3E+00 5.4E+02 1.1E+03 2.1E+02 
14 1.2E+00 2.2E+00 4.3E-01 1.2E+01 2.2E+01 4.3E+00 5.9E+02 1.1E+03 2.1E+02 
30 1.4E+00 2.2E+00 4.3E-01 1.4E+01 2.2E+01 4.3E+00 6.8E+02 1.1E+03 2.1E+02 
60 1.6E+00 2.3E+00 4.3E-01 1.6E+01 2.3E+01 4.3E+00 7.9E+02 1.1E+03 2.1E+02 
90 1.8E+00 2.3E+00 4.0E-01 1.8E+01 2.3E+01 4.0E+00 8.9E+02 1.2E+03 2.0E+02 
180 2.0E+00 2.3E+00 4.0E-01 2.0E+01 2.3E+01 4.0E+00 1.0E+03 1.2E+03 2.0E+02 
365 2.0E+00 2.2E+00 3.8E-01 2.0E+01 2.2E+01 3.8E+00 1.0E+03 1.1E+03 1.9E+02 
730 1.8E+00 2.0E+00 3.4E-01 1.8E+01 2.0E+01 3.4E+00 9.1E+02 9.8E+02 1.7E+02 
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Table 13.7.  Reference Levels and Derived Reference Levels for 154Eu 
 
10-mrem HE,50 Reporting Level 100-mrem HE,50 Investigation Level 5,000-mrem Ht,50 Compliance Level 
Days Post Intake 
0.5-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
0.5-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
0.5-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
Intake (nCi) 3.3E+01 3.6E+01 1.3E+03 3.3E+02 3.6E+02 1.3E+04 1.7E+04 1.8E+04 6.7E+05 
Whole Body Count Bioassay (nCi) 
0 2.0E+01 3.2E+01 1.3E+03 2.0E+02 3.2E+02 1.3E+04 9.9E+03 1.6E+04 6.7E+05 
1 1.8E+01 2.9E+01 9.5E+02 1.8E+02 2.9E+02 9.5E+03 9.2E+03 1.4E+04 4.7E+05 
2 1.5E+01 1.9E+01 4.3E+02 1.5E+02 1.9E+02 4.3E+03 7.7E+03 9.7E+03 2.1E+05 
5 9.3E+00 6.4E+00 2.5E+01 9.3E+01 6.4E+01 2.5E+02 4.7E+03 3.2E+03 1.3E+04 
7 8.3E+00 5.4E+00 3.9E+00 8.3E+01 5.4E+01 3.9E+01 4.2E+03 2.7E+03 1.9E+03 
14 7.7E+00 5.0E+00 5.5E-01 7.7E+01 5.0E+01 5.5E+00 3.8E+03 2.5E+03 2.7E+02 
30 7.0E+00 4.6E+00 5.3E-01 7.0E+01 4.6E+01 5.3E+00 3.5E+03 2.3E+03 2.7E+02 
60 5.7E+00 4.3E+00 5.2E-01 5.7E+01 4.3E+01 5.2E+00 2.8E+03 2.1E+03 2.6E+02 
90 4.7E+00 3.9E+00 5.2E-01 4.7E+01 3.9E+01 5.2E+00 2.3E+03 2.0E+03 2.6E+02 
180 3.7E+00 3.6E+00 4.9E-01 3.7E+01 3.6E+01 4.9E+00 1.8E+03 1.8E+03 2.5E+02 
365 3.0E+00 3.2E+00 4.5E-01 3.0E+01 3.2E+01 4.5E+00 1.5E+03 1.6E+03 2.3E+02 
730 2.5E+00 2.8E+00 4.0E-01 2.5E+01 2.8E+01 4.0E+00 1.3E+03 1.4E+03 2.0E+02 
Skeleton Bioassay (nCi) 
0 7.0E-02 1.6E-01 3.2E-04 7.0E-01 1.6E+00 3.2E-03 3.5E+01 7.9E+01 1.6E-01 
1 7.0E-01 1.5E+00 2.4E-01 7.0E+00 1.5E+01 2.4E+00 3.5E+02 7.7E+02 1.2E+02 
2 7.7E-01 1.6E+00 2.7E-01 7.7E+00 1.6E+01 2.7E+00 3.8E+02 8.2E+02 1.3E+02 
5 8.0E-01 1.6E+00 2.7E-01 8.0E+00 1.6E+01 2.7E+00 4.0E+02 8.2E+02 1.3E+02 
7 8.0E-01 1.6E+00 2.7E-01 8.0E+00 1.6E+01 2.7E+00 4.0E+02 8.2E+02 1.3E+02 
14 8.7E-01 1.6E+00 2.7E-01 8.7E+00 1.6E+01 2.7E+00 4.3E+02 8.2E+02 1.3E+02 
30 1.0E+00 1.7E+00 2.7E-01 1.0E+01 1.7E+01 2.7E+00 5.0E+02 8.4E+02 1.3E+02 
60 1.2E+00 1.7E+00 2.7E-01 1.2E+01 1.7E+01 2.7E+00 5.8E+02 8.6E+02 1.3E+02 
90 1.3E+00 1.7E+00 2.5E-01 1.3E+01 1.7E+01 2.5E+00 6.5E+02 8.6E+02 1.3E+02 
180 1.5E+00 1.7E+00 2.5E-01 1.5E+01 1.7E+01 2.5E+00 7.3E+02 8.6E+02 1.3E+02 
365 1.4E+00 1.6E+00 2.3E-01 1.4E+01 1.6E+01 2.3E+00 7.2E+02 8.1E+02 1.1E+02 
730 1.3E+00 1.4E+00 2.0E-01 1.3E+01 1.4E+01 2.0E+00 6.3E+02 7.0E+02 1.0E+02 
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Table 13.8.  Reference Levels and Derived Reference Levels for 155Eu 
 
10-mrem HE,50 Reporting Level 100-mrem HE,50 Investigation Level 5,000-mrem Ht,50 Compliance Level 
Days Post Intake 
0.5-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
0.5-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
0.5-mm 
Inhalation 
5-mm 
Inhalation Ingestion 
Intake (nCi) 2.2E+02 2.4E+02 7.7E+03 2.2E+03 2.4E+03 7.7E+04 1.1E+05 1.2E+05 3.9E+06 
Skeleton Bioassay (nCi) 
0 4.7E-01 1.0E+00 1.8E-03 4.7E+00 1.0E+01 1.8E-02 2.3E+02 5.2E+02 9.2E-01 
1 4.7E+00 1.0E+01 1.4E+00 4.7E+01 1.0E+02 1.4E+01 2.3E+03 5.1E+03 6.9E+02 
2 5.1E+00 1.1E+01 1.5E+00 5.1E+01 1.1E+02 1.5E+01 2.6E+03 5.5E+03 7.7E+02 
5 5.3E+00 1.1E+01 1.5E+00 5.3E+01 1.1E+02 1.5E+01 2.7E+03 5.5E+03 7.7E+02 
7 5.3E+00 1.1E+01 1.5E+00 5.3E+01 1.1E+02 1.5E+01 2.7E+03 5.5E+03 7.7E+02 
14 5.8E+00 1.1E+01 1.5E+00 5.8E+01 1.1E+02 1.5E+01 2.9E+03 5.5E+03 7.7E+02 
30 6.7E+00 1.1E+01 1.5E+00 6.7E+01 1.1E+02 1.5E+01 3.3E+03 5.6E+03 7.7E+02 
60 7.8E+00 1.1E+01 1.5E+00 7.8E+01 1.1E+02 1.5E+01 3.9E+03 5.6E+03 7.3E+02 
90 8.4E+00 1.1E+01 1.5E+00 8.4E+01 1.1E+02 1.5E+01 4.2E+03 5.7E+03 7.3E+02 
180 9.3E+00 1.1E+01 1.4E+00 9.3E+01 1.1E+02 1.4E+01 4.7E+03 5.6E+03 6.9E+02 
365 9.1E+00 1.0E+01 1.2E+00 9.1E+01 1.0E+02 1.2E+01 4.6E+03 5.1E+03 6.2E+02 
730 7.3E+00 8.3E+00 1.0E+00 7.3E+01 8.3E+01 1.0E+01 3.7E+03 4.2E+03 5.0E+02 
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 Table 13.9. Hanford In Vivo Measurement Detection Capability 
for 152Eu, 154Eu, and 155Eu, nCi 
 
Measurement Type Organ/Tissue 152Eu 154Eu 155Eu 
NaI Preview Count Whole Body 20(a) 3.7(b) NA 
Coaxial Germanium 
Count Whole Body 5.5(a) 1.7(b) NA 
Chest Count Lung 0.4(a) 0.3(a) 0.6(a) 
Skull Count Skeleton 0.8(a) 0.5(a) 1.0(a) 
(a) Not part of routine library.  Estimated based on peak search 
algorithm. 
(b) From In Vivo Monitoring Project Manual, PNL-MA-574. 
NA = not applicable. 
 
Europium-152 is not part of the routine whole body count library 
search algorithm, but is detectable by the peak search algorithm at 
whole body count levels of about 20 nCi. 
 
Special measurements of lung, skeleton, or liver content may be 
desired to establish individual-specific patterns of distribution and 
retention.  Because europium is a liver- and bone-seeking radio-
nuclide, chest counts performed more than several weeks after intake 
may be detecting activity in the liver, the bones of the chest, and the 
lung, in any combination.  Therefore, any quantification of lung 
activity should consider the contribution from the bones and the 
liver.  Skeleton activity is estimated from a head count.  A correction 
factor can then be derived for obtaining lung activity from a chest 
count.  These calculations are performed by the In Vivo Measure-
ment Program staff.  Likewise, the presence of europium in the liver 
must also be considered for its potential impact on a chest count. 
 
Minimum detectable committed effective dose equivalents for 154Eu, 
based on whole body counting, are shown in Table 13.10 (0.5-mm-
AMAD inhalation), Table 13.11 (5-mm-AMAD inhalation), and 
13.12 (ingestion).  Corresponding values for 152Eu are shown in 
Tables 13.13, 13.14, and 13.15. 
 
13.4.2 Routine Bioassay Monitoring Protocol 
 
Routine bioassay monitoring for europium at Hanford can be 
accomplished by whole body counting.  From Table 13.10, it is 
apparent that annual whole body counting for 154Eu using the NaI 
preview counter provides sufficient sensitivity for detecting inhala-
tion intakes resulting in doses well below 100 mrem, even when an 
equal amount of 155Eu is included with 154Eu at the time of intake.  
The minimum detectable dose from ingestion of a mixture of 154Eu  
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Table 13.10. 154Eu Minimum Detectable Intakes and Doses (HE,50) 
for 0.5-mm-AMAD Class W Inhalation 
 
NaI System(a) Minimum 
Detectable 
Coax Ge System(b) Minimum 
Detectable 
Days Post Intake Intake (nCi) Dose (mrem) Intake (nCi) Dose (mrem) 
0 6.3 1.9 2.9 0.9 
1 6.7 2.0 3.1 0.9 
2 8.0 2.4 3.7 1.1 
5 13 4.0 6.1 1.8 
7 15 4.4 6.8 2.0 
14 16 4.8 7.4 2.2 
30 18 5.3 8.1 2.4 
60 22 6.5 10 3.0 
90 26 7.9 12 3.6 
180 34 10 15 4.6 
365 42 12 19 5.7 
730 49 15 23 6.8 
1825 77 23 35 11 
3600 161 48 74 22 
7300 740 220 340 100 
(a) Based on MDA of 3.7 nCi. 
(b) Based on MDA of 1.7 nCi. 
 
Table 13.11. 154Eu Minimum Detectable Intakes and Doses (HE,50) 
for 5-mm-AMAD Class W Inhalation 
 
NaI System(a) Minimum 
Detectable 
Coax Ge System(b) Minimum 
Detectable 
Days Post Intake Intake (nCi) Dose (mrem) Intake (nCi) Dose (mrem) 
0 4.1 1.1 1.9 0.5 
1 4.6 1.3 2.1 0.6 
2 6.9 1.9 3.1 0.9 
5 21 5.8 9.4 2.6 
7 25 6.9 11 3.2 
14 26 7.4 12 3.4 
30 28 8.0 13 3.7 
60 31 8.6 14 4.0 
90 34 9.4 15 4.3 
180 37 10 17 4.8 
365 41 11 19 5.2 
730 47 13 22 6.1 
1825 74 21 34 10 
3600 160 45 74 21 
7300 710 200 330 92 
(a) Based on MDA of 3.7 nCi. 
(b) Based on MDA of 1.7 nCi. 
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Table 13.12. 154Eu Minimum Detectable Intakes and Doses (HE,50) 
for Ingestion 
 
NaI System(a) Minimum 
Detectable 
Coax Ge System(b) Minimum 
Detectable 
Days Post Intake Intake (nCi) Dose (mrem) Intake (nCi) Dose (mrem) 
0 3.7E+00 <0.1 1.7E+00 <0.1 
1 5.2E+00 <0.1 2.4E+00 <0.1 
2 1.2E+01 0.1 5.3E+00 <0.1 
5 1.9E+02 1.5 8.9E+01 0.7 
7 1.3E+03 10 5.9E+02 4.4 
14 9.0E+03 68 4.1E+03 31 
30 9.3E+03 69 4.3E+03 32 
60 9.5E+03 71 4.4E+03 33 
90 9.5E+03 71 4.4E+03 33 
180 1.0E+04 75 4.6E+03 34 
365 1.1E+04 82 5.0E+03 38 
730 1.2E+04 93 5.7E+03 43 
1825 1.9E+04 150 8.9E+03 67 
3600 4.2E+04 320 1.9E+04 140 
7300 1.9E+05 1500 8.9E+04 670 
(a) Based on MDA of 3.7 nCi. 
(b) Based on MDA of 1.7 nCi. 
 
Table 13.13. 152Eu Minimum Detectable Intakes and Doses (HE,50) 
for 0.5-mm-AMAD Class W Inhalation 
 
NaI System(a) Minimum 
Detectable 
Coax Ge System(b) Minimum 
Detectable 
Days Post Intake Intake (nCi) Dose (mrem) Intake (nCi) Dose (mrem) 
0 3.4E+01 7.5 9.3E+00 2.1 
1 3.6E+01 8.0 1.0E+01 2.2 
2 4.3E+01 9.6 1.2E+01 2.6 
5 7.1E+01 16 2.0E+01 4.3 
7 8.0E+01 18 2.2E+01 4.8 
14 8.7E+01 19 2.4E+01 5.3 
30 9.5E+01 21 2.6E+01 5.8 
60 1.2E+02 26 3.2E+01 7.1 
90 1.4E+02 31 3.9E+01 8.6 
180 1.8E+02 40 5.0E+01 11 
365 2.2E+02 48 6.0E+01 13 
730 2.5E+02 55 6.9E+01 15 
1825 3.6E+02 80 1.0E+02 22 
3600 6.9E+02 1.5E+02 1.9E+02 42 
7300 2.4E+03 5.2E+02 6.5E+02 1.4E+02 
(a) Based on MDA of 20 nCi. 
(b) Based on MDA of 5.5 nCi. 
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Table 13.14. 152Eu Minimum Detectable Intakes and Doses (HE,50) 
for 5-mm-AMAD Class W Inhalation 
 
NaI System(a) Minimum 
Detectable 
Coax Ge System(b) Minimum 
Detectable 
Days Post Intake Intake (nCi) Dose (mrem) Intake (nCi) Dose (mrem) 
0 2.2E+01 4.6 6.0E+00 1.3 
1 2.5E+01 5.2 6.8E+00 1.4 
2 3.7E+01 7.8 1.0E+01 2.1 
5 1.1E+02 23 3.1E+01 6.4 
7 1.3E+02 28 3.7E+01 7.7 
14 1.4E+02 30 3.9E+01 8.3 
30 1.5E+02 32 4.2E+01 8.9 
60 1.7E+02 35 4.6E+01 9.6 
90 1.8E+02 38 5.0E+01 11 
180 2.0E+02 42 5.5E+01 12 
365 2.1E+02 45 5.9E+01 12 
730 2.4E+02 51 6.6E+01 14 
1825 3.5E+02 74 9.6E+01 20 
3600 6.5E+02 140 1.8E+02 37 
7300 2.4E+03 510 6.6E+02 140 
(a) Based on MDA of 20 nCi. 
(b) Based on MDA of 5.5 nCi. 
 
Table 13.15. 152Eu Minimum Detectable Intakes and Doses (HE,50) 
for Ingestion 
 
NaI System(a) Minimum 
Detectable 
Coax Ge System(b) Minimum 
Detectable 
Days Post Intake Intake (nCi) Dose (mrem) Intake (nCi) Dose (mrem) 
0 2.0E+01 0.1 5.5E+00 <0.1 
1 2.8E+01 0.1 7.7E+00 <0.1 
2 6.3E+01 0.3 1.7E+01 0.1 
5 1.1E+03 4.9 2.9E+02 1.4 
7 6.9E+03 32 1.9E+03 8.9 
14 4.9E+04 230 1.3E+04 63 
30 5.0E+04 240 1.4E+04 65 
60 5.1E+04 240 1.4E+04 66 
90 5.1E+04 240 1.4E+04 66 
180 5.3E+04 250 1.4E+04 68 
365 5.7E+04 270 1.6E+04 74 
730 6.5E+04 300 1.8E+04 83 
1825 9.5E+04 450 2.6E+04 120 
3600 1.7E+05 780 4.6E+04 220 
7300 6.1E+05 2800 1.7E+05 780 
(a) Based on MDA of 20 nCi. 
(b) Based on MDA of 5.5 nCi. 
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and 155Eu, as monitored by an annual whole body count, is also less 
than 100-mrem, assuming a ratio of 154Eu:155Eu of 4.7 in 2000.  
Annual whole body counting with the NaI preview counter is also 
sufficient for 152Eu, even though that nuclide would be found by the 
less sensitive peak search routine rather than a library search.  The 
fact that the source of 152Eu appears to be different from 154,155Eu 
suggests that concurrent exposure to all three nuclides seems 
unlikely.  Routine bioassay monitoring for 155Eu is not required 
because its presence can be inferred from the detection of 154Eu, 
which is the more predominant nuclide due to its longer radioactive 
half-life. 
 
A supplemental skeleton count to establish the 155Eu:154Eu ratio 
would allow determination of the total body content of 155Eu.  This 
measurement is warranted for an initial detection of 154Eu on a whole 
body count, but need not be a routine bioassay. 
 
Routine measurements in which a europium radionuclide is detected 
should be confirmed by follow-up in vivo measurements.  The 
recommended protocol is to use high-resolution germanium detector 
whole body counting to confirm the identity and magnitude of 
activity indicated by the preview counter.  Because of the adequate 
sensitivity of whole body counting, routine chest and skeleton 
measurements are not generally warranted for intake or dose 
assessment unless unusual retention or distribution is suspected. 
 
13.4.3 Special Bioassay for Suspected Intakes 
 
An in vivo whole body examination should be performed following a 
suspected intake.  However, unless the exposure appears to be of 
such magnitude that actions to hasten the removal of the material 
from the body are considered, the initial examination can be at the 
earliest convenient time during normal working hours.  A measure-
ment of the chest or skeleton is warranted to establish the 155Eu:154Eu 
ratio. 
 
Because there is much movement of inhaled material in the body 
during the first hours following an inhalation intake, early in vivo 
measurements should be considered semi-quantitative.  Where early 
measurements suggest that the committed effective dose equivalent 
might exceed 100 mrem, follow-up measurements should be 
performed after about 5 days to allow for early clearance of material 
via the GI tract.  Likewise, specialized measurements to estimate 
clearance rates from specific organs (i.e., chest counts and skeleton 
counts) should also be delayed until early GI tract clearance is 
complete. 
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13.5 Assessment of Internal Dose 
 
The assessment of internal dose equivalent from europium is accom-
plished by evaluating in vivo measurement results.  Assessments 
must consider the contribution of all radionuclides present in the 
mixture.  For mixtures of 154Eu and 155Eu, the activity ratio should be 
established based on in vivo (e.g., skeleton) measurements of the two 
nuclides or determined from an isotopic analysis of a characteristic 
sample of the material.  If the intake occurred many years before the 
measurements, decay correction must be made to determine the 
composition at the time of intake.  Alternatively, if 155Eu measure-
ment data are not available, the amount of 155Eu can be approximated 
from 154Eu by back-calculating the 154Eu value by radioactive decay 
correction from the time of intake to the reactor shutdown calendar 
year 1986 (a time when the 154Eu:155Eu ratio was approximately 2:1 
[Weetman and DeHaven, 1982]), dividing the 154Eu 1986 value by 2 
(to account for the 2:1 ratio), and then decaying the resulting 155Eu 
1982 activity value to the time of intake. 
 
The committed effective dose equivalent is calculated for confirmed 
occupational intakes from incidents discovered promptly in the 
workplace.  A 10-mrem screening level is applied to possible 
detections as part of routine bioassay monitoring.  Committed dose 
equivalents to specific organs and tissues are determined based on 
the criteria also presented in the Hanford Internal Dosimetry 
Program Manual.(a)  Several methods exist to evaluate in vivo results 
in order to assess the internal dose equivalent.  The simplest method, 
and the one recommended for initial evaluation of in vivo results, as 
well as for final evaluations when doses are low, involves fitting the 
in vivo measurement data to the expected internal activity using the 
biokinetic model prescribed by the ICRP in publication 30.  This 
model is implemented using CINDY.  For this evaluation, it is 
assumed that the material is in its most insoluble form; that the 
intake date, if unknown, is the midpoint of the period during which 
the intake could have occurred; and that the intake consisted of an 
inhalation of a class W aerosol with 0.5-mm-AMAD particles.  Data-
fitting is performed using CINDY.  Alternatively, a hand calculation 
can be performed using the factors tabulated in this chapter. 
 
If the intake could potentially result in a committed effective dose 
equivalent exceeding 100 mrem, then an investigation should be 
performed to determine the radionuclide composition of the involved 
mixture and to assess the dose equivalent from all radionuclides 
                                                     
(a) Pacific Northwest National Laboratory.  1999.  Hanford Internal Dosimetry Program Manual.  
PNL-MA-552, Richland, Washington.  (Internal manual.)  Available URL:  
http://www.pnl.gov/eshs/pub/pnnl552.htm 
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present in the mixture.  Additional in vivo measurements to confirm 
the assumed retention function, or to develop a case-specific reten-
tion function, should also be performed. 
 
Observed in vivo retention of europium should be used in place of 
the ICRP biokinetic model for evaluations of internal doses that 
potentially exceed 100 mrem or when sufficient in vivo data are 
available for such an analysis.  This can be accomplished by modify-
ing distribution and retention parameters in CINDY to achieve better 
agreement between the model and the observed in vivo measurement 
data.  Modifications to default model parameters must be document-
ed in the internal dose assessment report. 
 
13.6 Management of Internal Contamination Cases 
 
Although, historically, there have been intakes involving europium 
radionuclides at Hanford, in no case have the intakes resulted in 
significant internal doses relative to occupational exposure limits.  
Because europium radionuclides are no longer produced, the 
concentrations of europium radionuclides at Hanford are slowly 
diminishing. 
 
In vivo measurements performed following a potential intake 
provide an initial indication of the significance of an intake, although 
external contamination and rapid translocation of the material 
through the body may interfere with the accuracy of the measure-
ment.  If a significant intake is indicated, then various mitigative 
actions are possible (NCRP 1980; Bhattacharyya et al. 1992).  
Purgatives or laxatives, as well as enemas or colonic irrigations, may 
reduce the residence time of the radionuclide in the GI tract, thereby 
reducing absorption by the blood.  Antacids may reduce the absorp-
tion rate from the GI tract.  Once absorbed, diethylene triamine penta 
acetate (DTPA) may be considered as a chelating agent.  All of these 
mitigative actions require prescription by medical authority.  HEHF 
Occupational Medicine should be notified immediately upon indica-
tion of a severe intake potentially requiring mitigative action. 
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Appendix A 
 
 
 
Glossary 
 
 
This glossary is a limited compilation of specialized terms used in 
this manual which are pertinent to internal dosimetry and, in 
particular, the Hanford Internal Dosimetry Program.  It is not 
intended to be a general glossary of health physics or internal 
dosimetry definitions.  For more detailed compilations or cross 
references for health physics definitions, see 10 CFR 835.2, the U.S 
Department of Energy Internal Dosimetry Program Guide (DOE 
1999a), and the DOE Internal Dosimetry Standard (DOE 1999b).  
Most terms used in this manual are generally consistent with 
standard technical usage by the International Commission on 
Radiological Protection (ICRP), National Council on Radiation 
Protection and Measurements, Health Physics Society, DOE, and the 
Nuclear Regulatory Commission. 
 
absorption type  an ICRP 66 respiratory tract model concept describing the relative 
speed of dissolution and translocation to blood of material within the 
respiratory tract.  It is related to the physical chemistry of the 
material.  The ICRP 66 model defines three absorption types:  type F 
(fast solubilization), type M (moderate rate of solubilization), and 
type S (slow solubilization). 
 
bioassay the determination of kinds, quantities, and, in some cases, locations 
of radioactive material in the human body, whether by direct (in 
vivo) measurement or by indirect analysis of material removed or 
excreted from the body. 
 
burden the instantaneous quantity of material in an organ or tissue of interest 
(e.g., lung, bone surfaces, whole body, wound site).  Same as 
retained quantity. 
 
committed dose equivalent, HT,50 dose equivalent to an organ or tissue calculated for a 50-year period 
following an acute intake or onset of chronic intake.  It does not 
include contributions from external dose. 
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committed effective dose  the effective dose equivalent calculated for a 50-year period 
equivalent, HT,50 following an acute intake or onset of chronic intake.  It does not 
include contributions from external dose. 
 
DAC-hours  the time- and concentration-integrated exposure to airborne 
radioactivity.  Exposure to 1 DAC-hour implies the equivalent of one 
hour exposure to air at the DAC value. 
 
decision level The quantity of material in a measurement above which the analyte 
is interpeted as being present (i.e., analyte is detected).  See 
Appendix B for discussion. 
 
decorporation The chemical acceleration of the removal of radioactive atoms from 
the body using chelating agents, which bind the atoms and cause 
them to be excreted. 
 
deposition 1) process of material being initially retained from an intake, 2) the 
material initially deposited at an entry site, 3) Hanford historical 
usage:  the total input to an organ or tissue for a specified period of 
time.  See also systemic deposition. 
 
derived reference levels bioassay measurement values corresponding to retention or excretion 
associated with an intake of the reference level.  Derived reference 
levels are discussed in Section 2.12 of this manual and provided for 
nuclides in the respective chapters. 
 
detection level a general term relating to the smallest amount of material detectable 
as a function of the measurement method and instrument 
background.  (The precise way that detection level has been used at 
Hanford has changed over the years.  At times it has been defined as 
the minimum detectable activity, and at other times it has been 
defined as the decision level.) 
 
inhalation class an ICRP 30 respiratory tract model concept describing the relative 
rate of clearance from the pulmonary region of the lungs.  ICRP 30 
defined three inhalation classes for materials, class D (clearance half-
time less than 10 days), class W (10 to 100 days), and class Y 
(greater than 100 days).  Hanford has described a super-Y class as 
having a nominal clearance half-time of 10,000 days. 
 
injection any means whereby the radioactive material is placed in direct 
contact with the blood, excluding through the lung or gastrointestinal 
tract. 
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instantaneous uptake material translocated from a point of intake to the blood with 
essentially no delay.  In concept, a direct injection to the blood. 
 
intake The amount of a radionuclide that enters the body.  For inhalation, it 
is the material inhaled (including material that is subsequently 
exhaled).  For material absorbed through the intact skin, it is the 
amount absorbed through the skin.  For a wound or abraded skin, it is 
the amount absorbed through the skin; for practical purposes, it does 
not include material on the skin near the wound or material in the 
wound that is easily and promptly washed away.  However, it does 
include material that is later removed by medical treatment if the 
time from deposition to treatment is deemed long enough to allow 
some material to reach the systemic circulation prior to treatment.  
Intake is independent of time. 
 
in vivo refers to measuring radioactivity directly in a living organism.  In 
vivo is synonymous with the word “direct” when used in the phrase 
“direct bioassay.” 
 
minimum detectable  the smallest activity of a radionuclide in a sample (or organ) that wil 
activity, MDA be detected with a specified level of confidence.  See Appendix B for 
details. 
 
presystemic deposition a mathematical or schematic component (or components) of the 
deposition at the entry site that is available for translocation to the 
blood.  It excludes material that is permanently retained at the entry 
site or by the lymph system. 
 
preview counter a standup whole body counter consisting of five NaI detectors.  It is 
the principal counter used for routine whole body counts and 
incident screening counts, provided good resolution of photopeaks is 
not needed. 
 
reference level Hanford usage:  a magnitude of intake used as a basis for some 
action (see derived reference level).  Reference levels are discussed 
in Section 2.12 of this manual and provided for nuclides in the 
respective chapters. 
 
retained quantity synonymous with burden. 
 
retention the retained quantity (or burden) as a fraction of the uptake or intake.  
It can apply to any organ, tissue, system of tissues (e.g., 
gastrointestinal or respiratory tracts) or to the whole body.  
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systemic deposition Hanford historical usage:  activity retained for an extended period 
of time in all systemic organs and tissue.  Differs from uptake in that 
activity that stays in the transfer compartment and is ultimately 
excreted without going to systemic organs (for instance, because of 
chelation) is included in the term uptake but not in the term 
systemic deposition. 
 
transfer compartment a mathematical or schematic representation of the blood circulation 
system through which radioactive material is transported to organs, 
tissues, or excretion. 
 
transportable  material that is transferred from the site of initial deposition to the 
blood.  As applied to material in the lung, readily transportable  
material would be considered inhalation class D, whereas poorly 
transportable  material would be inhalation class Y.  It is generally 
equivalent to the term “soluble” as applied to human physiology, but 
it is not necessarily equivalent to chemical solubility in aqueous 
solutions. 
 
transportability class Generic term used at Hanford to designate the respiratory tract 
inhalation class or absorption type . 
 
uptake quantity of a radionuclide taken up by the systemic circulation or a 
specified organ or tissue via the blood.  Uptake can occur by direct 
injection into the blood, by absorption from compartments in the 
respiratory or gastrointestinal tracts, or by absorption through the 
skin or through wounds in the skin. 
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Appendix B 
 
 
 
Statistical Methods for Internal Dosimetry 
 
 
The Hanford Internal Dosimetry Program (HIDP) uses statistical 
methods to interpret bioassay data.  Some of the principal statistical 
methods used by the HIDP are described in this appendix, including 
those used to 1) determine when a sample result indicates the pres-
ence of something (i.e., when the analyte is detected), 2) describe the 
overall capability of the bioassay method for continual assurance of 
detection of the analyte, 3) normalize data, and 4) fit data to retention 
or excretion functions to calculate intake.  An additional issue is the 
determination that a detected analyte is significantly different from 
the normal presence of that analyte in a sample due to natural back-
ground.  This latter item is particularly important for uranium in 
urine and is discussed in that context in Chapter 7.0. 
 
The HIDP follows the concepts of critical level for decision, Lc, (also 
called the decision level, DL) and minimum detectable amount (or 
activity) MDA (also called detection level, Ld, or lower limit of 
detection, LLD in various publications), as described by Currie 
(1968; 1984), Brodsky (1986), the Health Physics Society 
(HPS 1996), and many others. 
 
B.1 Decision Level 
 
The Lc is the parameter that is used to indicate that an analyte has 
been detected.  The Lc is dependent on the probability of obtaining 
false positive results (i.e., the probability of a type I error) that one is 
willing to accept.  Decision levels for in vivo measurements are 
determined as described in the In Vivo Monitoring Program 
Manual.(a)  Decision levels for excreta samples are described below. 
 
Until April 2000, the decision levels by which excreta samples 
containing elevated quantities of radioactive material were identified 
were all specified in the contract with the analytical laboratory as 
absolute activity values.  The contract specified an upper bound for 
                                                 
(a) Pacific Northwest National Laboratory (PNNL).  In Vivo Monitoring Project Manual.  
PNNL-MA-574, Richland, Washington.  (Internal manual.) 
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the MDA for each analysis—called the contract limit, CL—and 
established the decision level at one-half the CL.  For most alpha 
spectrometry analyses the CL was 0.02 dpm per sample.  The deci-
sion level was applied to the activity result, rather than the count 
data.  The detection criterion was therefore insensitive to sample 
specific variables such as chemical yield and detector efficiency. 
 
In order to select a better procedure, an investigation of the 
American National Standard HPS N13.30 (1996) and other proposed 
decision level equations was initiated.  The investigation concluded 
that the N13.30 equation significantly underestimates the number of 
false positive results (MacLellan 2000).  The maximum number of 
false positive results peaks at about one background count during the 
counting period, but remains significant up to an expected 
100 counts.  The N13.30 equation answers the question, “How large 
a net count will be expected, less than ‘alpha’ percent of the time, for 
a given background count rate if there is no activity in the sample?”  
An equation proposed by Altshuler and Pasternack (1963) was found 
to be far superior: 
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where )1 is the decision level, ka is the false positive error term, and 
nb is the background count.  That equation answers the question 
“How much activity can be in a sample, and the confidence interval 
for the net count still include zero?”  The decision level obtained 
from the Altshuler and Pasternack equation remains unbiased down 
to an expected three counts during the counting period. 
 
For alpha spectrometry analyses, the concept of the Altshuler and 
Pasternack equation was adopted for the Hanford bioassay program, 
but an additional simplification was incorporated.  Although the 
form of the equation investigated previously calculates the decision 
level based only on the number of expected background counts, the 
original form of the equation used in the derivation equates the 
decision level with a multiple of the standard deviations estimate of a 
net count value ()1).  That is, the decision level is derived from the 
following equation: 
 
 bn21kbngnk1 +Da=+a=D  (B.2) 
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where (ng + nb) is used as the estimate of the net count variance, ng is 
the gross count, and nb is the background count.  Equation B.1 was 
derived by solving Equation B.2 for )1.  Hanford denotes the decision 
level by Lc, rather than the )1 used in Equations B.1 and B.2. 
 
Equations B.1 and B.2 are based on counts, however, the Hanford 
bioassay contract requires an estimate of the total propagated 
uncertainty (TPU) for each result reported.  A sample specific 
decision level has been implemented based on the TPU.  Rather than 
using Equation B.1, Hanford alpha spectrometry decision levels are 
set from Equation B.2, substituting the TPU for the radical.  A k" 
value of 2 was chosen in order to maintain the average decision level 
near historic levels.  The decision level, Lc, then takes the following 
simple form: 
 
 TPU2Lc ´=  (B.3) 
 
Any sample result that is equal to or greater than the Lc is considered 
positive, i.e., the analyte has been detected.  It is inherent in this 
method that when dealing with large numbers of samples some 
samples containing no activity will be declared positive.  Using the 
above criteria, about two percent of the results are expected to be 
false positives assuming a normal distribution of the net count. 
 
B.2 Minimum Detectable Amount 
 
The minimum detectable amount (or activity), MDA, provides a 
statement of the overall capability of the bioassay method to provide 
continual assurance of analyte detection.  The MDA is a function of 
the probabilities of both false positive and false negative (type II 
error) results.  For excreta bioassay results, the probability of each 
kind of error is set at 5%.  The MDA is determined annually from 
analysis of blank samples, using the methods of HPS N13.30 (1996).  
Annual MDAs are compared with values set by contract with the 
bioassay laboratory.  (The MDAs must be less than contractual 
detection levels or corrective action is required.)  It is the contractual 
detection levels that are referenced throughout this document 
because only the contractual detection levels are enforceable and are 
generally applicable over long periods of time.  At any time though, 
actual MDAs are usually somewhat lower than the contractual 
detection levels quoted in this document. 
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Determinations of in vivo measurement MDAs are described in the 
In Vivo Monitoring Program Manual.(a) 
 
B.3 Normalization of Excreta Bioassay Data 
 
Excreta bioassay data may be normalized differently according to the 
type of the sample.  Generally, urine data are normalized to total 
24-hour excretion based on the sampling protocol.  Total urine 
sampling for 24 hours does not require normalization, however, that 
protocol is generally not convenient for workers.  Thus, an approxi-
mate 24-hour sample is generally used.  The approximate 24-hour 
sample protocol (historically referred to as a “simulated 24-hour 
collection”) involves collecting all urine voided between one-half to 
one hour before retiring at night through the first voiding after 
getting up in the morning, this done for two consecutive nights.  
Provided the sample is collected properly, a total or approximate 
24-hour urine sample result is used as is; no further normalization is 
done.  An overnight sample is considered to represent approximately 
12 hours of urine collection, and is normalized by doubling the 
result.  Alternate normalization methods are described in 
Chapter 2.0, and may be used if they are more appropriate for the 
actual data. 
 
B.4 Treatment of Recounted Data Before Using It with 
Once-Counted Samples 
 
Results from samples that have been recounted should not be used 
directly with results from once-counted samples in analysis programs 
such as CINDY.  The best estimate of the mean value of the 
recounted sample and the best estimate of the uncertainty of the 
mean value need to be determined first so that each sample has only 
one value.  The mean value (xavg) should be determined by the 
following formula for a weighted average: 
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(a) Pacific Northwest National Laboratory (PNNL).  In Vivo Monitoring Project Manual.  
PNNL-MA-574, Richland, Washington.  (Internal manual.) 
 
Issued:  September 30, 2000  PNNL-MA-860 Appendix B 
Supersedes:  New  Page B.5 
where xi is each measurement result and si is the total propagated 
uncertainty associated with the measurement. 
 
The best estimate of the uncertainty of the mean value should be 
determined by the following formula for a weighted uncertainty: 
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This approach provides consistency in the way recounted sample 
data are used in dose assessments, and prevents recounted data from 
acquiring unwarranted weight relative to once-counted data for 
curve-fitting purposes. 
 
B.5 Curve-Fitting Techniques 
 
When multiple data of a similar nature (e.g., urine results) are 
obtained following an intake, some kind of curve fit is performed to 
fit an appropriate retention or excretion function to the data.  The 
CINDY computer code (Strenge et al. 1992) is most commonly used 
for the fitting of data, and the fitting algorithms available in that code 
are briefly discussed in Appendix D.  A recent study has shown that 
the “average of the slopes” fit method in CINDY is preferred if the 
predominant variance comes from the biology and not sample 
analysis (Skrable 2000).  Alternatively, simple data fits may be 
accomplished using one of the following techniques. 
 
The weighted least-squares fit is appropriate when two results of the 
measurement process are known—the result itself (whether zero, 
negative, or positive), xi, and its variance, s2—and when the 
variances are all determined in the same manner.  The weighting 
factor is the inverse of the sum of the variances.  The intake is 
given by 
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where ri is the value of the fractional retention or excretion function 
at the same time after intake as the sample result xi (Bevington 
1969).  Use of the weighted least-squares fit avoids having the 
calculation of intake or uptake dominated by a few large data points 
that may have poor precision, such as a hastily analyzed urine 
sample collected shortly after an intake. 
 
If the variances are unknown, are known to be equal, or were 
determined differently (such as counting uncertainty versus total 
propagated uncertainty), then the unweighted (or uniform weighting) 
least-squares fit is appropriate for use.  The unweighted least-squares 
fit is represented by Equation B.6 when all variances are set equal to 
one, or as shown below: 
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Data that are listed only as “less than” some value are difficult to use 
in a mathematical fitting technique.  At times, the HIDP has arbitrar-
ily set the value for the measurement as one-half of the less-than 
value for use in least-squares fitting techniques.  This does not work 
well if too many of the data are less-than values.  If there are many 
less-than values and a few well-known data, then the dosimetrist may 
need to use only the well-known data in the least-squares fitting 
technique, making sure that the best fit does not seem unreasonable 
with regard to the many less-than data. 
 
An “eye-ball” fit consists of plotting a line through a data set and 
graphically extracting the required intercepts and slope.  This 
approach involves subjective judgment by the dosimetrist and is not 
an objective statistical fit.  An “eye-ball” fit may be necessary if too 
many data are “less-than” values or if the analytical sensitivity varied 
greatly from datum to datum.  Caution must be used in exercising 
eye-ball fits, because the quality of data obtained will vary 
depending on the type of axis (linear, logarithmic). 
 
In all cases, outliers, or data that are not relevant to the equation 
being fit, should not be included in a fitting technique.  Examples 
would include urine data influenced by diethylene triamine penta  
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acetic acid (DTPA) therapy or a datum with a very high less-than 
result.  The assessment should document which data are being 
ignored and why. 
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Appendix C 
 
 
 
Biokinetic Models 
 
 
 
Biokinetic models are used to describe the initial deposition, and 
subsequent movement and retention of material throughout the body.  
The Hanford Internal Dosimetry Program (HIDP) seeks to use 
realistic and generally accepted, peer-reviewed biokinetic models to 
the extent practicable.  The specific models used for various 
elements are detailed in the various chapters of this manual.  General 
models applicable to any element include the respiratory tract and 
gastrointestinal (GI) tract models, which are described in this 
appendix. 
 
C.1 ICRP Respiratory Tract Model 
 
The HIDP uses the International Commission on Radiological 
Protection (ICRP) publication 30 (1979) Respiratory Tract Model 
shown in Figure C.1.  The deposition fractions, DN-P, DT-B, and DP, as 
given in Figure C.1, apply to an aerosol with an activity median 
aerodynamic diameter (AMAD) of 1 mm.  Figure C.2, also from 
ICRP 30, shows how the deposition fractions vary as a function of 
AMAD.  Deposition fractions for particle sizes other than 1 mm may 
be estimated from Figure C.2, may be obtained from Table C.1, or 
may be determined using the CINDY computer code.  From Figure 
C.2, it is evident that DN-P and DP change with particle size, whereas 
DT-B is essentially constant at 0.08 over the respirable particle size 
range. 
 
Other respiratory tract models of interest include the ICRP 66 human 
respiratory tract model (ICRP 1994) and the National Council on 
Radiation Protection and Measurements Report No. 125 model 
(NCRP 1997).  Although the ICRP 66 model has received 
considerable international acceptance for both technical and 
regulatory applications, the HIDP has not sufficiently evaluated the 
tool for implementation. 
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 Figure C.1. Mathematical Model Used to Describe Clearance from the Respiratory System  (The values 
for the removal half-times, Ta-j and compartmental fractions, Fa-j, are given in the tabular 
portion of the figure for each of the three classes of retained materials.  The values given 
for DN-P, DT-B, and DP [left column] are the regional depositions for an aerosol with an 
AMAD of 1 mm.  The schematic drawing identifies the various clearance pathways from 
compartments a-j in the four respiratory regions, nasal passages [N-P], tracheal-bronchial 
tree [T-B], pulmonary [P], and lymph nodes [L].) 
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 Figure C.2. Deposition of Dust in the Respiratory System  (The percentage of activity or mass of an 
aerosol that is deposited in the N-P, T-B, and P regions is given in relation to the AMAD.  
The model is intended for use with aerosol distributions with AMADs between 0.2 and 
10 mm and with geometric standard deviations of less then 4.5.  Provisional estimates of 
deposition further extending the size range are given by the dashed lines.  For an unusual 
distribution with an AMAD of greater than 20 mm, complete deposition in the N-P region 
can be assumed.  The model does not apply to aerosols with AMADs of less than 
0.1 mm.) 
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Table C.1.  Deposition Fractions as a Function of Aerosol AMAD(a) 
 
Deposition Fractions  
AMAD, mm N-P(b) P(c) 
0.2 0.050 0.50 
0.3 0.088 0.43 
0.4 0.13 0.38 
0.5 0.16 0.34 
0.6 0.19 0.32 
0.7 0.23 0.30 
0.9 0.26 0.28 
1.0 0.30 0.25 
2.0 0.50 0.17 
3.0 0.61 0.13 
4.0 0.69 0.10 
5.0 0.74 0.088 
6.0 0.78 0.076 
7.0 0.81 0.067 
8.0 0.84 0.060 
9.0 0.86 0.055 
10.0 0.87 0.050 
(a) From NUREG/CR-1962, p. 25 (Eckerman, Watson, 
and Ford 1981).  The deposition fraction for the T-B 
region is 0.08, independent of AMAD. 
(b) N-P = nasal-passage region. 
(c) P = pulmonary region. 
 
C.2 The Gastrointestinal Tract Model 
 
The HIDP uses the ICRP 30 (1979) GI Tract Model shown in Figure 
C.3.  The model is integral to the CINDY computer code.  The 
fraction of material passing through the GI tract that is absorbed into 
the blood is defined as the f1 factor and specific values are reported 
in the various radioelement chapters of this manual.  This model 
assumes that uptake to blood within the GI tract only occurs from the 
small intestine (SI).  An absorption rate to the blood from the GI tract 
can be calculated as follows: 
 
 
1
SI1
f1
f
B -
l
=l  (C.1) 
 
where lSI is assumed to be 6 d-1. 
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Figure C.3.  Biokinetic Model for the Gastrointestinal Tract (From ICRP 30 [1979]) 
 
C.3 Fecal Sampling Model 
 
Fecal sampling can be a valuable  aid for estimating the magnitude of 
an inhalation intake.  Through application of the lung and GI tract 
models (ICRP 1979), estimates can be made of the expected daily 
fecal excretion following an inhalation intake.  For class W and 
class Y radionuclides, the expected fecal excretion can be divided 
into two components:  that which represents rapid clearance from the 
respiratory tract and that which represents longer-term clearance 
from the pulmonary region of the lung.  Measurement of the quantity 
of a class W or Y radionuclide excreted via feces in the rapid 
clearance phase (first few days following an intake) can provide an 
early estimate of intake that is often more sensitive than other 
 
PNNL-MA-860 Appendix C  Issued:  September 30, 2000 
Page C.6 
bioassay measurements.  This estimate may be especially helpful for 
class Y radionuclides with little absorption from the GI tract and for 
which in vivo counting is difficult, e.g., class Y forms of plutonium, 
uranium, and 147Pm.  Additionally, fecal sampling during the rapid 
clearance phase may be helpful with more readily transported forms 
when the use of therapeutic methods invalidates the use of normal 
systemic retention or excretion models, e.g., during chelation 
therapy.  
 
Figure C.4 shows the expected daily fecal excretion as a fraction of 
intake of 1-mm-AMAD particles for class W (curve A) and class Y 
(curve B) material for which radioactive decay, uptake from the GI 
tract, and systemic excretion to the GI tract are negligible (from 
NUREG/CR-4884 [Lessard et al. 1987] using 239Pu as the model).  
Nearly half of the intake is excreted via feces in the first 5 days, 
which makes fecal sampling a very sensitive indicator of intake at 
that time.  Excretion during the next 5 to 10 days decreases rapidly, 
and the daily excretion beyond about 15 days is relatively constant, 
representing the slowly clearing component from the pulmonary 
region.  Note that excretion during the rapid clearance phase is  
 
 
 
Figure C.4. Daily Fecal Excretion of Plutonium as a Fraction of Inhalation Intake for Three Intake 
Scenarios (all 1-mm-AMAD particle size)  
 A – inhalation of 1 unit of class W plutonium 
 B – inhalation of 1 unit of class Y plutonium 
 C – inhalation of 1 unit and ingestion of 1 unit of class Y plutonium 
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relatively independent of inhalation class, and that excretion after 
about 10 days is unaffected by ingestion that may have occurred 
along with the inhalation. 
 
Table C.2 lists fecal excretion fractions and accumulated fractional 
excretion during the rapid clearance phase for the material described 
in the above paragraph (Lessard et al. 1987).  Use of the accumulated 
fecal excretion data in Table C.2 may be preferred over use of the 
daily fractional excretion data because of the difficulty in collecting 
(or at least in knowing that you have collected) a day’s excretion.  
(See below for pitfalls discussion of this problem.)  Because of 
problems discussed below, fecal sampling is best used in combina-
tion with other bioassay measurements.  When the quality of data 
from the other bioassay measurements is good, e.g., the data are not 
near the detection level or are not biased by the effects of medica-
tion, then preference should be given to estimates of intake from the 
other bioassay measurements.  However, for moderately or poorly 
absorbed radionuclides, fecal sampling during the first few days after 
an inhalation intake is a very sensitive indicator. 
 
The extent of use of fecal sampling depends on the expected severity 
of the intake.  For intakes that are estimated (based on workplace 
monitoring) to result in a committed effective dose equivalent of less 
than 100 mrem, or for situations where confirmation that an intake 
did not occur is desired, two fecal samples collected from 24 to 
72 hours after the potential intake are recommended.  If the samples 
show significant detectable activity (e.g., implying a dose greater 
than 100-mrem), additional bioassay measurements should be  
 
 Table C.2. Fraction of Intake Excreted via Feces Following an Acute  
Inhalation of Poorly Absorbed Material(a) 
 
Intake Fraction Excreted During Interval 
1-µm-AMAD 5-µm-AMAD 1-µm-AMAD 5-µm-AMAD 
Days Post Intake 
Class  
W 
Class  
Y 
Class 
W 
Class 
Y 
Class  
W 
Class  
Y 
Class  
W 
Class  
Y 
1 ( 0 – 24 hours) 0.044 0.054 0.091 0.106 0.044 0.054 0.091 0.106 
2 (24 – 48 hours) 0.13 0.160 0.26 0.30 0.17 0.21 0.35 0.41 
3 (48 – 72 hours) 0.11 0.130 0.20 0.23 0.28 0.34 0.55 0.64 
4 (72 – 96 hours) 0.063 0.071 0.11 0.12 0.35 0.42 0.66 0.76 
5 (96 – 120 hours) 0.033 0.035 0.048 0.053 0.38 0.45 0.71 0.81 
(a) Modeled using 239Pu with f1 factors as given in Section 8.2.2. 
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obtained, including additional fecal samples collected from 20 to 100 
days post intake, after early clearance to aid in distinguishing 
ingestion, class W, or Y components.  In some situations these 
additional fecal samples may still be more sensitive to intake than 
other bioassay measurements, but special care is necessary to avoid 
further small intakes prior to collection of these additional samples.  
Samples collected after 5 to 7 days post intake show a marked 
decrease in sensitivity to intake detection. 
 
If workplace monitoring results indicate a more serious intake, all 
fecal excretion from about 6 to 72 hours post intake should be 
collected.  The total result from all samples collected during this 
period is divided by the fractional accumulated excretion for the first 
3 days post intake to provide an estimate of intake.  Table C.2 can be 
used for isotopes of plutonium and uranium (also other radionuclides 
where GI absorption and radioactive decay can be neglected); 
NUREG/CR-4884 (Lessard et al. 1987) can be used for other 
radionuclides (1-mm-AMAD particles only). 
 
The fecal samples obtained after 20 days post intake can help deter-
mine the inhalation class and clearance rate from the pulmonary 
region to the GI tract.  But recognize that, despite appearances in the 
ICRP lung model, the clearance rate from the pulmonary region to 
the GI tract (compartment g) is not necessarily identical to the clear-
ance rates from the pulmonary region to the blood or lymph system 
(compartments e and h).  Urine data provide the best estimates of the 
latter clearance rates.  Lacking good urine data, default values should 
be used.  For example, if fecal data indicate a long-term clearance 
half-time of 400 days and urine data are lacking or are not definitive, 
the material should be assumed to be class Y and clearance half-
times of 500 days should be used for compartments e and h. 
 
Reference Man (ICRP 1974) excretion for adult’s ranges from 60 to 
500 g/day, with a recommended average of 135 g/day for an adult 
male and 110 g/day for an adult female.  Note that these values 
represent excretion “per day” not excretion “per bowel movement.”  
When a single bowel movement is collected, it is generally interpret-
ed as representing excretion for 1 day.  If the sample is greater than 
60 g, no normalization is used.  If the sample is less than 60 g, the 
sample results should be normalized to 135 g for males and 110 g for 
females.  If total accumulated excretion over a time period was 
requested and there is no apparent reason to suspect that total excre-
tion was not provided, then all sample results should be used as is, 
without regard for the mass of individual samples.  If excretions 
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were missed during the time period, then normalization of the total 
mass to the total mass expected based on the reference values given 
above should be used. 
 
There are problems with interpretation of fecal data for which the 
dosimetrist needs to stay alert.  One is the possibility of interference 
by ingested material.  In Figure C.4, curve C shows the expected 
daily fecal excretion from a unit intake of class Y material by 
inhalation and a unit intake by ingestion.  Note that curve C follows 
the same general shape of the other curves, and hence a combined 
inhalation/ ingestion intake of nearly equal proportions would not be 
readily discernible using early fecal data.  Also note that the 
influence of the ingestion remains significant until about 8 days post 
intake.  The accumulated fecal excretion in the first 3 days from this 
intake would be 3.5 times the accumulated fecal excretion from 
inhalation alone, and hence the estimate of intake determined in this 
manner would be 3.5 times too great.  The point is that because 
ingested material contributes in toto to fecal excretion, it has a 
magnifying effect on the determination of inhalation intake.  For 
sufficiently large intakes, this problem can be overcome by sampling 
during the slow clearance phase. 
 
Interpretation of fecal data is also sensitive to the size of the particles 
inhaled.  For example, Figure C.5 shows fractional daily excretion 
for class W and class Y plutonium for 3- and 8-mm-AMAD particles.  
In these cases collection of the first 3 days’ feces and assumption of 
1-mm-AMAD particles would result in overestimation of the intake 
by 1.7 and 2.2 for intakes actually involving class W 3- and 8-mm-
AMAD particles, respectively, and by 1.6 and 2.0 for class Y 3- and 
8-mm-AMAD particles, respectively.  Additional error would then be 
made in the calculation of doses to the lung and systemic organs 
because the fraction of intake deposited in the pulmonary region of 
the lung and/or transferred to the blood would be overestimated also. 
 
Another difficulty arises from single-voiding samples.  These are 
generally easier to obtain than total excretion over a specific period.  
But both inter- and intra-individual variation in the regularity of 
bowel movements can introduce large uncertainties if a single void-
ing is used to represent daily excretion.  Normalization by mass can 
help reduce error when a single sample represents a fraction of a 
day’s excretion, but it does not help when a single sample represents 
excretion for several days. 
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Contamination of a fecal sample by urine should be avoided, but 
generally will not introduce significant error if it occurs. 
 
For uranium, natural daily ingestion (about 2 mg but variable [ICRP 
1979]) needs to be taken into account. 
 
 
 
 Figure C.5. Daily Fecal Excretion of Plutonium as a Fraction of Inhalation  
Intake for Four Intake Scenarios 
 A – class W, 3-mm-AMAD particles 
 B – class W, 8-mm-AMAD particles 
 C – class Y, 3-mm-AMAD particles 
 D – class Y, 8-mm-AMAD particles 
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Appendix D 
 
 
 
Computer Codes 
 
 
Computer codes are important to internal dosimetry because of the 
number and complexity of biokinetic models used for bioassay 
interpretation and dose assessment.  The models have to factor in 
basic radiological decay parameters, intake parameters such as 
particle size and breathing rate, initial deposition within the body, 
subsequent distribution and translocation within body organs and 
tissues, excretion pathways, energy absorption in a target tissue from 
a radionuclide decay in a source tissue, and the various tissue 
weighting factors.  An appropriate data-fitting routine is required for 
assessment of bioassay data and codes need various output routines 
to display data in useful formats such as reports and graphs.  The 
Hanford Internal Dosimetry Program (HIDP) has several computer 
programs at its disposal to aid with internal dosimetry evaluations.  
These programs are listed below and discussed in the following 
sections: 
 
· CINDY 
 
· PUCALC 
 
· AMERIN 
 
· PU.EXE 
 
The HIDP maintains historical archives of computer codes used.  
This appendix only addresses codes in current use.  In addition to the 
currently used codes, the HIDP may have codes that are undergoing 
consideration or testing but are not used for formal Hanford applica-
tions.  Also, common commercially available spreadsheet and 
database software are not described here. 
 
D.1 CINDY 
 
The Code for INternal DosimetrY (CINDY) is the principal 
computer code used by the HIDP for dosimetry.  The code can do 
intake calculations based on curve-fitting of bioassay data; calculate 
committed (or any specified interval) organ, tissue, and effective 
dose equivalents; and make bioassay projections.  The wide range of 
radionuclides encompassed by the code library includes all those 
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addressed by this manual.  A two-part manual details the conceptual 
models used by the code (Strenge et al. 1992a) and provides a user’s 
guide to loading and executing the code (Strenge et al. 1992b).  The 
HIDP currently uses Version 1.4. 
 
The code was developed at Pacific Northwest National Laboratory 
(PNNL) in the late 1980s and early 1990s under U.S. Department of 
Energy (DOE) funding specifically for implementing the dose 
provisions originally specified in DOE 5480.11 (1988).  It is 
commercially available through Canberra Nuclear, Inc.(a)  The code 
was originally designed for a DOS-based personal computer.  The 
HIDP has also used the code on WINDOWS 3.1, WINDOWS 95, 
and WINDOWS 98 platforms.  Difficulty was encountered when 
installing the code onto a WINDOWS 98 machine from the original 
disks.  This was overcome by copying the files directly from a 
WINDOWS 95 machine.  Initial attempts to install the code on a 
WINDOWS 2000 platform have been problematic. 
 
D.1.1 Models Included in CINDY 
 
CINDY incorporates the International Commission on Radiological 
Protection publication 30 (ICRP 1979) models for radionuclides, but 
permits modification of many parameters.  Identification of some of 
the key adjustable parameters is discussed below. 
 
The exposure scenario options permit inhalation, ingestion, and 
direct intake (which can be considered as either absorption through 
skin or wound injection).  Inhalation and ingestion intakes use the 
ICRP 30 models.  Inhalation permits use of class D, W, or Y, or any 
combination thereof, and allows for specification of particle size.  
Ingestion may be of soluble or insoluble forms (with user-variable 
f1 factors).  Direct intake allows uptake to blood from one or more 
independent compartments, each exhibiting a user-defined clearance 
half-time to blood.  Exposures may be either acute (instantaneous) 
intakes or chronic (continuous over a user-specified interval). 
 
The respiratory tract model permits adjustment of both the 
compartment fraction and clearance half-time for the individual 
compartments of the ICRP 30 model.  Regional deposition fractions 
for the nasal-pharengeal, tracheobronchial, and pulmonary regions 
are set by the code based on the particle size specified. 
 
The gastrointestinal (GI) tract model permits adjustment of the mean 
resident times (in hours) for the stomach, small intestine, upper large  
                                                 
(a) Canberra Nuclear, Inc., One State Street, Meriden, CT.  06450.  Phone (203) 238-2351. 
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intestine, and lower large intestine.  Absorption within the GI tract is 
established by setting the GI uptake (f1) factor for individual 
radionuclide biokinetic models.  
 
Systemic distribution, retention, and excretion models are provided 
based on chemical elements.  Typically the parameters for 
distribution compartment fractions and clearance half-times are 
adjustable by the user.  The default model used by CINDY for most 
elements is the ICRP 30 model, however element-specific models 
are also provided for iodine, alkaline earths, radium/radon, tritium, 
carbon, tellurium/iodine, and uranium.  The GI uptake (f1) factor is 
an element-specific variable.  Detailed descriptions of the specific 
models are contained in Part 1 of the CINDY manual (Strenge et al. 
1992a) 
 
D.1.2 Bioassay Data Input  
 
The excretion models used by CINDY are based on daily excretion 
rates.  Because bioassay data are often provided using different 
formats, protocols for automatically manipulating data to give total 
daily bioassay values are incorporated into CINDY.  The user must 
be aware of these protocols, otherwise biased conclusions can be 
reached by unanticipated, unrecognized, or unintended data adjust-
ment.  Table D.1 contains the CINDY bioassay data normalization 
protocols. 
 
Table D.1.  CINDY Normalization Protocols for Biosassay Data 
 
Input Data 
Sample 
Period 
Sample 
Volume Manipulation for Daily Result Used in Curve Fitting 
Total activity units Unknown  
(no input) 
Unknown  
(no input) 
Sample is assumed to be 1-day excretion.  No data 
normalization. 
Total activity units Known  
(input) 
Unknown  
(no input) 
Sample is normalized to 24-hour period. 
Total activity units Unknown  
(no input) 
Known  
(input) 
Sample is normalized using reference daily volume. 
Total activity units Known  
(input) 
Known  
(input) 
Sample is normalized to 24-hour period.  Volume ignored. 
Concentration units Unknown  
(no input) 
Unknown  
(no input) 
Concentration assumed for one day and daily result calculated 
based on reference daily volume. 
Concentration units Known  
(input) 
Unknown  
(no input) 
Daily result is calculated based on reference daily volume.  
Period ignored. 
Concentration units Unknown  
(no input) 
Known  
(input) 
Concentration assumed for one day and daily result calculated 
based on reference daily volume. 
Concentration units Known  
(input) 
Known  
(input) 
Concentration multiplied by volume and normalized by period 
to give daily result. 
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On the other hand, bioassay projection values, based on user-input 
intake values, are provided as instantaneous rates, so for the first few 
days after an intake, CINDY-generated excretion rates will not be 
exactly representative of total 24-hour excretion. 
 
D.1.3 Intake Assessment Curve-Fitting Routines 
  
Four methods for intake assessment by curve-fitting of bioassay data 
are included in CINDY.  All are based on assumptions about the 
variance of the measurement value.  Brief descriptions of the 
techniques are given below. 
 
The unweighted least-squares (or uniform weighting) method 
assumes that weighting factors are constant and equal, implying that 
the variance is independent of the measurement magnitudes.  This 
method is appropriate if all measured values are believed to have 
similar accuracy and are significantly above the detection limits of 
the measurement method. 
 
The ratio of the means (or weighted least-squares) method assumes 
that data point weighting factors are inversely proportional to the 
expected value, implying that the variance is proportional to the 
magnitude of the expected value.  This method avoids having the 
calculation dominated by a few large data points that may have poor 
precision. 
 
The average of the slopes method assumes data point weighting 
factors are inversely proportional to the square of the expected value, 
implying that the variance is proportional to the square of the 
expected value.  This method is appropriate when the variance is due 
primarily to biological factors rather than the detection precision of 
the measurement. 
 
CINDY also has a user-defined weighting method in which the user 
supplies the estimate of variance for each measurement value.  The 
weighting factors are calculated by CINDY as the inverse of the 
supplied variance. 
 
D.1.4 Dose Calculation 
 
CINDY calculates organ and tissue doses by determining the number 
of radionuclide transformations in a source organ or tissue over the 
time frame of interest (i.e., the time-integrated activity) and 
multiplying it by the specific effective energy (SEE) factor for the 
appropriate source-to-target combination contained in the code  
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library.  The library SEE factors were obtained from the Oak Ridge 
National Laboratory (ORNL) modeling group that developed them 
for ICRP 30. 
 
D.1.5 Acceptance Testing by the HIDP 
 
Prior to its initial adoption in 1991 at Hanford, the CINDY Code 
underwent extensive testing and benchmarking by the HIDP.  It was 
compared with the standard Hanford code then being used 
(GENMOD) and was found to be in reasonable agreement.  The 
1995 revision to CINDY (Version 1.4) also underwent HIDP testing 
prior to acceptance. 
 
D.1.6 HIDP User Experience with CINDY 
 
After 9 years of using CINDY, the HIDP has identified a number of 
caveats and recommendations for its use.  Among them are the 
following: 
 
· Don’t mix intake units for different radionuclides in the same 
calculation.  All units have to be the same. 
 
· CINDY automatically uses three types of curve-fitting routines 
to determine intake from bioasaay data, and it allows for the user 
to insert a fourth method.  Experience has not shown that any 
one method is always best.  The user should carefully review the 
plot of the various fits to the actual data before choosing an 
intake value.  An average intake value may be acceptable if none 
of the fits appear to be the best choice.  The intake assessment 
mode data-plotting routine plots only those data used in a 
“connect-the-dots” straight-line approach.  The bioassay projec-
tion mode shows the actual retention pattern, but does not show 
the bioassay data points themselves. 
 
· Using the user-defined inverse variance method for curve-fitting 
can result in the greatest weight being given to data that show no 
detectable activity, even though bracketed by data showing 
detectable activity.  Caution is needed no matter which curve-
fitting scheme is used. 
 
· The end time for a chronic intake cannot be given as 12/31/xxxx 
24:00 or as 01/01/xxxx 00:00 (the exact end or start of a year).  
The end time must be offset by at least one minute if the end 
time is the actual end of the year.  Otherwise, the year of the 
specified end time will not be reported in the calendar year 
results and a 2-year period will be used in its place. 
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· The maximum number of report times allowed for a calculation 
is 70 (69 for continuous intakes).  More data may be inputted, 
but some must then be flagged to reduce the total number of data 
points used in any given calculation to 70. 
 
· In the bioassay projection mode, including a report time of “0” 
can eliminate reporting of some organs that might be of interest 
(e.g., thyroid retention for iodines, bone surface for uranium, 
plutonium).  If retention for a time immediately post intake is 
needed, 0.1 or 0.01 day can be used and will provide results for 
the full scope of organs and tissues included in the nuclide 
library. 
 
· Bioassay projections for accumulated excretion values for early 
times post intake can be obtained by running the bioassay 
projection mode using increments of 0.1 day for the first few 
days of interest and summing the resulting instantaneous 
excretion rates over the period of interest. 
 
· For tritium, the inhalation intake mode automatically factors in a 
skin absorption component equal to 50% of the inhalation.  
Thus, the total uptake from an inhalation is 1.5 times the 
inhalation intake. 
 
· When two uranium isotopes are flagged as isotopes of concern, 
the intake assessment mode calculates the intake of the first 
correctly, but not the second.  Run the uranium isotopes 
separately in the intake assessment mode. 
 
· Ingrowth of 241Am from 241Pu is not accounted for in the intake 
assessment mode.  Don’t use long-term 241Am in the lung to 
determine plutonium intakes if 241Am ingrowth is a potential 
concern.  Ingrowth is appropriately addressed in the bioassay 
projection mode. 
 
· The error tolerance setting should be 1E-06 or 1E-07 when 
performing analyses using the Jones or Durbin excretion models.  
Instabilities can occur in the intake assessment or bioassay 
projection modes using the Jones or Durbin excretion models, 
usually at times following intake on the order of 1,000 to 
10,000 days.  The instabilities are easily observed in the display 
graphic results to screen mode.  If instabilities are observed, 
rerun the case with a different error tolerance.  Generally 1E-06 
will provide acceptable results; be cautious of 1E-08. 
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D.2 PUCALC Family 
 
PUCALC is a family of computer codes developed by the HIDP in 
the mid-1980s to simplify the process of determining the presystemic 
deposition of plutonium in an individual, based on urine data.  The 
code uses the Jones excretion model to allow matching of observed 
excretion data to predicted excretion by varying the presystemic 
deposition magnitude and the its transfer rate into the systemic 
compartment.  The PUCALC program creates a database of urine 
sample results.  PCPLOT graphs the data points on the computer 
screen using a log-log scale, and upon input of values for 
presystemic deposition and transfer rate, overlays a curve on the 
screen.  By iteration, the dosimetrist can quickly compare many 
different combinations and subjectively select a preferred fit.  With 
the adoption of CINDY, the PUCALC family became seldom used, 
though it does include capability for addressing multiple intakes, 
which CINDY lacks.  Much of the PUCALC family has been 
rendered obsolete by advances in personal computer (PC) technology 
and the code is seldom used now.  No effort has been made to update 
the family to advanced microprocessors beyond the 486 and 
Pentium. 
 
D.3 AMERIN 
 
The AMERIN code is used for calculating the biological half-life 
and ingrowth for mixtures of 241Am and 241Pu.  The code is 
executable on a PC from a WINDOWS 95 or 98 environment.  It can 
calculate the biological clearance half-time from a single compart-
ment using 241Pu and 241Am activities, or alternatively, calculate the 
activity of 241Am at various times after intake when the biological 
half-time is given.  The code was developed by the HIDP for use 
primarily with in vivo measurement data. 
 
D.4 PU.EXE 
 
PU.EXE is a plutonium utility developed at Hanford to calculate 
information about mixtures of plutonium isotopes.  The HIDP uses it 
to show the isotopic composition of plutonium mixtures by weight, 
total mass, and total activity, and then age those mixtures and 
recompute the compositions.  Heat generation rates, neutron 
production rates, and an inhalation dose factor are included in the 
utility but are not used by the HIDP.  The utility was developed by 
Paul Rittman, based on his earlier work (Rittman 1984). 
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Appendix E 
 
 
 
Mixtures and Tracer Radionuclides 
 
 
Mixtures of radionuclides at Hanford can be found in reactor facili-
ties, former processing facilities, waste management facilities, and 
laboratories.  The radionuclides most commonly encountered in 
mixtures include 137Cs, 90Sr, and plutonium, although others are also 
possible.  This appendix discusses the bioassay capability for mix-
tures of 137Cs and 90Sr, 137Cs and plutonium, and 90Sr and plutonium. 
 
Where the composition of a mixture can be well-characterized, (e.g., 
a potential intake identified at the time by field indicators), then 
bioassay for a tracer radionuclide may provide optimum monitoring 
capability, with determination of nuclides not detectable by bioassay 
inferred by ratio using intake characterization information, such as a 
representative nasal or surface smear or an air sample.  Depending 
upon the isotope ratios in the mixture, the tracer radionuclide may be 
important from a bioassay perspective, but may not be a dominant 
contributor to internal dose. 
 
Bioassay for a tracer radionuclide can provide a reasonable indicator 
of potential intake as a cost-effective alternative to multiple bio-
assays when the mixture is well-characterized.  However, detection 
of the tracer radionuclide as a high routine measurement can lead to 
complicated assessments.  For high routine bioassay measurements, 
there may not be any obvious specific material to which a worker 
was exposed.  For many years an assumption of a 1:1 137Cs:90Sr 
activity ratio was used as a fission product mixture, however, the 
wide range of waste management practices that have occurred at 
Hanford do not provide assurance that the 1:1 ratio is valid.  Thus, 
where one nuclide is used as an indicator for others, detection of that 
nuclide by routine measurement is most appropriately used as a 
trigger for supplemental bioassay for other, potentially significant, 
radionuclides.  Once the bioassay analyses have been completed, 
intakes are confirmed only for those nuclides detected or that can 
confidently be inferred from tracer nuclide detection and knowledge 
of the workplace mixture. 
 
Bioassay capability (in terms of minimum detectable doses) has been 
evaluated for combinations of 137Cs and 90Sr, 137Cs and plutonium, 
and 90Sr and plutonium.  For convenience, it is considered irrelevant 
as to whether the plutonium is 239Pu, 238Pu, Pu-alpha, or 241Am, 
because the dose coefficients are reasonably close.  The dose 
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coefficients and retention fractions used for these analyses are taken 
from the chapters of this manual that address the specific 
radioisotopes. 
 
E.1 Cesium-137 and Strontium-90 Mixtures 
 
Mixtures of 137Cs and 90Sr are particularly common in waste manage-
ment facilities and are especially prevalent in the 200 Area tank 
farms.  It is assumed that both nuclides are class D.  Table E.1 and 
Figure E.1 show the minimum detectable doses associated with a 
preview whole body count and a 90Sr urinalysis for several mixtures 
of 137Cs and 90Sr.  Collectively, these show that an annual whole 
body count using the NaI Preview Counter meets the 100-mrem 
bioassay goal for minimum detectable committed effective dose 
equivalent for mixtures having 137Cs:90Sr activity ratios of up to 
approximately 1:20.  Use of the germanium coaxial counter 
improves the ratio to about 1:40 for meeting the 100-mrem bioassay 
goal, as shown in Table E.1 and Figure E.2. 
 
E.2 Cesium-137 and Plutonium Mixtures 
 
Mixtures of 137Cs and plutonium can be found primarily in facilities 
associated with spent fuel management, and in wastes associated 
with such buildings.  Examples include the spent fuel basins, fuel 
processing hot cells, and waste tank sludges.  By radioactivity, these 
mixtures are likely to be mostly 137Cs, with 137Cs:plutonium ratios 
ranging from perhaps 1000:1 to 1:1.  Until the mid-1990s, little 
attention was given to trace amounts of plutonium in predominantly 
fission product contamination.  However, recognition of the 
dosimetric importance of trace plutonium developed with the 
implementation of the committed dose system and as more detailed 
facility contamination characterization data became available.  
Determining whether the plutonium might be class W or Y is 
problematic; if the plutonium contamination resulted from leaching 
out of fuel or residuals from processing of fuel, then a class W 
assumption would be appropriate.  If it resulted from corroded, 
unreprocessed fuel, then a class Y assumption would probably be 
more appropriate. 
 
Bioassay program capabilities for 137Cs and 239Pu as tracer nuclides 
for several cesium-plutonium mixtures are shown in Table E.2 and 
Figures E.3 and E.4.  The source material considered here is assumed 
to be class D 137Cs and class W plutonium.  This assumption 
provides a reasonably conservative estimate of minimum detectable 
dose (MDD) based on a whole body count and the assumed isotopic 
ratio.  Doses associated with plutonium detection by urinalysis 
would be substantially higher if the plutonium was a class Y form.  
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Table E.1. Minimum Detectable Dose (HE,50, in mrem) for Mixtures(a) of 137Cs and 90Sr Based on Tracer Nuclide Bioassay 
 
1:1 Cs:Sr 1:10 Cs:Sr 1:20 Cs:Sr Days Post 
Intake Preview(b) Coax (c) Urine (d) Preview(b) Coax (c) Urine (d) Preview(b) Coax (c) Urine (d) 
1 0.46 0.28 0.03 4.0 2.5 0.02 8.0 4.9 0.02 
2 0.48 0.29 0.03 4.2 2.6 0.03 8.2 5.1 0.03 
7 0.52 0.32 0.08 4.5 2.8 0.07 9.0 5.5 0.07 
14 0.55 0.34 0.25 4.8 2.9 0.22 9.4 5.8 0.22 
30 0.60 0.37 2.2 5.2 3.2 1.9 10 6.4 1.9 
60 0.73 0.45 7.5 6.4 3.9 6.5 13 7.8 6.5 
90 0.89 0.55 9.5 7.8 4.8 8.2 15 9.5 8.2 
180 1.6 0.97 15 14 8.4 13 27 17 13 
365 5.1 3.2 30 45 27 26 88 54 26 
730 52 32 71 450 280 62 900 550 61 
1:40 Cs:Sr 1:100 Cs:Sr 1:1000 Cs:Sr Days Post 
Intake Preview(b) Coax (c) Urine (d) Preview(b) Coax (c) Urine (d) Preview(b) Coax (c) Urine (d) 
1 16 9.7 0.02 40 24 0.02 394 243 0.02 
2 16 10 0.03 41 25 0.03 408 251 0.03 
7 18 11 0.07 45 27 0.07 444 273 0.07 
14 19 12 0.21 47 29 0.21 468 288 0.21 
30 21 13 1.9 52 32 1.8 516 318 1.8 
60 25 15 6.4 63 39 6.4 627 386 6.4 
90 31 19 8.1 76 47 8.1 763 470 8.1 
180 54 33 13 135 83 13 1350 831 13 
365 180 110 26 439 270 26 4388 2700 26 
730 1800 1100 61 4500 2700 61 44,000 27,000 61 
(a) Assumes acute inhalation of class D, 5-mm-AMAD particles for both 137Cs and 90Sr. 
(b) Preview count MDA of 1.3 nCi 137Cs. 
(c) Coaxial count MDA of 0.8 nCi 137Cs. 
(d) 90Sr urinalysis MDA of 10 dpm/d. 
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Figure E.1. Bioassay Capability Comparison for 137Cs:90Sr Mixtures Based on Preview Whole Body 
Count (WBC) and 90Sr Urinalysis (SrU) 
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Figure E.2. Bioassay Capability Comparison for 137Cs:90Sr Mixtures Based on Coaxial Whole Body 
Count (WBC) and 90Sr Urinalysis (SrU) 
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 Table  E.2.  Minimum Detectable Dose (HE,50, in mrem) for Mixtures(a) of 137Cs and 239Pu Based on Tracer Nuclide Bioassay 
 
1000:1 Cs:Pu 100:1 Cs:Pu 80:1 Cs:Pu Days Post 
Intake Preview(b) Coax (c) Urine (d) Preview(b) Coax (c) Urine (d) Preview(b) Coax (c) Urine (d) 
1 0.77 0.47 14 7.1 4.4 12 8.8 5.4 12 
2 0.80 0.49 22 7.3 4.5 20 9.1 5.6 20 
7 0.87 0.53 69 8.0 4.9 63 9.9 6.1 63 
14 0.91 0.56 108 8.4 5.2 99 10 6.4 99 
30 1.0 0.62 169 9.3 5.7 160 12 7.1 160 
60 1.2 0.75 237 11 6.9 220 14 8.6 220 
90 1.5 0.91 338 14 8.4 310 17 11 310 
180 2.6 1.6 431 24 15 400 30 19 400 
365 8.5 5.3 585 79 48 540 98 60 540 
730 87 53 970 800 490 890 1000 610 890 
40:1 Cs:Pu 10:1 Cs:Pu 1:1 Cs:Pu Days Post 
Intake Preview(b) Coax (c) Urine (d) Preview(b) Coax (c) Urine (d) Preview(b) Coax (c) Urine (d) 
1 18 10.8 12 70 43 12 701 430 12 
2 18 11 20 73 45 20 730 450 20 
7 20 12 63 79 49 63 790 490 63 
14 21 13 99 83 51 98 830 510 98 
30 23 14 160 92 57 160 920 570 150 
60 28 17 220 110 69 220 1100 690 220 
90 34 21 310 140 84 310 1400 840 310 
180 60 37 400 240 150 390 2400 1500 390 
365 200 120 540 780 480 530 7800 4800 530 
730 20,000 1200 890 7900 4900 880 79,000 49,000 880 
(a) Assumes acute inhalation of class D, 5-mm-AMAD particles for 137Cs and class W, 5-mm-AMAD particles for 239Pu. 
(b) Preview count MDA of 1.3 nCi 137Cs. 
(c) Coaxial count MDA of 0.8 nCi 137Cs. 
(d) 239Pu urinalysis MDA of 0.02 dpm/d. 
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Figure E.3. Bioassay Capability Comparison for 137Cs:239Pu Mixtures Based on Preview Whole Body 
Count (WBC) and 239Pu Urinalysis (PuU) 
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Figure E.4. Bioassay Capability Comparison for 137Cs:239Pu Mixtures Based on Coaxial Whole Body 
Count (WBC) and 239Pu Urinalysis (PuU) 
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Based on the data presented, an annual whole body count using the 
preview counter is capable of meeting the 100-mrem bioassay goal 
for mixtures down to about an 80:1 ratio of 137Cs:plutonium.  Using 
the coax counter allows reduction to approximately 40:1.  If the 
potential exists for exposure to material with 137Cs:plutonium ratios 
lower than these, then the worker should be considered for routine 
plutonium bioassay as might be performed for a pure plutonium 
source. 
 
E.3 Strontium-90 and Plutonium Mixtures 
 
Mixtures of 90Sr and plutonium are considered most likely to occur 
in tank farm facilities, probably associated with contamination 
originating from waste tank sludges.  The 90Sr is assumed to be a 
class D material and the plutonium a class W material, consistent 
with the nitrate nature of most waste tank contents.  It is possible that 
dry plutonium contamination exposed to dry air and a normal 
building/outdoor temperature environment could undergo gradual 
oxidation over long time periods and approach a class Y material.  
However, the use of class W dose coefficients for plutonium 
provides a conservative approach to the estimations of MDD based 
on 90Sr as a tracer radionuclide. 
 
Bioassay program capabilities for 90Sr and 239Pu as tracer nuclides for 
several strontium-plutonium mixtures are shown in Table E.3 and 
Figures E.5.  The source material considered here is assumed to be 
class D 90Sr and class W plutonium.  This assumption provides a 
reasonably conservative estimate of MDD based on radiostronitum 
urinalysis and the assumed isotopic ratio.  Doses associated with 
plutonium detection by urinalysis would be substantially higher if the 
plutonium was a class Y form.  Based on the data presented, an 
annual 90Sr urinalysis is capable of meeting the 100-mrem bioassay 
goal for mixtures down to about a 600:1 ratio of 90Sr:plutonium.  The 
mixture for which a 90Sr urinalysis would provide essentially equal 
MDD capability with a plutonium urinalysis for class W material 
was calculated to be 86:1, and the MDD was calculated to be 560 
mrem.  If the potential exists for exposure to material with 
90Sr:plutonium ratios lower than these, then the worker should be 
considered for routine plutonium bioassay as might be performed for 
a pure plutonium source. 
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Table E.3. Minimum Detectable Dose (HE,50, in mrem) for Mixtures(a) of 90Sr and 239Pu Based on  
Tracer Nuclide Bioassay 
 
 1000:1 90Sr:Pu 600:1 90Sr:Pu 100:1 90Sr:Pu 10:1 90Sr:Pu 
Days Post 
Intake 
90Sr 
Urine(b) 
239Pu 
Urine(c) 
90Sr 
Urine(b) 
239Pu 
Urine(c) 
90Sr 
Urine(b) 
239Pu 
Urine(c) 
90Sr 
Urine(b) 
239Pu 
Urine(c) 
1 0.06 19 0.1 17 0.4 13 4.0 12 
2 0.08 31 0.1 26 0.5 21 4.9 20 
7 0.20 98 0.3 84 1.3 66 13 63 
14 0.59 150 0.8 130 4 104 38 99 
30 5.1 240 7.3 210 35 160 330 160 
60 18 340 25 290 120 230 1100 220 
90 23 480 32 410 150 330 1500 310 
180 36 610 52 530 250 420 2300 400 
365 72 830 100 710 490 560 4600 540 
730 170 1400 240 1200 1100 930 11,000 890 
(a) Assumes acute inhalation of class D, 5-mm-AMAD particles for 90Sr and class W, 5-mm particles for plutonium. 
(b) 90Sr urinalysis MDA of 10 dpm/d. 
(c) 239Pu urinalysis MDA of 0.02 dpm/d. 
 
 
Figure E.5. Bioassay Capability Comparison for 90Sr:239Pu Mixtures Based on 90S Urinalysis (SrU)r and 
239Pu Urinalysis (PuU) 
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